0001014739-25-000012.txt : 20250226 0001014739-25-000012.hdr.sgml : 20250226 20250226160109 ACCESSION NUMBER: 0001014739-25-000012 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 102 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250226 DATE AS OF CHANGE: 20250226 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Option Care Health, Inc. CENTRAL INDEX KEY: 0001014739 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-HOME HEALTH CARE SERVICES [8082] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 050489664 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11993 FILM NUMBER: 25669839 BUSINESS ADDRESS: STREET 1: 3000 LAKESIDE DR STREET 2: SUITE 300N CITY: BANNOCKBURN STATE: IL ZIP: 60015 BUSINESS PHONE: 312 940 2443 MAIL ADDRESS: STREET 1: 3000 LAKESIDE DR STREET 2: SUITE 300N CITY: BANNOCKBURN STATE: IL ZIP: 60015 FORMER COMPANY: FORMER CONFORMED NAME: BioScrip, Inc. DATE OF NAME CHANGE: 20050314 FORMER COMPANY: FORMER CONFORMED NAME: MIM CORP DATE OF NAME CHANGE: 19960516 10-K 1 bios-20241231.htm 10-K bios-20241231
00010147392024FYFALSEP15YP2YP2YP3Yhttp://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrentP3YP7YP1Yiso4217:USDxbrli:sharesiso4217:USDxbrli:sharesbios:pharmacybios:suitebios:segmentxbrli:pure00010147392024-01-012024-12-3100010147392024-06-2800010147392025-02-2100010147392024-12-3100010147392023-12-3100010147392023-01-012023-12-3100010147392022-01-012022-12-3100010147392022-12-3100010147392021-12-310001014739us-gaap:PreferredStockMember2021-12-310001014739us-gaap:CommonStockMember2021-12-310001014739us-gaap:TreasuryStockCommonMember2021-12-310001014739us-gaap:AdditionalPaidInCapitalMember2021-12-310001014739us-gaap:RetainedEarningsMember2021-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001014739us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001014739us-gaap:RetainedEarningsMember2022-01-012022-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001014739us-gaap:PreferredStockMember2022-12-310001014739us-gaap:CommonStockMember2022-12-310001014739us-gaap:TreasuryStockCommonMember2022-12-310001014739us-gaap:AdditionalPaidInCapitalMember2022-12-310001014739us-gaap:RetainedEarningsMember2022-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001014739us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001014739us-gaap:TreasuryStockCommonMember2023-01-012023-12-310001014739us-gaap:RetainedEarningsMember2023-01-012023-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001014739us-gaap:PreferredStockMember2023-12-310001014739us-gaap:CommonStockMember2023-12-310001014739us-gaap:TreasuryStockCommonMember2023-12-310001014739us-gaap:AdditionalPaidInCapitalMember2023-12-310001014739us-gaap:RetainedEarningsMember2023-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001014739us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310001014739us-gaap:TreasuryStockCommonMember2024-01-012024-12-310001014739us-gaap:RetainedEarningsMember2024-01-012024-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-12-310001014739us-gaap:PreferredStockMember2024-12-310001014739us-gaap:CommonStockMember2024-12-310001014739us-gaap:TreasuryStockCommonMember2024-12-310001014739us-gaap:AdditionalPaidInCapitalMember2024-12-310001014739us-gaap:RetainedEarningsMember2024-12-310001014739us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-12-310001014739us-gaap:CommonStockMemberbios:SecondaryOfferingMember2023-01-012023-12-3100010147392023-03-032023-03-030001014739bios:LegacyHealthSystemsMember2024-12-310001014739us-gaap:CustomerListsMembersrt:MinimumMember2024-12-310001014739us-gaap:CustomerListsMembersrt:MaximumMember2024-12-310001014739us-gaap:TrademarksAndTradeNamesMembersrt:MinimumMember2024-12-310001014739us-gaap:TrademarksAndTradeNamesMembersrt:MaximumMember2024-12-310001014739us-gaap:OtherIntangibleAssetsMembersrt:MinimumMember2024-12-310001014739us-gaap:OtherIntangibleAssetsMembersrt:MaximumMember2024-12-310001014739bios:InfusionPumpsMember2024-12-310001014739us-gaap:EquipmentMembersrt:MinimumMember2024-12-310001014739us-gaap:EquipmentMembersrt:MaximumMember2024-12-310001014739us-gaap:ComputerSoftwareIntangibleAssetMember2024-12-310001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001014739bios:LargestPayerMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-12-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-12-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberus-gaap:RevenueFromContractWithCustomerMember2022-01-012022-12-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberbios:AccountsReceivableBenchmarkMember2024-01-012024-12-310001014739us-gaap:GovernmentContractsConcentrationRiskMemberbios:GovernmentHealthcareProgramsMemberbios:AccountsReceivableBenchmarkMember2023-01-012023-12-310001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2024-01-012024-12-310001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2023-01-012023-12-310001014739bios:FourVendorsMemberus-gaap:SupplierConcentrationRiskMemberus-gaap:CostOfGoodsProductLineMember2022-01-012022-12-310001014739bios:AmedisysIncMemberbios:OptionCareCombinedCompanyMember2023-05-030001014739bios:AmedisysIncMember2023-06-260001014739bios:RevitalizedLLCMember2023-05-310001014739bios:RevitalizedLLCMember2023-05-012023-05-3100010147392022-12-012022-12-310001014739bios:RochesterHomeInfusionIncMember2022-08-310001014739bios:RochesterHomeInfusionIncMember2022-08-012022-08-310001014739bios:SpecialtyPharmacyNursingNetworkIncMember2022-04-300001014739bios:SpecialtyPharmacyNursingNetworkIncMember2022-04-012022-04-300001014739bios:CommercialCustomerMember2024-01-012024-12-310001014739bios:CommercialCustomerMember2023-01-012023-12-310001014739bios:CommercialCustomerMember2022-01-012022-12-310001014739bios:GovernmentCustomerMember2024-01-012024-12-310001014739bios:GovernmentCustomerMember2023-01-012023-12-310001014739bios:GovernmentCustomerMember2022-01-012022-12-310001014739bios:PatientCustomerMember2024-01-012024-12-310001014739bios:PatientCustomerMember2023-01-012023-12-310001014739bios:PatientCustomerMember2022-01-012022-12-310001014739us-gaap:StateAndLocalJurisdictionMember2024-03-012024-03-310001014739us-gaap:StateAndLocalJurisdictionMember2023-09-012023-09-300001014739us-gaap:StateAndLocalJurisdictionMember2024-12-310001014739bios:MergerOperatingLossCarryforwardMemberus-gaap:DomesticCountryMember2024-12-310001014739us-gaap:DomesticCountryMember2024-12-310001014739bios:IndefiniteCarryforwardPeriodMemberus-gaap:DomesticCountryMember2024-12-310001014739bios:InterestLimitationCarryforwardsMember2024-12-310001014739bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMemberus-gaap:StateAndLocalJurisdictionMember2024-12-310001014739us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001014739us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-310001014739us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310001014739us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-310001014739us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-310001014739us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-01-012024-12-310001014739us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2024-12-310001014739us-gaap:WarrantMember2024-01-012024-12-310001014739us-gaap:WarrantMember2023-01-012023-12-310001014739us-gaap:WarrantMember2022-01-012022-12-310001014739us-gaap:StockOptionMember2024-01-012024-12-310001014739us-gaap:StockOptionMember2023-01-012023-12-310001014739us-gaap:StockOptionMember2022-01-012022-12-310001014739bios:RestrictedStockAwardMember2024-01-012024-12-310001014739bios:RestrictedStockAwardMember2023-01-012023-12-310001014739bios:RestrictedStockAwardMember2022-01-012022-12-310001014739bios:PerformanceStockUnitMember2024-01-012024-12-310001014739bios:PerformanceStockUnitMember2023-01-012023-12-310001014739bios:PerformanceStockUnitMember2022-01-012022-12-310001014739bios:AmedisysIncMember2023-12-310001014739bios:InfusionPumpsMember2024-12-310001014739bios:InfusionPumpsMember2023-12-310001014739bios:EquipmentFurnitureAndOtherMember2024-12-310001014739bios:EquipmentFurnitureAndOtherMember2023-12-310001014739us-gaap:LeaseholdImprovementsMember2024-12-310001014739us-gaap:LeaseholdImprovementsMember2023-12-310001014739us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2024-12-310001014739us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2023-12-310001014739us-gaap:AssetUnderConstructionMember2024-12-310001014739us-gaap:AssetUnderConstructionMember2023-12-310001014739us-gaap:CostOfSalesMember2024-01-012024-12-310001014739us-gaap:CostOfSalesMember2023-01-012023-12-310001014739us-gaap:CostOfSalesMember2022-01-012022-12-310001014739us-gaap:OperatingExpenseMember2024-01-012024-12-310001014739us-gaap:OperatingExpenseMember2023-01-012023-12-310001014739us-gaap:OperatingExpenseMember2022-01-012022-12-310001014739us-gaap:CustomerListsMember2024-12-310001014739us-gaap:CustomerListsMember2023-12-310001014739us-gaap:TrademarksAndTradeNamesMember2024-12-310001014739us-gaap:TrademarksAndTradeNamesMember2023-12-310001014739us-gaap:OtherIntangibleAssetsMember2024-12-310001014739us-gaap:OtherIntangibleAssetsMember2023-12-310001014739us-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2024-12-310001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-12-310001014739bios:SecondLienTermLoanMemberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-12-310001014739bios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2023-12-310001014739bios:SecondLienTermLoanMemberus-gaap:SeniorNotesMember2023-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-05-080001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-05-072024-05-070001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-05-082024-05-080001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-01-012024-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMemberus-gaap:InterestRateFloorMember2024-01-012024-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMemberus-gaap:BaseRateMember2024-01-012024-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-12-310001014739us-gaap:SeniorLienMemberbios:FirstLienCreditAgreementThirdAmendmentMemberus-gaap:SeniorNotesMember2023-01-012023-12-310001014739us-gaap:SeniorLienMemberbios:NewFirstLienTermLoanMemberus-gaap:SeniorNotesMember2021-10-310001014739bios:SecondLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-12-070001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2024-12-310001014739bios:SecondLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2024-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-12-310001014739bios:SecondLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-12-310001014739bios:SecondLienCreditAgreementMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMemberus-gaap:BaseRateMember2024-01-012024-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-01-120001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-01-130001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMemberus-gaap:BaseRateMembersrt:MinimumMember2023-01-012023-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMemberus-gaap:BaseRateMembersrt:MaximumMember2023-01-012023-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMemberus-gaap:InterestRateFloorMember2023-01-012023-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2023-01-012023-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2023-01-012023-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMembersrt:MinimumMember2023-01-012023-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMembersrt:MaximumMember2023-01-012023-12-310001014739bios:CreditAgreementsEnteredInto2019Memberus-gaap:RevolvingCreditFacilityMemberus-gaap:SeniorNotesMember2023-01-012023-12-310001014739bios:NewSeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2021-10-310001014739bios:NewSeniorUnsecuredNotesMemberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2023-12-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2023-01-012023-12-310001014739us-gaap:JuniorLienMemberbios:CreditAgreementsEnteredInto2019Memberus-gaap:SeniorNotesMember2024-01-012024-12-310001014739us-gaap:FairValueInputsLevel1Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:FairValueInputsLevel2Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:FairValueInputsLevel3Memberbios:FirstLienTermLoanMemberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:SeniorNotesMember2024-12-310001014739us-gaap:FairValueInputsLevel1Memberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:FairValueInputsLevel2Memberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:FairValueInputsLevel3Memberus-gaap:SeniorNotesMember2024-12-310001014739us-gaap:FairValueInputsLevel1Member2024-12-310001014739us-gaap:FairValueInputsLevel2Member2024-12-310001014739us-gaap:FairValueInputsLevel3Member2024-12-310001014739bios:FirstLienTermLoanMemberus-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-10-310001014739bios:FirstLienTermLoanMemberus-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SeniorNotesMember2021-10-012021-10-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2024-12-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-12-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2024-12-310001014739us-gaap:InterestRateCapMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherNoncurrentAssetsMember2023-12-310001014739us-gaap:InterestRateCapMember2024-01-012024-12-310001014739us-gaap:InterestRateCapMember2023-01-012023-12-310001014739us-gaap:InterestRateCapMember2022-01-012022-12-310001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2024-01-012024-12-310001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2023-01-012023-12-310001014739us-gaap:InterestExpenseMemberus-gaap:InterestRateCapMember2022-01-012022-12-310001014739bios:A2018PlanMember2024-05-012024-05-310001014739bios:A2018PlanMember2024-12-310001014739bios:A2018PlanMember2023-12-310001014739us-gaap:EmployeeStockOptionMembersrt:MinimumMember2024-01-012024-12-310001014739us-gaap:EmployeeStockOptionMembersrt:MaximumMember2024-01-012024-12-310001014739srt:MinimumMember2024-01-012024-12-310001014739srt:MaximumMember2024-01-012024-12-310001014739us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001014739us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001014739us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001014739us-gaap:EmployeeStockOptionMember2023-12-310001014739us-gaap:EmployeeStockOptionMember2024-12-310001014739bios:OptionExercisePriceRangeOneMember2024-01-012024-12-310001014739bios:OptionExercisePriceRangeOneMember2024-12-310001014739bios:OptionExercisePriceRangeTwoMember2024-01-012024-12-310001014739bios:OptionExercisePriceRangeTwoMember2024-12-310001014739bios:OptionExercisePriceRangeThreeMember2024-01-012024-12-310001014739bios:OptionExercisePriceRangeThreeMember2024-12-310001014739bios:OptionExercisePriceRangeFourMember2024-01-012024-12-310001014739bios:OptionExercisePriceRangeFourMember2024-12-310001014739us-gaap:RestrictedStockMembersrt:MinimumMember2024-01-012024-12-310001014739us-gaap:RestrictedStockMembersrt:MaximumMember2024-01-012024-12-310001014739us-gaap:RestrictedStockMembersrt:DirectorMember2024-01-012024-12-310001014739us-gaap:RestrictedStockMember2024-01-012024-12-310001014739us-gaap:RestrictedStockMember2023-01-012023-12-310001014739us-gaap:RestrictedStockMember2022-01-012022-12-310001014739us-gaap:RestrictedStockMember2023-12-310001014739us-gaap:RestrictedStockMember2024-12-310001014739bios:PerformanceStockUnitsMember2024-01-012024-12-310001014739bios:PerformanceStockUnitsMembersrt:MinimumMember2024-01-012024-12-310001014739bios:PerformanceStockUnitsMembersrt:MaximumMember2024-01-012024-12-310001014739bios:PerformanceStockUnitsMember2023-01-012023-12-310001014739bios:PerformanceStockUnitsMember2022-01-012022-12-310001014739bios:PerformanceStockUnitsMember2024-12-310001014739bios:A2024PerformanceStockUnitsMember2024-01-012024-12-310001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2019-08-060001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2017-06-290001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2024-12-310001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2023-12-310001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2022-12-310001014739bios:A2017WarrantsMemberus-gaap:CommonStockMember2024-01-012024-12-310001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2015-03-090001014739bios:A2015WarrantsMemberus-gaap:CommonStockMembersrt:MinimumMember2015-03-090001014739bios:A2015WarrantsMemberus-gaap:CommonStockMembersrt:MaximumMember2015-03-090001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2019-08-060001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2024-01-012024-12-310001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2023-01-012023-12-310001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2022-01-012022-12-310001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2024-12-310001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2023-12-310001014739bios:A2015WarrantsMemberus-gaap:CommonStockMember2022-12-310001014739us-gaap:CommonStockMember2023-02-200001014739us-gaap:CommonStockMember2023-12-060001014739us-gaap:CommonStockMemberus-gaap:SubsequentEventMember2025-01-310001014739us-gaap:CommonStockMember2023-01-012023-12-310001014739us-gaap:CommonStockMember2024-01-012024-12-310001014739us-gaap:CorporateJointVentureMemberbios:ManagementFeeIncomeMember2024-01-012024-12-310001014739us-gaap:CorporateJointVentureMemberbios:ManagementFeeIncomeMember2023-01-012023-12-310001014739us-gaap:CorporateJointVentureMemberbios:ManagementFeeIncomeMember2022-01-012022-12-310001014739us-gaap:CorporateJointVentureMember2024-12-310001014739us-gaap:CorporateJointVentureMember2023-12-3100010147392023-02-282023-02-280001014739bios:IntramedPlusMemberus-gaap:SubsequentEventMember2025-01-242025-01-2400010147392024-10-012024-12-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 10-K
(Mark One)
☑ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the fiscal year ended December 31, 2024
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 For the transition period from     to             
Commission file number: 001-11993
optioncarehealthrgba06.jpg
OPTION CARE HEALTH, INC.
(Exact name of registrant as specified in its charter)
Delaware05-0489664
(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.)
3000 Lakeside Dr. Suite 300N, Bannockburn, IL
60015
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code:
312-940-2443
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.0001 par value per shareOPCHNasdaq Global Select Market
Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.  Yes ☑     No ☐
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.  Yes ☐     No ☑
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☑     No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☑ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☑     Accelerated filer ☐     Non-accelerated filer ☐      Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  ☑
If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐
Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to § 240.10D-1(b). ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐     No ☑
The aggregate market value of the registrant’s Common Stock held by non-affiliates of the registrant as of June 28, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, was approximately $4,748,081,376 based on the closing price of the registrant’s Common Stock on the Nasdaq Global Select Market on such date.
As of February 21, 2025, there were 165,315,961 shares of the registrant’s Common Stock outstanding.


DOCUMENTS INCORPORATED BY REFERENCE
Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (the “SEC”) within 120 days after the close of the registrant’s fiscal year are incorporated by reference into Part III of this Annual Report on Form 10-K.


TABLE OF CONTENTS
  Page
Number
PART I
PART II
PART III
PART IV
 
2
Forward-Looking Statements
This Annual Report on Form 10-K (“Annual Report”) contains statements not purely historical and which may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), including statements regarding our expectations, beliefs, future plans and strategies, anticipated events or trends concerning matters that are not historical facts or that necessarily depend upon future events. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “could,” “would,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “predict,” “potential,” “intend,” and similar expressions. This Annual Report contains, among others, forward-looking statements based upon current expectations that involve numerous risks and uncertainties, including those described in Item 1A. “Risk Factors”.
Investors are cautioned that any such forward-looking statements are not guarantees of future performance, involve risks and uncertainties and that actual results may differ materially from those possible results discussed in the forward-looking statements as a result of various factors.
Do not place undue reliance on such forward-looking statements as they speak only as of the date they are made. Except as required by law, Option Care Health, Inc. assumes no obligation to publicly update or revise any forward-looking statement even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized.
3
PART I
Item 1.    Business
Overview
Option Care Health, Inc. (“Option Care Health”, “we”, “us”, “our”, or the “Company”) is the largest independent provider of home and alternate site infusion services through its national network of 185 locations in 43 states. Option Care Health draws on over 40 years of clinical care experience to offer patient-centered, cost-effective infusion therapy. Option Care Health’s infusion services include the clinical management of infusion therapy, nursing support and care coordination. Option Care Health’s multidisciplinary team of more than 5,000 clinicians, including pharmacists, pharmacy technicians, nurses and dietitians, are able to provide infusion service coverage for nearly all patients across the United States (“U.S.”) needing treatment for complex and chronic medical conditions.
On April 7, 2015, HC Group Holdings II, Inc. (“HC II”) and its sole shareholder, HC Group Holdings I, LLC. (“HC I”), collectively acquired Walgreens Infusion Services, Inc. and its subsidiaries from Walgreen Co., and the business was rebranded as Option Care, Inc. (“Option Care”).
On March 14, 2019, HC I and HC II entered into a definitive agreement to merge with and into a wholly-owned subsidiary of BioScrip, Inc. (“BioScrip”) (the “Merger”), a national provider of infusion and home care management solutions, which was completed on August 6, 2019 (the “Merger Date”). Following the close of the Merger, BioScrip was rebranded as Option Care Health, Inc.
Option Care Health contracts with managed care organizations, third-party payers, hospitals, physicians and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. Our services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to each patient’s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, chronic inflammatory disorders, neurological disorders, immunoglobulin therapy, and other therapies for chronic and acute conditions. The Company operates in one segment, infusion services.
The Company’s operating model enables it to provide favorable outcomes to its stakeholders as follows:
•Patients. The Company improves patients’ quality of life by allowing them to receive infusion therapy at home or at one of its ambulatory infusion suites. In addition, the Company helps manage patients’ conditions through counseling and education regarding their treatment and by providing ongoing monitoring to encourage patient compliance with the prescribed therapy. The Company also provides services to help patients receive reimbursement benefits.
•Payers. The Company provides payers with a comprehensive approach to meeting their pharmacy service needs and providing a cost-effective solution. The Company’s provision of infusion pharmacy services in the patient’s home or at one of its local ambulatory infusion suites offers a lower cost alternative to providing these therapies in a hospital setting. The Company also provides payers with utilization and outcome data to evaluate therapy effectiveness.
•Providers. The Company provides providers with timely patient clinical support by providing care management related to their patients’ pharmacy needs and improving compliance with therapy protocols. The Company eliminates the need for providers to carry inventories of high-cost prescriptions by distributing the medications directly to patients’ homes.
•Pharmaceutical Manufacturers. The Company collaborates with pharmaceutical manufacturers to provide a broad distribution channel for their existing pharmaceuticals and their new product launches. The Company implements patient monitoring programs that encourage compliance with the prescribed therapy. The Company also provides valuable clinical information in the form of outcomes and compliance data to manufacturers to aid in their evaluation of the efficacy of their products.
•Health Systems. The Company partners with health systems across the country to provide seamless transitional care within an effective post-acute care network to manage patients across the continuum of care. The Company assists partnered health systems in monitoring key metrics that tie back to what most payers monitor in their value-based contracts.
4
Quality
Quality is at the core of the Company’s mission as it strives to deliver quality healthcare, leading to favorable outcomes and more cost-effective care. The Company offers comprehensive services that align with specific healthcare provider needs and has demonstrated success in improving outcomes across a broad range of therapies through improved clinical-reported patient adherence rates and decreased rates of unplanned hospital readmissions.
The Company’s commitment to continuous quality improvement to provide optimal outcomes for its patients is evidenced by its national accreditations, including accreditations from Accreditation Commission for Health Care (“ACHC”), Pharmacy Compounding Accreditation Board (“PCAB”), American Society of Health-System Pharmacists (“ASHP”) and Utilization Review Accreditation Commission (“URAC”).
ACHC accreditation is awarded to healthcare organizations that meet regulatory requirements and accreditation standards, and PCAB accreditation offers the most comprehensive compliance solution in the industry based on more than 40 sterile compounding standards in the U.S. Pharmacopeia Pharmaceutical Compounding - Sterile Preparations Standards (“USP 797”).
5
Services
The Company is the largest independent provider of home and alternate site infusion services. The Company’s services are most typically provided in the patient’s home, but may also be provided at clinics, physicians’ offices or ambulatory infusion suites. The Company provides a broad therapy portfolio through its network of 92 full-service pharmacies and 93 stand-alone ambulatory infusion suites. The Company’s home infusion services include medication and supplies for administration and use at home or within one of its ambulatory infusion suites, consultation and education regarding the patient’s condition and the prescribed medication nursing support, clinical monitoring and assistance in monitoring potential side effects, and assistance in obtaining reimbursement. The Company administers a wide variety of therapies and services, including the following:
•Anti-Infectives Infusion. The Company provides comprehensive home infusion services to combat serious infections in patients of all ages. The Company’s anti-infective therapy and services help avoid hospitalizations for many infections that can be safely treated at home.
•Nutrition Support. The Company delivers comprehensive nutrition support across pediatric, adult, and geriatric patients. The Company’s expert team provides home parenteral nutrition and enteral nutrition support for numerous acute and chronic conditions negatively affecting nutritional status, such as stroke, cancer, and gastrointestinal diseases.
•Immunoglobulin Infusion. The Company offers expertise, access, and support in immunoglobulin (“IG”) infusion therapy designed to treat immune deficiencies. Immune deficiencies are disorders that reduce the patient’s ability to identify and destroy substances that do not belong in the human body and are characterized by reduced levels of antibodies. Intravenous IG infusions are concentrated antibodies that have been purified from large numbers of human blood donors.
•Chronic Inflammatory Disorders. The Company treats chronic inflammatory disorders, which include Crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
•Neurological Disorders. The Company provides an array of treatments to manage the progression of neurological disorders such as Duchenne Muscular Dystrophy, Multiple Sclerosis, Alzheimer’s Disease, and other neurological disorders.
•Bleeding Disorders Infusion. As a provider of home infusion therapy for hemophilia and von Willebrand disease, the Company streamlines the administrative burdens associated with infusion therapies for bleeding disorders. The Company works with medical specialists across the country to offer access to all approved factor products, a full range of therapies, and dedicated support services.
•Naven Health. The Company offers a nationwide home infusion nursing network and clinical platform. Naven Health focuses on delivering highly specialized, infusion care.
•Women’s Health. The Company offers therapies that women need to survive and thrive through high-risk pregnancies. Personalized programs in prematurity, nausea and vomiting hyperemesis, diabetes in pregnancy, and hypertension help meet the needs of each mother.
•Heart Failure. The Company administers home infusion services to treat heart failure, either in anticipation of cardiac transplant or to provide palliation of heart failure symptoms.
•Other. The Company offers a range of other infusion therapies to treat a variety of conditions, including pain management, chemotherapy and respiratory medication.
The Company also provides nursing services to support the above therapies, comprised of its nursing team of approximately 2,900 employees, and through its network of sub-contracted nursing agencies.
6
Sales and Marketing
The Company’s sales and marketing efforts focus on three primary objectives: (1) building new relationships and expanding existing contracts with managed care organizations; (2) establishing, maintaining and strengthening relationships with local and regional patient referral sources; and (3) maintaining existing and developing new relationships with pharmaceutical manufacturers to gain distribution access as they release new products.
The Company’s sales structure is focused on maintaining and expanding its relationships with drug manufacturers to establish its position as a participating provider when they release new products. In addition, the Company’s sales structure allows it to leverage its national managed care relationships to provide sales and contract pull-through by the Company’s local field-based sales personnel. This cross-utilization enables the Company to market its services to numerous sources of patient referrals, including physicians, hospital discharge planners, hospital personnel, Health Maintenance Organizations (“HMOs”) and Preferred Provider Organizations (“PPOs”).
Competition
The Company competes in the large and highly fragmented home and alternative site infusion market for contracts with managed care organizations and other third-party payers to receive referrals from physicians, case managers and hospital discharge planners. Competition in the home infusion market is based on quality of care, clinical outcomes, pricing and cost of service, reputation, and reliability of service. The Company’s competitors within the home infusion market include Optum Infusion Pharmacy (a unit of the United Healthcare Insurance Company), Coram CVS/specialty infusion services (a division of CVS Health), Amerita Specialty Pharmacy (a division of BrightSpring Health), KabaFusion, Soleo Health, Vital Care and many smaller regional and local home infusion companies, ambulatory infusion centers, or specialty pharmacies including Accredo, CVS Caremark, Optum Rx, and Orsini. The Company believes that its reputation for providing quality services, the strength of its national presence and its ability to effectively market its services at national, regional and local levels places it in a strong position against existing and potential competitors.
Intellectual Property
Option Care Health and its subsidiaries own a variety of trademarks, licenses, and service marks, including but not limited to: “Option Care Health”, “Option Care”, “Critical Care Systems”, “Clinical Specialties”, “BioScrip”, “BioScrip Infusion Services”, “HomeChoice Partners”, “InfuScience”, “InfusionCare”, “Infusion Partners”, “Infusion Solutions”, “New England Home Therapies”, “Professional Home Care Services”, “Wilcox Home Infusion”, “Home Solutions”, Home Solutions Infusion Therapy”, “Naven Health”, “Naven Connect”, “Restore+ by Option Care Health”, “IG Complete+”, “Care Nav+ by Option Care Health”, “BioCure”, “DP Diabetes in Pregnancy Program”, “HP Hypertension in Pregnancy Program”, “NV Nausea and Vomiting Hyperemesis Program”, “PM Prematurity Program”, “Factor Ape”, as well as several others.
7
Suppliers
The Company purchases pharmaceuticals and medical supplies directly through pharmaceutical manufacturers, authorized distributors and group purchasing organizations. As a national pharmacy provider with broad coverage and clinical expertise of its 92 full-service pharmacies, the Company provides pharmaceutical manufacturers with an extensive distribution channel for its existing and prospective pharmaceutical products. Many of the pharmaceuticals that the Company purchases are available from multiple sources and are available in sufficient quantities to meet the needs of the Company and its patients. However, some drugs are only available through sole distribution sources and/or limited distribution models from the manufacturer that may be subject to limits on distribution. In such cases, it is important that the Company establishes and maintains good working relationships with the manufacturer to secure a sufficient supply to meet its patients’ needs. Additionally, certain drugs may become subject to supply shortages. Such shortages can result in cost increases or hamper the Company’s ability to obtain sufficient quantities to meet the needs of its patients. The Company actively manages its relationships with direct manufacturers and distributors to provide differentiated access and service to ensure consistent supply and cost-effective procurement. These relationships provide the Company the opportunity to become a selected partner in the launch of their new products. The Company may also receive fees, which it records as revenue, from certain biotech manufacturers for providing them with bona fide services often focused around clinical outcomes/data. The Company’s continued growth will be dependent on maintaining its existing relationships with manufacturers and establishing new relationships with additional manufacturers as the Company launches new products.
For the year ended December 31, 2024, approximately 58% of the Company’s pharmaceutical and medical supply purchases were from three vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue, which could adversely affect the Company’s financial condition or operating results.
Through the purchasing power of its national platform, the Company is able to negotiate favorable terms and economics, including volume purchase rebates and vendor administration fees. Such fees are recorded as reductions to cost of revenue when the pharmaceuticals are delivered to the patient.
Billing & Significant Payers
The Company generates most of its revenue from contracts with third-party payers, including managed care organizations, insurance companies, self-insured employers, Medicare, and Medicaid programs. Where permissible, the Company bills patients for any amounts not reimbursed by third-party payers. The majority of the Company’s infusion pharmacy revenue consists of reimbursements for both the cost of the pharmaceuticals sold and the cost of services provided. Pharmaceuticals are typically reimbursed on a percentage discount from the published average wholesale price (“AWP”) of each drug or on a percentage premium to average sales price (“ASP”). Nursing services are typically billed separately, while other patient support services, such as pharmacy compounding service, delivery service and ancillary medical supplies are reimbursed either separately or on a per diem basis, as applicable.
The Company’s largest payer represented approximately 15% of its revenue for the year ended December 31, 2024. No other single payer represented more than 10% of its revenue. The Company also provides services that are directly reimbursable through government healthcare programs such as Medicare and state Medicaid programs. For the year ended December 31, 2024, approximately 12% of the Company’s revenue was reimbursable through direct governmental programs, such as Medicare and Medicaid.
Matters Affecting Drug Prices
Pricing benchmarks in the pharmacy industry are periodically published by third parties such as Red Book, Medi-Span, RJ Health, and the Centers for Medicare & Medicaid Services (“CMS”), and the benchmark reimbursement varies by payer contract. The most commonly used benchmarks are AWP and ASP. AWP is based on self-reported prices charged by wholesalers and manufacturers and reimbursement is generally AWP minus a percentage and may include a per diem fee or a fixed dispensing fee. ASP is based on actual sales transactions reported by wholesalers and is generally lower than AWP; reimbursement is generally ASP plus a percentage. The Company may also receive a fixed dispensing fee or a per diem fee for each day a patient is on service. Changes to these pricing benchmarks may have a significant impact on the profitability of the Company’s business.
8
Governmental Regulation
The home infusion industry is subject to extensive regulation by a number of federal, state and local governmental entities. The industry is also subject to frequent regulatory changes. Laws and regulations in the healthcare industry are complex and, at times, the industry does not benefit from significant regulatory or judicial interpretation that would clarify how these laws and regulations should be applied. Moreover, the Company’s business is also impacted by certain laws and regulations that are applicable to its managed care and other clients. If the Company fails to comply with the laws and regulations directly applicable to its business, the Company could suffer civil and/or criminal penalties, and the Company could be excluded from participating in Medicare, Medicaid and other federal and state healthcare programs, which would have an adverse impact on its business.
Professional Licensure
Nurses, pharmacists and certain other healthcare professionals employed by the Company are required to be individually licensed or certified under applicable state law. The Company performs criminal and other background checks on employees and takes steps to ensure that its employees possess all necessary licenses and certifications, and the Company believes that its employees comply in all material respects with applicable licensure laws.
Pharmacy Licensing and Registration
State laws require that each pharmacy location be licensed as an in-state pharmacy to dispense pharmaceuticals in that state. Certain states also require that pharmacy locations be licensed as out-of-state pharmacies if the Company delivers prescription pharmaceuticals into those states from locations outside of the state. The Company believes that it materially complies with all applicable state licensing laws. If the Company is unable to maintain its licenses or if states place burdensome regulations on non-resident pharmacies, its ability to operate in some states would be limited, which could have an adverse impact on its business. Laws enforced by the Drug Enforcement Administration (“DEA”), as well as some similar state agencies, require its pharmacy locations to individually register in order to handle controlled substances, including prescription pharmaceuticals. A separate registration is required at each principal place of business where the Company dispenses controlled substances. Federal and state laws also require that the Company follow specific labeling, reporting and record-keeping requirements for controlled substances. The Company maintains federal and state controlled substance registrations for each of its facilities that require such registration and materially follows procedures intended to comply with all applicable federal and state requirements regarding controlled substances.
Many states in which the Company operates also require home infusion companies to be licensed as home health agencies. The Company believes it is in material compliance with these laws, as applicable.
Privacy and Security Requirements
The Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) as amended by the Health Information Technology for Economic and Clinical Health Act (“HITECH”), and its implementing regulations, regulate the use, disclosure, confidentiality, availability and integrity of individually identifiable health information, known as “protected health information,” and provide for a number of individual rights with respect to such information. The federal privacy regulations are designed to protect health-related information that could be used to identify an individual’s protected health information.
The requirements imposed by HIPAA are extensive, and the Company has taken and intends to continue to take steps to ensure its policies and procedures are in material compliance with the applicable provisions.
9
Regulations
Food, Drug and Cosmetic Act. Certain provisions of the Food, Drug and Cosmetic Act (“FDCA”) govern the handling and distribution of pharmaceutical products. This law exempts certain pharmaceuticals and medical devices from federal labeling and packaging requirements as long as they are not adulterated or misbranded and are dispensed in accordance with and pursuant to a valid prescription. The Company believes it materially complies with all applicable requirements. The FDCA also governs interstate commerce for pharmaceutical products. The Company cannot predict the impact of any future FDCA regulations on its ability to ship drugs to different states from its pharmacies.
The Drug Quality and Security Act (“DQSA”) amended the FDCA to grant the Food and Drug Administration (“FDA”) authority to regulate the manufacturing of compounded pharmaceutical drugs. The Company materially complies with the PCAB Accreditation Standards for Sterile and Non-Sterile Pharmacy Compounding and pursues accreditation from quality associations. The Company believes it complies in all material respects with all applicable requirements of a non-outsourcing-facility pharmacy.
The FDA also regulates certain medical devices, such as infusion pumps, the Company uses to provide its services. In recent years, the FDA has increased its oversight of infusion pumps, resulting in additional requirements around patient education and adverse event reporting. The Company believes it complies in all material respects with all applicable requirements and that its employees have the level of proficiency required to use these devices and provide training to its patients.
Anti-Kickback Statute. The federal Anti-Kickback Statute prohibits individuals and entities from knowingly and willfully paying, offering, receiving, or soliciting money or anything else of value in order to induce the referral of patients or to induce a person to purchase, lease, order, arrange for, or recommend services or goods covered by Medicare, Medicaid, or other government healthcare programs. The Anti-Kickback Statute is broad and potentially covers many standard business arrangements. A number of states also have statutes and regulations that prohibit the same general types of conduct as those prohibited by the Anti-Kickback Statute described above. Violations can lead to significant criminal or civil penalties, including imprisonment. The Office of the Inspector General (“OIG”) could also seek Civil Monetary Penalties (“CMP”) or exclusion against individuals or entities who knowingly and willfully: (1) offer or pay remuneration, directly or indirectly, to induce referrals of government healthcare program business; or (2) solicit or receive remuneration, directly or indirectly, in return for referrals of government healthcare program business. The OIG of the U.S. Department of Health and Human Services (“HHS”) has published clarifying regulations that identify a limited number of safe harbors from criminal enforcement or civil administrative actions. The Company attempts to structure its business relationships to materially comply with these statutes and to satisfy an applicable safe harbor, where applicable. However, in situations where a business relationship does not fully satisfy the elements of a safe harbor, or where no safe harbor exists, the Company attempts to satisfy as many elements of an applicable or equivalent safe harbor as possible.
False Claims Act. The Company is subject to state and federal laws that govern the submission of claims for reimbursement. These laws generally prohibit an individual or entity from knowingly and willfully presenting a claim or causing a claim to be presented for payment from a federal healthcare program that is false or fraudulent. The standard for “knowing and willful” may include conduct that amounts to a reckless disregard for the accuracy of information presented to payers. Penalties under these statutes include substantial civil and criminal fines, exclusion from the Medicare or Medicaid programs and imprisonment. One of the most prominent of these laws is the federal False Claims Act, which may be enforced by the federal government directly or by a private plaintiff by filing a whistleblower lawsuit on the government’s behalf. Under the False Claims Act, the government and private plaintiffs, if any, may recover monetary penalties in the amount of $13,946 to $27,894 per false claim, as well as an amount equal to three times the amount of damages sustained by the government as a result of the false claim. A number of states, including states in which the Company operates, have adopted their own false claims statutes as well as statutes that allow individuals to bring whistleblower actions. The Company believes that it has procedures in place to ensure the material accuracy of its claims.
10
Ethics in Patient Referrals Law (“Stark Law”)
The Stark Law exempts certain business relationships that meet its exception requirements. However, unlike the Anti-Kickback Statute under which an activity may fall outside a safe harbor and still be lawful, a referral for certain Designated Health Services (“DHS”) that does not fall within an exception is strictly prohibited by the Stark Law. In addition to the Stark Law, many of the states in which the Company operates have comparable restrictions on the ability of physicians to refer patients for certain services to entities with which the Company has a financial relationship. Certain of these state statutes mirror the Stark Law while others may be more restrictive. The Company attempts to structure all of its business relationships with physicians to comply with the Stark Law and any applicable state self-referral laws.
The federal Stark Law generally prohibits a physician from making referrals for certain DHS, reimbursable by Medicare or Medicaid, to entities with which the physician or an immediate family member has a financial relationship, unless an exception applies. A financial relationship is generally defined as an ownership, investment or compensation relationship. DHS includes outpatient pharmaceuticals, parenteral and enteral nutrition products, home health services, durable medical equipment, physical and occupational therapy services, and inpatient and outpatient hospital services. Among other sanctions, a CMP may be imposed for each bill or claim for a service a person knows or should know is for a service for which payment may not be made due to the Stark Law. Such persons or entities are also subject to exclusion from the Medicare and Medicaid programs. Any person or entity participating in a circumvention scheme to avoid the referral prohibitions is liable for CMPs, and additional fines may be imposed for failure to comply with reporting requirements regarding an entity’s ownership, investment and compensation arrangements for each day for which reporting is required to have been made under the Stark Law.
Human Capital Resources
The Company’s mission is to transform healthcare by providing innovative services that improve outcomes, reduce costs and deliver hope for patients and their families. The values we embody support each of our team members as they deliver life-changing, extraordinary care.
As of December 31, 2024, the Company employed 6,015 persons on a full-time basis and 2,073 persons on a part-time basis. The majority of its part-time employees are clinicians due to the nature and timing of the services the Company provides.
Attracting and retaining a highly skilled and diverse team to deliver extraordinary care is a top priority. The Company’s strategy includes four distinct areas to empower our people so that they remain focused on providing extraordinary care that changes lives:
•Talent Development. The Company strives to empower our team members by giving them the tools and resources to strengthen and expand their knowledge and skills and advance their careers through training, leadership development programs, continuing functional education and other professional development opportunities. The Company also focuses on performance management, 360 degree feedback, and succession planning through calibration assessments on each team leader’s potential, performance and readiness for advancement.
•Employee Engagement. The Company believes that highly engaged team members deliver a better patient experience. The foundation of our engagement strategy is a culture that connects our team members to our mission and values while promoting a sense of community, while also aligning behind business priorities. Our approach to employee engagement is to cultivate our culture and build relationships across geographically distributed team members. The Company promotes employee engagement with engagement surveys, an internal social media platform, quarterly and annual peer recognition programs, and company newsletters.
•Health and Well-being. The Company provides a holistic range of resources and programs to our team members to address each person’s unique needs, including physical, mental and financial health and well-being with programs to support healthy lifestyles, specialized programs to help manage chronic conditions, behavioral health education, coaching, and counseling, and financial wellness resources.
•Inclusion and Belonging. The Company believes that a workforce with a variety of backgrounds, experiences, and viewpoints makes us stronger, more innovative and better able to serve our patients. The Company strives to foster an inclusive workplace where team members feel valued, respected, and empowered to contribute their unique perspectives. We assess the effectiveness of our inclusion efforts through qualitative and quantitative insights, ensuring that our workplace supports the development and success of all team members.




11

The Company relies on its ability to attract and retain nursing staff, pharmacists and other professionals who possess the skills, experience and licenses necessary to meet the requirements of their job responsibilities. The Company’s ability to attract and retain personnel depends on several factors, including the ability to provide them with engaging assignments and competitive salaries and benefits. The Company is committed to fostering a workplace where team members feel valued and supported through initiatives focused on professional development, employee engagement, and overall well-being.

Available Information
The Company’s corporate headquarters is located at 3000 Lakeside Drive, Suite 300N, Bannockburn, IL 60015. The Company maintains a website at www.optioncarehealth.com. The information contained on its website is not incorporated by reference into this Annual Report and should not be considered part of this Annual Report. The Company’s Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and Proxy Statements are available through its website at https://investors.optioncarehealth.com, free of charge, as soon as reasonably practicable after they are filed with or furnished to the SEC.
The SEC maintains a website that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC at www.sec.gov.
12
Item 1A.    Risk Factors
Investors should carefully consider the following Company-specific and general risk factors.
Company-Specific Risk Factors
Our revenue and profitability will decline if the pharmaceutical industry undergoes certain changes, including limiting or discontinuing research, development, production and marketing of the pharmaceuticals that are compatible with the services we provide.
Our business is highly dependent on the ability of pharmaceutical manufacturers to develop, supply and market pharmaceuticals that are compatible with the services we provide. Our revenue and profitability will decline if those companies were to sell pharmaceuticals directly to the public, fail to support existing pharmaceuticals or develop new pharmaceuticals with different administration requirements than our service offerings are currently equipped to handle. Our business could also be harmed if the pharmaceutical industry experiences any supply shortages, pharmaceutical recalls, changes in the FDA approval processes, or changes to how pharmaceutical manufacturers finance, promote or sell pharmaceutical products. The Company has experienced drug and supply shortages and has leveraged its relationships with direct manufacturers and distributors to ensure consistent supply and cost-effective procurement. A reduction in the supply of and market for pharmaceuticals that are compatible with the services we provide may have a material adverse effect on our financial condition and results of operations.
If we lose relationships with managed care organizations (“MCOs”) and other non-governmental third-party payers, we could lose access to a significant number of patients and our revenue and profitability could decline.
We are highly dependent on reimbursement from MCOs, government programs such as Medicare and Medicaid and commercial insurers (collectively, “Third-Party Payers”). For the year ended December 31, 2024, 88% of our revenue came from MCOs and other non-governmental payers, including Medicare Advantage plans, Managed Medicaid plans, pharmacy benefit managers (“PBMs”), and self-pay patients. Many payers seek to limit the number of providers that supply pharmaceuticals to their enrollees in order to build volume that justifies their discounted pricing. From time to time, payers with whom we have relationships require that we bid against our competitors to keep their business. As a result of this bidding process, we may not be retained, and even if we are retained, the prices at which we are able to retain the business may be reduced. The loss of a payer relationship could significantly reduce the number of patients we serve and have a material adverse effect on our revenue and net income, and a reduction in pricing could reduce our gross margins and net income.
The healthcare industry is highly competitive.
The healthcare industry is highly competitive. We compete directly with national, regional and local healthcare providers. There are many other companies and individuals currently providing healthcare services that we provide, many of which have been in business longer and/or have substantially more resources. Other companies could enter the healthcare industry in the future and divert some or all of our business. We expect to continue to encounter competition in the future that could limit our ability to grow revenue and/or maintain acceptable pricing levels.
Some of our competitors have vertically integrated business models with commercial payers or are under common control with, or owned by, pharmaceutical wholesalers and distributors, MCOs, PBMs or retail pharmacy chains and may be better positioned with respect to the cost-effective distribution of pharmaceuticals. In addition, some of our competitors may have secured long-term supply or distribution arrangements for prescription pharmaceuticals necessary to treat certain chronic disease states on price terms substantially more favorable than the terms currently available to us. Consequently, we may be less price competitive than some of our competitors with respect to certain pharmaceutical products.
Accountable Care Organizations (“ACOs”) and other clinical integration models may result in lower reimbursement rates. Some of our competitors may negotiate exclusivity provisions with managed care plans or otherwise interfere with the ability of MCOs to contract with us. Increasing consolidation in the payer and supplier industries, including vertical integration efforts among insurers, providers, and suppliers, and cost-reduction strategies by large employer groups and their affiliates may limit our ability to negotiate favorable terms and conditions in our contracts and otherwise intensify competitive pressure. In addition, our competitive position could be adversely affected by any inability to obtain access to new biotech pharmaceutical products.
13
If we are unable to maintain relationships with existing patient referral sources, our business and consolidated financial condition, results of operations, and cash flows could be materially adversely affected.
Our success depends on referrals from physicians, hospitals, and other sources in the communities we serve and on our ability to maintain good relationships with existing referral sources. Our referral sources are not contractually obligated to refer patients to us and may refer their patients to other providers. Our growth and profitability depend, in part, on our ability to establish and maintain close working relationships with these patient referral sources and to increase awareness and acceptance of the benefits of home infusion by our referral sources and their patients. Our loss of, or failure to maintain, existing relationships or our failure to develop new referral relationships could have a material adverse effect on our business and consolidated financial condition, results of operations, and cash flows.
Changes in industry pricing benchmarks could adversely affect our financial performance.
Our contracts generally use certain published benchmarks to establish pricing for the reimbursement of prescription medications we dispense. These benchmarks include AWP, wholesale acquisition cost, ASP and average manufacturer price. Many of our contracts utilize the AWP benchmark. Publication of the AWP benchmark was expected to cease in 2011 as a result of the settlement of class-action lawsuits brought against First Databank and Medi-Span, third-party publishers of various pricing benchmarks. However, Medi-Span continues to publish the AWP benchmark and has indicated that it will continue to do so until a new benchmark is widely accepted. Several industry participants have explored establishing a new benchmark but there is not currently a viable generally accepted alternative to the AWP benchmark. Without a suitable pricing benchmark in place, many of our contracts may need to be modified, which could potentially change the economic structure of our agreements.
Changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing, could adversely affect our business and financial results.
We have contractual relationships with pharmaceutical manufacturers to purchase the pharmaceuticals that we dispense. In order to have access to these pharmaceuticals, and to be able to participate in the launch of new pharmaceuticals, we must maintain a good working relationship with these manufacturers. Most of the manufacturers of the pharmaceuticals we sell have the right to cancel their supply contracts with us without cause and after giving only minimal notice. Any changes to these relationships, including, but not limited to, the loss of a manufacturer relationship, drug shortages or changes in pricing, could have an adverse effect on our business and financial results. For example, in October 2024, we received notice of a manufacturer’s intention to significantly reduce the spread at which we procure a certain therapy relative to drug reference prices beginning in early 2025, which is expected to negatively impact gross profit by approximately $60 million to $70 million dollars in 2025.
Some pharmaceutical manufacturers attempt to limit the number of preferred distributors that may market certain of their pharmaceutical products. We cannot provide assurance that we will be selected and retained as a preferred distributor or that we can remain a preferred distributor to market these products. Although we believe we can effectively meet our suppliers’ requirements, we cannot provide assurance that we will be able to compete effectively with other providers to retain our position as a distributor of each of our core products. Our failure to retain our position as a distributor of each of our core products could have a material adverse effect on our financial condition and results of operations.
A disruption in pharmaceutical and medical supply could adversely impact our business.
For the year ended December 31, 2024, approximately 58% of our pharmaceutical and medical supply purchases were from three vendors. Most of the pharmaceuticals that we purchase are available from multiple sources, and we believe they are available in sufficient quantities to meet our needs and the needs of our patients. We keep safety stock to ensure continuity of service for reasonable, but limited, periods of time. Should a supply disruption result in our inability to obtain especially high margin drugs and compound components necessary for patient care, our consolidated financial statements could be negatively impacted.
In addition, there is currently significant uncertainty with respect to trade policies, treaties, tariffs and customs duties and taxes. If tariffs, trade restrictions or trade barriers are expanded, increased or interpreted by a court or governmental agency to apply to more of our products, then our exposure to future taxes and duties on such imported products and components could be significant and could have a material effect on our financial results.



14
A shortage of qualified registered nursing staff, pharmacists and other professionals could adversely affect our ability to attract, train and retain qualified personnel and could increase operating costs.
Our business relies on our ability to attract, train and retain nursing staff, pharmacists and other professionals who possess the skills, experience and licenses necessary to meet the requirements of their job responsibilities. From time to time, and particularly in recent years, there have been shortages of nursing staff, pharmacists and other professionals in certain local and regional markets. As a result, we are often required to compete for personnel with other healthcare systems and our competitors. Our ability to attract, train and retain personnel depends on several factors, including our ability to provide them with engaging assignments and competitive salaries and benefits. We may not be successful in any of these areas.
In addition, where labor shortages arise in markets in which we operate, we have faced higher costs to attract personnel and we have had to provide them with more attractive benefit packages than originally anticipated or are being paid in other markets where such shortages do not exist at the time. In either case, such circumstances cause operating costs to increase and our profitability to decline. Finally, if we expand our operations into geographic areas where healthcare providers historically have unionized or unionization occurs in our existing geographic areas, negotiating collective bargaining agreements may have a negative effect on our ability to timely and successfully recruit qualified personnel and on our financial results. If we are unable to attract, train and retain nursing staff, pharmacists and other professionals, the quality of our services may decline and we could lose patients and referral sources, which could have a material adverse effect on our business and consolidated financial condition, results of operations and cash flows.
Introduction of new drugs, accelerated adoption of existing lower margin drugs or withdrawal of existing drugs could adversely affect our revenues and profitability when prescribers prescribe these drugs for their patients or they are mandated by Third-Party Payers.
The pharmaceutical industry pipeline of new drugs includes many drugs that over the long term may replace older, more expensive therapies. As a result of such older drugs losing patent protection and being replaced by generic substitutes, new and less expensive delivery methods (such as when an infusion or injectable drug is replaced with an oral drug) or additional products that are added to a therapeutic class, increase price competition among competing manufacturers’ products in that therapeutic category. In such cases, manufacturers have the ability to increase drug acquisition costs or lower the selling price of replaced products. These actions could negatively impact our revenues and/or profitability.
Failure to develop new services or adapt to changes and trends within the healthcare industry may adversely affect our business.
We operate in a highly competitive environment. We develop new services from time to time to assist our clients. If we are unsuccessful in developing innovative services, our ability to attract new clients and retain existing clients may suffer.
Technology, including the ability to capture and report outcomes, is also an important component of our business as we continue to utilize new and better channels to communicate and interact with our clients, members and business partners. If our competitors are more successful than us in employing new technology, our ability to attract new clients, retain existing clients and operate efficiently may suffer. Any significant shifts in the structure of the healthcare products and services industry in general could alter the industry dynamics and adversely affect our ability to attract or retain clients. Our failure to anticipate or appropriately adapt to changes in the industry could negatively impact our competitive position and adversely affect our business and results of operations.
15
Changes in future business conditions could cause business investments and/or recorded goodwill to become impaired, and our financial condition and results of operations could suffer if there is an impairment of goodwill.
Our acquisitions resulted in significant goodwill reported on our financial statements. Goodwill results when the purchase price exceeds the fair value of the identifiable tangible and intangible assets and liabilities acquired. We may not realize the full value of this goodwill. As such, we evaluate on at least an annual basis whether events and circumstances indicate that all or some of the carrying value of goodwill is no longer recoverable, in which case we would recognize the unrecoverable goodwill as a charge against our earnings. The Company completes its goodwill impairment test annually in the fourth quarter on a qualitative basis. If the fair value is more likely than not less than the carrying value, a quantitative assessment will be performed. When evaluating goodwill for potential impairment on a quantitative basis, we compare the fair value of our reporting units to their respective carrying amounts. We estimate the fair value of our reporting units using the income approach. If the carrying amount of a reporting unit exceeds its estimated fair value, a goodwill impairment loss is recognized in an amount equal to the excess to the extent of the goodwill balance. The income approach requires us to estimate a number of factors for our reporting units, including projected future operating results, economic projections, anticipated future cash flows, and discount rates. The fair value determined using the income approach is then compared to marketplace fair value data from within a comparable industry grouping for reasonableness. Because of the significance of our goodwill, any future impairment could result in material non-cash charges to our results of operations, which could have an adverse effect on our financial condition and results of operations.
A significant change in, or noncompliance with, governmental regulations and other legal requirements could have a material adverse effect on our reputation and profitability.
We operate in complex, highly regulated environments and could be materially and adversely affected by changes to applicable legal requirements including related interpretations and enforcement practices, new legal requirements and/or any failure to comply with applicable regulations. Our home infusion and alternate site infusion businesses are subject to numerous federal, state and local regulations including licensing and other requirements for pharmacies and reimbursement arrangements.
The federal and state statutes and regulations to which we are subject include, but are not limited to, laws requiring the registration and regulation of pharmacies; laws governing the dispensing of pharmaceuticals and controlled substances; laws regulating the protection of the environment and health and safety matters, including those governing exposure to, and the management and disposal of, hazardous substances; laws regarding food and drug safety, including those of the FDA and the DEA; applicable governmental payer regulations, including those applicable to Medicare and Medicaid; data privacy and security laws, including HIPAA and its associated regulations; federal and state fraud and abuse laws, including, but not limited to, the Anti-Kickback Statute and false claims laws; trade regulations, including those of the U.S. Federal Trade Commission (“FTC”), the U.S. Foreign Corrupt Practices Act (the “FCPA”) and similar anti-corruption laws in connection with the services provided by certain of our contractors; and consumer protection and safety laws, including those of the Consumer Product Safety Commission.
We are required to hold valid DEA and state-level licenses, meet various security and operating standards and comply with federal and various state controlled substance acts and related regulations governing the sale, dispensing, disposal, holding and distribution of controlled substances. The DEA, the FDA and state regulatory authorities have broad enforcement powers, including the ability to seize or recall products and impose significant criminal, civil and administrative sanctions for violations of these laws and regulations.
We use, disclose and otherwise process personally identifiable information, including health information, making us subject to HIPAA and other federal and state privacy and security regulations, and failure to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm and, in turn, could have a material adverse effect on our patient base and revenue.
We are also governed by federal and state laws of general applicability, including laws regulating matters of working conditions, health and safety and equal employment opportunity and other labor and employment matters as well as employee benefits, competition, antitrust, taxation and escheatment matters. Material violations of any such laws could have a material adverse effect on our patient base and revenue. In addition, we could have significant exposure if we are found to have infringed another party’s intellectual property rights.
16
Changes in laws, regulations and policies and the related interpretations and enforcement practices may alter the landscape in which we do business and may significantly affect our cost of doing business, the impact of which generally cannot be predicted. Such changes may require extensive system and operational changes, be difficult to implement, increase our operating costs and require significant capital expenditures. Ultimately, our noncompliance with applicable laws and regulations could result in the imposition of civil and criminal penalties that could adversely affect the continued operation of our business, including: suspension of payments from government programs; loss of required government certifications; loss of authorizations to participate in or exclusion from government programs, including the Medicare and Medicaid programs; loss of licenses; and significant fines or monetary penalties. Any failure to comply with applicable regulatory requirements could result in significant legal and financial exposure, damage our reputation, and have a material adverse effect on our business operations, financial condition and results of operations.
Federal actions and legislation may reduce reimbursement rates from governmental payers and adversely affect our results of operations.
In recent years, Congress has passed legislation reducing payments to healthcare providers. The Budget Control Act of 2011, as amended, requires automatic spending reductions to reduce the federal deficit, including Medicare spending reductions of up to 2% per fiscal year that extend through 2027. The Center for Medicare & Medicaid Services (“CMS”) began imposing a 2% reduction on Medicare claims on April 1, 2013. The Affordable Care Act provides for material reductions in the growth of Medicare program spending. The 21st Century Cures Act (the “Cures Act”) significantly reduced the amount paid by Medicare for drug costs, while delaying the implementation of a clinical services payment, although Congress also passed a temporary transitional service payment that took effect January 1, 2019. In addition, from time to time, CMS revises the reimbursement systems used to reimburse healthcare providers, which may result in reduced Medicare payments. Most recently, the Inflation Reduction Act of 2022 (the “IRA”) granted CMS the authority to negotiate drug prices under Medicare Part D, with price controls taking effect in 2026. In August 2024, CMS announced the results of its first round of drug price negotiations, which included a 66% reduction from 2023 list price for one therapy in our portfolio. The manufacturer of this therapy subsequently informed us in October 2024 of its intent to significantly reduce our procurement spread relative to drug reference prices beginning in early 2025. The direct and indirect impact IRA-mandated price negotiations and future CMS determinations is expected to negatively impact our results of operations.
For the year ended December 31, 2024, 12% of our revenue was derived from reimbursement by direct federal and state programs such as Medicare and Medicaid. Reimbursement from these and other government programs is subject to statutory and regulatory requirements, administrative rulings, interpretations of policy, implementation of reimbursement procedures, retroactive payment adjustments, governmental funding restrictions and changes to or new legislation, all of which may materially affect the amount and timing of reimbursement payments to us. Changes to the way Medicare pays for our services, including mandatory payment reductions, such as sequestration, may reduce our revenue and profitability on services provided to Medicare patients and increase our working capital requirements. In addition, we are sensitive to possible changes in state Medicaid programs.
Because most states must operate with balanced budgets and because the Medicaid program is often a state’s largest program, some states have enacted or may consider enacting legislation designed to reduce their Medicaid expenditures. Further, many states have taken steps to reduce coverage and/or enroll Medicaid recipients in managed care programs. The current economic environment has increased the budgetary pressures on many states, and these budgetary pressures have resulted, and will likely continue to result, in decreased spending, or decreased spending growth, for Medicaid programs and the Children’s Health Insurance Program in many states.
In some cases, Third-Party Payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from Third-Party Payers. Current or future healthcare reform and deficit reduction efforts, changes in other laws or regulations affecting government healthcare programs, changes in the administration of government healthcare programs and changes in payment rates by Third-Party Payers could have a material, adverse effect on our financial position and results of operations.
17
Delays in reimbursement may adversely affect our liquidity, cash flows and results of operations.
The reimbursement process for the services we provide is complex, resulting in delays between the time we bill for a service and receipt of payment that can be significant. Reimbursement and procedural issues often require us to resubmit claims multiple times and respond to multiple administrative requests before payment is remitted. The collection of accounts receivable is challenging and requires constant focus and involvement by management and ongoing enhancements to information systems and billing center operating procedures. While management believes that our controls and processes are satisfactory, there can be no assurance that collections of accounts receivable will continue at historical rates. The risks associated with third-party payers and the inability to collect outstanding accounts receivable could have a material adverse effect on our liquidity, cash flows and results of operations. For example, in the first quarter of 2024, Change Healthcare, a subsidiary of UnitedHealth Group, experienced a cybersecurity incident that disrupted its operations, causing us to disconnect from certain Change Healthcare applications until the end of the quarter, preventing us from processing claims for services and reducing our cash flows from operations in the first quarter of 2024. The majority of previously unprocessed claims were recognized in the second quarter of 2024. While we have substantially addressed the backlog and resumed normal billing operations as of the fourth quarter of 2024, we continue to evaluate the impact of the incident on our broader revenue cycle management processes.

We are subject to pricing pressures and other risks involved with Third-Party Payers.
Competition to provide healthcare services, efforts by traditional Third-Party Payers to contain or reduce healthcare costs, and the increasing influence of managed care payers such as HMOs, has resulted in reduced rates of reimbursement for home infusion and specialty pharmacy services. Changes in reimbursement policies of governmental Third-Party Payers, including policies relating to Medicare, Medicaid and other federal and state funded programs, could reduce the amounts reimbursed to our customers for our products and, in turn, the amount these customers would be willing to pay for our products and services, or could directly reduce the amounts payable to us by such payers. Pricing pressures by Third-Party Payers may continue, and these trends may adversely affect our business.
Also, continued growth in managed care plans has pressured healthcare providers to find ways of becoming more cost competitive. MCOs have grown substantially in terms of the percentage of the population they cover and in terms of the portion of the healthcare economy they control. MCOs have continued to consolidate to enhance their ability to influence the delivery of healthcare services and to exert pressure to control healthcare costs. A rapid concentration of revenue derived from individual managed care payers could harm our business.
We face periodic reviews and billing audits by governmental and private payers, which could result in adverse findings that may negatively impact our business.
As a result of our participation in the Medicare and Medicaid programs, we are subject to various governmental reviews and audits to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various government programs in which third-party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. Third-Party Payers may also conduct audits. Disputes with payers can arise from these reviews. Payers can claim that payments based on certain billing practices or billing errors were made incorrectly. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all claims filed, which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend claims, reviews and audits may be significant and could have a material adverse effect on our business and financial condition, results of operations and cash flows. Moreover, an adverse claim, review or audit could result in:
•required refunding or retroactive adjustment of amounts we have been paid by governmental payers or Third-Party Payers;
•state or federal agencies imposing fines, penalties and other sanctions on us;
•suspension or exclusion from the Medicare program, state programs, or one or more third-party payer networks; or
•damage to our business and reputation in various markets.
These results could have a material adverse effect on our business and financial condition, results of operations and cash flows.
18
If any of our pharmacies fail to comply with the conditions of participation in the Medicare program, that pharmacy could be terminated from Medicare, which could adversely affect our consolidated financial statements.
Our pharmacies must comply with the extensive conditions of participation in the Medicare program. If a pharmacy fails to meet any of the Medicare supplier standards, that pharmacy could be terminated from the Medicare program. We respond in the ordinary course to deficiency notices issued by surveyors, and none of our pharmacies has ever been terminated from the Medicare program for failure to comply with the Medicare supplier standards. Any termination of one or more of our pharmacies from the Medicare program for failure to satisfy the Medicare supplier standards could adversely affect our consolidated financial statements.
We cannot predict the impact of changing requirements on compounding pharmacies.
The operation of compounding pharmacies are regulated by federal and state governmental agencies. We believe that our compounding is performed in safe environments, and we have clinically appropriate policies and procedures in place. We do not believe that our current compounding practices qualify us as an outsourcing facility because we only compound pursuant to a patient-specific prescription and do so in compliance with the applicable United States Pharmacopeia, Chapter 797 (“USP 797”) standards and applicable state pharmacy laws. Should state regulators or the FDA disagree, or should our business practices change to qualify us as an outsourcing facility, there is risk of regulatory action and/or increased resources required to comply with federal requirements imposed pursuant to the Drug Quality & Safety Act (“DQSA”) on outsourcing facilities that could significantly increase our costs or otherwise affect our results of operations. Furthermore, we cannot predict the overall impact of increased scrutiny on compounding pharmacies.
The (“DQSA”) amended the Federal Drug & Cosmetic Act (“FDCA”) to grant the FDA additional authority to regulate and monitor the manufacturing of compounded pharmaceutical drugs. In 2013, Congress passed the DQSA, which creates a new category of compounding facilities called outsourcing facilities that are regulated by the FDA. The Company complies with all federal and state regulations, as well as all PCAB Accreditation Standards for Sterile and Non-Sterile Pharmacy Compounding, and pursues accreditation from quality associations. The Company believes it complies in all material respects with all applicable requirements of a non-outsourcing-facility pharmacy, as outlined in Section 503A of the FDCA. Title II of this measure, known as the Drug Supply Chain Security Act (“DSCSA”), established requirements in November 2013 to facilitate the tracing of prescription drug products through the pharmaceutical supply distribution chain. These requirements included a 10-year timeline culminating in the building of "an electronic, interoperable system to identify and trace certain prescription drugs as they are distributed in the United States.” The law’s track and trace requirements are applicable to manufacturers, wholesalers, re-packagers and dispensers (e.g., pharmacies) of prescription drugs. The Company is currently materially compliant with the DSCSA provisions currently in effect. As an eligible trading partner, the Company believes it is materially compliant with the additional provisions of DSCSA, which requires the electronic receipt and exchange of transaction information (with specific product identifiers for each package) and transaction statements. Please note that the FDA has issued an exemption from the enhanced drug distribution security requirements of section 582 of the FDCA for eligible trading partners until November 27, 2025. These regulatory measures, future DSCSA regulatory measures and the potential for increased DSCSA enforcement by the FDA could increase pharmacy costs. Noncompliance with these regulations could have an adverse impact on our reputation and profitability.
19
Risks Relating to Our Indebtedness
Our existing indebtedness could adversely affect our business and growth prospects.
As of December 31, 2024, we had $1,131.6 million of outstanding borrowings, including (i) $631.6 million under our First Lien Term Loan (as defined herein) and (ii) $500.0 million under our 4.375% Senior Unsecured Notes due 2029 (the “Senior Notes”). All obligations under the First Lien Term Loan are secured by first-priority perfected security interests in substantially all of our assets and the assets of our subsidiaries, subject to permitted liens and other exceptions. Our indebtedness, or any additional indebtedness we may incur, could require us to divert funds identified for other purposes for debt service and impair our liquidity position. If we cannot generate sufficient cash flow from operations to service our debt, we may need to refinance our debt, dispose of assets or issue equity to obtain necessary funds. We do not know whether we will be able to take any of these actions on a timely basis, on terms satisfactory to us or at all.
Our indebtedness, the cash flow needed to satisfy our debt and the covenants contained in our credit agreements and indenture have important consequences, including but not limited to:
•limiting funds otherwise available for financing our capital expenditures by requiring us to dedicate a portion of our cash flows from operations to the repayment of debt and the interest on this debt;
•limiting our ability to incur additional indebtedness;
•limiting our ability to capitalize on significant business opportunities;
•making us more vulnerable to rising interest rates; and
•making us more vulnerable in the event of a downturn in our business.
Our level of indebtedness may place us at a competitive disadvantage to our competitors that are not as highly leveraged. Fluctuations in interest rates can increase borrowing costs. Increases in interest rates may directly impact the amount of interest we are required to pay and reduce earnings accordingly. In addition, developments in tax policy, such as the disallowance of tax deductions for interest paid on outstanding indebtedness, could have an adverse effect on our liquidity and our business, financial condition and results of operations. Further, our credit agreements and indenture contain customary affirmative and negative covenants and certain restrictions on operations that could impose operating and financial limitations and restrictions on us, including restrictions on our ability to enter into particular transactions and to engage in other actions that we may believe are advisable or necessary for our business. Our First Lien Term Loan is also subject to mandatory prepayments in certain circumstances and requires a prepayment of a certain percentage of our excess cash flow. This excess cash flow payment, and future required prepayments, will reduce our cash available for investment in our business.
We expect to use cash flow from operations to meet current and future financial obligations, including funding our operations, debt service requirements and capital expenditures. The ability to make these payments depends on our financial and operating performance, which is subject to prevailing economic, industry and competitive conditions and to certain financial, business, economic and other factors beyond our control.
Despite our indebtedness, we may still incur significantly more debt, which could exacerbate the risks associated with our substantial leverage.
We may incur additional indebtedness, including additional secured indebtedness, in the future, in connection with future acquisitions, strategic investments and strategic relationships. Although the financing documents governing our indebtedness contain covenants and restrictions on the incurrence of additional debt, these restrictions are subject to a number of qualifications and exceptions and, under certain circumstances, debt incurred in compliance with these restrictions, including secured debt, could be substantial. Adding additional debt to current debt levels could exacerbate the leverage-related risks described above.
20
We may not be able to generate sufficient cash flow to service all of our indebtedness and may be forced to take other actions to satisfy our obligations under such indebtedness, which may not be successful.
Our ability to make scheduled payments or to refinance outstanding debt obligations depends on our financial and operating performance, which will be affected by prevailing economic, industry and competitive conditions and by financial, business and other factors beyond our control. We may not be able to maintain a sufficient level of cash flow from operating activities to permit us to pay the principal, premium, if any, and interest on our indebtedness. Any failure to make payments of interest and principal on our outstanding indebtedness on a timely basis would likely result in a reduction of our credit rating, which would also harm our ability to incur additional indebtedness.
If our cash flow and capital resources are insufficient to fund our debt service obligations, we may be required to reduce or delay capital expenditures, sell assets, seek additional capital or seek to restructure or refinance our indebtedness. Any refinancing of our indebtedness could be at higher interest rates and may require us to comply with more onerous covenants. These alternative measures may not be successful and may not permit us to meet our scheduled debt service obligations. In the absence of such cash flow and resources, we could face substantial liquidity problems and might be required to sell material assets or operations to attempt to meet our debt service obligations. The financing documents governing our First Lien Term Loan, Revolver Facility (as defined herein) and our Senior Notes restrict our ability to conduct asset sales and/or use the proceeds from asset sales. We may not be able to consummate these asset sales to raise capital or sell assets at prices and on terms that we believe are fair and any proceeds that we do receive may not be adequate to meet any debt service obligations then due. If we cannot meet our debt service obligations, the holders of our indebtedness may accelerate such indebtedness and, to the extent such indebtedness is secured, foreclose on our assets. In such an event, we may not have sufficient assets to repay all of our indebtedness.
21
Risks Relating to Our Common Stock
Provisions of our corporate governance documents could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management, even if it is beneficial to our stockholders.
Our third amended and restated certificate of incorporation contains provisions that could make it more difficult for a third party to acquire us, even if doing so might be beneficial to our stockholders. Among other things, these provisions:
•allow us to authorize the issuance of undesignated preferred stock, the terms of which may be established and the shares of which may be issued without stockholder approval, and which may include supermajority voting, special approval, dividend, or other rights or preferences superior to the rights of stockholders;
•provide that directors may be removed with or without cause only by the affirmative vote of holders of at least 66 2∕3% of the voting power of all the then-outstanding shares of our stock entitled to vote thereon, voting together as a single class;
•prohibit stockholder action by written consent; and
•provide that any amendment, alteration, rescission or repeal of our bylaws or certificate of incorporation by our stockholders will require the affirmative vote of the holders of at least 66 2∕3% of the voting power of all the then-outstanding shares of our stock entitled to vote thereon, voting together as a single class.
These and other provisions in our certificate of incorporation, bylaws and Delaware law could make it more difficult for shareholders or potential acquirers to obtain control of our Board of Directors or initiate actions that are opposed by our then-current Board, including delaying or impeding a merger, tender offer or proxy contest involving the Company. The existence of these provisions could negatively affect the price of our common stock and limit opportunities to realize value in a corporate transaction.
Moreover, Section 203 of the Delaware General Corporation Law (“DGCL”) may discourage, delay, or prevent a change of control of the Company. Section 203 of the DGCL imposes certain restrictions on mergers, business combinations, and other transactions between us and holders of 15% or more of our common stock.
Our third amended and restated certificate of incorporation designates the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
Pursuant to our third amended and restated certificate of incorporation, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees and stockholders to us or our stockholders, (iii) any action asserting a claim against us arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware, our third amended and restated certificate of incorporation or our bylaws or (iv) any other action asserting a claim against us that is governed by the internal affairs doctrine; provided that, for the avoidance of doubt, the forum selection provision that identifies the Court of Chancery of the State of Delaware as the exclusive forum for certain litigation, including any “derivative action”, will not apply to suits to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Our third amended and restated certificate of incorporation will further provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to the provisions of our third amended and restated certificate of incorporation described above. The forum selection clause in our third amended and restated certificate of incorporation may have the effect of discouraging lawsuits against us or our directors and officers and may limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us.
We may issue shares of preferred stock in the future, which could make it difficult for another company to acquire us or could otherwise adversely affect holders of our common stock, which could depress the price of our common stock.
Our third amended and restated certificate of incorporation authorizes us to issue one or more series of preferred stock. Our Board of Directors has the authority to determine the preferences, limitations and relative rights of the shares of preferred stock and to fix the number of shares constituting any series and the designation of such series, without any further vote or action by our stockholders. Our preferred stock could be issued with voting, liquidation, dividend and other rights superior to the rights of our common stock. The potential issuance of preferred stock may delay or prevent a change in control, discouraging bids for our common stock at a premium to the market price, and materially and adversely affecting the market price and the voting and other rights of the holders of our common stock.
22
We cannot guarantee that our stock repurchase program will be fully implemented or that it will enhance long-term stockholder value.
We cannot guarantee that our stock repurchase program will be fully implemented or that it will enhance long-term stockholder value. In January 2025, the Board of Directors approved a new stock repurchase program authorizing the repurchase of up to $500 million of our common stock. The repurchase program does not have an expiration date, and we are not obligated to repurchase a specified number or dollar value of shares, on any particular timetable or at all. There can be no assurance that we will repurchase stock at favorable prices. The repurchase program may be suspended or terminated at any time and, even if fully implemented, may not enhance long-term stockholder value.
23
General Risk Factors
Pending and future litigation could subject us to significant monetary damages and/or require us to change our business practices.
We employ pharmacists, dietitians, nurses and other healthcare professionals. We are subject to liability for negligent acts, omissions, or injuries occurring at any of our clinics or caused by any of our employees. We are subject to risks relating to asserted claims, litigation, and other proceedings in connection with our operations. We are facing, or may face, claims or become a party to a variety of legal actions that affect our business, including breach of contract actions, employment and employment discrimination-related suits, employee benefit claims, stockholder suits and other securities laws claims, and tort claims. Due to the nature of our business, we, through our employees and caregivers who provide services on our behalf, may be the subject of medical malpractice claims. A court could find these individuals should be considered our agents, and as a result, we could be held liable for their acts or omissions.
We may incur substantial expenses in defending such claims or litigation, regardless of merit, and such claims or litigation could result in a significant diversion of the efforts of our management personnel. Successful claims against us may result in monetary liability or a material disruption in the conduct of our business. Similarly, if we settle such legal proceedings, it may affect how we operate our business. See Note 14, Commitments and Contingencies, of the consolidated financial statements included in Item 8 of this Annual Report for a description of material proceedings pending against the Company. We believe that these proceedings are without merit and, to the extent they are not already concluded, we intend to contest them vigorously. However, an adverse outcome in one or more of these proceedings may have a material adverse effect on our consolidated results of operations, consolidated financial position, and/or consolidated cash flow from operations, or may require us to make material changes to our business practices.
We may be subject to liability claims for damages and other expenses that are not covered by insurance.
As a result of operating in the home infusion industry, our business is subject to inherent risk of claims, losses and potential lawsuits alleging incidents involving our employees that are likely to occur in a patient’s home. We maintain professional liability insurance to provide coverage to us and our subsidiaries against these risks. A successful product or professional liability claim in excess of our insurance coverage could harm our consolidated financial statements. Various aspects of our business may subject us to litigation and liability for damages. For example, a prescription drug dispensing error could result in a patient receiving the wrong amount of medication, which could lead to personal injury or death. Our business and consolidated financial statements could suffer if we pay damages or defense costs in connection with a claim that is outside the scope of any applicable contractual indemnity or insurance coverage.
Our insurance coverage also includes property and business interruption liability, cyber liability, clinical trials liability, crime liability, auto liability, intercompany transit liability, workers’ compensation, employers’ liability, executive liability policies (employment practices liability, fiduciary liability, directors’ and officers’ liability), umbrella/excess liability and general liability with varying limits. We cannot assure that the insurance we maintain will satisfy claims made against us or that insurance coverage will continue to be available to us at commercially reasonable rates, in adequate amounts or on satisfactory terms or at all. Claims made against us will be subject to the terms, conditions and exclusions of the insurance policies we maintain. Any claims made against us, regardless of their merit or eventual outcome, could damage our reputation and business.
Pressures relating to downturns in the economy could adversely affect our business and consolidated financial statements.
Medicare, and other federal and state payers, account for a portion of our revenues. During economic downturns and periods of stagnant or slow economic growth, federal and state budgets are typically negatively affected, resulting in reduced reimbursements or delayed payments by the federal and state government healthcare coverage programs in which we participate, including Medicare, Medicaid, and other federal or state assistance plans. Government programs could also slow or temporarily suspend payments, negatively impacting our cash flow and increasing our working capital needs and interest payments. We have seen, and believe we will continue to see, Medicare and state Medicaid programs institute measures aimed at controlling spending growth, including reductions in reimbursement rates.
Higher unemployment rates and significant employment layoffs and downsizings may lead to lower numbers of patients enrolled in employer-provided plans. Adverse economic conditions could also cause employers to stop offering, or limit, healthcare coverage, or modify program designs, shifting more costs to the individual and exposing us to greater credit risk from patients or the discontinuance of therapy.
24
General levels of inflation and specific inflationary pressures may impact areas such as labor, transportation and medical supplies and may persist due to events outside of our control, for example, potential pandemic events, supply chain disruptions, and the broader macroeconomic environment. The rise of inflation may adversely impact our business operations, financial condition and results of operations.
Acquisitions, strategic investments and strategic relationships involve certain risks.
We may pursue acquisitions of strategic investments in, or strategic relationships with businesses and technologies. Acquisitions may entail numerous risks, including difficulties in assessing values for acquired businesses, intangible assets and technologies, difficulties in the assimilation of acquired operations and products, diversion of management’s attention from other business concerns, assumption of unknown material liabilities of acquired companies, amortization of acquired intangible assets that could reduce future reported earnings, and potential loss of clients or key employees of acquired companies. We may not be able to successfully integrate the operations, personnel, services or products that we have acquired or may acquire in the future. Strategic investments may also entail some of the risks described above. If these investments are unsuccessful, we may need to incur charges against earnings.
We may also pursue a number of strategic relationships. These relationships may be important to our business and growth prospects. However, we may not be able to maintain these relationships or develop new strategic alliances.
Our business depends on our information systems. A cyber-attack, security breach or our inability to effectively integrate, manage and keep our information systems secure and operational could disrupt our operations.

Cybersecurity refers to the combination of technologies, processes and procedures established to protect information technology systems and data from unauthorized access, attack, or damage. The Company relies on its information systems to provide security for processing, transmitting, and storing confidential information about patients, customers, and personnel, such as names, addresses and other individually identifiable information protected by HIPAA and other privacy laws. Cybersecurity risks could compromise our information and expose us to liability, which may harm our ability to operate effectively and may cause harm to our business and reputation. Cyber incidents can result from deliberate attacks or unintentional events. The regulatory environment surrounding information security and privacy is increasingly demanding, with the frequent imposition of new and changing requirements. Compliance with changes in privacy and information security laws and with rapidly evolving industry standards may result in the Company incurring significant expense due to increased investment in technology and the development of new operational processes.
We may experience interruptions, delays and outages in service and availability from time to time, including infrastructure changes, human or software errors, upgrade disruptions and capacity constraints. We have not experienced any material known attacks on our information technology systems that compromised any confidential information. We maintain our information technology systems with safeguards against cyber-attacks including passive intrusion protection, firewalls and virus detection software. In addition, we provide our employees with extensive training on best ways to protect our patient information, including, among others, avoiding phishing emails and sharing access to sensitive information on a need-only basis. However, these safeguards do not ensure that a significant cyber-attack could not occur. Although we have taken steps to protect the security of our information technology systems and the data maintained in those systems, it is possible that our safety and security measures will not prevent the systems’ improper functioning or damage or the improper access or disclosure of personal health information or personally identifiable information such as in the event of cyber-attacks.
Security breaches, including physical or electronic break-ins, computer viruses, attacks by hackers and similar breaches can create system disruptions or shutdowns or the unauthorized use or disclosure of confidential information. If personal information or protected health information is improperly accessed, tampered with or disclosed as a result of a security breach, we may incur significant costs to notify, and mitigate potential harm to the affected individuals, and we may be subject to sanctions and civil or criminal penalties if we are found to be in violation of the privacy or security rules under HIPAA or other federal or state laws protecting confidential personal information. In addition, a security breach of our information technology systems could damage our reputation, subject us to liability claims or regulatory penalties for compromised personal information and could have a materially adverse effect on our business, financial condition, and results of operations.
25
Our business is dependent on the services provided by third-party information technology vendors.
Our information technology infrastructure includes hosting services provided by third parties. While we believe these third parties are high-performing organizations with secure platforms and customary certifications, they could suffer a security breach or business interruption, which in turn could impact our operations negatively. In addition, changes in pricing terms charged by our technology vendors may adversely affect our financial performance.
We use, and may continue to expand our use of, machine learning and artificial intelligence (“AI”) technologies to deliver our services and operate our business.
If we fail to successfully integrate AI into our platform and business processes, or if we fail to keep pace with rapidly evolving AI technological developments, including attracting and retaining talented AI developers and programmers, we may face a competitive disadvantage. At the same time, the use or offering of AI technologies may result in new or expanded risks and liabilities, including enhanced government or regulatory scrutiny, litigation, compliance issues, ethical concerns, confidentiality, reputational harm and security risks. It is not possible to predict all of the risks related to the use of AI and changes in laws, rules, directives, and regulations governing the use of AI may adversely affect our ability to develop and use AI or subject us to legal liability. The cost of complying with laws and regulations governing AI could be significant and would increase our operating expenses, which could adversely affect our business, financial condition and results of operations. Further, market demand and acceptance of AI technologies are uncertain, and we may be unsuccessful in efforts to further incorporate AI into our processes.
Failure to maintain effective internal control over our financial reporting could have an adverse effect on our ability to report our financial results on a timely and accurate basis.
Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Exchange Act, and is required to evaluate the effectiveness of these controls and procedures on a periodic basis and publicly disclose the results of these evaluations and related matters in accordance with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002. Effective internal control over financial reporting is necessary for us to provide reliable financial reports, to help mitigate the risk of fraud and to operate successfully. Any failure to implement and maintain effective internal controls could result in material weaknesses or material misstatements in our consolidated financial statements.
If we fail to maintain effective internal control over financial reporting, or our independent registered public accounting firm is unable to provide us with an unqualified attestation report on our internal control, we may be required to take corrective measures or restate the affected historical financial statements. In addition, we may be subjected to investigations and/or sanctions by federal and state securities regulators and/or civil lawsuits by security holders. Any of the foregoing could also cause investors to lose confidence in our reported financial information and in us and would likely result in a decline in the market price of our stock and in our ability to raise additional financing if needed in the future.
Acts of God, such as major weather disturbances, could disrupt our business.
Acts of God, such as major weather disturbances, natural disasters, or other force majeure events, could disrupt our operations, supply chain, and the services we provide to patient. Our business relies on a network of prescribers, providers, patients and facilities that can be negatively impacted by local weather disturbances and other force majeure events. For example, in anticipation of major weather events, patients with impaired health may be moved to alternate sites. After a major weather event, availability of electricity, clean water and transportation can impact our ability to provide service in patients’ homes. Additionally, such events could impact key suppliers or vendors, disrupting the services or materials they provide to us. Climate change, or legal, regulatory or market measures to address climate change, could adversely affect our business and results of operations. In addition, acts of God and other force majeure events may cause a reduction in our business or increased costs, such as increased costs in our operations as we incur overtime charges or redirect services to other locations, delays in our ability to work with payers, hospitals, physicians and other strategic partners on new business initiatives, and disruption to referral patterns as patients are moved out of facilities affected by such events or are unable to return to sites of service in patients’ homes.
26
Item 1B.    Unresolved Staff Comments
None.
Item 1C.    Cybersecurity
Risk Management and Strategy
We have developed and implemented a cybersecurity framework designed to identify, detect, protect, respond to and recover from risks stemming from threats to the security of our information, systems and network using a governance-led risk-based approach. The framework is informed, in part, by the National Institute of Standards and Technology (NIST) Cybersecurity Framework, although this does not necessarily mean that we meet all technical standards, specifications or requirements outlined in the NIST framework. Additionally, we maintain a Systems and Organization Controls (SOC) 2 Type 2 attestation.
Our goal is to maintain an information technology infrastructure that implements physical, administrative, and technical controls. These controls are adjusted based on risk and designed to protect the confidentiality, integrity, and availability of our information systems, including the customer information, personal information, and proprietary information stored on our networks.
We have a cybersecurity incident response plan and dedicated teams to respond to cybersecurity incidents. When a cybersecurity incident occurs, we have cross-functional teams that are responsible for leading the initial assessment of priority and severity. Our information security team assists in taking any remedial action in response to an incident, and external experts may also be engaged as appropriate.
Our overarching approach to cybersecurity risk management centers on governance, people, processes, and technology. We provide security awareness training to help employees understand their information protection and cybersecurity responsibilities. This includes mandatory annual cybersecurity training and monthly phishing simulations. We also perform periodic internal tabletops or simulation exercises involving technical experts, business and functional leaders, as well as separate exercises with select critical third-party service providers.
We conduct third-party assessments of potential new vendors who process, store or transmit our data, which include a formal security review. This can include the review of documentation related to a vendor’s security attestations, such as SOC 2 Type 2 or HITRUST certifications.
We leverage third-party cybersecurity companies to assess our cybersecurity program and procedures and reaffirm our compliance with SOC 2 standards as well as the HIPAA Security Rule. These assessments aid in continual improvement and help us identify and address risks from cybersecurity threats.
We also consider cybersecurity, along with our other top risks, within our enterprise risk management framework. This framework involves internal reporting at the business and enterprise levels, considering key risk indicators, trends and countermeasures. Our Senior Vice President, Chief Information Security Officer (CISO) serves on the Enterprise Risk Committee that assesses our enterprise-wide risks and oversees risk mitigation activities.
We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us or our results of operations, cash flow or financial condition. However, the scope and impact of any future incident, or the identification of new information related to prior cybersecurity incidents, cannot be predicted. See “Item 1A. Risk Factors” for more information about our cybersecurity-related risks.
27
Governance
The Quality and Compliance Committee of our Board of Directors provides board-level oversight of cybersecurity risk. As part of its oversight role, the Quality and Compliance Committee receives reports about our practices, programs, or notable threats or incidents related to cybersecurity throughout the year, including through periodic updates from our CISO and other leaders. The Quality and Compliance Committee provides regular reports to the full Board about these matters and other areas within its responsibility, and the CISO and other leaders provide updates regarding cybersecurity matters to the full Board as appropriate.
Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. Our CISO collaborates with senior leaders and other members of our organization to identify and analyze cybersecurity risks and implement controls as appropriate and feasible to mitigate these risks. The CISO also supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, including by collaborating with internal and external stakeholders. Our CISO is supported by a management-led Security Council, which consists of our Chief Executive Officer, Chief Financial Officer and other senior leaders throughout our organization, and which reviews and discusses our cybersecurity program as well as emerging cyber risks, threats, and industry trends, among other topics.
Item 2.    Properties
We currently lease all of our properties from third parties under various lease terms expiring over periods extending through 2039, in addition to a number of non-material month-to-month leases. Our corporate headquarters is located at 3000 Lakeside Drive, Suite 300N, Bannockburn, IL 60015. Our other properties mainly consist of infusion pharmacies equipped with clean room and compounding capabilities. Some infusion pharmacies are co-located with an ambulatory infusion center where patients receive infusion treatments. As of December 31, 2024, we have 92 pharmacies and 93 stand-alone ambulatory infusion suites that support our infusion services business in 43 states.
Item 3.    Legal Proceedings
 For a summary of material legal proceedings, if any, refer to Note 14, Commitments and Contingencies, of the consolidated financial statements included in Item 8 of this Annual Report.
Item 4.    Mine Safety Disclosures
Item not applicable.
28
PART II
Item 5.    Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Common Stock
Our Common Stock, par value $0.0001 per share, is traded on the Nasdaq Global Select Market under the symbol “OPCH”.
Holders of Record
As of February 21, 2025, there were 76 stockholders of record of our Common Stock.
Dividend Policy
We have never paid cash dividends on our Common Stock and do not anticipate doing so in the foreseeable future.
Securities Authorized for Issuance under Equity Compensation Plans
See Item 12. “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters” of this Annual Report.
Recent Sale of Unregistered Securities and Use of Proceeds
Issuer Purchases of Equity Securities
On February 20, 2023, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $250 million of common stock of the Company. On December 6, 2023, the Company’s Board of Directors approved an increase to its stock repurchase program authorization from $250 million to $500 million. This program was completed in December 2024.
The following table provides certain information with respect to the Company’s repurchases of common stock from October 1, 2024 through December 31, 2024:
PeriodTotal Number of Shares PurchasedAverage Price Paid per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsApproximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs
October 1, 2024 - October 31, 2024— $— — $90,004,547 
November 1, 2024 - November 30, 20241,862,546 22.48 1,862,546 48,139,183 
December 1, 2024 - December 31, 20242,075,862 23.19 2,075,862 — 
3,938,408 $22.85 3,938,408 $— 

In January 2025, the Board of Directors approved a new stock repurchase program authorizing the repurchase of up to $500 million of our common stock.
29
Stock Performance Graph
The following graph compares the total cumulative returns of Option Care Health, the Nasdaq Composite Index and the S&P Health Care Services Select Industry Index for the five-year period from December 31, 2019 through December 31, 2024. The graph shows the performance of a $100 investment in our Common Stock and each index as of December 31, 2019.
Picture1.jpg
* $100 invested on December 31, 2019 in stock or index, including reinvestment of dividends.
Year Ended December 31,
201920202021202220232024
Option Care Health, Inc.$100.00 $104.83 $190.62 $201.68 $225.80 $155.50 
Nasdaq Composite Index$100.00 $143.64 $174.36 $116.65 $167.30 $215.22 
S&P Health Care Services Select Industry Index$100.00 $133.00 $145.57 $116.36 $121.70 $123.45 
30
Item 6.    Reserved
Item 7.    Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following Management’s Discussion and Analysis of Financial Condition and Results of Operations is designed to assist the reader in understanding our consolidated financial statements, the changes in certain key items in those financial statements from year-to-year and the primary factors that accounted for those changes as well as how certain accounting principles affect our consolidated financial statements.
Except for the historical information contained herein, the following discussion contains forward-looking statements that are subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially from those expressed or implied by such forward-looking statements. We discuss such risks, uncertainties and other factors throughout this Annual Report and specifically under the caption “Forward-Looking Statements” and in Item 1A. “Risk Factors” in this Annual Report. In addition, the following discussion of financial condition and results of operations should be read in conjunction with the consolidated financial statements and notes thereto appearing in Item 8 in this Annual Report.
Business Overview
Option Care Health and its wholly-owned subsidiaries provide infusion therapy and other ancillary healthcare services through a national network of 185 locations around the United States. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other non-hospital settings. Our services are provided in coordination with, and under the direction of, the patient’s physician. Our multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to each patient’s specific needs. We provide home infusion services consisting of anti-infectives, nutrition support, therapies for neurological disorders and chronic inflammatory disorders, immunoglobulin therapy, and other therapies for chronic and acute conditions. The Company operates in one segment, infusion services.
Update on the Impact of the Change Healthcare Cybersecurity Incident
As previously disclosed, on February 21, 2024, Change Healthcare, a subsidiary of UnitedHealth Group, experienced an incident in which a cybersecurity threat actor gained access to some of its information technology systems (“Change Healthcare Cybersecurity Incident”). Since the time of the system disruption, Option Care Health has worked continuously to find alternative processes to help maintain patient care and overall operations.
As of December 31, 2024, the Company has not identified any compromise or unauthorized access of its systems or networks due to this third party incident. As of the end of the second quarter of 2024, the Company reconnected to key applications maintained by Change Healthcare and as of the end of the fourth quarter of 2024, the Company has fully recovered.
During the fourth quarter of 2024, the Company did not experience a material financial impact from the Change Healthcare Cybersecurity Incident on the financial results as reported. The Company continues to maintain strong liquidity and, having resumed submission of all claims to payers, has determined that the Change Healthcare Cybersecurity Incident did not materially impact the Company, including its business operations, financial condition or results of operations.
31
Composition of Results of Operations
The following results of operations include the accounts of Option Care Health and our subsidiaries for the years ended December 31, 2024 and 2023.
Gross Profit
Gross profit represents our net revenue less cost of revenue.
Net Revenue. Infusion and related healthcare services revenue is reported at the estimated net realizable amounts from third-party payers and patients for goods sold and services rendered. When pharmaceuticals are provided to a patient, revenue is recognized upon delivery of the goods. When nursing services are provided, revenue is recognized when the services are rendered.
Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded.
Cost of Revenue. Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients. In addition to product costs, cost of revenue includes warehousing costs, purchasing costs, depreciation expense relating to revenue-generating assets, such as infusion pumps, shipping and handling costs, and wages and related costs for the pharmacists, nurses, and all other employees and contracted workers directly involved in providing service to the patient.
The Company receives volume-based rebates and prompt payment discounts from some of its pharmaceutical and medical supplies vendors. These payments are recorded as a reduction of inventory and are accounted for as a reduction of cost of revenue when the related inventory is sold.
Operating Costs and Expenses
Selling, General and Administrative Expenses. Selling, general and administrative expenses consist principally of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.
Depreciation and Amortization Expense. Depreciation within this caption relates to property and equipment and amortization relates to intangibles. Depreciation of revenue-generating assets, such as infusion pumps, is included in cost of revenue.
32
Other Income (Expense)
Interest Expense, Net. Interest expense consists principally of interest and fee payments on the Company’s outstanding borrowings under the ABL Facility, First Lien Term Loan, Revolver Facility, Senior Notes, amortization of discount and deferred financing fees, payments associated with the interest rate cap, and interest income earned on cash and cash equivalents. Refer to the “Liquidity and Capital Resources” section below for further discussion of these outstanding borrowings.
Equity in Earnings of Joint Ventures. Equity in earnings of joint ventures consists of our proportionate share of equity earnings or losses from equity investments in two infusion joint ventures with health systems.
Other, Net. During the year ended December 31, 2024, other income (expense) primarily includes activity related to non-operating income and expenses. During the year ended December 31, 2023, other income (expense) primarily includes the termination fee, net of merger-related expenses, received on behalf of Amedisys, Inc. (“Amedisys”). On May 3, 2023, the Company entered into a definitive merger agreement (the “Amedisys Merger Agreement”) with Amedisys, a leading provider of healthcare in home health and hospice settings. On June 26, 2023, the Company entered into an agreement to terminate the Amedisys Merger Agreement (the “Mutual Termination Agreement”). Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys (the “Termination Fee”).
Income Tax Expense. The Company is subject to taxation in the United States and various states. The Company’s income tax expense is reflective of the current federal and state tax rates.
Change in Unrealized (Loss) Gain on Cash Flow Hedge, Net of Income Tax Benefit (Expense). Change in unrealized (loss) gain on cash flow hedge, net of income tax benefit (expense), consists of the (loss) gain associated with the changes in the fair value of hedging instruments related to the interest rate cap, net of income taxes.
33
Results of Operations
The following table presents Option Care Health’s consolidated results of operations for the years ended December 31, 2024 and 2023 (in thousands, except for percentages). For a discussion of Option Care Health’s consolidated results of operations for the year ended December 31, 2023 compared to the year ended December 31, 2022, refer to Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 22, 2024.
Year Ended December 31,
 20242023
Amount% of RevenueAmount% of Revenue
NET REVENUE$4,998,202 100.0 %$4,302,324 100.0 %
COST OF REVENUE3,985,209 79.7 %3,321,101 77.2 %
GROSS PROFIT1,012,993 20.3 %981,223 22.8 %
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses630,251 12.6 %607,427 14.1 %
Depreciation and amortization expense60,909 1.2 %59,201 1.4 %
Total operating expenses691,160 13.8 %666,628 15.5 %
OPERATING INCOME321,833 6.4 %314,595 7.3 %
 
OTHER INCOME (EXPENSE):
Interest expense, net(49,029)(1.0)%(51,248)(1.2)%
Equity in earnings of joint ventures5,964 0.1 %5,530 0.1 %
Other, net4,831 0.1 %89,865 2.1 %
Total other (expense) income(38,234)(0.8)%44,147 1.0 %
 
INCOME BEFORE INCOME TAXES283,599 5.7 %358,742 8.3 %
INCOME TAX EXPENSE71,776 1.4 %91,652 2.1 %
NET INCOME$211,823 4.2 %$267,090 6.2 %
 
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,284 and $2,158, respectively
(3,931)(0.1)%(6,181)(0.1)%
OTHER COMPREHENSIVE (LOSS) INCOME(3,931)(0.1)%(6,181)(0.1)%
NET COMPREHENSIVE INCOME$207,892 4.2 %$260,909 6.1 %
34
Year Ended December 31, 2024 Compared to Year Ended December 31, 2023
The following table presents selected consolidated comparative results of operations for the years ended December 31, 2024 and 2023:
Gross Profit
 Year Ended December 31,
 20242023Variance
(in thousands, except for percentages)
Net revenue$4,998,202$4,302,324$695,878 16.2 %
Cost of revenue3,985,2093,321,101664,108 20.0 %
Gross profit$1,012,993$981,223$31,770 3.2 %
Gross profit margin20.3%22.8%
The increase in net revenue during the year ended December 31, 2024 was primarily driven by organic growth in the Company’s portfolio of therapies, consisting of acute revenue that had high single digits growth relative to the prior year while chronic revenue grew in the high teens. The increase in cost of revenue was primarily driven by the growth in revenue, therapy mix, and acute drug supply chain disruption, as well as the comparable impact of certain temporary favorable therapy procurement dynamics in the prior year. The decrease in gross profit margin was primarily due to the launch of certain new higher cost therapies included within chronic growth (including rare and orphan therapies) and to the same comparable impact of certain temporary favorable procurement dynamics in the prior year that did not continue into 2024. Additionally, the Company received notice of a manufacturer’s intention to significantly reduce the spread at which the Company procures a certain therapy relative to drug reference prices beginning in early 2025, which is expected to negatively impact gross profit by approximately $60 million to $70 million in 2025.
Operating Expenses
 Year Ended December 31,
 20242023Variance
(in thousands, except for percentages)
Selling, general and administrative expenses$630,251 $607,427 $22,824 3.8 %
Depreciation and amortization expense60,909 59,201 1,708 2.9 %
Total operating expenses$691,160 $666,628 $24,532 3.7 %
The increase in selling, general and administrative expenses during the year ended December 31, 2024 was primarily due to an increase in salaries, benefits, and general costs to support the business; however, these expenses have declined as a percentage of revenue to 12.6% for the year ended December 31, 2024 compared to 14.1% for the year ended December 31, 2023, due to the Company’s focus on leveraging existing infrastructure to control spending.
35
Other Income (Expense)
 Year Ended December 31,
20242023Variance
(in thousands, except for percentages)
Interest expense, net$(49,029)$(51,248)$2,219 (4.3)%
Equity in earnings of joint ventures5,964 5,530 434 7.8 %
Other, net4,831 89,865 (85,034)(94.6)%
Total other (expense) income$(38,234)$44,147 $(82,381)(186.6)%
The decrease in interest expense, net during the year ended December 31, 2024 was primarily attributable to additional interest income generated from our cash and cash equivalents, partially offset by an increase in the Company’s First Lien Term Loan principal balance, compared to the year ended December 31, 2023. See Note 11, Indebtedness, of the consolidated financial statements for further information.
The decrease in other, net during the year ended December 31, 2024 was due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the year ended December 31, 2023. There was no comparable activity during the year ended December 31, 2024.
Income Tax Expense
 Year Ended December 31,
 20242023Variance
(in thousands, except for percentages)
Income tax expense$71,776 $91,652 $(19,876)21.7 %

The Company recorded income tax expense of $71.8 million and $91.7 million, which represents an effective tax rate of 25.3% and 25.5% for the years ended December 31, 2024 and 2023, respectively. The variance in the Company’s effective tax rate of 25.3% and 25.5% for the years ended December 31, 2024 and 2023, respectively, was primarily attributable to the difference in state taxes, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 25.3% for the year ended December 31, 2024, compared to the federal statutory rate of 21%, was also primarily attributable to state taxes, various non-deductible expenses, and a change in state valuation allowance. The income tax expense for the year ended December 31, 2023 includes $21.8 million of tax expense related to the Termination Fee received, under the terms of the Mutual Termination Agreement, net of merger-related expenses, and the release of $5.8 million of state valuation allowance in September 2023.
36
Net Income and Other Comprehensive (Loss) Income
 Year Ended December 31,
 20242023Variance
(in thousands, except for percentages)
Net income$211,823 $267,090 $(55,267)(20.7)%
Other comprehensive (loss) income, net of tax:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense)(3,931)(6,181)2,250 (36.4)%
Other comprehensive (loss) income(3,931)(6,181)2,250 (36.4)%
Net comprehensive income$207,892 $260,909 $(53,017)(20.3)%
The change in net income for the year ended December 31, 2024 was attributable to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the year ended December 31, 2023. There was no comparable activity during the year ended December 31, 2024.
For the years ended December 31, 2024 and 2023, the change in unrealized (loss) gain on cash flow hedge, net of income tax benefit (expense) was related to the change in fair market value of the $300.0 million interest rate cap hedge executed in October 2021.
Net comprehensive income decreased to $207.9 million for the year ended December 31, 2024, compared to net comprehensive income of $260.9 million for the year ended December 31, 2023, primarily as a result of the changes in net income discussed above.
37
Liquidity and Capital Resources
For the years ended December 31, 2024 and 2023, the Company’s primary sources of liquidity were cash and cash equivalents of $412.6 million and $343.8 million, respectively. As of December 31, 2024, the Company had $395.9 million of borrowings available under its credit facilities (net of $4.1 million undrawn letters of credit issued and outstanding), described further below. During the year ended December 31, 2023, the Company’s positive cash flows from operations have enabled investments in pharmacy, infusion suites, and information technology infrastructure to support growth and create additional capacity in the future, as well as to pursue acquisitions and share repurchases.
The Company’s primary uses of cash and cash equivalents include supporting our ongoing business activities, investment in capital expenditures in both facilities and technology, and the pursuit of acquisitions and share repurchases. Ongoing operating cash outflows are associated with procuring and dispensing drugs, personnel and other costs associated with servicing patients, as well as paying cash interest on outstanding debt and cash taxes. Ongoing investing cash flows are primarily associated with capital projects and business acquisitions, the improvement and maintenance of our pharmacy facilities and investment in our information technology systems. Ongoing financing cash flows are primarily associated with the quarterly principal payments on its outstanding debt, along with potential future share repurchases.
Our business strategy includes the deployment of capital to pursue acquisitions that complement our existing operations. We continue to evaluate acquisition opportunities and view acquisitions as a key part of our growth strategy. The Company historically has funded its acquisitions with cash and cash equivalents with the exception of the Merger. The Company may require additional capital in excess of current availability in order to complete future acquisitions. It is impossible to predict the amount of capital that may be required for acquisitions, and there is no assurance that sufficient financing for these activities will be available on acceptable terms.
Short-Term and Long-Term Liquidity Requirements
The Company’s ability to make principal and interest payments on any borrowings under our credit facilities and our ability to fund planned capital expenditures will depend on our ability to generate cash and cash equivalents in the future, which to a certain extent, is subject to general economic, financial, competitive, regulatory and other conditions. Based on our current level of operations and planned capital expenditures, we believe that our existing cash and cash equivalents balances and expected cash flows generated from operations will be sufficient to meet our operating requirements for at least the next 12 months and beyond. We may require additional borrowings under our credit facilities and alternative forms of financings or investments to achieve our longer-term strategic plans.
38
Credit Facilities
On May 8, 2024, the Company entered into the third amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (the “Third Amendment”). The Third Amendment, among other things, (i) provides for an additional $50.0 million of incremental First Lien Term Loan indebtedness and (ii) reduces the interest rate on the First Lien Term Loan from Term Secured Overnight Financing Rate (“SOFR”) (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25% and removes the credit spread adjustment with respect to such First Lien Term Loan.
The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.6 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Under the Third Amendment, interest on the First Lien Term Loan is payable monthly on either (i) SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.25% for Term SOFR Loans (as such term is defined in the Third Amendment); or (ii) a base rate determined in accordance with the Third Amendment, plus 1.25% for Base Rate Loans (as such term is defined in the Third Amendment).
On December 7, 2023, the Company entered into the second amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021 (the “Second Amendment”). The Second Amendment, among other things, provides for revolving credit commitments by the applicable Revolving Credit Lenders in an aggregate amount of $400.0 million (the “Revolver Facility”) pursuant to which such lenders have agreed to make Revolving Credit Loans to the Company. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility will bear interest at a rate equal to, at the option of the Company, either (i) the Term SOFR applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the Second Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent Compliance Certificate received by the Administrative Agent pursuant to the terms of the Credit Agreement. As of December 31, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million.
The Senior Notes bear interest at a rate of 4.375% per annum, which are payable semi-annually in arrears on October 31 and April 30 of each year, and which began on April 30, 2022. The Senior Notes mature on October 31, 2029.
Interest payments over the course of long-term debt obligations total an estimated $271.1 million based on final maturity dates of the Company’s credit facilities. Interest payments are calculated based on current rates as of December 31, 2024. Actual payments are based on changes in SOFR and exclude the interest rate cap derivative instrument.
39
Cash Flows
Year Ended December 31, 2024 Compared to Year Ended December 31, 2023
The following table presents selected data from Option Care Health’s consolidated statements of cash flows for the years ended December 31, 2024 and 2023:
 Year Ended December 31,
 20242023Variance
(in thousands)
Net cash provided by operating activities$323,392 $371,295 $(47,903)
Net cash used in investing activities(36,470)(56,506)20,036 
Net cash used in financing activities(218,206)(265,126)46,920 
Net increase in cash and cash equivalents68,716 49,663 19,053 
Cash and cash equivalents - beginning of period343,849 294,186 49,663 
Cash and cash equivalents - end of period$412,565 $343,849 $68,716 
Cash Flows from Operating Activities
The decrease in cash provided by operating activities during the year ended December 31, 2024 was primarily due to the $106.0 million payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses during the year ended December 31, 2023, changes in accounts receivable and accrued compensation and employee benefits. Additionally, changes in accounts payable and inventory were driven by organic growth in the Company as well as strategic supply chain purchases.
Cash Flows from Investing Activities
The decrease in cash used in investing activities during the year ended December 31, 2024 was primarily due to prior year acquisition activity with no comparable activity during the year ended December 31, 2024. See Note 3, Business Acquisitions and Divestitures, of the consolidated financial statements for more information.
Cash Flows from Financing Activities
The decrease in cash used in financing activities was primarily related to the Company’s debt refinancing in May 2024, in which $50.0 million in proceeds from issuance of debt was received, which partially offset $250.0 million in repurchase of common stock during the year ended December 31, 2024, whereas the cash used in financing activities during the year ended December 31, 2023 was primarily related to the Company’s $250.0 million repurchase of common stock.
40
Critical Accounting Estimates
The Company prepares its consolidated financial statements in accordance with United States generally accepted accounting principles (“GAAP”), which require the Company to make estimates and assumptions. The Company evaluates its estimates and judgments on an ongoing basis. Estimates and judgments are based on historical experience and on various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. The Company’s actual results may differ from these estimates, and different assumptions or conditions may yield different estimates.
The following discussion is not intended to be a comprehensive list of all the accounting policies, estimates or judgments made in the preparation of our financial statements. A discussion of our significant accounting policies, including further discussion of the accounting policies described below, can be found in Note 2, Summary of Significant Accounting Policies, within the notes to the consolidated financial statements included in Item 8 of this Annual Report.
Revenue Recognition and Accounts Receivable
Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services. Revenues are from commercial payers, government payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.
Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available.
The Company assesses the expected consideration to be received at the time of patient acceptance based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body.
The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service.
The Company’s accounts receivable are reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental healthcare programs, such as Medicare and Medicaid.
Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons.
Included in accounts receivable are earned but unbilled gross receivables. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.
After applying the criteria from ASC 606, an allowance for doubtful accounts is established only as a result of an adverse change in the payers’ ability to pay outstanding billings. As of December 31, 2024 and 2023, the Company had no allowance for doubtful accounts. The Company recorded an allowance for implicit price concessions based on its historical experience of additional revenue being recorded or revenue being written off when amounts received are greater than or less than the originally estimated net realizable value. The detailed assessments included, among other factors, current over/under payments which had not yet been applied to an account, historical contractual adjustments, and historical payments. Contractual allowance estimates are adjusted to actual amounts as cash is received and claims are settled.
41
Business Acquisitions
The Company accounts for business acquisitions in accordance with ASC Topic 805, Business Combinations (“ASC 805”), with assets and liabilities being recorded at their acquisition date fair values and goodwill being calculated as the purchase price in excess of the net identifiable assets. The application of ASC 805 requires management to make estimates and assumptions when determining the acquisition date fair values of acquired assets and assumed liabilities. Management’s estimates and assumptions include, but are not limited to, the future cash flows an asset is expected to generate and the weighted-average cost of capital. See Note 3, Business Acquisitions and Divestitures, for further discussion of business acquisitions.
Item 7A.    Quantitative and Qualitative Disclosures about Market Risk
Interest Rate Risk
The Company’s primary market risk exposure is to changing SOFR‑based interest rates. Interest rate risk is highly sensitive due to many factors, including U.S. monetary and tax policies, U.S. and international economic factors and other factors beyond our control. At December 31, 2024, we had outstanding debt of $631.6 million under our First Lien Term Loan with a variable interest rate component. See Note 11, Indebtedness, of the consolidated financial statements for more information.
To reduce interest rate risk, the Company has utilized an interest rate derivative contract to hedge against fluctuations in SOFR rates on the First Lien Term Loan. In conjunction with the October 2021 debt refinancing, the Company entered into an interest rate cap hedge with a notional amount of $300.0 million for a five-year term, effective on November 30, 2021. See Note 12, Derivative Instruments, of the consolidated financial statements for more information.
A hypothetical 100-basis point increase or decrease in market interest rates associated with the unhedged variable-rate debt over a 12-month period would result in a change to interest expense of approximately $3.3 million.
42
Item 8.    Financial Statements and Supplementary Data
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Option Care Health, Inc.:
Opinion on the Consolidated Financial Statements
We have audited the accompanying consolidated balance sheets of Option Care Health, Inc. and subsidiaries (the Company) as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 26, 2025 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion
These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matter
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.

Sufficiency of audit evidence over the evaluation of transaction price adjustments
As discussed in Notes 2 and 4 to the consolidated financial statements, net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing goods and services. Revenues are from commercial payers, government payers, and patients for infusion therapy and other ancillary health care services. The Company estimates the transaction price adjustments based on the verification of the patient’s insurance coverage, historical price concessions, and historical payments.

We identified the sufficiency of audit evidence over the evaluation of transaction price adjustments as a critical audit matter. Complex auditor judgment was required to evaluate the sufficiency of audit evidence obtained due to the large volume of data and information technology (IT) applications utilized in the transaction price adjustment process to capture and aggregate the data.

43
The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls over the Company’s transaction price adjustment process, including general IT controls and IT application controls. We involved IT professionals with specialized skills and knowledge who assisted in the identification and testing of certain IT systems used by the Company for processing and recording of transaction price adjustments. We tested the relevance and reliability of the underlying data that served as the basis for the transaction price adjustments by agreeing a selection of certain data elements to underlying support. We assessed the sufficiency of audit evidence obtained related to transaction price adjustments by evaluating the cumulative results of the audit procedures.

/s/ KPMG LLP
We have served as the Company’s auditor since 2015.
Chicago, Illinois
February 26, 2025
44
OPTION CARE HEALTH, INC.
CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT SHARES AND PER SHARE AMOUNTS)
December 31,
20242023
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$412,565 $343,849 
Accounts receivable, net409,733 377,658 
Inventories388,131 274,004 
Prepaid expenses and other current assets112,198 98,744 
Total current assets1,322,627 1,094,255 
NONCURRENT ASSETS:
Property and equipment, net127,367 120,630 
Operating lease right-of-use asset86,528 84,159 
Intangible assets, net16,993 20,092 
Referral sources, net284,017 315,304 
Goodwill1,540,246 1,540,246 
Other noncurrent assets43,965 42,349 
Total noncurrent assets2,099,116 2,122,780 
TOTAL ASSETS $3,421,743 $3,217,035 
LIABILITIES AND STOCKHOLDERS’ EQUITY  
CURRENT LIABILITIES:  
Accounts payable$610,779 $426,513 
Accrued compensation and employee benefits63,028 92,508 
Accrued expenses and other current liabilities77,783 75,010 
Current portion of operating lease liability22,044 18,278 
Current portion of long-term debt6,512 6,000 
Total current liabilities780,146 618,309 
NONCURRENT LIABILITIES:
Long-term debt, net of discount, deferred financing costs and current portion1,104,641 1,056,650 
Operating lease liability, net of current portion84,776 85,484 
Deferred income taxes47,576 34,920 
Other noncurrent liabilities366 — 
Total noncurrent liabilities1,237,359 1,177,054 
Total liabilities2,017,505 1,795,363 
STOCKHOLDERS’ EQUITY:
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2024 and 2023, respectively.
— — 
Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December 31, 2023.
18 18 
Treasury stock; 17,585,613 and 8,330,022 shares outstanding, at cost, as of December 31, 2024 and 2023, respectively.
(507,598)(255,107)
Paid-in capital1,231,435 1,204,270 
Retained earnings669,336 457,513 
Accumulated other comprehensive income11,047 14,978 
Total stockholders’ equity1,404,238 1,421,672 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY$3,421,743 $3,217,035 
The accompanying notes to consolidated financial statements are an integral part of these statements.
45
OPTION CARE HEALTH, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)
Year Ended December 31,
 202420232022
NET REVENUE$4,998,202 $4,302,324 $3,944,735 
COST OF REVENUE3,985,209 3,321,101 3,077,817 
GROSS PROFIT1,012,993 981,223 866,918 
OPERATING COSTS AND EXPENSES:
Selling, general and administrative expenses630,251 607,427 566,122 
Depreciation and amortization expense60,909 59,201 60,565 
Total operating expenses691,160 666,628 626,687 
OPERATING INCOME321,833 314,595 240,231 
 
OTHER INCOME (EXPENSE):
Interest expense, net(49,029)(51,248)(53,806)
Equity in earnings of joint ventures5,964 5,530 5,125 
Other, net4,831 89,865 14,218 
Total other (expense) income(38,234)44,147 (34,463)
 
INCOME BEFORE INCOME TAXES283,599 358,742 205,768 
INCOME TAX EXPENSE71,776 91,652 55,212 
NET INCOME$211,823 $267,090 $150,556 
 
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,284, $2,158 and $(7,259), respectively
$(3,931)$(6,181)$21,610 
OTHER COMPREHENSIVE (LOSS) INCOME(3,931)(6,181)21,610 
NET COMPREHENSIVE INCOME$207,892 $260,909 $172,166 
EARNINGS PER COMMON SHARE:
Earnings per share, basic$1.23 $1.49 $0.83 
Earnings per share, diluted$1.23 $1.48 $0.83 
Weighted average common shares outstanding, basic171,567 178,973 181,105 
Weighted average common shares outstanding, diluted172,845 180,375 182,075 
The accompanying notes to consolidated financial statements are an integral part of these statements.
46
OPTION CARE HEALTH, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
Year Ended December 31,
 202420232022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income$211,823 $267,090 $150,556 
Adjustments to reconcile net income to net cash provided by operations:
Depreciation and amortization expense63,498 62,200 65,434 
Non-cash operating lease costs22,581 18,533 19,713 
Deferred income taxes - net12,656 12,766 49,187 
Gain on sale of assets— — (9,403)
Loss on extinguishment of debt377 — — 
Amortization of deferred financing costs4,628 4,446 4,304 
Equity in earnings of joint ventures(5,964)(5,530)(5,125)
Stock-based incentive compensation expense36,143 30,479 16,783 
Distribution from equity method investments2,400 4,000 5,875 
Other adjustments(4,504)(1,244)— 
Changes in operating assets and liabilities:
Accounts receivable, net(32,075)224 (36,889)
Inventories(114,127)(51,000)(41,010)
Prepaid expenses and other current assets(15,601)(6,290)(16,798)
Accounts payable183,395 47,703 98,885 
Accrued compensation and employee benefits(29,480)15,546 (7,770)
Accrued expenses and other current liabilities6,133 (1,727)10,535 
Operating lease liabilities(21,911)(17,529)(21,395)
Other noncurrent assets and liabilities3,420 (8,372)(15,335)
Net cash provided by operating activities323,392 371,295 267,547 
CASH FLOWS FROM INVESTING ACTIVITIES:
Acquisition of property and equipment(35,606)(41,866)(35,358)
Proceeds from sale of assets— 3,743 14,670 
Business acquisitions, net of cash acquired— (12,494)(87,364)
Other investing activities(864)(5,889)— 
Net cash used in investing activities(36,470)(56,506)(108,052)
CASH FLOWS FROM FINANCING ACTIVITIES:
Stock-based compensation tax withholdings(12,382)(3,115)352 
Purchase of company stock and related excise taxes(252,726)(250,261)— 
Proceeds from warrant exercises— — 20,916 
Proceeds from issuance of debt49,959 — — 
Repayments of debt principal(6,384)(6,000)(6,000)
Deferred financing costs(77)— — 
Other financing activities3,404 (5,750)— 
Net cash (used in) provided by financing activities(218,206)(265,126)15,268 
 
NET INCREASE IN CASH AND CASH EQUIVALENTS68,716 49,663 174,763 
Cash and cash equivalents - beginning of the period343,849 294,186 119,423 
CASH AND CASH EQUIVALENTS - END OF PERIOD$412,565 $343,849 $294,186 
Supplemental disclosure of cash flows information:
Cash paid for interest$71,553 $69,804 $50,372 
Cash paid for income taxes$64,522 $75,241 $13,438 
Cash paid for operating leases$28,505 $27,391 $25,311 
The accompanying notes to consolidated financial statements are an integral part of these statements.
47
OPTION CARE HEALTH, INC.
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(IN THOUSANDS)
Preferred StockCommon StockTreasury StockPaid-in CapitalRetained EarningsAccumulated Other Comprehensive Income (Loss)Total Stockholders’ Equity
Balance - December 31, 2021$— $18 $(2,403)$1,138,855 $39,867 $(451)$1,175,886 
Stock-based incentive compensation— — — 16,783 — — 16,783 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — 352 — — 352 
Exercise of warrants— — — 20,916 — — 20,916 
Net income— — — — 150,556 — 150,556 
Other comprehensive income— — — — — 21,610 21,610 
Balance - December 31, 2022$— $18 $(2,403)$1,176,906 $190,423 $21,159 $1,386,103 
Stock-based incentive compensation— — — 30,479 — — 30,479 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (3,115)— — (3,115)
Purchase of company stock, and related tax effects— — (252,704)— — — (252,704)
Net income— — — — 267,090 — 267,090 
Other comprehensive loss— — — — — (6,181)(6,181)
Balance - December 31, 2023$— $18 $(255,107)$1,204,270 $457,513 $14,978 $1,421,672 
Stock-based incentive compensation— — — 36,143 — — 36,143 
Exercise of stock options, vesting of restricted stock, and related tax withholdings— — — (8,978)— — (8,978)
Purchase of company stock, and related tax effects— — (252,491)— — — (252,491)
Net income— — — — 211,823 — 211,823 
Other comprehensive loss— — — — — (3,931)(3,931)
Balance - December 31, 2024$— $18 $(507,598)$1,231,435 $669,336 $11,047 $1,404,238 
The accompanying notes to consolidated financial statements are an integral part of these statements.
48
OPTION CARE HEALTH, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
Corporate Organization and Business — The Company’s stock is listed on the Nasdaq Global Select Market as of December 31, 2024. During the year ended December 31, 2023, HC Group Holdings I, LLC. (“HC I”), a former affiliated shareholder, completed sales of 23,771,926 shares of its Option Care common stock which resulted in the full divestment by HC 1 at that time. In addition, the Company repurchased 2,475,166 shares from HC I on March 3, 2023 under the Company’s share repurchase program. See Note 16, Stockholders’ Equity, for further discussion of the Company’s share repurchase program.
Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary healthcare services through a national network of 92 full service pharmacies and 93 stand-alone ambulatory infusion sites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services.
Basis of Presentation — The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States. GAAP requires management to make certain estimates and assumptions in determining assets, liabilities, revenue, expenses, and related disclosures. Actual amounts could differ materially from those estimates.
Principles of Consolidation — The Company’s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the consolidated statements of comprehensive income. See “Equity-Method Investments” within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.
49
2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents consisted of money market funds.
Accounts Receivable — The Company’s accounts receivable are reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental healthcare programs, such as Medicare and Medicaid.
Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), an allowance for doubtful accounts is established only as a result of an adverse change in the Company’s payers’ ability to pay outstanding billings. In addition, the company assesses if there have been any changes to historical credit losses to determine if an allowance for credit losses is needed. The Company had an immaterial allowance for doubtful accounts and credit losses as of December 31, 2024 and 2023.
Included in accounts receivable are earned but unbilled gross receivables of $105.3 million and $89.1 million as of December 31, 2024 and 2023, respectively. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.
See Revenue Recognition for a further discussion of the Company’s revenue recognition policy.
Inventories — Inventories, which consist primarily of pharmaceuticals, is stated at the lower of first‑in, first‑out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.
Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $54.4 million and $52.0 million for the years ended December 31, 2024 and 2023, respectively.
Leases — The Company has lease agreements for facilities, warehouses, office space and property and equipment. At the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (“ROU asset”) and operating lease liabilities in the consolidated financial statements.
ROU assets, which represent the Company’s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The rates are estimated primarily using a methodology dependent on the Company’s financial condition, creditworthiness, and availability of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.
Leases may contain rent escalations; however, the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.
The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. See Note 8, Leases, for further discussion of leases.
50
Goodwill, Intangible Assets, Property and Equipment, and Referral Sources — Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic 350, Intangibles-Goodwill and Other. The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate that impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter on a qualitative basis. See Note 10, Goodwill and Other Intangible Assets, for further discussion of the Company’s goodwill and other intangible assets.
Intangible assets arising from the Company’s acquisitions are amortized on a straight‑line basis over the estimated useful life of each asset. Referral sources have a useful life of fifteen to twenty years. Trademarks/names have a useful life ranging from two to fifteen years. The useful lives for other amortizable intangible assets range from approximately two to nine years. The Company does not have any indefinite‑lived intangible assets.
Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight‑line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and three to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight‑line basis over the software’s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.
The Company assesses long‑lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. If circumstances require that a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flows basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value.
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December 31, 2024 and 2023, the balance of the investments was $24.5 million and $20.9 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $6.0 million, $5.5 million and $5.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December 31, 2024, 2023 and 2022, the Company received distributions from the investees of $2.4 million, $4.0 million and $5.9 million, respectively. See Note 17, Related-Party Transactions, for discussion of related-party transactions with these investees.
Hedging Instruments — The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, Derivative Instruments, for additional information.
At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.
51
Revenue Recognition — Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing goods and services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.
Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available.
The Company assesses the expected consideration to be received at the time of patient acceptance, based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body.
The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service.
The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. See Note 4, Revenue for a further discussion of revenue.
Cost of Revenue — Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.
The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.
Selling, General and Administrative Expenses — Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.
Stock Based Incentive Compensation — The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, Compensation-Stock Compensation (“ASC 718”). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company’s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs.
Business Acquisitions — The Company accounts for business acquisitions in accordance with ASC Topic 805, Business Combinations, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets. See Note 3, Business Acquisitions and Divestitures, for further discussion of the Company’s business acquisitions.
52
Income Taxes — The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized.
The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense (benefit). Tax related interest and penalties are classified as a component of income tax expense (benefit).
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15%, 14% and 14% for the years ended December 31, 2024, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.
For the years ended December 31, 2024, 2023 and 2022, approximately 12%, 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December 31, 2024 and 2023, approximately 11% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the year ended December 31, 2024, approximately 58% of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the years ended December 31, 2023 and 2022, approximately 72% and 73%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue or decreased gross profit, which could adversely affect the Company’s financial condition or operating results.
Fair Value Measurements — The fair value measurement accounting standard, ASC Topic 820, Fair Value Measurement (“ASC 820”), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:
•Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
53
Recently Issued Accounting Pronouncements — In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU improves the disclosures around a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development). The amendments in this ASU do not change or remove current presentation requirements or current expense disclosure requirements. However, the amendments affect where this information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The Company is required to adopt this ASU for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The ASU allows investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. This ASU also improves the effectiveness and comparability of disclosures by adding disclosures of pretax income (loss) and income tax expense (benefit) to be consistent with U.S. Securities and Exchange Commission (“SEC”) Regulation S-X and removing disclosures that no longer are considered cost beneficial or relevant. The Company is required to adopt this ASU for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU improves the disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities, including those public entities that have a single reportable segment, to enable investors to develop more decision-useful financial analyses. The Company is required to adopt this ASU for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU was adopted during the year ended December 31, 2024 and applied retrospectively to all prior periods presented in the financial statements. The adoption did not have any material impact on the Company’s results of operations, cash flows, financial position, or disclosures. See Note 18, Segment Reporting, for further discussion.

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This ASU is the result of the Board’s decision to incorporate into the Codification 14 disclosures referred by the SEC. The ASU represents changes to clarify or improve disclosure and presentation requirements of a variety of Topics. Many of the amendments allow users to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the SEC’s requirements. Also, the amendments align the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption permitted. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
54
3. BUSINESS ACQUISITIONS AND DIVESTITURES
Amedisys, Inc. — On May 3, 2023, the Company entered into a definitive merger agreement with Amedisys. Under the terms of the merger agreement, the Company would issue new shares of its common stock to Amedisys stockholders, which would result in the Company’s stockholders holding approximately 64.5% of the combined company.
On June 26, 2023, the Company entered into an agreement to terminate the Amedisys Merger Agreement. Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys. The Termination Fee is included in Other, net in the consolidated statements of comprehensive income and in Net cash provided by operating activities in the consolidated statements of cash flows.
During the year ended December 31, 2023, the Company incurred $21.1 million in merger-related expenses, which are included in Other, net in the consolidated statements of comprehensive income and in Net cash provided by operating activities in the consolidated statements of cash flows.
Revitalized, LLC — In May 2023, pursuant to the equity purchase agreement dated May 1, 2023, the Company completed the acquisition of 100% of the membership interests in Revitalized, LLC for a purchase price, net of cash acquired, of $12.5 million, which primarily consisted of $6.7 million of goodwill and $5.5 million of intangible assets.
Respiratory Therapy Asset Sale — The Company closed the transaction in December 2022, for a sale price of $18.4 million comprised of $14.7 million in proceeds received at the time of closing and $3.7 million recorded as a current asset which was paid in the year ended December 31, 2023. Pursuant to the final transaction terms, $8.8 million of assets were sold, along with $0.7 million of liabilities that were previously classified as held for sale at the lower of their carrying amount or fair values less cost to sell. As a result of the transaction, a $10.3 million pre-tax gain on sale was recorded within Other, net in the Company’s consolidated statements of comprehensive income within the year ended December 31, 2022.
Rochester Home Infusion, Inc. — In August 2022, pursuant to the stock purchase agreement dated June 10, 2022, the Company completed the acquisition of 100% of the equity interests in Rochester Home Infusion, Inc. (“RHI”) for a purchase price, net of cash acquired, of $27.4 million.
Specialty Pharmacy Nursing Network, Inc. — In April 2022, pursuant to the equity purchase agreement dated February 7, 2022, the Company completed the acquisition of 100% of the equity interests in Specialty Pharmacy Nursing Network, Inc. (“SPNN”) for a purchase price, net of cash acquired, of $59.9 million.
4. REVENUE
The following table sets forth the net revenue earned by category of payer for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year Ended December 31,
202420232022
Commercial payers$4,348,991 $3,747,568 $3,421,888 
Government payers584,271 500,891 477,818 
Patients64,940 53,865 45,029 
Net revenue$4,998,202 $4,302,324 $3,944,735 
5. EMPLOYEE BENEFIT PLANS
The Company maintains a 401(k) plan and matches 100% of employee contributions, up to 4% of employee compensation. The Company recorded expense for the defined contribution plan of $13.3 million, $13.1 million and $12.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. In the years ended December 31, 2024, 2023 and 2022, Company contributions of $13.3 million, $12.4 million and $11.8 million, respectively, were paid.
55
6. INCOME TAXES
The income tax expense (benefit) consists of the following for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year Ended December 31,
202420232022
U.S. federal income tax expense (benefit):
Current$47,239 $56,474 $4,103 
Deferred16,396 18,739 38,810 
63,635 75,213 42,913 
State income tax expense (benefit):
Current10,597 20,253 9,182 
Deferred(2,456)(3,814)3,117 
8,141 16,439 12,299 
Total income tax expense (benefit)$71,776 $91,652 $55,212 
The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December 31, 2024, 2023 and 2022:
Year Ended December 31,
202420232022
U.S. federal statutory tax rate21.0 %21.0 %21.0 %
State and local income taxes net of federal tax benefit3.5 %4.8 %5.0 %
Valuation allowance(0.8)%(1.5)%0.0 %
Share based compensation impacts1.2 %0.7 %0.4 %
Other, net0.4 %0.5 %0.4 %
Effective income tax rate25.3 %25.5 %26.8 %

The Company recorded income tax expense of $71.8 million, $91.7 million, and $55.2 million, which represents an effective tax rate of 25.3%, 25.5%, and 26.8% for the years ended December 31, 2024, 2023, and 2022, respectively. In March 2024, the Company released $2.2 million of state valuation allowance. The variance in the Company’s effective tax rate of 25.3% for the year ended December 31, 2024 compared to the federal statutory rate of 21% is primarily attributable to the difference in state taxes, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 25.3% and 25.5% for the years ended December 31, 2024 and 2023, respectively, is also primarily attributable to the difference in state taxes, various non-deductible expenses, and a change in state valuation allowance. The income tax expense for the year ended December 31, 2023 includes $21.8 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. In September 2023, the Company released $5.8 million of state valuation allowance. The variance in the Company’s effective tax rate of 25.5% and 26.8% for the years ended December 31, 2023 and 2022, respectively, is primarily attributable to the difference in state taxes, various nondeductible expenses, and a change in state valuation allowance.
56
The components of deferred income tax assets and liabilities were as follows as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Deferred tax assets:
Price concessions$8,053 $5,365 
Compensation and benefits6,166 7,609 
Interest limitation carryforward5,768 13,802 
Operating lease liability23,880 26,378 
Net operating losses50,860 56,980 
Other12,676 7,556 
Deferred tax assets before valuation allowance107,403 117,690 
Valuation allowance(3,337)(6,371)
Deferred tax assets net of valuation allowance104,066 111,319 
Deferred tax liabilities:
Accelerated depreciation(12,630)(8,882)
Operating lease right-of-use asset(18,883)(21,504)
Intangible assets(48,412)(52,502)
Goodwill(59,303)(52,188)
Other(12,414)(11,163)
Deferred tax liabilities(151,642)(146,239)
Net deferred tax liabilities$(47,576)$(34,920)
Deferred tax assets are generally required to be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. For the year ended December 31, 2024, the Company maintains a valuation allowance of $3.3 million against certain state net operating losses (“NOL”). In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income and tax-planning strategies, in making this assessment. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.
At December 31, 2024, the Company had $35.6 million of tax-effected federal NOL carryforwards all of which are currently available to offset future taxable income in the United States and reflected as a deferred tax asset of the company. Tax-effected federal NOL carryforwards of $24.6 million expire beginning in 2028 through 2036, and $11.0 million of tax-effected federal NOLs have an indefinite carryforward period. At December 31, 2024, the Company had $5.8 million tax-effected amounts of interest limitation carryforwards which have an indefinite carryforward period. At December 31, 2024, the Company also had $15.3 million tax-effected amounts of cumulative state NOL carryforwards available to offset future taxable income in various states. These state NOL carryforwards will begin to expire beginning in 2025 through 2043, with some having an indefinite carryforward period.
At December 31, 2024, 2023 and 2022, there were no unrecognized tax benefits for uncertain tax positions. Tax related interest and penalties are classified as a component of income tax expense.
57
The following table presents the valuation allowance for deferred tax assets for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Additions
DescriptionBalance at Beginning of PeriodCharged (Benefit) to Costs and ExpensesCharged (Benefit) to Other AccountsBalance at End of Period
2022: Valuation allowance for deferred tax assets$13,151 $(95)$— $13,056 
2023: Valuation allowance for deferred tax assets$13,056 $(6,685)$— $6,371 
2024: Valuation allowance for deferred tax assets$6,371 $(3,034)$— $3,337 
The company files income tax returns in the U.S. and various state and local jurisdictions. There are no ongoing Federal or state income tax audits as of December 31, 2024. The statute remains open for examination by the Internal Revenue Service beginning with year 2021 in state jurisdictions for periods beginning in 2020.
7. EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the years ended December 31, 2024, 2023 and 2022 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Year Ended December 31,
202420232022
Warrants———
Stock option awards854,5451,214,560629,690
Restricted stock awards376,743340,331205,652
Performance stock unit awards286,881——
58
The following tables present the Company’s basic and diluted earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Earnings per Common Share:
Earnings per common share, basic$1.23 $1.49 $0.83 

Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Effect of dilutive securities1,278 1,402 970 
Weighted average number of common shares outstanding, diluted172,845 180,375 182,075 
Earnings per Common Share:
Earnings per common share, diluted$1.23 $1.48 $0.83 

(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions and Divestitures, for further discussion.
(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, Business Acquisitions and Divestitures, for further discussion.
59
8. LEASES
During the years ended December 31, 2024, 2023 and 2022, the Company incurred operating lease expenses of $32.7 million, $30.6 million, and $29.1 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income. As of December 31, 2024 and December 31, 2023, the weighted-average remaining lease term was 6.5 years and 6.8 years, respectively, and the weighted-average discount rate was 6.56% and 6.16%, respectively.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$28,286 
202625,523 
202720,406 
202813,907 
20299,306 
2030 and beyond36,515 
Total lease payments133,943 
Less: interest(27,123)
Present value of lease liabilities$106,820 
During the years ended December 31, 2024, 2023 and 2022, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the consolidated statements of cash flows of $25.0 million, $30.5 million, and $17.2 million, respectively, related to the increases in the operating lease ROU asset and operating lease liabilities. As of December 31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.
60
9. PROPERTY AND EQUIPMENT
Property and equipment was as follows as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Infusion pumps$37,659 $36,943 
Equipment, furniture and other24,055 23,593 
Leasehold improvements116,675 99,725 
Computer software, purchased and internally developed46,532 50,572 
Assets under development22,990 33,668 
247,911 244,501 
Less: accumulated depreciation(120,544)(123,871)
Property and equipment, net$127,367 $120,630 
Depreciation expense is recorded within cost of revenue and operating expenses within the consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year ended December 31,
202420232022
Depreciation expense in cost of revenue$2,590 $2,999 $4,869 
Depreciation expense in operating expenses26,503 24,820 27,374 
Total depreciation expense$29,093 $27,819 $32,243 
61
10. GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill is not amortized, but is evaluated for impairment annually in the fourth quarter of the fiscal year, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.
Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; and the results of testing for recoverability of a significant asset group within a reporting unit.
A qualitative impairment analysis was performed in the fourth quarter of 2024, 2023 and 2022, to assess whether it is more likely than not that the fair value of the Company’s reporting units are less than their carrying value. The Company assessed relevant events and circumstances including macroeconomic conditions, industry and market considerations, overall financial performance, entity-specific events, and changes in the Company’s stock price. The Company determined that there was no goodwill impairment in 2024, 2023 or 2022.
The determination of fair value for acquisitions and the allocation of that value requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, and capital expenditures. Actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting unit, the amount of the goodwill impairment charge, or both. The Company did not recognize any accumulated impairment losses at the beginning of the period.
Changes in the carrying amount of goodwill consist of the following activity for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Balance at December 31, 2021$1,477,564 
Acquisitions54,543 
Purchase accounting adjustments1,317 
Balance at December 31, 2022$1,533,424 
Acquisitions6,998 
Purchase accounting adjustments(176)
Balance at December 31, 2023$1,540,246 
Acquisitions— 
Purchase accounting adjustments— 
Balance at December 31, 2024$1,540,246 
62
The carrying amount and accumulated amortization of intangible assets consist of the following as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Gross intangible assets:
Referral sources$514,388 $514,388 
Trademarks/names39,136 39,136 
Other amortizable intangible assets985 995 
Total gross intangible assets554,509 554,519 
Accumulated amortization:
Referral sources(230,371)(199,084)
Trademarks/names(22,599)(19,698)
Other amortizable intangible assets(529)(341)
Total accumulated amortization(253,499)(219,123)
Total intangible assets, net$301,010 $335,396 
Amortization expense for intangible assets was $34.4 million, $34.2 million and $32.9 million for the years ended December 31, 2024, 2023 and 2022, respectively.
Expected future amortization expense for intangible assets recorded at December 31, 2024, is as follows (in thousands):
Amount
2025$34,176 
202634,071 
202733,931 
202833,880 
202933,875 
2030 and beyond131,077 
Total$301,010 
63
11. INDEBTEDNESS
Long-term debt consisted of the following as of December 31, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan631,617 (5,537)(7,555)618,525 
Senior Notes500,000 — (7,372)492,628 
$1,131,617 $(5,537)$(14,927)1,111,153 
Less: current portion(6,512)
Total long-term debt$1,104,641 
Long-term debt consisted of the following as of December 31, 2023 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan588,000 (6,974)(9,678)571,348 
Senior Notes500,000 — (8,698)491,302 
$1,088,000 $(6,974)$(18,376)1,062,650 
Less: current portion(6,000)
Total long-term debt$1,056,650 
On May 8, 2024, the Company entered into the Third Amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021. The Third Amendment, among other things, (i) increases borrowings by $50.0 million and (ii) reduces the interest rate on the First Lien Term Loan from Term SOFR (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25% and removes the credit spread adjustment with respect to such First Lien Term Loan.
The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.6 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Under the Third Amendment, interest on the First Lien Term Loan is payable monthly on either (i) SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.25% for Term SOFR Loans (as such term is defined in the Third Amendment); or (ii) a base rate determined in accordance with the Third Amendment, plus 1.25% for Base Rate Loans (as such term is defined in the Third Amendment). The interest rate on the First Lien Term Loan was 6.82% and 8.21% as of December 31, 2024 and 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.61% and 7.83% for the years ended December 31, 2024 and 2023, respectively.
The Company assessed whether the repayment of the First Lien Term Loan indebtedness resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the First Lien Term Loan and Senior Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $0.4 million of the First Lien Term Loan were extinguished. The First Lien Term Loan had insubstantial modifications for lenders that participated in both debt instruments, which resulted in a cash inflow from financing activities of $50.0 million in the consolidated statements of cash flows. The Company incurred $1.6 million in fees, of which $0.1 million was capitalized, relative to the First Lien Term Loan and an immaterial amount of the total fees incurred was netted against the $50.0 million of debt proceeds as financing activities within the consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $0.4 million included in the line entitled “Other, net” in the consolidated statements of comprehensive income.
Effective June 30, 2023, the Company entered into an agreement, dated as of June 8, 2023, to amend the First Lien Term Loan to replace LIBOR and related definitions and provisions with SOFR as the new reference rate. The Company entered into the First Lien Term Loan Agreement (the “First Lien Credit Agreement Amendment”), which commenced in October 2021 (the “October 2021 Refinancing”) to provide $600.0 million of refinanced borrowings.
64
On December 7, 2023, the Company entered into the Second Amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021. The Second Amendment, among other things, creates a Revolver Facility which provides for borrowings up to $400.0 million. As of December 31, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million. As of December 31, 2023, the Company had $5.3 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $394.7 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility bear interest at a rate equal to, at the option of the Company, either (i) the Term SOFR applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the Second Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent Compliance Certificate received by the Administrative Agent pursuant to the terms of the Credit Agreement.
Concurrently with the creation of the Revolver Facility, the Company terminated the asset-based lending revolving credit facility (the “ABL Facility”) with a maturity date of October 27, 2026. Prior to the transition to the Revolver Facility, the ABL Facility had been in effect from August 6, 2019 to December 7, 2023. Effective January 13, 2023, the Company entered into an agreement to amend the ABL Facility and increase the amount of borrowing availability from $175.0 million by $50.0 million to $225.0 million total borrowing availability. As a result of the amended agreement, SOFR was established as the new reference rate, replacing LIBOR. Prior to the termination of the ABL Facility in December 2023, the ABL Facility bore interest at a rate equal to, at the Company’s election, either (i) a base rate determined in accordance with the ABL Credit Agreement plus an applicable margin, which is equal to between 0.25% and 0.75% based on the historical excess availability as a percentage of the Line Cap (as such term is defined in the ABL Credit Agreement); and (ii) SOFR (with a floor of —% per annum) plus an applicable margin, which is equal to between 1.25% and 1.75% based on the historical excess availability as a percentage of the Line Cap. The ABL Facility contained commitment fees payable on the unused portion ranging from 0.25% to 0.375%, depending on various factors including the Company’s leverage ratio, type of loan and rate type, and letter of credit fees of 2.50%. Borrowings under the ABL Facility were secured by a first priority security interest in the Company’s and each of its subsidiaries’ inventory, accounts receivable, cash, deposit accounts and certain assets and property related thereto (the “ABL Priority Collateral”), in each case subject to certain exceptions, and a third priority security interest in each of the Company’s subsidiaries’ capital stock (subject to certain exceptions) and substantially all of the Company’s property and assets (other than the ABL Priority Collateral).
In conjunction with the October 2021 Refinancing, the Company also issued $500.0 million in aggregate principal of unsecured senior notes (“Senior Notes”). The Senior Notes bear interest at a rate of 4.375% per annum payable semi-annually in arrears on October 31 and April 30 of each year, commencing on April 30, 2022. The Senior Notes mature on October 31, 2029. The interest rate on the Senior Notes was 4.375% as of both December 31, 2024 and 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for both years ended December 31, 2024 and 2023.
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$6,512 
20266,512 
20276,512 
2028612,081 
2029500,000 
Total$1,131,617 
During the year ended December 31, 2024, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 12, Derivative Instruments, for further discussion.
65
The following table presents the estimated fair values of the Company’s debt obligations as of December 31, 2024 (in thousands):
Financial InstrumentCarrying Value as of December 31, 2024Markets for Identical Item (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
First Lien Term Loan$618,525 $— $634,774 $— 
Senior Notes492,628 — 460,000 — 
Total debt instruments$1,111,153 $— $1,094,774 $— 
66
12. DERIVATIVE INSTRUMENTS
The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.
In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300.0 million for a five-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.
The following table summarizes the amount and location of the Company’s derivative instruments in the consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionDecember 31, 2024December 31, 2023
Interest rate cap designated as cash flows hedgePrepaid expenses and other current assets$8,034 $9,746 
Interest rate cap designated as cash flows hedgeOther noncurrent assets6,680 10,183 
Total derivative assets$14,714 $19,929 
The gain and loss associated with the changes in the fair value of the effective portion of hedging instruments are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the hedging instrument is recognized in net income through interest expense. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s consolidated statements of comprehensive income (in thousands):
Year Ended December 31,
Derivative202420232022
Interest rate cap designated as cash flows hedge$(5,215)$(8,339)$28,869 
The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s consolidated statement of comprehensive income related to the Company’s derivative instruments (in thousands):
Year Ended December 31,
DerivativeIncome Statement Caption202420232022
Interest rate cap designated as cash flows hedgeInterest expense, net$11,527 $10,974 $1,090 
The Company expects to reclassify $2.8 million of total interest rate costs from accumulated other comprehensive income (loss) against interest expense during the next 12 months.
67
13. FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The three levels of inputs within the fair value hierarchy are defined in Note 2, Summary of Significant Accounting Policies. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 11, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s consolidated balance sheets (Level 1 inputs).
There were no other assets or liabilities measured at fair value at December 31, 2024 or 2023.
14. COMMITMENTS AND CONTINGENCIES
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.
The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated balance sheets.
However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
68
15. STOCK-BASED INCENTIVE COMPENSATION
Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company’s Compensation Committee, a standing committee of the Board of Directors. In May 2024, an additional 4,000,000 shares were authorized for issuance under the amended 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance as of December 31, 2024. As of December 31, 2023, a total of 9,101,734 shares of common stock were authorized for issuance under the amended 2018 Plan.
Stock Options — Options granted under the 2018 Plan typically vest over a three- or four-year period and, in certain instances, may fully vest upon a change in control of the Company. The options also typically have an exercise price that may not be less than 100% of its fair market value on the date of grant and are exercisable seven to ten years after the date of grant, subject to earlier termination in certain circumstances.
Compensation expense from stock options is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to stock options of $5.9 million, $6.5 million and $2.5 million, respectively.
There were no options granted during the year ended December 31, 2024. The weighted average grant-date fair value of options granted during the years ended December 31, 2023 and 2022 was $15.72 and $12.51, respectively. The fair value of stock options granted was estimated on the date of grant using a Black-Scholes pricing model. The assumptions used to compute the fair value of options for the years ended December 31, 2023 and 2022 are as follows:
Year Ended December 31,
20232022
Expected volatility51.43%51.19%
Risk-free interest rate4.16%3.91%
Expected life of options6.2 years6.2 years
Dividend rate——
A summary of stock option activity for the year ended December 31, 2024 is as follows:
OptionsWeighted Average Exercise PriceAggregate Intrinsic Value (thousands)Weighted Average Remaining Contractual Life
Balance at December 31, 20231,746,272 $25.08 $15,028 
Granted— $— $— 
Exercised(161,553)$18.14 $1,875 
Forfeited and expired(101,486)$26.05 $32 
Balance at December 31, 20241,483,233 $25.79 $1,590 7.35 years
Exercisable at December 31, 2024595,984 $22.96 $1,365 6.52 years
During the years ended December 31, 2024, 2023 and 2022, an immaterial number of shares were surrendered to satisfy tax withholding obligations on the exercise of stock options. No cash was received from stock option exercises under share-based payment arrangements for the years ended December 31, 2024, 2023 and 2022.
69
The maximum term of stock options under these plans is ten years. Options outstanding as of December 31, 2024 expire on various dates ranging from September 2025 through July 2033. The following table outlines the outstanding and exercisable stock options as of December 31, 2024:
Options OutstandingOptions Exercisable
Range of Option Exercise PriceOutstanding OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual LifeOptions ExercisableWeighted Average Exercise Price
$0.00 - $8.24
9,901 $6.52 2.19,901 $6.52 
$8.24 - $16.52
64,775 $12.14 4.064,775 $12.14 
$16.52 - $24.76
355,616 $21.54 6.7200,513 $21.05 
$24.76 - $33.00
1,052,941 $28.25 7.8320,795 $26.85 
All options1,483,233 595,984 
As of December 31, 2024, there was $5.8 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 0.95 years.
Restricted Stock — Restricted stock grants subject solely to an employee’s continued service with the Company generally will become fully vested within one to four years from the grant date and, in certain instances, may fully vest upon a change in control of the Company. Restricted stock grants subject solely to a Director’s continued service with the Company generally will become fully vested on a pro-rata basis over three years from the date of grant.
Compensation expense from restricted stock is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to restricted stock awards of $21.4 million, $16.6 million and $10.2 million, respectively.
The grant-date fair value of restricted stock is valued as the closing price of the Company’s common stock on the date of the grant.
A summary of restricted stock award activity for the year ended December 31, 2024 is as follows:
Restricted StockWeighted Average Grant Date Fair Value
Balance at December 31, 20231,883,116 $26.28 
Granted 723,027 $32.71 
Vested and issued(770,137)$25.16 
Forfeited and expired(170,594)$28.25 
Balance at December 31, 20241,665,412 $29.41 
During the years ended December 31, 2024, 2023 and 2022, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $7.1 million, $4.4 million and $1.4 million, respectively.
As of December 31, 2024, there was $28.8 million in unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.09 years. The total fair value of restricted stock awards vested during the years ended December 31, 2024, 2023 and 2022 was $19.4 million, $9.9 million and $3.7 million, respectively.
70
Performance Stock Units — Performance-based stock units (“PSU”) are generally earned based on the attainment of specified goals achieved over a designated performance period. During the years ended December 31, 2024, 2023 and 2022, the Company’s Compensation Committee approved PSU awards to certain senior executives of the Company with grant dates in 2024, 2023 and 2022, respectively. All PSU awards offer a three-year-cliff vesting schedule. Each PSU award reflects a target number of shares (“Target Shares”) that may be issued to the award recipient. PSU awards may be earned upon the completion of a two-year-average or three-year-average performance period.
Whether PSU awards are earned at the end of the performance period will be determined based on the achievement of certain performance objectives over the performance period. The performance objectives include achieving a target growth for adjusted EBITDA and revenue combined in addition to a target growth for cash flows from operations over the performance period. Depending on the results achieved during the performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the Target Shares granted. Each period begins with 100% of the Target Shares and true-up or true-down adjustments are considered every quarter-end based on the forecasted performance period results.
The fair value of the Target Shares and PSU awards are based on the fair value of the underlying shares as of market close on the grant date. Compensation expense for PSU awards is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to the PSU awards of $8.8 million, $7.5 million and $4.1 million, respectively. During the years ended December 31, 2024, shares were surrendered to satisfy tax withholding obligations on the performance-based stock units with a cost basis of $4.9 million. There were no shares surrendered to satisfy tax withholding obligations on the PSU awards during the years ended December 31, 2023 or 2022. As of December 31, 2024, there were $11.6 million in unrecognized compensation expense related to unvested PSU awards that are expected to be recognized over a weighted-average period of 1.32 years.
71
16. STOCKHOLDERS’ EQUITY
During the year ended December 31, 2023, HC I completed secondary offerings of 23,771,926 shares of common stock. As of December 31, 2023, HC I no longer held shares of the Company’s common stock.
2017 Warrants — Prior to the Merger, BioScrip issued warrants to certain debt holders pursuant to a Warrant Purchase Agreement dated as of June 29, 2017. In conjunction with the Merger, the 2017 Warrants were amended to entitle the purchasers of the warrants to purchase 2.1 million shares of common stock. The 2017 Warrants have a 10-year term and an exercise price of $8.00 per share and may be exercised by payment of the exercise price in cash or surrender of shares of common stock into which the 2017 Warrants are being converted in an aggregate amount sufficient to cover the exercise price. The 2017 Warrants are classified as equity instruments, and the fair value of these warrants of $14.1 million was recorded in paid-in capital as of the Merger Date. During the years ended December 31, 2024, 2023, and 2022, warrant holders exercised warrants to purchase 0, 188,350, and 1,130,089 shares of common stock, respectively. No proceeds were received from these exercises as the warrant holders elected to surrender shares to pay the exercise price. At December 31, 2024, 2023, and 2022, the remaining warrant holders are entitled to purchase 51,838, 51,838, and 240,188 shares of common stock, respectively.
2015 Warrants — Prior to the Merger, BioScrip issued warrants pursuant to a Common Stock Warrant Agreement dated as of March 9, 2015 which entitle the holders to purchase 0.9 million shares of common stock. The 2015 Warrants have a 10-year term and have exercise prices in a range of $20.68 per share to $25.80 per share. The 2015 Warrants were assumed by the Company in conjunction with the Merger and are classified as equity instruments, and the fair value of these warrants of $4.6 million was recorded in paid in capital as of the Merger Date. During the years ended December 31, 2024 and 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. During the year ended December 31, 2022, warrant holders exercised warrants to purchase 900,272 shares of common stock. During the years ended December 31, 2024 and 2023, no cash proceeds were received from warrant exercises. During the year ended December 31, 2022, $20.9 million of cash was received as proceeds from warrant exercises. At December 31, 2024, 2023, and 2022, the remaining warrant holders are entitled to purchase 11,765, 13,888, and 15,231 shares of common stock, respectively.
Share Repurchase Program — On February 20, 2023, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $250.0 million of common stock of the Company. On December 6, 2023, the Company’s Board of Directors approved an increase to its share repurchase program authorization from $250.0 million to $500 million. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.
During the years ended December 31, 2024 and 2023, the Company purchased 9,255,591 and 7,946,301 shares of common stock for an average share price of $27.01 and $31.46, totaling $250.0 million and $250.0 million, respectively. All repurchased shares became treasury stock. As of December 31, 2024, the Company completed share repurchases under its prior share repurchase program. In January 2025, the Company’s Board of Directors approved a new $500.0 million stock repurchase program. This program has no specified expiration date.
Shares Outstanding — The following table shows the Company’s changes in shares of common stock for the years ended December 31, 2024 and 2023 (in thousands):
Balance at December 31, 2022181,958 
Equity award issuances564 
Share repurchases(7,946)
Balance at December 31, 2023174,576 
Equity award issuances941 
Share repurchases(9,256)
Balance at December 31, 2024166,261 
Treasury Stock — As of December 31, 2024 and 2023, the Company held 17,585,613 and 8,330,022 shares of treasury stock, respectively.
Preferred Stock — The Company had no preferred stock outstanding as of December 31, 2024 or 2023.
72
17. RELATED-PARTY TRANSACTIONS
Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $6.2 million, $5.3 million and $4.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Management fees are recorded in net revenues in the accompanying consolidated statements of comprehensive income.
The Company had amounts due to its joint ventures totaling $1.4 million as of December 31, 2024. The Company had amounts due to its joint ventures of $0.5 million and due from its joint ventures of $0.1 million as of December 31, 2023. These receivables were included in prepaid expenses and other current assets in the accompanying balance sheets and these payables were included in accrued expenses and other current liabilities in the accompanying balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.
Share Repurchase Agreement — On February 28, 2023, we entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with HC I, pursuant to which we agreed to repurchase, subject to the terms and conditions contained therein, up to $75.0 million of our common stock then held by HC I at the same purchase price per share as the underwriter in a concurrent underwritten public offering of our common stock held by HC I. On March 3, 2023, the transactions contemplated by the Share Repurchase Agreement closed, and we repurchased directly from HC I 2,475,166 shares of our common stock.
18. SEGMENT REPORTING
The Company has adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures and has revised prior year disclosures to conform with the current year presentation. The Company operates as a single reportable segment, infusion services. Infusion services derives revenue through the clinical management of infusion therapy, nursing support and care coordination in order to provide solutions to complex patient conditions in the home or other nonhospital settings. The Company’s infusion services segment activities are managed on a consolidated basis and therapies are distributed and administered in a similar manner.
Operating segments have been identified based on the financial information utilized by the Company’s Chief Executive Officer, the chief operating decision maker (“CODM”). The CODM uses net income as a measure of profitability to assess segment performance and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.
The following table reflects results of operations of the Company’s reportable segment (in thousands):

Year Ended December 31,
202420232022
Infusion services net revenue$4,911,591 $4,222,656 $3,869,036 
Other revenue (1)86,611 79,668 $75,699 
Total Option Care Health revenue4,998,202 4,302,324 $3,944,735 
(Expense) Income:
Cost of net revenues - drugs(3,446,735)(2,812,531)$(2,562,494)
Salaries, benefits, and other employee expense(787,922)(760,499)$(709,916)
Other segment items (2)(380,803)(355,498)$(371,529)
Depreciation and amortization expense(60,909)(59,201)$(60,565)
Interest expense, net(49,029)(51,248)$(53,806)
Equity in earnings of joint ventures5,964 5,530 $5,125 
Other, net4,831 89,865 $14,218 
Income tax expense(71,776)(91,652)$(55,212)
Net Income$211,823 $267,090 $150,556 
(1) Represents business activities related to other miscellaneous revenue streams.
(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.
19. SUBSEQUENT EVENTS
The Company has evaluated whether any subsequent events occurred since December 31, 2024 and noted the following subsequent event:
On January 24, 2025 the Company completed the acquisition of all equity interests in Intramed Plus, Inc., a leading provider of home and alternate site infusion services in the Southeastern United States. The total purchase price for the transaction was approximately $117 million, paid in cash.
73
Item 9.    Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
None.
Item 9A.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s principal executive officer and principal financial officer have concluded that the Company’s disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act were effective as of December 31, 2024 to provide reasonable assurance that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms and (ii) accumulated and communicated to the Company’s management, including its Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate to allow timely decisions regarding required disclosure.
Management Annual Report on Internal Control Over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the Company, as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. Our internal control system is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the Company’s financial statements for external purposes in accordance with U.S. GAAP.
Our management, with the participation of the CEO and CFO, assessed the effectiveness of the Company’s internal control over financial reporting. Based on the criteria for effective internal control over financial reporting established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”), management concluded that the internal control over financial reporting was effective as of December 31, 2024. The Company’s independent registered public accounting firm, KPMG LLP, has issued an audit report on the Company’s internal control over financial reporting, which appears elsewhere in this Annual Report.
All internal control systems, no matter how well designed, have inherent limitations and may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control Over Financial Reporting
There has been no change during the quarter ended December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
74
Report of Independent Registered Public Accounting Firm
To the Stockholders and Board of Directors
Option Care Health, Inc.
Opinion on Internal Control Over Financial Reporting
We have audited Option Care Health, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2024 and 2023, the related consolidated statements of comprehensive income, stockholders’ equity, and cash flows for each of the years in the three-year period ended December 31, 2024, and the related notes (collectively, the consolidated financial statements), and our report dated February 26, 2025 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP
Chicago, Illinois
February 26, 2025
75
Item 9B.    Other Information
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements
No director or officer of the Company has adopted, modified or terminated a Rule 10b5-1 plan or non-Rule 10b5-1 trading arrangement during the three months ended December 31, 2024.
Item 9C.    Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
Not applicable.
PART III
Item 10.    Directors, Executive Officers and Corporate Governance
We have adopted a Code of Ethics that applies to all of our directors, officers and employees, including our principal executive, principal financial and principal accounting officers, or persons performing similar functions. Our Code of Business Conduct is posted on our website located at https://investors.optioncarehealth.com/corporate-governance/governance-resources. We intend to disclose future amendments to certain provisions of the Code of Business Conduct, and waivers of the Code of Business Conduct granted to executive officers and directors, on our website.
The other information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.
Item 11.    Executive Compensation
The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.
Item 12.    Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.
Item 13.    Certain Relationships and Related Transactions, and Director Independence
The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.
Item 14.    Principal Accountant Fees and Services
The information required by this item is incorporated by reference from the information contained in our definitive proxy statement to be filed with the SEC no later than 120 days after December 31, 2024 in connection with our 2025 Annual Meeting of Stockholders.
76
PART IV
Item 15.     Exhibits and Financial Statement Schedules
(a)(3) Exhibits.
Index to Exhibits
Exhibit Number Description
3.1
3.2
3.3
3.4
4.1
4.2
4.3
10.1†
10.2†
10.3
10.4
10.5
10.6
77
10.7
10.8†
10.9†
10.10
10.11†
10.12†
10.13†
10.14†
19
21.1
23.1
31.1
31.2
32.1
32.2
97
101
The following financial information from the Company’s Form 10-K for the fiscal year ended December 31, 2024, formatted in XBRL (Extensible Business Reporting Language): (i) Consolidated Statements of Comprehensive Income (Loss) for the fiscal years ended December 31, 2024, 2023 and 2022, (ii) Consolidated Balance Sheets as of December 31, 2024 and 2023, (iii) Consolidated Statements of Stockholders’ Equity for the fiscal years ended December 31, 2024, 2023 and 2022, (iv) Consolidated Statements of Cash Flows for the fiscal years ended December 31, 2024, 2023 and 2022, and (v) Notes to Consolidated Financial Statements.
101.INSXBRL Instance Document
101.SCHXBRL Taxonomy Extension Schema Document
101.CALXBRL Taxonomy Extension Calculation Linkbase Document
101.DEFXBRL Taxonomy Extension Definition Linkbase Document
101.LABXBRL Taxonomy Extension Labels Linkbase Document
101.PREXBRL Taxonomy Extension Presentation Linkbase Document
104XBRL Formatted Cover Page
†Designates the Company’s management contracts or compensatory plan or arrangement.
+Certain schedules attached to the Agreement and Plan of Merger have been omitted pursuant to Item 601(b)(2) of Regulation S-K. The Company will furnish copies of the omitted schedules to the Securities and Exchange Commission upon request by the Commission.
Item 16.    Form 10-K Summary
None.
78
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on February 26, 2025.
                                                          OPTION CARE HEALTH, INC.
 
                                                        /s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Executive Vice President
(Principal Financial Officer and Duly Authorized Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities on the dates indicated.
SignatureTitle(s)Date
/s/ John C. Rademacher
John C. Rademacher
Chief Executive Officer, President and Director
(Principal Executive Officer)
February 26, 2025
/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Executive Vice President
(Principal Financial Officer)
February 26, 2025
   
/s/ Nicole Maggio
Nicole Maggio
Senior Vice President, Corporate Controller
(Principal Accounting Officer)
February 26, 2025
/s/ Harry M. Jansen Kraemer, Jr.
Harry M. Jansen Kraemer, Jr.
Non-Executive Chairman of the Board
February 26, 2025
/s/ Elizabeth Q. Betten
Elizabeth Q. Betten
Director
February 26, 2025
/s/ Elizabeth D. Bierbower
Elizabeth D. Bierbower
Director
February 26, 2025
/s/ Barbara W. Bodem
Barbara W. Bodem
Director
February 26, 2025
/s/ Eric K. Brandt
Eric K. Brandt
Director
February 26, 2025
/s/ Natasha Deckmann
Natasha Deckmann
Director
February 26, 2025
   
/s/ David W. Golding
David W. Golding
Director
February 26, 2025
/s/ R. Carter Pate
R. Carter Pate
Director
February 26, 2025
/s/ Timothy P. Sullivan
Timothy P. Sullivan
Director
February 26, 2025
/s/ Norman L. Wright
Norman L. Wright
Director
February 26, 2025
79
 EX-19 2 ex19-insidertradingpolicy.htm EX-19 Document



Insider Trading Policy
(Effective December 13, 2024)


PURPOSE:
Federal and state securities laws prohibit individuals from trading in the securities of a company while they are aware of material information about that company that is not generally known or available to the public. Such trading is often referred to as “insider trading.” The purpose of this Insider Trading Policy (this “Policy”) is to prevent insider trading or allegations of insider trading, and to protect the reputation for integrity and ethical conduct of Option Care Health, Inc. (“Option Care Health”).

POLICY:
Applicability of Policy and Certain Definitions
A.Material Nonpublic Information means material information (described below) that has either not been disclosed to the public generally or has been disclosed so recently that sufficient time has not yet passed to allow the information to become widely available among investors and the financial community. Generally, information is public only if it has been disseminated through a widely circulated press release, a filing made with the Securities and Exchange Commission or a conference call or webcast that was announced in advance and publicly accessible.
B.Material Information means information about a company a reasonable investor would consider important to an investment decision, or information that could reasonably be expected to influence the price of that company’s securities. While the materiality of information will depend on the specific facts and circumstances, examples of categories of information that are more likely to be considered material, or may be presumptively material, include:
◦Financial results or significant changes to financial condition
◦Projections of future financial results, including earnings or losses
◦Significant new products or services
◦Significant pricing changes
◦Gain or loss of a major contract or strategic alliance
◦New equity or debt offerings or other significant financing transactions
◦Significant litigation or regulatory exposure due to actual or threatened litigation or regulatory action
◦Significant cybersecurity incidents
◦Major management changes or changes in control of the company
◦News of a pending or proposed merger, or significant divestiture or acquisition
◦Default under a significant financing arrangement, or financial liquidity problems
◦Major restructuring actions or asset impairments
◦Changes in auditors
◦Major events regarding a company’s securities (such as defaults, redemptions, stock splits, repurchase plans, changes in dividends)
I.Covered Persons. This Policy applies to:


1.All Option Care Health Personnel. All directors, officers and employees of Option Care Health and its subsidiaries (“Option Care Health Personnel”), as well as members of their immediate families and others living in the same household.
2.Related Parties. Any other person or entity, including a trust, corporation, partnership or other association, whose transactions in Option Care Health’s securities are directed by any person covered by paragraph C(1) or are subject to that person’s influence or control.
The individuals and entities described in paragraphs C(1) and C(2) are “Covered Persons.”

In the event of a termination of employment or service to Option Care Health, any person who ceases to be a Covered Person when they are aware of material nonpublic information will continue to be subject to the restrictions of this Policy until that information becomes public or is no longer material. Accordingly, the blackout periods and pre-clearance may continue to apply after ceasing to be a Covered Person based on the circumstances at the time of separation.
I.Covered Transactions. The securities trading that this Policy covers includes purchases and sales of Option Care Health common stock, options to acquire common stock and any other securities Option Care Health may issue from time to time, such as preferred stock, warrants and convertible debentures, and purchases and sales of derivative securities relating to Option Care Health’s stock, whether or not issued by Option Care Health, such as exchange- traded options. Trading covered by this Policy may or may not include transactions under Option Care Health sponsored plans as follows:
1.Stock Option Exercises. The Policy’s trading restrictions do not apply to the purchase of Option Care Health stock through the exercise of stock options granted by Option Care Health (whether by cash exercise, stock swap or net exercise, to the extent such forms of exercise are permitted by Option Care Health). The trading restrictions do apply to any subsequent sale of Option Care Health stock acquired through an option exercise; and, therefore, do apply to a broker-assisted cashless exercise.
2.Restricted Stock/Unit and Performance Stock/Unit Awards. The Policy’s trading restrictions do not apply to the vesting of restricted stock/units or performance stock/units, or to the exercise of a tax withholding right pursuant to which the person elects to have Option Care Health withhold shares of stock to satisfy tax withholding requirements upon vesting, to the extent such withholding is permitted by Option Care Health. The trading restrictions do apply to any market sales of shares.
3.Certain Gifts. The Policy’s trading restrictions do not apply to a bona fide gift of Option Care Health stock so long as either (i) the recipient of the gift is subject to the same trading restrictions under this Policy as are applicable to you, or (ii) you otherwise have no reason to believe that the recipient intends to sell the securities during any period in effect at the time of the gift pursuant to which you would not be permitted to trade pursuant to the terms of this Policy. Directors and Section 16 officers of Option Care Health must obtain pre-clearance of any gift of Option Care Health stock as set forth below.

Statement of Policy



Insider trading involves trading at any time when the person making the purchase or sale is aware of material nonpublic information regarding the company whose securities are being traded. If you have a doubt or question about whether you are aware of material nonpublic information concerning Option Care Health or another company, you should contact Option Care Health’s General Counsel at OCH-CorporateSecretary@optioncare.com.

A.No Trading on Material Nonpublic Information
a.Option Care Health Securities. If you are a Covered Person, you must not purchase or sell any Option Care Health securities, or otherwise advise or assist any third- party trading Option Care Health securities, while you are aware of material nonpublic information regarding Option Care Health.
b.Other Companies’ Securities. If you are a Covered Person and you obtain material nonpublic information about any other publicly-held company as a result of your work on behalf of Option Care Health or any of its subsidiaries, you must not trade in that company’s securities. These other publicly-held companies may include suppliers, customers, business partners, competitors and potential merger or acquisition targets.
A.No Disclosure to Others Who Might Trade. If you are a Covered Person, you must not communicate material nonpublic information to any person who does not need that information for a legitimate business purpose or recommend to anyone the purchase or sale of securities when you are aware of material nonpublic information about the company involved. This practice, known as “tipping,” also violates the securities laws and can result in the same civil and criminal penalties that apply to insider trading, even though you did not actually trade and did not benefit from another’s trading.
B.Protect Material Nonpublic Information. To reduce the possibility that material nonpublic information will be inadvertently disclosed:
a.You must treat material nonpublic information as confidential, exercise the utmost caution in preserving the confidentiality of that information, and should not discuss it with any other person who does not need to know it for a legitimate business purpose.
b.You should refrain from discussing material nonpublic information relating to Option Care Health or any public company in public places where such discussions can be overheard.
c.If you become aware of any unauthorized disclosure of material nonpublic information, whether inadvertent or otherwise, you should report such disclosure immediately to Option Care Health’s General Counsel at OCH-CorporateSecretary@optioncare.com.
I.Specific Material Developments. From time to time, material developments known only to a limited number of Option Care Health Personnel may occur and cause Option Care Health to impose on an appropriate group of Option Care Health Personnel additional restrictions on trading. You will be notified if you become part of such a group, and you should not disclose to others the fact that you have been so notified or that additional restrictions on your trading have been imposed.

Policy Prohibiting Pledging, Hedging and Other Speculative Trading

Option Care Health Personnel, as well as family members and anyone designated to engage in securities transactions on behalf of Option Care Health Personnel, are


prohibited at all times from engaging in the following transactions with respect to Option Care Health securities:
•holding any Option Care Health securities in a margin account or pledging Option Care Health securities as collateral for a loan;
•engaging in transactions in puts, calls, or other derivative transactions relating to Option Care Health securities;
•short sales of Option Care Health securities (selling securities not owned at the time of sale); and
•purchasing any financial instruments (including prepaid variable forward contracts, equity swaps, zero cost collars and exchange funds) that are designed to hedge or offset any decrease in the market value of Option Care Health securities.
These restrictions apply to all Option Care Health securities owned directly or indirectly by Option Care Health Personnel, including Option Care Health securities owned by family members where the Option Care Health Personnel is deemed to beneficially own such securities, and their respective designees. However, the restrictions do not prevent any Option Care Health Personnel or their family members or their designees from engaging in general portfolio diversification or investing in broad-based index funds.

Additional Restrictions on Corporate Insiders

Directors and Section 16 officers of Option Care Health and other officers and key employees of Option Care Health and its subsidiaries who have been designated as “Corporate Insiders” by the General Counsel, as well as related parties of such individuals, are subject to additional restrictions on trading Option Care Health securities as set out in the attached Addendum. Option Care Health may also, from time to time, impose on all or an appropriate group of Covered Persons additional restrictions on trading Option Care Health securities when circumstances warrant. You will be notified by the General Counsel if you are subject to these additional Covered Persons restrictions.

Application of the Policy to Option Care Health

It is Option Care Health’s policy that any transactions by Option Care Health, including repurchases of Option Care Health securities, will comply with applicable laws with respect to insider trading, and Option Care Health will not trade in its own securities when there is material nonpublic information about Option Care Health.

Consequences of Violating Laws and Policy
A.Disciplinary Action. Option Care Health Personnel who fail to comply with this Policy will be subject to appropriate disciplinary action, which may include, among other consequences, the ineligibility to participate in Option Care Health’s equity incentive plans or termination of employment.
B.Civil and Criminal Penalties. Under federal securities laws, the penalties for violating insider trading laws are severe. If you trade on (or tip) material nonpublic information, you are subject to civil penalties of up to three times the profit gained or loss avoided, criminal fines of up to $5,000,000 and up to 20 years imprisonment.
Questions


Questions regarding any of the provisions or procedures of this Insider Trading Policy should be directed to the General Counsel at OCH-CorporateSecretary@optioncare.com.

ADDENDUM TO INSIDER TRADING POLICY
Additional Requirements and Responsibilities for Corporate Insiders

Purpose

This Addendum supplements the Option Care Health Insider Trading Policy and applies to
Corporate Insiders, as defined below. Corporate Insiders are subject to both the requirements of the Insider Trading Policy as well as to additional procedures and requirements described below to help prevent inadvertent violations of federal securities laws, to avoid even the appearance of impermissible insider trading, and to facilitate their compliance with certain legal requirements not applicable to Option Care Health Personnel generally.

Persons Covered

The individuals and entities described below are “Corporate Insiders.”

•Directors and Section 16 Officers. All provisions of this Addendum apply to the directors and officers of Option Care Health subject to Section 16 of the Securities Exchange Act of 1934 (together, referred to herein as “Section 16 Persons”).
•Other Officers and Key Employees. Designated provisions of this Addendum apply to certain other officers and key employees of Option Care Health and its subsidiaries. These other officers and key employees, whose duties cause them to regularly have access to material nonpublic information about Option Care Health, will be notified by the General Counsel that they are subject to this Addendum.
•Related Parties. If you are covered by either of the above categories, then this Addendum also applies to the same extent to your immediate family members and other individuals living in your household (“Family Members”), and to any other person or entity, including a trust, corporation, partnership or other association, whose transactions in Option Care Health securities are directed by you or your Family Members or are subject to the influence or control of you or your Family Members. Also, you are responsible for informing all Family Members and such related parties of the requirements of this Addendum.
Blackout Periods for Corporate Insiders

Trading Not Permitted During Blackout Periods. If you are a Corporate Insider, you may not purchase, sell or otherwise trade Option Care Health securities during the period beginning on the 15th day of the last calendar month of each fiscal quarter and continuing through the second trading day following the public release of Option Care Health’s financial results for that fiscal quarter (each such period being a “blackout period”). For the sake of clarity, if quarterly financial results are release before the open


of market on a certain day, that day will count as the first trading day following the public release of such results. If a Corporate Insider wishes to trade outside of a blackout period, the person may do so only if he or she is not then aware of any material nonpublic information and has complied with the notification and pre-clearance procedures described below.

Illustration – Blackout Period: If financial results for the quarter ended March 31 are released after the stock market closes on April 26, then Corporate Insiders are prohibited from trading from March 1 through April 28, but could trade from April 29 through June 14, if April 27 and 28 are trading days on the Nasdaq Stock Market and unless they are aware of material nonpublic information or have not complied with the notification and pre-clearance procedures below.

Preclearance Requirements for Trades Outside of Blackout Periods

Notices of Intended Transaction and Requests for Approval. If you are a Corporate Insider, you may not engage in any transaction involving Option Care Health securities outside blackout periods without first obtaining pre-clearance of that transaction from Option Care Health’s General Counsel. Prior to initiating any transaction in Option Care Health securities outside a blackout period, you must deliver to the General Counsel an electronic notice (at the e-mail address below) that includes the type and maximum number of Option Care Health securities you wish to trade, the terms of the proposed transaction (if any), and the certifications set forth on the attached Exhibit A. This form should be submitted via e-mail to OCH-CorporateSecretary@optioncare.com. The General Counsel may approve modifications to this notice process and pre-clearance notice form or require additional certifications in connection with providing clearance.

Clearance to Proceed with a Transaction. No pre-clearance notice will be an effective clearance to a trade unless and until the General Counsel or his or her designee responds to the notice with his or her approval in writing. Any such approval will be valid for two full trading days following approval, unless an earlier deadline is imposed by the General Counsel. However, the overarching prohibition on trading when you are aware of material nonpublic information regarding Option Care Health remains in effect.

Exceptions for Approved 10b5-1 Plans
Transactions by Corporate Insiders in Option Care Health securities that are executed pursuant to a 10b5-1 plan approved in writing in advance by the General Counsel are not subject to prohibition on trading based on material nonpublic information or the restrictions in this Addendum relating to the pre-clearance approval process or window periods.

Rule 10b5-1 provides an affirmative defense from insider trading liability under the federal securities laws for trading plans that meet certain requirements. In general, a 10b5-1 plan must be entered into during a permitted trading period and when you are not aware of material nonpublic information and comply with the other requirements set forth on Exhibit B



The rules related to the adoption and administration of 10b5-1 plans are under heavy regulatory scrutiny and are subject to change. For more information about adopting a 10b5-1 plan, please contact the General Counsel at OCH-CorporateSecretary@optioncare.com.


EXHIBIT A

GENERAL FORM OF CORPORATE INSIDER REQUEST FOR APPROVAL TO TRADE

•I certify I do not have any material non-public information related to Option Care Health;
•In connection with my proposed transaction, I certify that, in making this request, I am complying with the applicable provisions of the Option Care Health, Inc. Insider Trading Policy;
•I understand that clearance for the transaction(s), if granted, will be valid only until the earlier of (i) the two full trading days after clearance is granted and (ii) the trading window closing; and
•If I become aware of any material non-public information prior to the trade occurring, I will not execute the trade.

EXHIBIT B

RULE 10B5-1 TRADING PLAN TRANSACTIONS POLICY
Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, provides a defense from insider trading liability under Rule 10b-5. In order to be eligible to rely on this defense, a person subject to this Policy must enter into a Rule 10b5-1 plan for transactions in Option Care Health securities that meets certain conditions specified in that rule. Once the plan is adopted, the person must not exercise any influence over the amount of securities to be traded, the price at which they are to be traded or the date of the trade. The plan must either specify the amount, pricing and timing of transactions in advance or delegate discretion on these matters to an independent third party.

The following guidelines apply to all Rule 10b5-1 Plans (unless otherwise approved by the General Counsel):

•For Section 16 Persons, no transaction may take place under a Rule 10b5-1 Plan until expiration of a cooling-off period consisting of the later of (a) 90 days after adoption or modification (as specified in Rule 10b5-1) of the Rule 10b5-1 Plan or (b) two business days following the disclosure of Option Care Health’s financial results in a Form 10-Q or Form 10-K for the fiscal quarter (Option Care Health’s fourth fiscal quarter in the case of a Form 10-K) in which the Rule 10b5-1 Plan was adopted or modified (as specified in Rule 10b5-1), but in any event, this required cooling-off period is subject to a maximum of 120 days after adoption of the plan.


•For persons other than Section 16 Persons, no transaction may take place under a Rule 10b5-1 Plan until the expiration of a cooling-off period that is 30 days following the adoption or modification (as specified in Rule 10b5-1) of a Rule 10b5-1 Plan.
•Subject to certain limited exceptions specified in Rule 10b5-1, you may not have more than one Rule 10b5-1 Plan in effect at any same time.
•Subject to certain limited exceptions specified in Rule 10b5-1, you may only enter into a Rule 10b5-1 Plan that is designed to effect an open market purchase or sale of the total amount of securities subject to the Rule 10b5-1 Plan as a single transaction (a “single-transaction plan”) if you have not entered into a “single-transaction plan” in the prior 12 months.
•You must act in good faith with respect to a Rule 10b5-1 Plan. A Rule 10b5-1 Plan cannot be entered into as part of a plan or scheme to evade the prohibition of Rule 10b5. Therefore, although modifications to an existing Rule 10b5-1 Plan are not prohibited, a Rule 10b5-1 Plan should be adopted with the intention that it will not be amended or terminated prior to its expiration.
•Section 16 Persons must include a representation in the Rule 10b5-1 Plan that (i) the person is not aware of material, nonpublic information about Option Care Health or Option Care Health securities and (ii) the person is adopting the plan in good faith and not as part of plan or scheme to evade the prohibitions of Rule 10b-5.
For purposes of the above, a modification as specified in Rule 10b5-1 includes any modification of a Rule 10b5-1 Plan that changes the amount, price or timing of the purchase or sale of securities underlying the 10b5-1 Plan.


 EX-21.1 3 ex211-listofsubsidiaries.htm EX-21.1 Document

EXHIBIT 21.1 

OPTION CARE HEALTH, INC. AND ITS SUBSIDIARIES
Entity NameState of IncorporationDoing Business As
BioScrip Infusion Services, Inc.CaliforniaBioScrip Infusion Services
BioScrip Infusion Services, LLCDelawareBioScrip Infusion Services
BioScrip PBM Services, LLCDelawareBioScrip PBM Services
BioScrip Pharmacy Services, Inc.OhioBioScrip Pharmacy Services
CHI Holding CorporationDelawareCHI Holding Corporation
Chronimed, LLCMinnesotaChronimed, LLC
CHS Holdings, LLCDelawareCHS Holdings, LLC
Clinical Holdings, Inc.OhioClinical Holdings, Inc.
Clinical Specialties Network Services of Illinois, Inc.OhioClinical Specialties Network Services of Illinois, Inc.
Clinical Specialties, Inc.OhioClinical Specialties
Crescent Healthcare, Inc.CaliforniaCrescent Healthcare
Critical Care Systems of New York, Inc.New YorkCritical Care Systems of New York, Inc.
Critical Care Systems, LLCDelawareOption Care
Critical Homecare Solutions, LLCDelawareCritical Homecare Solutions, LLC
CSI Managed Care, Inc.OhioCSI Managed Care, Inc.
CSI Network Services of Indiana, Inc.OhioCSI Network Services of Indiana, Inc.
CSI Network Services of Michigan, Inc.OhioCSI Network Services of Michigan, Inc.
Deaconess Enterprises, LLCOhioDeaconess Enterprises, LLC
Deaconess HomeCare, LLCDelawareDeaconess HomeCare, LLC
East Goshen Pharmacy, LLCPennsylvaniaBioScrip Infusion Services
HC Group Holdings II, LLCDelawareHC Group Holdings II, LLC
HC Group Holdings III, Inc.DelawareHC Group Holdings III, Inc.
Healthy Connections Homecare Services, Inc.TexasOption Care Women's Health
Home I.V. Specialists, Inc.ArkansasHome IV Specialists
HomeChoice Partners, LLCDelawareBioScrip Infusion Services
InfuScience South Carolina, LLCDelawareBioScrip Infusion Services
InfuScience, LLCDelawareBioScrip Infusion Services
Infusion Partners of Melbourne, LLCGeorgiaBioScrip Infusion Services
Infusion Partners, LLCOhioBioScrip Infusion Services
Infusion Solutions, Inc.New HampshireBioScrip Infusion Services
Knoxville Home Therapies, LLCTennesseeBioScrip Infusion Services
MedNow Infusion, LLCDelawareOption Care
Naven Health, Inc.FloridaNaven Health, Inc.
New England Home Therapies, Inc.MassachusettsBioScrip Infusion Services
Option Care Enterprises, Inc.DelawareOption Care
Option Care Health, Inc. (f/k/a BioScrip, Inc.)DelawareOption Care Health, Inc. (f/k/a BioScrip, Inc.)
Option Care Home Care, Inc.IllinoisOption Care


Option Care Infusion Services, Inc.DelawareOption Care Infusion Services, Inc.
Option Care Infusion Suites, LLCDelawareOption Care Infusion Suites, LLC
Option Care of New York, Inc.New YorkOption Care of New York, Inc.
OptioNet, Inc.DelawareOptioNet, Inc.
Professional Home Care Services, Inc.DelawareProfessional Home Care Services, Inc.
River City Pharmacy, Inc.CaliforniaOption Care
Scott-Wilson, Inc.KentuckyBioScrip Infusion Services
Specialty Pharma, Inc.DelawareSpecialty Pharma, Inc.
Springville Pharmacy Infusion Therapy, Inc.New YorkOption Care
Trinity HomeCare, LLCNew JerseyOption Care
Rochester Home Infusion, Inc.MinnesotaRochester Home Infusion
SPNN Holdings, LLCDelawareSPNN Holdings, LLC
Option Care at Legacy Health, LLCOregonOption Care at Legacy Health
Option Care Infusion Services, LLCTennesseeVanderbilt HC/Option Care IV Services
OCH Infusion Centers (Colorado), LLCDelawareOption Care Health Infusion Center
OCH Infusion Centers (Texas), LLCDelawareOption Care Health Infusion Center
OCH Infusion Clinic (Arizona), LLCDelawareOption Care Health Infusion Clinic
OCH Infusion Centers, LLCDelawareOCH Infusion Centers, LLC

 EX-23.1 4 ex231-12312024x10k.htm EX-23.1 Document

EXHIBIT 23.1 


Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the registration statements (Nos. 333-214039, 333-216630, and 333-216631) on Form S-3 and the registration statements (Nos. 333-228310 and 333-281145) on Form S-8 of our reports dated February 26, 2025, with respect to the consolidated financial statements of Option Care Health, Inc. and the effectiveness of internal control over financial reporting.
/s/ KPMG LLP
Chicago, Illinois
February 26, 2025

 EX-31.1 5 ex311-12312024x10k.htm EX-31.1 Document

EXHIBIT 31.1 

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, John Rademacher, certify that:
1.     I have reviewed this Annual Report on Form 10-K of Option Care Health, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 26, 2025


/s/ John Rademacher
John Rademacher
Chief Executive Officer, President and Director (Principal Executive Officer)


 EX-31.2 6 ex312-12312024x10k.htm EX-31.2 Document

EXHIBIT 31.2

CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael Shapiro, certify that:
1.     I have reviewed this Annual Report on Form 10-K of Option Care Health, Inc.;
2.     Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.     Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.     The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f))for the registrant and have:
(a)     Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)     Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)     Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)     Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.     The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)     All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)     Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 26, 2025


/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Executive Vice President (Principal Financial Officer)


EX-32.1 7 ex321-12312024x10k.htm EX-32.1 Document

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
    In connection with the Annual Report of Option Care Health, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John Rademacher, Chief Executive Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 26, 2025


/s/ John Rademacher
John Rademacher
Chief Executive Officer, President and Director (Principal Executive Officer)

    


 EX-32.2 8 ex322-12312024x10k.htm EX-32.2 Document

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
    In connection with the Annual Report of Option Care Health, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael Shapiro, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)     The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)    The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: February 26, 2025


/s/ Michael Shapiro
Michael Shapiro
Chief Financial Officer and Executive Vice President (Principal Financial Officer)






EX-101.SCH 9 bios-20241231.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER PAGE link:presentationLink link:calculationLink link:definitionLink 0000002 - Document - Audit Information link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - BUSINESS ACQUISITIONS AND DIVESTITURES link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - EMPLOYEE BENEFIT PLANS link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - PROPERTY AND EQUIPMENT link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - INDEBTEDNESS link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - DERIVATIVE INSTRUMENTS link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - FAIR VALUE MEASURMENTS link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 9952175 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9955512 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955513 - Disclosure - INCOME TAXES - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9955514 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9955515 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9955516 - Disclosure - PROPERTY AND EQUIPMENT (Tables) link:presentationLink link:calculationLink link:definitionLink 9955517 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955518 - Disclosure - INDEBTEDNESS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955519 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9955520 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9955521 - Disclosure - STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9955522 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9955523 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955525 - Disclosure - BUSINESS ACQUISITIONS AND DIVESTITURES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955526 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details) link:presentationLink link:calculationLink link:definitionLink 9955527 - Disclosure - EMPLOYEE BENEFIT PLANS (Details) link:presentationLink link:calculationLink link:definitionLink 9955528 - Disclosure - INCOME TAXES - Income Tax Benefit (Details) link:presentationLink link:calculationLink link:definitionLink 9955529 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 9955530 - Disclosure - INCOME TAXES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955531 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955532 - Disclosure - INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955533 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 9955534 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Details) link:presentationLink link:calculationLink link:definitionLink 9955535 - Disclosure - LEASES - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955536 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9955537 - Disclosure - PROPERTY AND EQUIPMENT (Details) link:presentationLink link:calculationLink link:definitionLink 9955538 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955539 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9955540 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955541 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - INDEBTEDNESS - Summary of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955542 - Disclosure - INDEBTEDNESS - Summary of Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9955543 - Disclosure - INDEBTEDNESS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955544 - Disclosure - INDEBTEDNESS - Long-term Debt Maturities (Details) link:presentationLink link:calculationLink link:definitionLink 9955545 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 9955546 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9955547 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9955548 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9955549 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9955550 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9955551 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955552 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details) link:presentationLink link:calculationLink link:definitionLink 9955553 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9955554 - Disclosure - STOCKHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9955555 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) link:presentationLink link:calculationLink link:definitionLink 9955556 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9955557 - Disclosure - SEGMENT REPORTING (Details) link:presentationLink link:calculationLink link:definitionLink 9955558 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 bios-20241231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 bios-20241231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 bios-20241231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Options Exercisable (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable Second Lien Credit Agreement Second Lien Credit Agreement [Member] Second Lien Credit Agreement Adjustments to reconcile net income to net cash provided by operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Acquisitions Goodwill, Acquired During Period Interest limitation carryforward Deferred Tax Asset, Interest Carryforward Statistical Measurement [Domain] Statistical Measurement [Domain] RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Assets under development Asset under Construction [Member] Cover [Abstract] 2030 and beyond Lessee, Operating Lease, Liability, to be Paid, after Year Five NET INCREASE IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Director Director [Member] Maturities of Lease Liabilities, Operating Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] 2017 Warrants 2017 Warrants [Member] 2017 Warrants [Member] Income Tax Jurisdiction [Domain] Income Tax Jurisdiction [Domain] Percentage of the combined company held Business Acquisition, Percentage of Voting Interests Acquired Trading Symbol Trading Symbol Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Ownership interest Equity Method Investment, Ownership Percentage All Trading Arrangements All Trading Arrangements [Member] Legacy Health Systems Legacy Health Systems [Member] Legacy Health Systems [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Basic and Diluted Earnings Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Derivative [Line Items] Derivative [Line Items] Cash paid for income taxes Income Taxes Paid, Net Purchase accounting adjustments Goodwill, Measurement Period Adjustment Investments in equity-method investees Equity Method Investments Cost of Goods and Service, Product and Service Benchmark Cost of Goods and Service, Product and Service Benchmark [Member] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Income Tax Examination [Line Items] Income Tax Examination [Line Items] Derivative [Table] Derivative [Table] Accrued expenses and other current liabilities Accrued Expenses And Other Current Liabilities Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations. Inventories Inventory, Policy [Policy Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] First Lien Credit Agreement, Third Amendment First Lien Credit Agreement, Third Amendment [Member] First Lien Credit Agreement, Third Amendment Stock-based compensation tax withholdings Proceeds from Stock Options Exercised Summary of Amount and Location of Derivatives in the Balance Sheet Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] FAIR VALUE MEASURMENTS Fair Value Disclosures [Text Block] Award Timing Disclosures [Line Items] Investment, Name [Domain] Investment, Name [Domain] Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Cash paid for operating leases Operating Lease, Payments, Use LEASES Lessee, Operating Leases [Text Block] Common stock, shares, outstanding (in shares) Balance, beginning of the year Balance, end of the period Common Stock, Shares, Outstanding Documents Incorporated by Reference Documents Incorporated by Reference [Text Block] Share-based Payment Arrangement, Option, Exercise Price Range [Table] Share-Based Payment Arrangement, Option, Exercise Price Range [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Operating lease liability, net of current portion Operating Lease, Liability, Noncurrent Total noncurrent assets Assets, Noncurrent Term of warrants Warrants and Rights Outstanding, Term Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] Plan Name [Domain] Plan Name [Domain] Federal income tax expense (benefit) Federal Income Tax Expense (Benefit), Continuing Operations Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Other noncurrent assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Total gross intangible assets Finite-Lived Intangible Assets, Gross Intangible Asset, Finite-Lived [Table] Intangible Asset, Finite-Lived [Table] Treasury stock, shares, acquired (in shares) Treasury Stock, Shares, Acquired Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Supplier [Domain] Supplier [Domain] Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Treasury Stock Treasury Stock, Common [Member] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Other segment items Other Cost and Expense, Operating Plan Name [Axis] Plan Name [Axis] Merger Operating Loss Carryforward Merger Operating Loss Carryforward [Member] Merger Operating Loss Carryforward [Member] Equity Components [Axis] Equity Components [Axis] Number of warrants exercised (in shares) Class of Warrant or Right, Number of Securities Exercised Class of Warrant or Right, Number of Securities Exercised Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Accounts Receivable Accounts Receivable [Policy Text Block] Weighted Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Management Fee Income Management Fee Income [Member] Management Fee Income Performance stock unit awards Performance Stock Unit [Member] Performance Stock Unit Adjustment to Compensation, Amount Adjustment to Compensation Amount Balance at December 31, 2023 Balance at December 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Deferred financing costs Payments of Debt Issuance Costs Tabular List, Table Tabular List [Table Text Block] 2029 Lessee, Operating Lease, Liability, to be Paid, Year Five Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Valuation allowance released Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Number of shares to be purchased (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Antidilutive securities excluded (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount EMPLOYEE BENEFIT PLANS Compensation and Employee Benefit Plans [Text Block] Audit Information [Abstract] Audit Information Operating lease cost Operating Lease, Expense Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Credit Facility [Domain] Credit Facility [Domain] Cost of Revenue Cost of Goods and Service [Policy Text Block] Cash and cash equivalents - beginning of the period CASH AND CASH EQUIVALENTS - END OF PERIOD Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Forfeited and expired Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value Concentrations of Business Risk Concentration Risk, Business Risk, Policy [Policy Text Block] Concentration Risk, Business Risk, Policy [Policy Text Block] Indefinite Carryforward Period Indefinite Carryforward Period [Member] Indefinite Carryforward Period CURRENT ASSETS: Assets, Current [Abstract] Goodwill Goodwill - net book value, beginning of period Goodwill - net book value, end of period Goodwill Stock-based compensation tax withholdings Payment, Tax Withholding, Share-Based Payment Arrangement OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX: Other Comprehensive Income (Loss), Net of Tax [Abstract] Share repurchase program, authorized amount Share Repurchase Program, Authorized, Amount Treasury stock, shares (in shares) Treasury Stock, Common, Shares Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration] Product and Service [Domain] Product and Service [Domain] Stock Option Share-Based Payment Arrangement, Option [Member] Vested and issued (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Depreciation expense Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Other financing activities Proceeds from (Payments for) Other Financing Activities Antidilutive Security, Excluded EPS Calculation [Table] Antidilutive Security, Excluded EPS Calculation [Table] NET COMPREHENSIVE INCOME Comprehensive Income (Loss), Net of Tax, Attributable to Parent First Lien Term Loan First Lien Term Loan First Lien Term Loan [Member] First Lien Term Loan [Member] Preferred stock, shares, outstanding (in shares) Preferred stock outstanding (in shares) Preferred Stock, Shares Outstanding Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member] Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member] Other, net Effective Income Tax Rate Reconciliation, Other Adjustments, Percent Warrants Warrant [Member] Security Exchange Name Security Exchange Name Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] Net deferred tax liabilities Deferred Tax Liabilities, Net Summary of Outstanding Options by Exercise Price Range Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block] 2015 Warrants 2015 Warrants [Member] 2015 Warrants [Member] Equity Interest Type [Axis] Equity Interest Type [Axis] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Restricted Stock Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net Repayments of debt principal Payments to extinguish debt Repayments of Debt ICFR Auditor Attestation Flag ICFR Auditor Attestation Flag Current Current State and Local Tax Expense (Benefit) Total liabilities Liabilities Salaries, benefits, and other employee expense Labor and Related Expense Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Termination fee income Termination Fee Income, Tax Effect Termination Fee Income, Tax Effect Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolver Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current portion of operating lease liability Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares, issued (in shares) Common Stock, Shares, Issued Senior Notes Second Lien Term Loan [Member] Second Lien Term Loan [Member] Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Concentration risk Concentration Risk, Percentage Net operating losses Deferred Tax Assets, Operating Loss Carryforwards Options Exercisable Options Exercisable [Abstract] Options Exercisable [Abstract] Assets held for sale Disposal Group, Including Discontinued Operation, Assets Aggregate Intrinsic Value Aggregate Intrinsic Value [Abstract] Aggregate Intrinsic Value [Abstract] Equipment Equipment [Member] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Subsequent Event [Line Items] Subsequent Event [Line Items] Property and equipment, gross Property, Plant and Equipment, Gross Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Pre-tax gains (losses) on interest rate derivatives recognized Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax Exercise of stock options, vesting of restricted stock, and related tax withholdings Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Goodwill, Intangible Assets, Property and Equipment, and Referral Sources Goodwill and Intangible Assets, Policy [Policy Text Block] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Class of Warrant or Right [Table] Class of Warrant or Right [Table] Business acquisitions, net of cash acquired Payments to Acquire Businesses, Net of Cash Acquired Weighted average interest rate paid on term loans during period Long-Term Debt, Weighted Average Interest Rate, over Time Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Weighted average common shares outstanding, diluted (in shares) Weighted average number of common shares outstanding, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Long-term Debt, Type [Axis] Long-Term Debt, Type [Axis] Net of cash acquired Business Combination, Consideration Transferred, Net Of Cash Acquired Business Combination, Consideration Transferred, Net Of Cash Acquired Total stockholders’ equity Equity, beginning balance Equity, ending balance Equity, Attributable to Parent Deferred tax assets before valuation allowance Deferred Tax Assets, Gross Entity Voluntary Filers Entity Voluntary Filers Proceeds from issuance of debt Proceeds from Issuance of Debt Statement of Financial Position Location, Balance [Axis] Statement of Financial Position Location, Balance [Axis] Hedging Designation [Domain] Hedging Designation [Domain] Interest expense, net Interest Expense, Nonoperating Deferred income taxes - net Deferred Income Tax Expense (Benefit) Gain (loss) location of derivative instruments Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Schedule of the Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] PROPERTY AND EQUIPMENT Property, Plant and Equipment Disclosure [Text Block] Computer software, purchased and internally developed Software and Software Development Costs [Member] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Equity in earnings of joint ventures Investment Income, Net Undrawn letters of credit issued and outstanding Letters of Credit Outstanding, Amount Charged (Benefit) to Other Accounts SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account Selling, general and administrative expenses Selling, General and Administrative Expense Defined contribution plan expense Defined Contribution Plan, Cost OTHER COMPREHENSIVE (LOSS) INCOME Other comprehensive income (loss) Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Interest rate cap designated as cash flows hedge Interest Rate Cap [Member] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Depreciation expense in cost of revenue Cost of Sales [Member] Company's stockholders, ownership percentage following merger Subsidiary, Ownership Percentage, Parent Governmental Programs Government Contracts Concentration Risk [Member] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Sale of Stock [Domain] Sale of Stock [Domain] Net Balance Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus 2028 Long-Term Debt, Maturity, Year Four All Executive Categories All Executive Categories [Member] Intangible assets, net Finite-Lived Intangible Assets, Net, Excluding Customer Lists Finite-Lived Intangible Assets, Net, Excluding Customer Lists Statement of Financial Position Location, Balance [Domain] Statement of Financial Position Location, Balance [Domain] Employer matching contribution percent Defined Contribution Plan, Employer Matching Contribution, Percent of Match 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted Average Remaining Contractual Life Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term BUSINESS ACQUISITIONS AND DIVESTITURES Mergers, Acquisitions and Dispositions Disclosures [Text Block] ASSETS Assets [Abstract] Proceeds from warrant exercises Proceeds from Warrant Exercises Dividend rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Operating lease liability Deferred Tax Assets, Lease Liability Deferred Tax Assets, Lease Liability Document Type Document Type Derivative Contract [Domain] Derivative Contract [Domain] Commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Effective rate on term loans at end of period Debt Instrument, Interest Rate, Effective Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Schedule of Results of Operations for Reportable Segment Schedule of Segment Reporting Information, by Segment [Table Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Treasury stock acquired, average cost per share (in dollars per share) Shares Acquired, Average Cost Per Share Option Care, Combined Company Option Care, Combined Company [Member] Option Care, Combined Company Computer Software Computer Software, Intangible Asset [Member] Document Annual Report Document Annual Report Secondary Offering Secondary Offering [Member] Secondary Offering Weighted Average Remaining Contractual Life Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Lower range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit OTHER INCOME (EXPENSE): Other Expense, Nonoperating [Abstract] Vested and issued (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Shares purchased from exercise of warrants (in shares) Class of Warrant or Right, Securities Exercised Class of Warrant or Right, Securities Exercised Depreciation and amortization expense Depreciation, Amortization and Accretion, Net Debt instrument, periodic payment, principal Debt Instrument, Periodic Payment, Principal Schedule of Future Amortization Expense for Intangible Assets Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Event [Table] Subsequent Event [Table] Maximum Maximum [Member] Amortization expense for intangible assets Amortization of Intangible Assets Options Outstanding (in shares) Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Total intangible assets, net Finite-Lived Intangible Assets, Net Change in Deferred Tax Asset Valuation Allowance SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Discount Debt Instrument, Unamortized Discount State income tax expense (benefit): State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract] Leasehold improvements Leasehold Improvements [Member] Schedule of Fair Value of Awards Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less: interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Beginning balance Ending balance SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount NONCURRENT ASSETS: Assets, Noncurrent [Abstract] Accelerated depreciation Deferred Tax Liabilities, Accelerated Depreciation Deferred Tax Liabilities, Accelerated Depreciation Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Class of warrant or right, outstanding (in shares) Class of Warrant or Right, Outstanding Options Outstanding Options Outstanding [Abstract] Options Outstanding [Abstract] Specialty Pharmacy Nursing Network, Inc. Specialty Pharmacy Nursing Network, Inc. [Member] Specialty Pharmacy Nursing Network, Inc. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] INCOME BEFORE INCOME TAXES Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type [Domain] Award Type [Domain] New First Lien Term Loan New First Lien Term Loan [Member] New First Lien Term Loan [Member] Name Outstanding Recovery, Individual Name Summary of Valuation Allowance Summary of Valuation Allowance [Table Text Block] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Goodwill impairment Goodwill, Impairment Loss Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Medical Supply Vendors Supplier Concentration Risk [Member] Non-PEO NEO Non-PEO NEO [Member] Title and Position [Axis] Title and Position [Axis] Intangible asset useful life (in years) Finite-Lived Intangible Asset, Useful Life Purchase of company stock, and related tax effects Stock Repurchased During Period, Value, Including Related Tax Effects Stock Repurchased During Period, Value, Including Related Tax Effects Paid-in Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Investment, Name [Axis] Investment, Name [Axis] Deferred tax liabilities: Deferred Tax Liabilities, Deferred Expense [Abstract] Unbilled receivables Unbilled Receivables, Current Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Class of Stock [Axis] Class of Stock [Axis] Earnings per share, diluted (in dollars per share) Earnings Per Share, Diluted Title and Position [Domain] Title and Position [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Total accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Non-cash operating lease costs Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name State State and Local Jurisdiction [Member] Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Price concessions Deferred Tax Assets, Bad Debt Reserve Deferred Tax Assets, Bad Debt Reserve Ownership [Axis] Ownership [Axis] Number of operating segments Number of Operating Segments Retirement Benefits [Abstract] Retirement Benefits [Abstract] Employer matching contribution percent of employees' gross pay Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Customer [Axis] Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Accrued expenses and other current liabilities Increase (Decrease) in Other Accounts Payable and Accrued Liabilities Consolidated balance sheet data: Statement of Financial Position [Abstract] Accounts receivable, net Increase (Decrease) in Receivables Stock-based incentive compensation expense Share-Based Payment Arrangement, Noncash Expense Deferred tax assets net of valuation allowance Deferred Tax Assets, Net of Valuation Allowance Other Deferred Tax Liabilities, Other Value of shares vested in period Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Gain on sale Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal INCOME TAX EXPENSE Total income tax expense (benefit) Income tax expense (benefit) INCOME TAX EXPENSE Income Tax Expense (Benefit) Notional amount of derivative Derivative, Notional Amount Total derivative assets Derivative Asset Forfeited and expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period Supplemental disclosure of cash flows information: Supplemental Cash Flow Information [Abstract] Weighted average period of recognition Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Depreciation expense in operating expenses Operating Expense [Member] NET REVENUE Infusion services net revenue Revenue from Contract with Customer, Excluding Assessed Tax Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss) Derivative Instruments, Gain (Loss) [Table Text Block] State income tax expense State and Local Income Tax Expense (Benefit), Continuing Operations Total other (expense) income Nonoperating Income (Expense) Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Auditor Firm ID Auditor Firm ID Effective income tax rate Effective income tax rate Effective Income Tax Rate Reconciliation, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities OPERATING INCOME Operating Income (Loss) Number of additional shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Variable Rate [Domain] Variable Rate [Domain] Income Tax Jurisdiction [Axis] Income Tax Jurisdiction [Axis] Business Acquisition [Line Items] Business Acquisition [Line Items] Share based compensation impacts Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent Equity Method Investments Equity Method Investments [Policy Text Block] TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity Other adjustments Other Operating Activities, Cash Flow Statement Subsequent Events Subsequent Events [Text Block] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Exercisable range of years Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accrued compensation and employee benefits Employee-related Liabilities, Current Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Initial percentage of target shares granted Share-Based Payment Arrangement, Initial Percentage Of Target Shares Granted Share-Based Payment Arrangement, Initial Percentage Of Target Shares Granted Hedging Designation [Axis] Hedging Designation [Axis] Business combination, acquisition-related expenses Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed DERIVATIVE INSTRUMENTS Derivative Instruments and Hedging Activities Disclosure [Text Block] Tax Credit Carryforward [Axis] Tax Credit Carryforward [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Summary of Restricted Stock Award Activity Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block] Number of infusion sites Number Of Infusion Sites Number Of Infusion Sites Schedule of Long-term Debt Maturities Schedule of Maturities of Long-Term Debt [Table Text Block] Right of use asset obtained in exchange for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Underlying Security Market Price Change Underlying Security Market Price Change, Percent Tax Credit Carryforward, Name [Domain] Tax Credit Carryforward, Name [Domain] Individual: Individual [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Value of shares surrendered to satisfy tax withholding obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Accumulated Other Comprehensive Income (Loss) AOCI Attributable to Parent [Member] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items] Expected life of options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Inventories Inventory, Net Liabilities held for sale Disposal Group, Including Discontinued Operation, Liabilities Long-term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service [Axis] Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Equipment, furniture and other Equipment, Furniture, And Other [Member] Equipment, Furniture, And Other [Member] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Intramed Plus Intramed Plus [Member] Intramed Plus Due to joint ventures Accounts Payable, Other Sale price Disposal Group, Including Discontinued Operation, Consideration OPERATING COSTS AND EXPENSES: Operating Expenses [Abstract] Schedule of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS’ EQUITY Liabilities and Equity [Abstract] Derivative term of contract Derivative, Term of Contract Hedging Instruments Derivatives, Policy [Policy Text Block] Valuation allowance Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent Infusion pumps Infusion Pumps [Member] Infusion Pumps [Member] Second Lien Term Loan Junior Lien [Member] Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Charged (Benefit) to Costs and Expenses SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Due from joint ventures Other Receivables Related Party Transactions [Abstract] Related Party Transactions [Abstract] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] Operating lease right-of-use asset Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Exercise Price Range [Domain] Exercise Price Range [Domain] Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Derivative Instrument [Axis] Derivative Instrument [Axis] U.S. federal statutory tax rate Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Principal Amount Total Long-Term Debt, Gross Exercise Price Award Exercise Price Schedule of Deferred Tax Assets and Liabilities Schedule of Deferred Tax Assets and Liabilities [Table Text Block] EARNINGS PER SHARE Earnings Per Share [Text Block] Accrued compensation and employee benefits Increase (Decrease) in Employee Related Liabilities Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Operating loss carryforwards Operating Loss Carryforwards LEASES Lessee, Finance Leases [Text Block] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Shares granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Federal Domestic Tax Jurisdiction [Member] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Derivative Asset, Statement of Financial Position [Extensible Enumeration] Income Taxes Income Tax, Policy [Policy Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Other Other Income Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table] Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table] Interest Rate Floor Interest Rate Floor [Member] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Accounts payable Increase (Decrease) in Accounts Payable, Trade Weighted Average Exercise Price (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals All Individuals [Member] Trademarks and Trade Names Trademarks/names Trademarks and Trade Names [Member] PEO PEO [Member] Variable Rate [Axis] Variable Rate [Axis] Termination fee Business Combination, Contingent Consideration, Asset, Termination Fee Business Combination, Contingent Consideration, Asset, Termination Fee Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Amedisys, Inc. Amedisys, Inc. [Member] Amedisys, Inc. Name Trading Arrangement, Individual Name Other, net Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Property, Plant and Equipment, Type [Axis] Long-Lived Tangible Asset [Axis] Entity Public Float Entity Public Float $24.76 - $33.00 Option Exercise Price, Range Four [Member] Option Exercise Price, Range Four [Member] Equity in earnings of joint ventures Proportionate share of earnings in equity-method investees Equity in earnings of joint ventures Income (Loss) from Equity Method Investments Treasury stock; 17,585,613 and 8,330,022 shares outstanding, at cost, as of December 31, 2024 and 2023, respectively. Treasury Stock, Common, Value Commitment fee, unused portion Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Percentage of target shares granted Share-Based Payment Arrangement, Percentage Of Target Shares Granted Share-Based Payment Arrangement, Percentage Of Target Shares Granted Stock-based compensation tax withholdings Proceeds, Tax Withholding, Share-Based Payment Arrangement Proceeds, Tax Withholding, Share-Based Payment Arrangement First Lien Term Loan Senior Lien [Member] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Related Party [Domain] Related and Nonrelated Parties [Domain] Total noncurrent liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Restricted stock awards Restricted Stock Award [Member] Restricted Stock Award [Member] Local Phone Number Local Phone Number Four Vendors Four Vendors [Member] Four Vendors Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Supplier [Axis] Supplier [Axis] Accounts Receivable Benchmark Accounts Receivable, Benchmark [Member] Accounts Receivable, Benchmark Valuation allowance Valuation allowance Deferred Tax Assets, Valuation Allowance Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Total operating expenses Operating Expenses Deferred income taxes Deferred Income Tax Liabilities, Net Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Number of service locations Number Of Service Locations Number Of Service Locations Interest expense, net Interest Expense [Member] Share repurchases Stock Repurchased During Period, Shares Rebate receivable Contract with Customer, Receivable, after Allowance for Credit Loss Average performance period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] NONCURRENT LIABILITIES: Liabilities, Noncurrent [Abstract] SOFR Secured Overnight Financing Rate (SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Derivative Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement [Abstract] Deferred Deferred Federal Income Tax Expense (Benefit) Property, Plant and Equipment, Type [Domain] Long-Lived Tangible Asset [Domain] Statement of Income Location, Balance [Axis] Statement of Income Location, Balance [Axis] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] 2030 and beyond Finite-Lived Intangible Asset, Expected Amortization, after Year Five Debt Disclosure [Abstract] Debt Disclosure [Abstract] Gain on sale of assets Gain (Loss) on Disposition of Other Assets Common Stock Common Stock [Member] Measure: Measure [Axis] Change in unrealized (loss) gain on cash flow hedges, income tax benefit (expense) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Additional shares issued (in shares) Stock Issued During Period, Shares, New Issues Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Entity Emerging Growth Company Entity Emerging Growth Company Income Tax, Examination [Table] Income Tax, Examination [Table] Segment Reporting [Abstract] Entity Central Index Key Entity Central Index Key 2029 Long-Term Debt, Maturity, Year Five Exercise of warrants Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants Patients Patient Customer [Member] Patient Customer [Member] Credit Agreements, Entered Into 2019 Credit Agreements, Entered Into 2019 [Member] Credit Agreements, Entered Into 2019 [Member] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount The 2018 Plan 2018 Plan [Member] 2018 Plan [Member] 2024 Performance Stock Units 2024 Performance Stock Units [Member] 2024 Performance Stock Units STOCKHOLDERS' EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Equity Component [Domain] Equity Component [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Current portion of long-term debt Less: current portion Long-Term Debt, Current Maturities Weighted Average Remaining Contractual Life Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based incentive compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Restricted Stock Restricted Stock [Member] Entity Shell Company Entity Shell Company Valuation Allowance [Line Items] Valuation Allowance [Line Items] Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Statement [Table] Statement [Table] Government Healthcare Programs Government Healthcare Programs [Member] Government Healthcare Programs SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Unrecognized tax benefits Unrecognized Tax Benefits City Area Code City Area Code CURRENT LIABILITIES: Liabilities, Current [Abstract] Auditor Location Auditor Location Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Markets for Identical Item (Level 1) Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Compensation and benefits Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Senior Notes Senior Notes [Member] Preferred Stock Preferred Stock [Member] Purchase of company stock and related excise taxes Payments for Repurchase of Common Stock Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number 2027 Long-Term Debt, Maturity, Year Three Valuation Allowance, Deferred Tax Assets SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt, net of discount, deferred financing costs and current portion Total long-term debt Long-Term Debt, Excluding Current Maturities Operating lease right-of-use asset Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Total interest rate costs expected to reclassify during next 12 months Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net Revitalized, LLC Revitalized, LLC [Member] Revitalized, LLC Intangible assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted-average grant-date fair value per share (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Entity Well-known Seasoned Issuer Entity Well-known Seasoned Issuer Subsequent Event Type [Axis] Subsequent Event Type [Axis] Other amortizable intangible assets Other Intangible Assets [Member] INCOME TAXES Income Tax Disclosure [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four EARNINGS PER COMMON SHARE: Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Retained earnings Retained Earnings (Accumulated Deficit) Lien Category [Axis] Lien Category [Axis] Class of Stock [Domain] Class of Stock [Domain] Forfeited and expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Inventories Increase (Decrease) in Inventories Equity Interest Issued or Issuable, Type [Domain] Equity Interest Issued or Issuable, Type [Domain] Debt issuance costs and third party fees Debt Issuance Costs, Gross Schedule of Debt Schedule of Debt [Table Text Block] 2026 Long-Term Debt, Maturity, Year Two New Senior Unsecured Notes New Senior Unsecured Notes [Member] New Senior Unsecured Notes [Member] Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Exercise Price Range [Axis] Exercise Price Range [Axis] Weighted-average discount rate, operating leases Operating Lease, Weighted Average Discount Rate, Percent Present value of lease liabilities Operating Lease, Liability Net cash (used in) provided by financing activities Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Credit Facility [Axis] Credit Facility [Axis] $0.00 - $8.24 Option Exercise Price, Range One [Member] Option Exercise Price, Range One [Member] Amendment Flag Amendment Flag Total debt instruments Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Cash paid for business acquired Payments to Acquire Businesses, Gross Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization expense Depreciation and amortization expense Depreciation, Depletion and Amortization GROSS PROFIT Gross Profit Deferred Deferred State and Local Income Tax Expense (Benefit) Fair Value as of Grant Date Award Grant Date Fair Value Largest Payer Largest Payer [Member] Largest Payer Customer Concentration Risk Customer Concentration Risk [Member] Subsequent Events [Abstract] Subsequent Events [Abstract] Selling, General and Administrative Expenses Selling, General and Administrative Expenses, Policy [Policy Text Block] Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Debt Issuance Costs Debt issuance costs Debt Issuance Costs, Net Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction INDEBTEDNESS Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] STOCKHOLDERS’ EQUITY: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Interest Limitation Carryforwards Interest Limitation Carryforwards [Member] Interest Limitation Carryforwards [Member] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Debt instrument, face amount Debt Instrument, Face Amount Schedule of Net Revenue Earned by Category of Payer Disaggregation of Revenue [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Principles of Consolidation Consolidation, Policy [Policy Text Block] Granted Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December 31, 2023. Common Stock, Value, Issued Document Financial Statement Error Correction Flag Document Financial Statement Error Correction [Flag] Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Other investing activities Payments for (Proceeds from) Other Investing Activities Other noncurrent assets Other Noncurrent Assets [Member] State and local income taxes net of federal tax benefit Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Joint Venture Corporate Joint Venture [Member] Auditor Name Auditor Name Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Other Deferred Tax Assets, Other Forfeited and expired (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Changes in Shares of Common Stock Schedule of Common Stock Outstanding Roll Forward [Table Text Block] Loss on extinguishment of debt Gain (Loss) on Extinguishment of Debt CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Concentration Risk [Line Items] Concentration Risk [Line Items] Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2024 and 2023, respectively. Preferred Stock, Value, Issued Options Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Deferred tax liabilities Deferred Tax Liabilities, Gross Earnings per share, basic (in dollars per share) Earnings Per Share, Basic Operating lease liabilities Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Stock option awards Equity Option [Member] Ownership [Domain] Ownership [Domain] $8.24 - $16.52 Option Exercise Price, Range Two [Member] Option Exercise Price, Range Two [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Designated as Hedging Instrument Designated as Hedging Instrument [Member] Property and Equipment Property, Plant and Equipment, Policy [Policy Text Block] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Stock, Class of Stock [Table] Stock, Class of Stock [Table] Intangible assets Deferred Tax Liabilities, Intangible Assets Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount TOTAL ASSETS Assets Distribution from equity method investments Proceeds from Equity Method Investment, Distribution 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One COST OF REVENUE Cost of Goods and Services Sold Increase in borrowing capacity Debt Instrument, Increase in Borrowing Capacity Debt Instrument, Increase in Borrowing Capacity Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block] Acquisition of property and equipment Payments to Acquire Property, Plant, and Equipment Other noncurrent liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Stock Based Incentive Compensation Share-Based Payment Arrangement [Policy Text Block] Business Acquisitions Business Combinations Policy [Policy Text Block] Government payers Government Customer [Member] Government Customer [Member] Schedule of Effective Income Tax Rate Reconciliation Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] Termination Date Trading Arrangement Termination Date Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Other noncurrent assets and liabilities Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Business Description and Basis of Presentation [Text Block] Related Party Transaction [Table] Related Party Transaction [Table] Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights NET REVENUE Net revenue Total Option Care Health revenue Revenues 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two 2025 Long-Term Debt, Maturity, Year One STOCK-BASED INCENTIVE COMPENSATION Share-Based Payment Arrangement [Text Block] Consideration receivable Disposal Group, Including Discontinued Operation, Consideration, Receivable Disposal Group, Including Discontinued Operation, Consideration, Receivable Entity Address, City or Town Entity Address, City or Town Goodwill Deferred Tax Liabilities, Goodwill Leases Lessee, Leases [Policy Text Block] Debt Instrument [Axis] Debt Instrument [Axis] Summary of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Schedule of Estimated Fair Values of Debt Obligations Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] Exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Share-based compensation expense Share-Based Payment Arrangement, Expense NET INCOME Net income Net Income (Loss) Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] $16.52 - $24.76 Option Exercise Price, Range Three [Member] Option Exercise Price, Range Three [Member] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Company contributions Defined Contribution Plan, Employer Discretionary Contribution Amount Forfeited and expired (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Available borrowing capacity Line of Credit Facility, Current Borrowing Capacity Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Income (Expense) [Abstract] Income (Expense) [Abstract] Income (Expense) REVENUE Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Equity award issuances Shares Issued During Period, Shares Shares Issued During Period, Shares Shares repurchased Treasury Stock, Value, Acquired, Cost Method Current Current Federal Tax Expense (Benefit) Performance Stock Units Performance Stock Units [Member] Performance Stock Units Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Name Forgone Recovery, Individual Name Exercisable at December 31, 2024 Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Weighted-average remaining lease term, operating leases Operating Lease, Weighted Average Remaining Lease Term Commercial payers Commercial Customer [Member] Commercial Customer [Member] 2029 Finite-Lived Intangible Asset, Expected Amortization, Year Five Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Base Rate Base Rate [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Lien Category [Domain] Lien Category [Domain] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three Deferred Tax Asset, Valuation Allowance [Table] Deferred Tax Asset, Valuation Allowance [Table] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Cost of net revenues - drugs Cost of Revenue Fair value of warrants Warrants and Rights Outstanding Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Document Transition Report Document Transition Report U.S. federal income tax expense (benefit): Federal Income Tax Expense (Benefit), Continuing Operations [Abstract] Referral sources Customer Lists [Member] Customer [Domain] Customer [Domain] Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Retained Earnings Retained Earnings [Member] Referral sources, net Finite Lived Customer Lists, Net Finite Lived Customer Lists, Net Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Upper range limit (in dollars per share) Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit Related Party [Axis] Related and Nonrelated Parties [Axis] Weighted average common shares outstanding, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Proceeds from sale of assets Proceeds from Sale of Productive Assets Amortization of deferred financing costs Amortization of Debt Issuance Costs and Discounts Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Deferred tax assets: Components of Deferred Tax Assets and Liabilities [Abstract] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Rochester Home Infusion, Inc Rochester Home Infusion, Inc [Member] Rochester Home Infusion, Inc Schedule of Income Tax Expense (Benefit) Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Entity Filer Category Entity Filer Category Statement of Income Location, Balance [Domain] Statement of Income Location, Balance [Domain] Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,284, $2,158 and $(7,259), respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Company Selected Measure Name Company Selected Measure Name EX-101.PRE 13 bios-20241231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 bios-20241231_g1.jpg GRAPHIC begin 644 bios-20241231_g1.jpg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end GRAPHIC 15 bios-20241231_g2.jpg GRAPHIC begin 644 bios-20241231_g2.jpg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htm IDEA: XBRL DOCUMENT v3.25.0.1
COVER PAGE - USD ($)
 12 Months Ended
Dec. 31, 2024
Feb. 21, 2025
Jun. 28, 2024
Cover [Abstract]      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Current Fiscal Year End Date --12-31    
Document Transition Report false    
Entity File Number 001-11993    
Entity Registrant Name OPTION CARE HEALTH, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 05-0489664    
Entity Address, Address Line One 3000 Lakeside Dr.    
Entity Address, Address Line Two Suite 300N    
Entity Address, City or Town Bannockburn    
Entity Address, State or Province IL    
Entity Address, Postal Zip Code 60015    
City Area Code 312    
Local Phone Number 940-2443    
Title of 12(b) Security Common Stock, $0.0001 par value per share    
Trading Symbol OPCH    
Security Exchange Name NASDAQ    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
ICFR Auditor Attestation Flag true    
Document Financial Statement Error Correction Flag false    
Entity Shell Company false    
Entity Public Float     $ 4,748,081,376
Entity Common Stock, Shares Outstanding   165,315,961  
Documents Incorporated by Reference
Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (the “SEC”) within 120 days after the close of the registrant’s fiscal year are incorporated by reference into Part III of this Annual Report on Form 10-K.
    
Entity Central Index Key 0001014739    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
XML 18 R2.htm IDEA: XBRL DOCUMENT v3.25.0.1
Audit Information
 12 Months Ended
Dec. 31, 2024
Audit Information [Abstract]  
Auditor Name KPMG LLP
Auditor Location Chicago, Illinois
Auditor Firm ID 185
XML 19 R3.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:    
Cash and cash equivalents $ 412,565 $ 343,849
Accounts receivable, net 409,733 377,658
Inventories 388,131 274,004
Prepaid expenses and other current assets 112,198 98,744
Total current assets 1,322,627 1,094,255
NONCURRENT ASSETS:    
Property and equipment, net 127,367 120,630
Operating lease right-of-use asset 86,528 84,159
Intangible assets, net 16,993 20,092
Referral sources, net 284,017 315,304
Goodwill 1,540,246 1,540,246
Other noncurrent assets 43,965 42,349
Total noncurrent assets 2,099,116 2,122,780
TOTAL ASSETS 3,421,743 3,217,035
CURRENT LIABILITIES:    
Accounts payable 610,779 426,513
Accrued compensation and employee benefits 63,028 92,508
Accrued expenses and other current liabilities 77,783 75,010
Current portion of operating lease liability 22,044 18,278
Current portion of long-term debt 6,512 6,000
Total current liabilities 780,146 618,309
NONCURRENT LIABILITIES:    
Long-term debt, net of discount, deferred financing costs and current portion 1,104,641 1,056,650
Operating lease liability, net of current portion 84,776 85,484
Deferred income taxes 47,576 34,920
Other noncurrent liabilities 366 0
Total noncurrent liabilities 1,237,359 1,177,054
Total liabilities 2,017,505 1,795,363
STOCKHOLDERS’ EQUITY:    
Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December 31, 2024 and 2023, respectively. 0 0
Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,846,725 shares issued and 166,261,112 shares outstanding as of December 31, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December 31, 2023. 18 18
Treasury stock; 17,585,613 and 8,330,022 shares outstanding, at cost, as of December 31, 2024 and 2023, respectively. (507,598) (255,107)
Paid-in capital 1,231,435 1,204,270
Retained earnings 669,336 457,513
Accumulated other comprehensive income 11,047 14,978
Total stockholders’ equity 1,404,238 1,421,672
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 3,421,743 $ 3,217,035
XML 20 R4.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 12,500,000 12,500,000
Preferred stock, shares, outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 250,000,000 250,000,000
Common stock, shares, issued (in shares) 183,846,725 182,905,559
Common stock, shares, outstanding (in shares) 166,261,112 174,575,537
Treasury stock, shares (in shares) 17,585,613 8,330,022
XML 21 R5.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
NET REVENUE $ 4,998,202 $ 4,302,324 $ 3,944,735
COST OF REVENUE 3,985,209 3,321,101 3,077,817
GROSS PROFIT 1,012,993 981,223 866,918
OPERATING COSTS AND EXPENSES:      
Selling, general and administrative expenses 630,251 607,427 566,122
Depreciation and amortization expense 60,909 59,201 60,565
Total operating expenses 691,160 666,628 626,687
OPERATING INCOME 321,833 314,595 240,231
OTHER INCOME (EXPENSE):      
Interest expense, net (49,029) (51,248) (53,806)
Equity in earnings of joint ventures 5,964 5,530 5,125
Other, net 4,831 89,865 14,218
Total other (expense) income (38,234) 44,147 (34,463)
INCOME BEFORE INCOME TAXES 283,599 358,742 205,768
INCOME TAX EXPENSE 71,776 91,652 55,212
NET INCOME 211,823 267,090 150,556
OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:      
Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,284, $2,158 and $(7,259), respectively (3,931) (6,181) 21,610
OTHER COMPREHENSIVE (LOSS) INCOME (3,931) (6,181) 21,610
NET COMPREHENSIVE INCOME $ 207,892 $ 260,909 $ 172,166
EARNINGS PER COMMON SHARE:      
Earnings per share, basic (in dollars per share) $ 1.23 $ 1.49 $ 0.83
Earnings per share, diluted (in dollars per share) $ 1.23 $ 1.48 $ 0.83
Weighted average common shares outstanding, basic (in shares) 171,567 178,973 181,105
Weighted average common shares outstanding, diluted (in shares) 172,845 180,375 182,075
XML 22 R6.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]      
Change in unrealized (loss) gain on cash flow hedges, income tax benefit (expense) $ 1,284 $ 2,158 $ (7,259)
XML 23 R7.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:      
Net income $ 211,823 $ 267,090 $ 150,556
Adjustments to reconcile net income to net cash provided by operations:      
Depreciation and amortization expense 63,498 62,200 65,434
Non-cash operating lease costs 22,581 18,533 19,713
Deferred income taxes - net 12,656 12,766 49,187
Gain on sale of assets 0 0 (9,403)
Loss on extinguishment of debt 377 0 0
Amortization of deferred financing costs 4,628 4,446 4,304
Equity in earnings of joint ventures (5,964) (5,530) (5,125)
Stock-based incentive compensation expense 36,143 30,479 16,783
Distribution from equity method investments 2,400 4,000 5,875
Other adjustments (4,504) (1,244) 0
Changes in operating assets and liabilities:      
Accounts receivable, net (32,075) 224 (36,889)
Inventories (114,127) (51,000) (41,010)
Prepaid expenses and other current assets (15,601) (6,290) (16,798)
Accounts payable 183,395 47,703 98,885
Accrued compensation and employee benefits (29,480) 15,546 (7,770)
Accrued expenses and other current liabilities 6,133 (1,727) 10,535
Operating lease liabilities (21,911) (17,529) (21,395)
Other noncurrent assets and liabilities 3,420 (8,372) (15,335)
Net cash provided by operating activities 323,392 371,295 267,547
CASH FLOWS FROM INVESTING ACTIVITIES:      
Acquisition of property and equipment (35,606) (41,866) (35,358)
Proceeds from sale of assets 0 3,743 14,670
Business acquisitions, net of cash acquired 0 (12,494) (87,364)
Other investing activities (864) (5,889) 0
Net cash used in investing activities (36,470) (56,506) (108,052)
CASH FLOWS FROM FINANCING ACTIVITIES:      
Stock-based compensation tax withholdings (12,382) (3,115)  
Stock-based compensation tax withholdings     352
Purchase of company stock and related excise taxes (252,726) (250,261) 0
Proceeds from warrant exercises 0 0 20,916
Proceeds from issuance of debt 49,959 0 0
Repayments of debt principal (6,384) (6,000) (6,000)
Deferred financing costs (77) 0 0
Other financing activities 3,404 (5,750) 0
Net cash (used in) provided by financing activities (218,206) (265,126) 15,268
NET INCREASE IN CASH AND CASH EQUIVALENTS 68,716 49,663 174,763
Cash and cash equivalents - beginning of the period 343,849 294,186 119,423
CASH AND CASH EQUIVALENTS - END OF PERIOD 412,565 343,849 294,186
Supplemental disclosure of cash flows information:      
Cash paid for interest 71,553 69,804 50,372
Cash paid for income taxes 64,522 75,241 13,438
Cash paid for operating leases $ 28,505 $ 27,391 $ 25,311
XML 24 R8.htm IDEA: XBRL DOCUMENT v3.25.0.1
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Preferred Stock
Common Stock
Treasury Stock
Paid-in Capital
Retained Earnings
Accumulated Other Comprehensive Income (Loss)
Equity, beginning balance at Dec. 31, 2021 $ 1,175,886 $ 0 $ 18 $ (2,403) $ 1,138,855 $ 39,867 $ (451)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based incentive compensation 16,783       16,783    
Exercise of stock options, vesting of restricted stock, and related tax withholdings 352       352    
Exercise of warrants 20,916       20,916    
Net income 150,556         150,556  
Other comprehensive income (loss) 21,610           21,610
Equity, ending balance at Dec. 31, 2022 1,386,103 0 18 (2,403) 1,176,906 190,423 21,159
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based incentive compensation 30,479       30,479    
Exercise of stock options, vesting of restricted stock, and related tax withholdings (3,115)       (3,115)    
Purchase of company stock, and related tax effects (252,704)     (252,704)      
Net income 267,090         267,090  
Other comprehensive income (loss) (6,181)           (6,181)
Equity, ending balance at Dec. 31, 2023 1,421,672 0 18 (255,107) 1,204,270 457,513 14,978
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Stock-based incentive compensation 36,143       36,143    
Exercise of stock options, vesting of restricted stock, and related tax withholdings (8,978)       (8,978)    
Purchase of company stock, and related tax effects (252,491)     (252,491)      
Net income 211,823         211,823  
Other comprehensive income (loss) (3,931)           (3,931)
Equity, ending balance at Dec. 31, 2024 $ 1,404,238 $ 0 $ 18 $ (507,598) $ 1,231,435 $ 669,336 $ 11,047
XML 25 R9.htm IDEA: XBRL DOCUMENT v3.25.0.1
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
 12 Months Ended
Dec. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS
Corporate Organization and Business — The Company’s stock is listed on the Nasdaq Global Select Market as of December 31, 2024. During the year ended December 31, 2023, HC Group Holdings I, LLC. (“HC I”), a former affiliated shareholder, completed sales of 23,771,926 shares of its Option Care common stock which resulted in the full divestment by HC 1 at that time. In addition, the Company repurchased 2,475,166 shares from HC I on March 3, 2023 under the Company’s share repurchase program. See Note 16, Stockholders’ Equity, for further discussion of the Company’s share repurchase program.
Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary healthcare services through a national network of 92 full service pharmacies and 93 stand-alone ambulatory infusion sites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services.
Basis of Presentation — The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States. GAAP requires management to make certain estimates and assumptions in determining assets, liabilities, revenue, expenses, and related disclosures. Actual amounts could differ materially from those estimates.
Principles of Consolidation — The Company’s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the consolidated statements of comprehensive income. See “Equity-Method Investments” within Note 2, Summary of Significant Accounting Policies, for further discussion of the Company’s equity-method investments.
XML 26 R10.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents consisted of money market funds.
Accounts Receivable — The Company’s accounts receivable are reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental healthcare programs, such as Medicare and Medicaid.
Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), an allowance for doubtful accounts is established only as a result of an adverse change in the Company’s payers’ ability to pay outstanding billings. In addition, the company assesses if there have been any changes to historical credit losses to determine if an allowance for credit losses is needed. The Company had an immaterial allowance for doubtful accounts and credit losses as of December 31, 2024 and 2023.
Included in accounts receivable are earned but unbilled gross receivables of $105.3 million and $89.1 million as of December 31, 2024 and 2023, respectively. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.
See Revenue Recognition for a further discussion of the Company’s revenue recognition policy.
Inventories — Inventories, which consist primarily of pharmaceuticals, is stated at the lower of first‑in, first‑out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.
Prepaid Expenses and Other Current Assets — Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $54.4 million and $52.0 million for the years ended December 31, 2024 and 2023, respectively.
Leases — The Company has lease agreements for facilities, warehouses, office space and property and equipment. At the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (“ROU asset”) and operating lease liabilities in the consolidated financial statements.
ROU assets, which represent the Company’s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The rates are estimated primarily using a methodology dependent on the Company’s financial condition, creditworthiness, and availability of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.
Leases may contain rent escalations; however, the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.
The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. See Note 8, Leases, for further discussion of leases.
Goodwill, Intangible Assets, Property and Equipment, and Referral Sources — Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic 350, Intangibles-Goodwill and Other. The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate that impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter on a qualitative basis. See Note 10, Goodwill and Other Intangible Assets, for further discussion of the Company’s goodwill and other intangible assets.
Intangible assets arising from the Company’s acquisitions are amortized on a straight‑line basis over the estimated useful life of each asset. Referral sources have a useful life of fifteen to twenty years. Trademarks/names have a useful life ranging from two to fifteen years. The useful lives for other amortizable intangible assets range from approximately two to nine years. The Company does not have any indefinite‑lived intangible assets.
Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight‑line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and three to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight‑line basis over the software’s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.
The Company assesses long‑lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. If circumstances require that a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flows basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value.
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December 31, 2024 and 2023, the balance of the investments was $24.5 million and $20.9 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $6.0 million, $5.5 million and $5.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December 31, 2024, 2023 and 2022, the Company received distributions from the investees of $2.4 million, $4.0 million and $5.9 million, respectively. See Note 17, Related-Party Transactions, for discussion of related-party transactions with these investees.
Hedging Instruments — The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, Derivative Instruments, for additional information.
At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.
Revenue Recognition — Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing goods and services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.
Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available.
The Company assesses the expected consideration to be received at the time of patient acceptance, based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body.
The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service.
The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. See Note 4, Revenue for a further discussion of revenue.
Cost of Revenue — Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.
The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.
Selling, General and Administrative Expenses — Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.
Stock Based Incentive Compensation — The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, Compensation-Stock Compensation (“ASC 718”). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company’s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs.
Business Acquisitions — The Company accounts for business acquisitions in accordance with ASC Topic 805, Business Combinations, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets. See Note 3, Business Acquisitions and Divestitures, for further discussion of the Company’s business acquisitions.
Income Taxes — The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized.
The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense (benefit). Tax related interest and penalties are classified as a component of income tax expense (benefit).
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15%, 14% and 14% for the years ended December 31, 2024, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.
For the years ended December 31, 2024, 2023 and 2022, approximately 12%, 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December 31, 2024 and 2023, approximately 11% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the year ended December 31, 2024, approximately 58% of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the years ended December 31, 2023 and 2022, approximately 72% and 73%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue or decreased gross profit, which could adversely affect the Company’s financial condition or operating results.
Fair Value Measurements — The fair value measurement accounting standard, ASC Topic 820, Fair Value Measurement (“ASC 820”), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:
•Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
Recently Issued Accounting Pronouncements — In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU improves the disclosures around a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development). The amendments in this ASU do not change or remove current presentation requirements or current expense disclosure requirements. However, the amendments affect where this information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The Company is required to adopt this ASU for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The ASU allows investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. This ASU also improves the effectiveness and comparability of disclosures by adding disclosures of pretax income (loss) and income tax expense (benefit) to be consistent with U.S. Securities and Exchange Commission (“SEC”) Regulation S-X and removing disclosures that no longer are considered cost beneficial or relevant. The Company is required to adopt this ASU for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU improves the disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities, including those public entities that have a single reportable segment, to enable investors to develop more decision-useful financial analyses. The Company is required to adopt this ASU for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU was adopted during the year ended December 31, 2024 and applied retrospectively to all prior periods presented in the financial statements. The adoption did not have any material impact on the Company’s results of operations, cash flows, financial position, or disclosures. See Note 18, Segment Reporting, for further discussion.

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This ASU is the result of the Board’s decision to incorporate into the Codification 14 disclosures referred by the SEC. The ASU represents changes to clarify or improve disclosure and presentation requirements of a variety of Topics. Many of the amendments allow users to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the SEC’s requirements. Also, the amendments align the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption permitted. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
XML 27 R11.htm IDEA: XBRL DOCUMENT v3.25.0.1
BUSINESS ACQUISITIONS AND DIVESTITURES
 12 Months Ended
Dec. 31, 2024
Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]  
BUSINESS ACQUISITIONS AND DIVESTITURES BUSINESS ACQUISITIONS AND DIVESTITURES
Amedisys, Inc. — On May 3, 2023, the Company entered into a definitive merger agreement with Amedisys. Under the terms of the merger agreement, the Company would issue new shares of its common stock to Amedisys stockholders, which would result in the Company’s stockholders holding approximately 64.5% of the combined company.
On June 26, 2023, the Company entered into an agreement to terminate the Amedisys Merger Agreement. Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys. The Termination Fee is included in Other, net in the consolidated statements of comprehensive income and in Net cash provided by operating activities in the consolidated statements of cash flows.
During the year ended December 31, 2023, the Company incurred $21.1 million in merger-related expenses, which are included in Other, net in the consolidated statements of comprehensive income and in Net cash provided by operating activities in the consolidated statements of cash flows.
Revitalized, LLC — In May 2023, pursuant to the equity purchase agreement dated May 1, 2023, the Company completed the acquisition of 100% of the membership interests in Revitalized, LLC for a purchase price, net of cash acquired, of $12.5 million, which primarily consisted of $6.7 million of goodwill and $5.5 million of intangible assets.
Respiratory Therapy Asset Sale — The Company closed the transaction in December 2022, for a sale price of $18.4 million comprised of $14.7 million in proceeds received at the time of closing and $3.7 million recorded as a current asset which was paid in the year ended December 31, 2023. Pursuant to the final transaction terms, $8.8 million of assets were sold, along with $0.7 million of liabilities that were previously classified as held for sale at the lower of their carrying amount or fair values less cost to sell. As a result of the transaction, a $10.3 million pre-tax gain on sale was recorded within Other, net in the Company’s consolidated statements of comprehensive income within the year ended December 31, 2022.
Rochester Home Infusion, Inc. — In August 2022, pursuant to the stock purchase agreement dated June 10, 2022, the Company completed the acquisition of 100% of the equity interests in Rochester Home Infusion, Inc. (“RHI”) for a purchase price, net of cash acquired, of $27.4 million.
Specialty Pharmacy Nursing Network, Inc. — In April 2022, pursuant to the equity purchase agreement dated February 7, 2022, the Company completed the acquisition of 100% of the equity interests in Specialty Pharmacy Nursing Network, Inc. (“SPNN”) for a purchase price, net of cash acquired, of $59.9 million.
XML 28 R12.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
The following table sets forth the net revenue earned by category of payer for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year Ended December 31,
202420232022
Commercial payers$4,348,991 $3,747,568 $3,421,888 
Government payers584,271 500,891 477,818 
Patients64,940 53,865 45,029 
Net revenue$4,998,202 $4,302,324 $3,944,735 
XML 29 R13.htm IDEA: XBRL DOCUMENT v3.25.0.1
EMPLOYEE BENEFIT PLANS
 12 Months Ended
Dec. 31, 2024
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
The Company maintains a 401(k) plan and matches 100% of employee contributions, up to 4% of employee compensation. The Company recorded expense for the defined contribution plan of $13.3 million, $13.1 million and $12.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. In the years ended December 31, 2024, 2023 and 2022, Company contributions of $13.3 million, $12.4 million and $11.8 million, respectively, were paid.
XML 30 R14.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
The income tax expense (benefit) consists of the following for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year Ended December 31,
202420232022
U.S. federal income tax expense (benefit):
Current$47,239 $56,474 $4,103 
Deferred16,396 18,739 38,810 
63,635 75,213 42,913 
State income tax expense (benefit):
Current10,597 20,253 9,182 
Deferred(2,456)(3,814)3,117 
8,141 16,439 12,299 
Total income tax expense (benefit)$71,776 $91,652 $55,212 
The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December 31, 2024, 2023 and 2022:
Year Ended December 31,
202420232022
U.S. federal statutory tax rate21.0 %21.0 %21.0 %
State and local income taxes net of federal tax benefit3.5 %4.8 %5.0 %
Valuation allowance(0.8)%(1.5)%0.0 %
Share based compensation impacts1.2 %0.7 %0.4 %
Other, net0.4 %0.5 %0.4 %
Effective income tax rate25.3 %25.5 %26.8 %

The Company recorded income tax expense of $71.8 million, $91.7 million, and $55.2 million, which represents an effective tax rate of 25.3%, 25.5%, and 26.8% for the years ended December 31, 2024, 2023, and 2022, respectively. In March 2024, the Company released $2.2 million of state valuation allowance. The variance in the Company’s effective tax rate of 25.3% for the year ended December 31, 2024 compared to the federal statutory rate of 21% is primarily attributable to the difference in state taxes, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 25.3% and 25.5% for the years ended December 31, 2024 and 2023, respectively, is also primarily attributable to the difference in state taxes, various non-deductible expenses, and a change in state valuation allowance. The income tax expense for the year ended December 31, 2023 includes $21.8 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. In September 2023, the Company released $5.8 million of state valuation allowance. The variance in the Company’s effective tax rate of 25.5% and 26.8% for the years ended December 31, 2023 and 2022, respectively, is primarily attributable to the difference in state taxes, various nondeductible expenses, and a change in state valuation allowance.
The components of deferred income tax assets and liabilities were as follows as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Deferred tax assets:
Price concessions$8,053 $5,365 
Compensation and benefits6,166 7,609 
Interest limitation carryforward5,768 13,802 
Operating lease liability23,880 26,378 
Net operating losses50,860 56,980 
Other12,676 7,556 
Deferred tax assets before valuation allowance107,403 117,690 
Valuation allowance(3,337)(6,371)
Deferred tax assets net of valuation allowance104,066 111,319 
Deferred tax liabilities:
Accelerated depreciation(12,630)(8,882)
Operating lease right-of-use asset(18,883)(21,504)
Intangible assets(48,412)(52,502)
Goodwill(59,303)(52,188)
Other(12,414)(11,163)
Deferred tax liabilities(151,642)(146,239)
Net deferred tax liabilities$(47,576)$(34,920)
Deferred tax assets are generally required to be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. For the year ended December 31, 2024, the Company maintains a valuation allowance of $3.3 million against certain state net operating losses (“NOL”). In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income and tax-planning strategies, in making this assessment. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.
At December 31, 2024, the Company had $35.6 million of tax-effected federal NOL carryforwards all of which are currently available to offset future taxable income in the United States and reflected as a deferred tax asset of the company. Tax-effected federal NOL carryforwards of $24.6 million expire beginning in 2028 through 2036, and $11.0 million of tax-effected federal NOLs have an indefinite carryforward period. At December 31, 2024, the Company had $5.8 million tax-effected amounts of interest limitation carryforwards which have an indefinite carryforward period. At December 31, 2024, the Company also had $15.3 million tax-effected amounts of cumulative state NOL carryforwards available to offset future taxable income in various states. These state NOL carryforwards will begin to expire beginning in 2025 through 2043, with some having an indefinite carryforward period.
At December 31, 2024, 2023 and 2022, there were no unrecognized tax benefits for uncertain tax positions. Tax related interest and penalties are classified as a component of income tax expense.
The following table presents the valuation allowance for deferred tax assets for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Additions
DescriptionBalance at Beginning of PeriodCharged (Benefit) to Costs and ExpensesCharged (Benefit) to Other AccountsBalance at End of Period
2022: Valuation allowance for deferred tax assets$13,151 $(95)$— $13,056 
2023: Valuation allowance for deferred tax assets$13,056 $(6,685)$— $6,371 
2024: Valuation allowance for deferred tax assets$6,371 $(3,034)$— $3,337 
The company files income tax returns in the U.S. and various state and local jurisdictions. There are no ongoing Federal or state income tax audits as of December 31, 2024. The statute remains open for examination by the Internal Revenue Service beginning with year 2021 in state jurisdictions for periods beginning in 2020.
XML 31 R15.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.
The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the years ended December 31, 2024, 2023 and 2022 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share.
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Year Ended December 31,
202420232022
Warrants———
Stock option awards854,5451,214,560629,690
Restricted stock awards376,743340,331205,652
Performance stock unit awards286,881——
The following tables present the Company’s basic and diluted earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Earnings per Common Share:
Earnings per common share, basic$1.23 $1.49 $0.83 

Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Effect of dilutive securities1,278 1,402 970 
Weighted average number of common shares outstanding, diluted172,845 180,375 182,075 
Earnings per Common Share:
Earnings per common share, diluted$1.23 $1.48 $0.83 

(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions and Divestitures, for further discussion.
(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, Business Acquisitions and Divestitures, for further discussion.
XML 32 R16.htm IDEA: XBRL DOCUMENT v3.25.0.1
LEASES
 12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
LEASES LEASES
During the years ended December 31, 2024, 2023 and 2022, the Company incurred operating lease expenses of $32.7 million, $30.6 million, and $29.1 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income. As of December 31, 2024 and December 31, 2023, the weighted-average remaining lease term was 6.5 years and 6.8 years, respectively, and the weighted-average discount rate was 6.56% and 6.16%, respectively.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$28,286 
202625,523 
202720,406 
202813,907 
20299,306 
2030 and beyond36,515 
Total lease payments133,943 
Less: interest(27,123)
Present value of lease liabilities$106,820 
During the years ended December 31, 2024, 2023 and 2022, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the consolidated statements of cash flows of $25.0 million, $30.5 million, and $17.2 million, respectively, related to the increases in the operating lease ROU asset and operating lease liabilities. As of December 31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.
LEASES LEASES
During the years ended December 31, 2024, 2023 and 2022, the Company incurred operating lease expenses of $32.7 million, $30.6 million, and $29.1 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income. As of December 31, 2024 and December 31, 2023, the weighted-average remaining lease term was 6.5 years and 6.8 years, respectively, and the weighted-average discount rate was 6.56% and 6.16%, respectively.
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$28,286 
202625,523 
202720,406 
202813,907 
20299,306 
2030 and beyond36,515 
Total lease payments133,943 
Less: interest(27,123)
Present value of lease liabilities$106,820 
During the years ended December 31, 2024, 2023 and 2022, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the consolidated statements of cash flows of $25.0 million, $30.5 million, and $17.2 million, respectively, related to the increases in the operating lease ROU asset and operating lease liabilities. As of December 31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.
XML 33 R17.htm IDEA: XBRL DOCUMENT v3.25.0.1
PROPERTY AND EQUIPMENT
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT PROPERTY AND EQUIPMENT
Property and equipment was as follows as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Infusion pumps$37,659 $36,943 
Equipment, furniture and other24,055 23,593 
Leasehold improvements116,675 99,725 
Computer software, purchased and internally developed46,532 50,572 
Assets under development22,990 33,668 
247,911 244,501 
Less: accumulated depreciation(120,544)(123,871)
Property and equipment, net$127,367 $120,630 
Depreciation expense is recorded within cost of revenue and operating expenses within the consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year ended December 31,
202420232022
Depreciation expense in cost of revenue$2,590 $2,999 $4,869 
Depreciation expense in operating expenses26,503 24,820 27,374 
Total depreciation expense$29,093 $27,819 $32,243 
XML 34 R18.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill is not amortized, but is evaluated for impairment annually in the fourth quarter of the fiscal year, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.
Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; and the results of testing for recoverability of a significant asset group within a reporting unit.
A qualitative impairment analysis was performed in the fourth quarter of 2024, 2023 and 2022, to assess whether it is more likely than not that the fair value of the Company’s reporting units are less than their carrying value. The Company assessed relevant events and circumstances including macroeconomic conditions, industry and market considerations, overall financial performance, entity-specific events, and changes in the Company’s stock price. The Company determined that there was no goodwill impairment in 2024, 2023 or 2022.
The determination of fair value for acquisitions and the allocation of that value requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, and capital expenditures. Actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting unit, the amount of the goodwill impairment charge, or both. The Company did not recognize any accumulated impairment losses at the beginning of the period.
Changes in the carrying amount of goodwill consist of the following activity for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Balance at December 31, 2021$1,477,564 
Acquisitions54,543 
Purchase accounting adjustments1,317 
Balance at December 31, 2022$1,533,424 
Acquisitions6,998 
Purchase accounting adjustments(176)
Balance at December 31, 2023$1,540,246 
Acquisitions— 
Purchase accounting adjustments— 
Balance at December 31, 2024$1,540,246 
The carrying amount and accumulated amortization of intangible assets consist of the following as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Gross intangible assets:
Referral sources$514,388 $514,388 
Trademarks/names39,136 39,136 
Other amortizable intangible assets985 995 
Total gross intangible assets554,509 554,519 
Accumulated amortization:
Referral sources(230,371)(199,084)
Trademarks/names(22,599)(19,698)
Other amortizable intangible assets(529)(341)
Total accumulated amortization(253,499)(219,123)
Total intangible assets, net$301,010 $335,396 
Amortization expense for intangible assets was $34.4 million, $34.2 million and $32.9 million for the years ended December 31, 2024, 2023 and 2022, respectively.
Expected future amortization expense for intangible assets recorded at December 31, 2024, is as follows (in thousands):
Amount
2025$34,176 
202634,071 
202733,931 
202833,880 
202933,875 
2030 and beyond131,077 
Total$301,010 
XML 35 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
INDEBTEDNESS
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
INDEBTEDNESS INDEBTEDNESS
Long-term debt consisted of the following as of December 31, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan631,617 (5,537)(7,555)618,525 
Senior Notes500,000 — (7,372)492,628 
$1,131,617 $(5,537)$(14,927)1,111,153 
Less: current portion(6,512)
Total long-term debt$1,104,641 
Long-term debt consisted of the following as of December 31, 2023 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan588,000 (6,974)(9,678)571,348 
Senior Notes500,000 — (8,698)491,302 
$1,088,000 $(6,974)$(18,376)1,062,650 
Less: current portion(6,000)
Total long-term debt$1,056,650 
On May 8, 2024, the Company entered into the Third Amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021. The Third Amendment, among other things, (i) increases borrowings by $50.0 million and (ii) reduces the interest rate on the First Lien Term Loan from Term SOFR (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25% and removes the credit spread adjustment with respect to such First Lien Term Loan.
The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.6 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Under the Third Amendment, interest on the First Lien Term Loan is payable monthly on either (i) SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.25% for Term SOFR Loans (as such term is defined in the Third Amendment); or (ii) a base rate determined in accordance with the Third Amendment, plus 1.25% for Base Rate Loans (as such term is defined in the Third Amendment). The interest rate on the First Lien Term Loan was 6.82% and 8.21% as of December 31, 2024 and 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.61% and 7.83% for the years ended December 31, 2024 and 2023, respectively.
The Company assessed whether the repayment of the First Lien Term Loan indebtedness resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the First Lien Term Loan and Senior Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $0.4 million of the First Lien Term Loan were extinguished. The First Lien Term Loan had insubstantial modifications for lenders that participated in both debt instruments, which resulted in a cash inflow from financing activities of $50.0 million in the consolidated statements of cash flows. The Company incurred $1.6 million in fees, of which $0.1 million was capitalized, relative to the First Lien Term Loan and an immaterial amount of the total fees incurred was netted against the $50.0 million of debt proceeds as financing activities within the consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $0.4 million included in the line entitled “Other, net” in the consolidated statements of comprehensive income.
Effective June 30, 2023, the Company entered into an agreement, dated as of June 8, 2023, to amend the First Lien Term Loan to replace LIBOR and related definitions and provisions with SOFR as the new reference rate. The Company entered into the First Lien Term Loan Agreement (the “First Lien Credit Agreement Amendment”), which commenced in October 2021 (the “October 2021 Refinancing”) to provide $600.0 million of refinanced borrowings.
On December 7, 2023, the Company entered into the Second Amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021. The Second Amendment, among other things, creates a Revolver Facility which provides for borrowings up to $400.0 million. As of December 31, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million. As of December 31, 2023, the Company had $5.3 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $394.7 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility bear interest at a rate equal to, at the option of the Company, either (i) the Term SOFR applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the Second Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent Compliance Certificate received by the Administrative Agent pursuant to the terms of the Credit Agreement.
Concurrently with the creation of the Revolver Facility, the Company terminated the asset-based lending revolving credit facility (the “ABL Facility”) with a maturity date of October 27, 2026. Prior to the transition to the Revolver Facility, the ABL Facility had been in effect from August 6, 2019 to December 7, 2023. Effective January 13, 2023, the Company entered into an agreement to amend the ABL Facility and increase the amount of borrowing availability from $175.0 million by $50.0 million to $225.0 million total borrowing availability. As a result of the amended agreement, SOFR was established as the new reference rate, replacing LIBOR. Prior to the termination of the ABL Facility in December 2023, the ABL Facility bore interest at a rate equal to, at the Company’s election, either (i) a base rate determined in accordance with the ABL Credit Agreement plus an applicable margin, which is equal to between 0.25% and 0.75% based on the historical excess availability as a percentage of the Line Cap (as such term is defined in the ABL Credit Agreement); and (ii) SOFR (with a floor of —% per annum) plus an applicable margin, which is equal to between 1.25% and 1.75% based on the historical excess availability as a percentage of the Line Cap. The ABL Facility contained commitment fees payable on the unused portion ranging from 0.25% to 0.375%, depending on various factors including the Company’s leverage ratio, type of loan and rate type, and letter of credit fees of 2.50%. Borrowings under the ABL Facility were secured by a first priority security interest in the Company’s and each of its subsidiaries’ inventory, accounts receivable, cash, deposit accounts and certain assets and property related thereto (the “ABL Priority Collateral”), in each case subject to certain exceptions, and a third priority security interest in each of the Company’s subsidiaries’ capital stock (subject to certain exceptions) and substantially all of the Company’s property and assets (other than the ABL Priority Collateral).
In conjunction with the October 2021 Refinancing, the Company also issued $500.0 million in aggregate principal of unsecured senior notes (“Senior Notes”). The Senior Notes bear interest at a rate of 4.375% per annum payable semi-annually in arrears on October 31 and April 30 of each year, commencing on April 30, 2022. The Senior Notes mature on October 31, 2029. The interest rate on the Senior Notes was 4.375% as of both December 31, 2024 and 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for both years ended December 31, 2024 and 2023.
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$6,512 
20266,512 
20276,512 
2028612,081 
2029500,000 
Total$1,131,617 
During the year ended December 31, 2024, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 12, Derivative Instruments, for further discussion.
The following table presents the estimated fair values of the Company’s debt obligations as of December 31, 2024 (in thousands):
Financial InstrumentCarrying Value as of December 31, 2024Markets for Identical Item (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
First Lien Term Loan$618,525 $— $634,774 $— 
Senior Notes492,628 — 460,000 — 
Total debt instruments$1,111,153 $— $1,094,774 $— 
XML 36 R20.htm IDEA: XBRL DOCUMENT v3.25.0.1
DERIVATIVE INSTRUMENTS
 12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
DERIVATIVE INSTRUMENTS DERIVATIVE INSTRUMENTS
The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.
In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300.0 million for a five-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.
The following table summarizes the amount and location of the Company’s derivative instruments in the consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionDecember 31, 2024December 31, 2023
Interest rate cap designated as cash flows hedgePrepaid expenses and other current assets$8,034 $9,746 
Interest rate cap designated as cash flows hedgeOther noncurrent assets6,680 10,183 
Total derivative assets$14,714 $19,929 
The gain and loss associated with the changes in the fair value of the effective portion of hedging instruments are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the hedging instrument is recognized in net income through interest expense. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s consolidated statements of comprehensive income (in thousands):
Year Ended December 31,
Derivative202420232022
Interest rate cap designated as cash flows hedge$(5,215)$(8,339)$28,869 
The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s consolidated statement of comprehensive income related to the Company’s derivative instruments (in thousands):
Year Ended December 31,
DerivativeIncome Statement Caption202420232022
Interest rate cap designated as cash flows hedgeInterest expense, net$11,527 $10,974 $1,090 
The Company expects to reclassify $2.8 million of total interest rate costs from accumulated other comprehensive income (loss) against interest expense during the next 12 months.
XML 37 R21.htm IDEA: XBRL DOCUMENT v3.25.0.1
FAIR VALUE MEASURMENTS
 12 Months Ended
Dec. 31, 2024
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASURMENTS FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The three levels of inputs within the fair value hierarchy are defined in Note 2, Summary of Significant Accounting Policies. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 11, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s consolidated balance sheets (Level 1 inputs).
There were no other assets or liabilities measured at fair value at December 31, 2024 or 2023.
XML 38 R22.htm IDEA: XBRL DOCUMENT v3.25.0.1
COMMITMENTS AND CONTINGENCIES
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.
The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated balance sheets.
However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.
XML 39 R23.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED INCENTIVE COMPENSATION
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED INCENTIVE COMPENSATION STOCK-BASED INCENTIVE COMPENSATION
Equity Incentive Plans — Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company’s Compensation Committee, a standing committee of the Board of Directors. In May 2024, an additional 4,000,000 shares were authorized for issuance under the amended 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance as of December 31, 2024. As of December 31, 2023, a total of 9,101,734 shares of common stock were authorized for issuance under the amended 2018 Plan.
Stock Options — Options granted under the 2018 Plan typically vest over a three- or four-year period and, in certain instances, may fully vest upon a change in control of the Company. The options also typically have an exercise price that may not be less than 100% of its fair market value on the date of grant and are exercisable seven to ten years after the date of grant, subject to earlier termination in certain circumstances.
Compensation expense from stock options is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to stock options of $5.9 million, $6.5 million and $2.5 million, respectively.
There were no options granted during the year ended December 31, 2024. The weighted average grant-date fair value of options granted during the years ended December 31, 2023 and 2022 was $15.72 and $12.51, respectively. The fair value of stock options granted was estimated on the date of grant using a Black-Scholes pricing model. The assumptions used to compute the fair value of options for the years ended December 31, 2023 and 2022 are as follows:
Year Ended December 31,
20232022
Expected volatility51.43%51.19%
Risk-free interest rate4.16%3.91%
Expected life of options6.2 years6.2 years
Dividend rate——
A summary of stock option activity for the year ended December 31, 2024 is as follows:
OptionsWeighted Average Exercise PriceAggregate Intrinsic Value (thousands)Weighted Average Remaining Contractual Life
Balance at December 31, 20231,746,272 $25.08 $15,028 
Granted— $— $— 
Exercised(161,553)$18.14 $1,875 
Forfeited and expired(101,486)$26.05 $32 
Balance at December 31, 20241,483,233 $25.79 $1,590 7.35 years
Exercisable at December 31, 2024595,984 $22.96 $1,365 6.52 years
During the years ended December 31, 2024, 2023 and 2022, an immaterial number of shares were surrendered to satisfy tax withholding obligations on the exercise of stock options. No cash was received from stock option exercises under share-based payment arrangements for the years ended December 31, 2024, 2023 and 2022.
The maximum term of stock options under these plans is ten years. Options outstanding as of December 31, 2024 expire on various dates ranging from September 2025 through July 2033. The following table outlines the outstanding and exercisable stock options as of December 31, 2024:
Options OutstandingOptions Exercisable
Range of Option Exercise PriceOutstanding OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual LifeOptions ExercisableWeighted Average Exercise Price
$0.00 - $8.24
9,901 $6.52 2.19,901 $6.52 
$8.24 - $16.52
64,775 $12.14 4.064,775 $12.14 
$16.52 - $24.76
355,616 $21.54 6.7200,513 $21.05 
$24.76 - $33.00
1,052,941 $28.25 7.8320,795 $26.85 
All options1,483,233 595,984 
As of December 31, 2024, there was $5.8 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 0.95 years.
Restricted Stock — Restricted stock grants subject solely to an employee’s continued service with the Company generally will become fully vested within one to four years from the grant date and, in certain instances, may fully vest upon a change in control of the Company. Restricted stock grants subject solely to a Director’s continued service with the Company generally will become fully vested on a pro-rata basis over three years from the date of grant.
Compensation expense from restricted stock is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to restricted stock awards of $21.4 million, $16.6 million and $10.2 million, respectively.
The grant-date fair value of restricted stock is valued as the closing price of the Company’s common stock on the date of the grant.
A summary of restricted stock award activity for the year ended December 31, 2024 is as follows:
Restricted StockWeighted Average Grant Date Fair Value
Balance at December 31, 20231,883,116 $26.28 
Granted 723,027 $32.71 
Vested and issued(770,137)$25.16 
Forfeited and expired(170,594)$28.25 
Balance at December 31, 20241,665,412 $29.41 
During the years ended December 31, 2024, 2023 and 2022, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $7.1 million, $4.4 million and $1.4 million, respectively.
As of December 31, 2024, there was $28.8 million in unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.09 years. The total fair value of restricted stock awards vested during the years ended December 31, 2024, 2023 and 2022 was $19.4 million, $9.9 million and $3.7 million, respectively.
Performance Stock Units — Performance-based stock units (“PSU”) are generally earned based on the attainment of specified goals achieved over a designated performance period. During the years ended December 31, 2024, 2023 and 2022, the Company’s Compensation Committee approved PSU awards to certain senior executives of the Company with grant dates in 2024, 2023 and 2022, respectively. All PSU awards offer a three-year-cliff vesting schedule. Each PSU award reflects a target number of shares (“Target Shares”) that may be issued to the award recipient. PSU awards may be earned upon the completion of a two-year-average or three-year-average performance period.
Whether PSU awards are earned at the end of the performance period will be determined based on the achievement of certain performance objectives over the performance period. The performance objectives include achieving a target growth for adjusted EBITDA and revenue combined in addition to a target growth for cash flows from operations over the performance period. Depending on the results achieved during the performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the Target Shares granted. Each period begins with 100% of the Target Shares and true-up or true-down adjustments are considered every quarter-end based on the forecasted performance period results.
The fair value of the Target Shares and PSU awards are based on the fair value of the underlying shares as of market close on the grant date. Compensation expense for PSU awards is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to the PSU awards of $8.8 million, $7.5 million and $4.1 million, respectively. During the years ended December 31, 2024, shares were surrendered to satisfy tax withholding obligations on the performance-based stock units with a cost basis of $4.9 million. There were no shares surrendered to satisfy tax withholding obligations on the PSU awards during the years ended December 31, 2023 or 2022. As of December 31, 2024, there were $11.6 million in unrecognized compensation expense related to unvested PSU awards that are expected to be recognized over a weighted-average period of 1.32 years.
XML 40 R24.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCKHOLDERS' EQUITY
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS’ EQUITY
During the year ended December 31, 2023, HC I completed secondary offerings of 23,771,926 shares of common stock. As of December 31, 2023, HC I no longer held shares of the Company’s common stock.
2017 Warrants — Prior to the Merger, BioScrip issued warrants to certain debt holders pursuant to a Warrant Purchase Agreement dated as of June 29, 2017. In conjunction with the Merger, the 2017 Warrants were amended to entitle the purchasers of the warrants to purchase 2.1 million shares of common stock. The 2017 Warrants have a 10-year term and an exercise price of $8.00 per share and may be exercised by payment of the exercise price in cash or surrender of shares of common stock into which the 2017 Warrants are being converted in an aggregate amount sufficient to cover the exercise price. The 2017 Warrants are classified as equity instruments, and the fair value of these warrants of $14.1 million was recorded in paid-in capital as of the Merger Date. During the years ended December 31, 2024, 2023, and 2022, warrant holders exercised warrants to purchase 0, 188,350, and 1,130,089 shares of common stock, respectively. No proceeds were received from these exercises as the warrant holders elected to surrender shares to pay the exercise price. At December 31, 2024, 2023, and 2022, the remaining warrant holders are entitled to purchase 51,838, 51,838, and 240,188 shares of common stock, respectively.
2015 Warrants — Prior to the Merger, BioScrip issued warrants pursuant to a Common Stock Warrant Agreement dated as of March 9, 2015 which entitle the holders to purchase 0.9 million shares of common stock. The 2015 Warrants have a 10-year term and have exercise prices in a range of $20.68 per share to $25.80 per share. The 2015 Warrants were assumed by the Company in conjunction with the Merger and are classified as equity instruments, and the fair value of these warrants of $4.6 million was recorded in paid in capital as of the Merger Date. During the years ended December 31, 2024 and 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. During the year ended December 31, 2022, warrant holders exercised warrants to purchase 900,272 shares of common stock. During the years ended December 31, 2024 and 2023, no cash proceeds were received from warrant exercises. During the year ended December 31, 2022, $20.9 million of cash was received as proceeds from warrant exercises. At December 31, 2024, 2023, and 2022, the remaining warrant holders are entitled to purchase 11,765, 13,888, and 15,231 shares of common stock, respectively.
Share Repurchase Program — On February 20, 2023, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $250.0 million of common stock of the Company. On December 6, 2023, the Company’s Board of Directors approved an increase to its share repurchase program authorization from $250.0 million to $500 million. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.
During the years ended December 31, 2024 and 2023, the Company purchased 9,255,591 and 7,946,301 shares of common stock for an average share price of $27.01 and $31.46, totaling $250.0 million and $250.0 million, respectively. All repurchased shares became treasury stock. As of December 31, 2024, the Company completed share repurchases under its prior share repurchase program. In January 2025, the Company’s Board of Directors approved a new $500.0 million stock repurchase program. This program has no specified expiration date.
Shares Outstanding — The following table shows the Company’s changes in shares of common stock for the years ended December 31, 2024 and 2023 (in thousands):
Balance at December 31, 2022181,958 
Equity award issuances564 
Share repurchases(7,946)
Balance at December 31, 2023174,576 
Equity award issuances941 
Share repurchases(9,256)
Balance at December 31, 2024166,261 
Treasury Stock — As of December 31, 2024 and 2023, the Company held 17,585,613 and 8,330,022 shares of treasury stock, respectively.
Preferred Stock — The Company had no preferred stock outstanding as of December 31, 2024 or 2023.
XML 41 R25.htm IDEA: XBRL DOCUMENT v3.25.0.1
RELATED-PARTY TRANSACTIONS
 12 Months Ended
Dec. 31, 2024
Related Party Transactions [Abstract]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONS
Transactions with Equity-Method Investees — The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $6.2 million, $5.3 million and $4.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Management fees are recorded in net revenues in the accompanying consolidated statements of comprehensive income.
The Company had amounts due to its joint ventures totaling $1.4 million as of December 31, 2024. The Company had amounts due to its joint ventures of $0.5 million and due from its joint ventures of $0.1 million as of December 31, 2023. These receivables were included in prepaid expenses and other current assets in the accompanying balance sheets and these payables were included in accrued expenses and other current liabilities in the accompanying balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.
Share Repurchase Agreement — On February 28, 2023, we entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with HC I, pursuant to which we agreed to repurchase, subject to the terms and conditions contained therein, up to $75.0 million of our common stock then held by HC I at the same purchase price per share as the underwriter in a concurrent underwritten public offering of our common stock held by HC I. On March 3, 2023, the transactions contemplated by the Share Repurchase Agreement closed, and we repurchased directly from HC I 2,475,166 shares of our common stock.
XML 42 R26.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT REPORTING
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
The Company has adopted ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures and has revised prior year disclosures to conform with the current year presentation. The Company operates as a single reportable segment, infusion services. Infusion services derives revenue through the clinical management of infusion therapy, nursing support and care coordination in order to provide solutions to complex patient conditions in the home or other nonhospital settings. The Company’s infusion services segment activities are managed on a consolidated basis and therapies are distributed and administered in a similar manner.
Operating segments have been identified based on the financial information utilized by the Company’s Chief Executive Officer, the chief operating decision maker (“CODM”). The CODM uses net income as a measure of profitability to assess segment performance and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.
The following table reflects results of operations of the Company’s reportable segment (in thousands):

Year Ended December 31,
202420232022
Infusion services net revenue$4,911,591 $4,222,656 $3,869,036 
Other revenue (1)86,611 79,668 $75,699 
Total Option Care Health revenue4,998,202 4,302,324 $3,944,735 
(Expense) Income:
Cost of net revenues - drugs(3,446,735)(2,812,531)$(2,562,494)
Salaries, benefits, and other employee expense(787,922)(760,499)$(709,916)
Other segment items (2)(380,803)(355,498)$(371,529)
Depreciation and amortization expense(60,909)(59,201)$(60,565)
Interest expense, net(49,029)(51,248)$(53,806)
Equity in earnings of joint ventures5,964 5,530 $5,125 
Other, net4,831 89,865 $14,218 
Income tax expense(71,776)(91,652)$(55,212)
Net Income$211,823 $267,090 $150,556 
(1) Represents business activities related to other miscellaneous revenue streams.
(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.
XML 43 R27.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUBSEQUENT EVENTS
 12 Months Ended
Dec. 31, 2024
Subsequent Events [Abstract]  
Subsequent Events SUBSEQUENT EVENTS
The Company has evaluated whether any subsequent events occurred since December 31, 2024 and noted the following subsequent event:
On January 24, 2025 the Company completed the acquisition of all equity interests in Intramed Plus, Inc., a leading provider of home and alternate site infusion services in the Southeastern United States. The total purchase price for the transaction was approximately $117 million, paid in cash.
XML 44 R28.htm IDEA: XBRL DOCUMENT v3.25.0.1
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Pay vs Performance Disclosure      
Net Income (Loss) $ 211,823 $ 267,090 $ 150,556
XML 45 R29.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Arrangements
 3 Months Ended
Dec. 31, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 46 R30.htm IDEA: XBRL DOCUMENT v3.25.0.1
Insider Trading Policies and Procedures
 12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 47 R31.htm IDEA: XBRL DOCUMENT v3.25.0.1
Cybersecurity Risk Management and Strategy Disclosure
 12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
We have developed and implemented a cybersecurity framework designed to identify, detect, protect, respond to and recover from risks stemming from threats to the security of our information, systems and network using a governance-led risk-based approach. The framework is informed, in part, by the National Institute of Standards and Technology (NIST) Cybersecurity Framework, although this does not necessarily mean that we meet all technical standards, specifications or requirements outlined in the NIST framework. Additionally, we maintain a Systems and Organization Controls (SOC) 2 Type 2 attestation.
Our goal is to maintain an information technology infrastructure that implements physical, administrative, and technical controls. These controls are adjusted based on risk and designed to protect the confidentiality, integrity, and availability of our information systems, including the customer information, personal information, and proprietary information stored on our networks.
We have a cybersecurity incident response plan and dedicated teams to respond to cybersecurity incidents. When a cybersecurity incident occurs, we have cross-functional teams that are responsible for leading the initial assessment of priority and severity. Our information security team assists in taking any remedial action in response to an incident, and external experts may also be engaged as appropriate.
Our overarching approach to cybersecurity risk management centers on governance, people, processes, and technology. We provide security awareness training to help employees understand their information protection and cybersecurity responsibilities. This includes mandatory annual cybersecurity training and monthly phishing simulations. We also perform periodic internal tabletops or simulation exercises involving technical experts, business and functional leaders, as well as separate exercises with select critical third-party service providers.
We conduct third-party assessments of potential new vendors who process, store or transmit our data, which include a formal security review. This can include the review of documentation related to a vendor’s security attestations, such as SOC 2 Type 2 or HITRUST certifications.
We leverage third-party cybersecurity companies to assess our cybersecurity program and procedures and reaffirm our compliance with SOC 2 standards as well as the HIPAA Security Rule. These assessments aid in continual improvement and help us identify and address risks from cybersecurity threats.
We also consider cybersecurity, along with our other top risks, within our enterprise risk management framework. This framework involves internal reporting at the business and enterprise levels, considering key risk indicators, trends and countermeasures. Our Senior Vice President, Chief Information Security Officer (CISO) serves on the Enterprise Risk Committee that assesses our enterprise-wide risks and oversees risk mitigation activities.
We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us or our results of operations, cash flow or financial condition. However, the scope and impact of any future incident, or the identification of new information related to prior cybersecurity incidents, cannot be predicted. See “Item 1A. Risk Factors” for more information about our cybersecurity-related risks.
Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block]
We have developed and implemented a cybersecurity framework designed to identify, detect, protect, respond to and recover from risks stemming from threats to the security of our information, systems and network using a governance-led risk-based approach. The framework is informed, in part, by the National Institute of Standards and Technology (NIST) Cybersecurity Framework, although this does not necessarily mean that we meet all technical standards, specifications or requirements outlined in the NIST framework. Additionally, we maintain a Systems and Organization Controls (SOC) 2 Type 2 attestation.
Our goal is to maintain an information technology infrastructure that implements physical, administrative, and technical controls. These controls are adjusted based on risk and designed to protect the confidentiality, integrity, and availability of our information systems, including the customer information, personal information, and proprietary information stored on our networks.
We have a cybersecurity incident response plan and dedicated teams to respond to cybersecurity incidents. When a cybersecurity incident occurs, we have cross-functional teams that are responsible for leading the initial assessment of priority and severity. Our information security team assists in taking any remedial action in response to an incident, and external experts may also be engaged as appropriate.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block]
The Quality and Compliance Committee of our Board of Directors provides board-level oversight of cybersecurity risk. As part of its oversight role, the Quality and Compliance Committee receives reports about our practices, programs, or notable threats or incidents related to cybersecurity throughout the year, including through periodic updates from our CISO and other leaders. The Quality and Compliance Committee provides regular reports to the full Board about these matters and other areas within its responsibility, and the CISO and other leaders provide updates regarding cybersecurity matters to the full Board as appropriate.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. Our CISO collaborates with senior leaders and other members of our organization to identify and analyze cybersecurity risks and implement controls as appropriate and feasible to mitigate these risks. The CISO also supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, including by collaborating with internal and external stakeholders. Our CISO is supported by a management-led Security Council, which consists of our Chief Executive Officer, Chief Financial Officer and other senior leaders throughout our organization, and which reviews and discusses our cybersecurity program as well as emerging cyber risks, threats, and industry trends, among other topics.
Cybersecurity Risk Role of Management [Text Block]
The Quality and Compliance Committee of our Board of Directors provides board-level oversight of cybersecurity risk. As part of its oversight role, the Quality and Compliance Committee receives reports about our practices, programs, or notable threats or incidents related to cybersecurity throughout the year, including through periodic updates from our CISO and other leaders. The Quality and Compliance Committee provides regular reports to the full Board about these matters and other areas within its responsibility, and the CISO and other leaders provide updates regarding cybersecurity matters to the full Board as appropriate.
Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. Our CISO collaborates with senior leaders and other members of our organization to identify and analyze cybersecurity risks and implement controls as appropriate and feasible to mitigate these risks. The CISO also supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, including by collaborating with internal and external stakeholders. Our CISO is supported by a management-led Security Council, which consists of our Chief Executive Officer, Chief Financial Officer and other senior leaders throughout our organization, and which reviews and discusses our cybersecurity program as well as emerging cyber risks, threats, and industry trends, among other topics.
Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] As part of its oversight role, the Quality and Compliance Committee receives reports about our practices, programs, or notable threats or incidents related to cybersecurity throughout the year, including through periodic updates from our CISO and other leaders. The Quality and Compliance Committee provides regular reports to the full Board about these matters and other areas within its responsibility, and the CISO and other leaders provide updates regarding cybersecurity matters to the full Board as appropriate.
Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. Our CISO collaborates with senior leaders and other members of our organization to identify and analyze cybersecurity risks and implement controls as appropriate and feasible to mitigate these risks. The CISO also supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, including by collaborating with internal and external stakeholders. Our CISO is supported by a management-led Security Council, which consists of our Chief Executive Officer, Chief Financial Officer and other senior leaders throughout our organization, and which reviews and discusses our cybersecurity program as well as emerging cyber risks, threats, and industry trends, among other topics.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 48 R32.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
 12 Months Ended
Dec. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation Basis of Presentation — The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States. GAAP
Principles of Consolidation
Principles of Consolidation — The Company’s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.
Cash and Cash Equivalents
Cash and Cash Equivalents — The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents consisted of money market funds.
Accounts Receivable
Accounts Receivable — The Company’s accounts receivable are reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental healthcare programs, such as Medicare and Medicaid.
Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, Revenue from Contracts with Customers (“ASC 606”), an allowance for doubtful accounts is established only as a result of an adverse change in the Company’s payers’ ability to pay outstanding billings.
Inventories
Inventories — Inventories, which consist primarily of pharmaceuticals, is stated at the lower of first‑in, first‑out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.
Leases
Leases — The Company has lease agreements for facilities, warehouses, office space and property and equipment. At the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (“ROU asset”) and operating lease liabilities in the consolidated financial statements.
ROU assets, which represent the Company’s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The rates are estimated primarily using a methodology dependent on the Company’s financial condition, creditworthiness, and availability of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.
Leases may contain rent escalations; however, the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.
The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants.
Goodwill, Intangible Assets, Property and Equipment, and Referral Sources
Goodwill, Intangible Assets, Property and Equipment, and Referral Sources — Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic 350, Intangibles-Goodwill and Other. The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate that impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter on a qualitative basis. See Note 10, Goodwill and Other Intangible Assets, for further discussion of the Company’s goodwill and other intangible assets.
Intangible assets arising from the Company’s acquisitions are amortized on a straight‑line basis over the estimated useful life of each asset. Referral sources have a useful life of fifteen to twenty years. Trademarks/names have a useful life ranging from two to fifteen years. The useful lives for other amortizable intangible assets range from approximately two to nine years. The Company does not have any indefinite‑lived intangible assets.
Property and Equipment
Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight‑line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and three to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight‑line basis over the software’s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.
The Company assesses long‑lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. If circumstances require that a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flows basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value.
Equity Method Investments
Equity-Method Investments — The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December 31, 2024 and 2023, the balance of the investments was $24.5 million and $20.9 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $6.0 million, $5.5 million and $5.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December 31, 2024, 2023 and 2022, the Company received distributions from the investees of $2.4 million, $4.0 million and $5.9 million, respectively. See Note 17, Related-Party Transactions, for discussion of related-party transactions with these investees.
Hedging Instruments
Hedging Instruments — The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, Derivative Instruments, for additional information.
At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.
Revenue Recognition
Revenue Recognition — Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing goods and services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.
Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available.
The Company assesses the expected consideration to be received at the time of patient acceptance, based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body.
The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service.
The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged.
Cost of Revenue
Cost of Revenue — Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.
The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.
Selling, General and Administrative Expenses Selling, General and Administrative Expenses — Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees.
Stock Based Incentive Compensation
Stock Based Incentive Compensation — The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, Compensation-Stock Compensation (“ASC 718”). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company’s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs.
Business Acquisitions Business Acquisitions — The Company accounts for business acquisitions in accordance with ASC Topic 805, Business Combinations, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets.
Income Taxes
Income Taxes — The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change.
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized.
The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense (benefit). Tax related interest and penalties are classified as a component of income tax expense (benefit).
Concentrations of Business Risk
Concentrations of Business Risk — The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15%, 14% and 14% for the years ended December 31, 2024, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.
For the years ended December 31, 2024, 2023 and 2022, approximately 12%, 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December 31, 2024 and 2023, approximately 11% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.
The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.
For the year ended December 31, 2024, approximately 58% of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the years ended December 31, 2023 and 2022, approximately 72% and 73%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue or decreased gross profit, which could adversely affect the Company’s financial condition or operating results.
Fair Value Measurements
Fair Value Measurements — The fair value measurement accounting standard, ASC Topic 820, Fair Value Measurement (“ASC 820”), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:
•Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.
•Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.
•Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.
While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
FAIR VALUE MEASUREMENTS
Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The three levels of inputs within the fair value hierarchy are defined in Note 2, Summary of Significant Accounting Policies. While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.
First Lien Term Loan: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, Indebtedness, for further discussion of the carrying amount and fair value of the First Lien Term Loan.
Senior Notes: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 11, Indebtedness, for further discussion of the carrying amount and fair value of the Senior Notes.
Interest Rate Cap: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, Derivative Instruments, for further discussion of the fair value of the interest rate cap.
Money Market Funds: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s consolidated balance sheets (Level 1 inputs).
There were no other assets or liabilities measured at fair value at December 31, 2024 or 2023.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements — In November 2024, the FASB issued ASU 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. This ASU improves the disclosures around a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&A, and research and development). The amendments in this ASU do not change or remove current presentation requirements or current expense disclosure requirements. However, the amendments affect where this information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The Company is required to adopt this ASU for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. This ASU addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The ASU allows investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. This ASU also improves the effectiveness and comparability of disclosures by adding disclosures of pretax income (loss) and income tax expense (benefit) to be consistent with U.S. Securities and Exchange Commission (“SEC”) Regulation S-X and removing disclosures that no longer are considered cost beneficial or relevant. The Company is required to adopt this ASU for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. This ASU improves the disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities, including those public entities that have a single reportable segment, to enable investors to develop more decision-useful financial analyses. The Company is required to adopt this ASU for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU was adopted during the year ended December 31, 2024 and applied retrospectively to all prior periods presented in the financial statements. The adoption did not have any material impact on the Company’s results of operations, cash flows, financial position, or disclosures. See Note 18, Segment Reporting, for further discussion.

In October 2023, the FASB issued ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative. This ASU is the result of the Board’s decision to incorporate into the Codification 14 disclosures referred by the SEC. The ASU represents changes to clarify or improve disclosure and presentation requirements of a variety of Topics. Many of the amendments allow users to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the SEC’s requirements. Also, the amendments align the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption permitted. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.
XML 49 R33.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE (Tables)
 12 Months Ended
Dec. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Net Revenue Earned by Category of Payer
The following table sets forth the net revenue earned by category of payer for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year Ended December 31,
202420232022
Commercial payers$4,348,991 $3,747,568 $3,421,888 
Government payers584,271 500,891 477,818 
Patients64,940 53,865 45,029 
Net revenue$4,998,202 $4,302,324 $3,944,735 
XML 50 R34.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES - Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Income Tax Expense (Benefit)
The income tax expense (benefit) consists of the following for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year Ended December 31,
202420232022
U.S. federal income tax expense (benefit):
Current$47,239 $56,474 $4,103 
Deferred16,396 18,739 38,810 
63,635 75,213 42,913 
State income tax expense (benefit):
Current10,597 20,253 9,182 
Deferred(2,456)(3,814)3,117 
8,141 16,439 12,299 
Total income tax expense (benefit)$71,776 $91,652 $55,212 
Schedule of Effective Income Tax Rate Reconciliation
The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December 31, 2024, 2023 and 2022:
Year Ended December 31,
202420232022
U.S. federal statutory tax rate21.0 %21.0 %21.0 %
State and local income taxes net of federal tax benefit3.5 %4.8 %5.0 %
Valuation allowance(0.8)%(1.5)%0.0 %
Share based compensation impacts1.2 %0.7 %0.4 %
Other, net0.4 %0.5 %0.4 %
Effective income tax rate25.3 %25.5 %26.8 %
Schedule of Deferred Tax Assets and Liabilities
The components of deferred income tax assets and liabilities were as follows as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Deferred tax assets:
Price concessions$8,053 $5,365 
Compensation and benefits6,166 7,609 
Interest limitation carryforward5,768 13,802 
Operating lease liability23,880 26,378 
Net operating losses50,860 56,980 
Other12,676 7,556 
Deferred tax assets before valuation allowance107,403 117,690 
Valuation allowance(3,337)(6,371)
Deferred tax assets net of valuation allowance104,066 111,319 
Deferred tax liabilities:
Accelerated depreciation(12,630)(8,882)
Operating lease right-of-use asset(18,883)(21,504)
Intangible assets(48,412)(52,502)
Goodwill(59,303)(52,188)
Other(12,414)(11,163)
Deferred tax liabilities(151,642)(146,239)
Net deferred tax liabilities$(47,576)$(34,920)
Summary of Valuation Allowance
The following table presents the valuation allowance for deferred tax assets for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Additions
DescriptionBalance at Beginning of PeriodCharged (Benefit) to Costs and ExpensesCharged (Benefit) to Other AccountsBalance at End of Period
2022: Valuation allowance for deferred tax assets$13,151 $(95)$— $13,056 
2023: Valuation allowance for deferred tax assets$13,056 $(6,685)$— $6,371 
2024: Valuation allowance for deferred tax assets$6,371 $(3,034)$— $3,337 
XML 51 R35.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE (Tables)
 12 Months Ended
Dec. 31, 2024
Earnings Per Share [Abstract]  
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive:
Year Ended December 31,
202420232022
Warrants———
Stock option awards854,5451,214,560629,690
Restricted stock awards376,743340,331205,652
Performance stock unit awards286,881——
Schedule of Basic and Diluted Earnings Per Share
The following tables present the Company’s basic and diluted earnings per share and shares outstanding (in thousands, except per share data):
Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Earnings per Common Share:
Earnings per common share, basic$1.23 $1.49 $0.83 

Year Ended December 31,
 202420232022
Numerator:  
Net income (1) (2)$211,823 $267,090 $150,556 
Denominator:  
Weighted average number of common shares outstanding171,567 178,973 181,105 
Effect of dilutive securities1,278 1,402 970 
Weighted average number of common shares outstanding, diluted172,845 180,375 182,075 
Earnings per Common Share:
Earnings per common share, diluted$1.23 $1.48 $0.83 

(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, Business Acquisitions and Divestitures, for further discussion.
(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, Business Acquisitions and Divestitures, for further discussion.
XML 52 R36.htm IDEA: XBRL DOCUMENT v3.25.0.1
LEASES (Tables)
 12 Months Ended
Dec. 31, 2024
Leases [Abstract]  
Maturities of Lease Liabilities, Operating
Operating leases mature as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$28,286 
202625,523 
202720,406 
202813,907 
20299,306 
2030 and beyond36,515 
Total lease payments133,943 
Less: interest(27,123)
Present value of lease liabilities$106,820 
XML 53 R37.htm IDEA: XBRL DOCUMENT v3.25.0.1
PROPERTY AND EQUIPMENT (Tables)
 12 Months Ended
Dec. 31, 2024
Property, Plant and Equipment [Abstract]  
Schedule of Property and Equipment
Property and equipment was as follows as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Infusion pumps$37,659 $36,943 
Equipment, furniture and other24,055 23,593 
Leasehold improvements116,675 99,725 
Computer software, purchased and internally developed46,532 50,572 
Assets under development22,990 33,668 
247,911 244,501 
Less: accumulated depreciation(120,544)(123,871)
Property and equipment, net$127,367 $120,630 
The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Year ended December 31,
202420232022
Depreciation expense in cost of revenue$2,590 $2,999 $4,869 
Depreciation expense in operating expenses26,503 24,820 27,374 
Total depreciation expense$29,093 $27,819 $32,243 
XML 54 R38.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of the Carrying Amount of Goodwill
Changes in the carrying amount of goodwill consist of the following activity for the years ended December 31, 2024, 2023 and 2022 (in thousands):
Balance at December 31, 2021$1,477,564 
Acquisitions54,543 
Purchase accounting adjustments1,317 
Balance at December 31, 2022$1,533,424 
Acquisitions6,998 
Purchase accounting adjustments(176)
Balance at December 31, 2023$1,540,246 
Acquisitions— 
Purchase accounting adjustments— 
Balance at December 31, 2024$1,540,246 
Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets
The carrying amount and accumulated amortization of intangible assets consist of the following as of December 31, 2024 and 2023 (in thousands):
December 31, 2024December 31, 2023
Gross intangible assets:
Referral sources$514,388 $514,388 
Trademarks/names39,136 39,136 
Other amortizable intangible assets985 995 
Total gross intangible assets554,509 554,519 
Accumulated amortization:
Referral sources(230,371)(199,084)
Trademarks/names(22,599)(19,698)
Other amortizable intangible assets(529)(341)
Total accumulated amortization(253,499)(219,123)
Total intangible assets, net$301,010 $335,396 
Schedule of Future Amortization Expense for Intangible Assets
Expected future amortization expense for intangible assets recorded at December 31, 2024, is as follows (in thousands):
Amount
2025$34,176 
202634,071 
202733,931 
202833,880 
202933,875 
2030 and beyond131,077 
Total$301,010 
XML 55 R39.htm IDEA: XBRL DOCUMENT v3.25.0.1
INDEBTEDNESS (Tables)
 12 Months Ended
Dec. 31, 2024
Debt Disclosure [Abstract]  
Schedule of Debt
Long-term debt consisted of the following as of December 31, 2024 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan631,617 (5,537)(7,555)618,525 
Senior Notes500,000 — (7,372)492,628 
$1,131,617 $(5,537)$(14,927)1,111,153 
Less: current portion(6,512)
Total long-term debt$1,104,641 
Long-term debt consisted of the following as of December 31, 2023 (in thousands):
Principal AmountDiscountDebt Issuance CostsNet Balance
Revolver Facility$— $— $— $— 
First Lien Term Loan588,000 (6,974)(9,678)571,348 
Senior Notes500,000 — (8,698)491,302 
$1,088,000 $(6,974)$(18,376)1,062,650 
Less: current portion(6,000)
Total long-term debt$1,056,650 
Schedule of Long-term Debt Maturities
Long-term debt matures as follows (in thousands):
Fiscal Year Ended December 31,Minimum Payments
2025$6,512 
20266,512 
20276,512 
2028612,081 
2029500,000 
Total$1,131,617 
Schedule of Estimated Fair Values of Debt Obligations
The following table presents the estimated fair values of the Company’s debt obligations as of December 31, 2024 (in thousands):
Financial InstrumentCarrying Value as of December 31, 2024Markets for Identical Item (Level 1)Significant Other Observable Inputs (Level 2)Significant Unobservable Inputs (Level 3)
First Lien Term Loan$618,525 $— $634,774 $— 
Senior Notes492,628 — 460,000 — 
Total debt instruments$1,111,153 $— $1,094,774 $— 
XML 56 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
DERIVATIVE INSTRUMENTS (Tables)
 12 Months Ended
Dec. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Summary of Amount and Location of Derivatives in the Balance Sheet
The following table summarizes the amount and location of the Company’s derivative instruments in the consolidated balance sheets (in thousands):
Fair Value - Derivatives in Asset Position
DerivativeBalance Sheet CaptionDecember 31, 2024December 31, 2023
Interest rate cap designated as cash flows hedgePrepaid expenses and other current assets$8,034 $9,746 
Interest rate cap designated as cash flows hedgeOther noncurrent assets6,680 10,183 
Total derivative assets$14,714 $19,929 
Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss) The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s consolidated statements of comprehensive income (in thousands):
Year Ended December 31,
Derivative202420232022
Interest rate cap designated as cash flows hedge$(5,215)$(8,339)$28,869 
The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s consolidated statement of comprehensive income related to the Company’s derivative instruments (in thousands):
Year Ended December 31,
DerivativeIncome Statement Caption202420232022
Interest rate cap designated as cash flows hedgeInterest expense, net$11,527 $10,974 $1,090 
XML 57 R41.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED INCENTIVE COMPENSATION (Tables)
 12 Months Ended
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Fair Value of Awards The assumptions used to compute the fair value of options for the years ended December 31, 2023 and 2022 are as follows:
Year Ended December 31,
20232022
Expected volatility51.43%51.19%
Risk-free interest rate4.16%3.91%
Expected life of options6.2 years6.2 years
Dividend rate——
Summary of Stock Option Activity
A summary of stock option activity for the year ended December 31, 2024 is as follows:
OptionsWeighted Average Exercise PriceAggregate Intrinsic Value (thousands)Weighted Average Remaining Contractual Life
Balance at December 31, 20231,746,272 $25.08 $15,028 
Granted— $— $— 
Exercised(161,553)$18.14 $1,875 
Forfeited and expired(101,486)$26.05 $32 
Balance at December 31, 20241,483,233 $25.79 $1,590 7.35 years
Exercisable at December 31, 2024595,984 $22.96 $1,365 6.52 years
Summary of Outstanding Options by Exercise Price Range The following table outlines the outstanding and exercisable stock options as of December 31, 2024:
Options OutstandingOptions Exercisable
Range of Option Exercise PriceOutstanding OptionsWeighted Average Exercise PriceWeighted Average Remaining Contractual LifeOptions ExercisableWeighted Average Exercise Price
$0.00 - $8.24
9,901 $6.52 2.19,901 $6.52 
$8.24 - $16.52
64,775 $12.14 4.064,775 $12.14 
$16.52 - $24.76
355,616 $21.54 6.7200,513 $21.05 
$24.76 - $33.00
1,052,941 $28.25 7.8320,795 $26.85 
All options1,483,233 595,984 
Summary of Restricted Stock Award Activity
A summary of restricted stock award activity for the year ended December 31, 2024 is as follows:
Restricted StockWeighted Average Grant Date Fair Value
Balance at December 31, 20231,883,116 $26.28 
Granted 723,027 $32.71 
Vested and issued(770,137)$25.16 
Forfeited and expired(170,594)$28.25 
Balance at December 31, 20241,665,412 $29.41 
XML 58 R42.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCKHOLDERS' EQUITY (Tables)
 12 Months Ended
Dec. 31, 2024
Equity [Abstract]  
Schedule of Changes in Shares of Common Stock The following table shows the Company’s changes in shares of common stock for the years ended December 31, 2024 and 2023 (in thousands):
Balance at December 31, 2022181,958 
Equity award issuances564 
Share repurchases(7,946)
Balance at December 31, 2023174,576 
Equity award issuances941 
Share repurchases(9,256)
Balance at December 31, 2024166,261 
XML 59 R43.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT REPORTING (Tables)
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Results of Operations for Reportable Segment
The following table reflects results of operations of the Company’s reportable segment (in thousands):

Year Ended December 31,
202420232022
Infusion services net revenue$4,911,591 $4,222,656 $3,869,036 
Other revenue (1)86,611 79,668 $75,699 
Total Option Care Health revenue4,998,202 4,302,324 $3,944,735 
(Expense) Income:
Cost of net revenues - drugs(3,446,735)(2,812,531)$(2,562,494)
Salaries, benefits, and other employee expense(787,922)(760,499)$(709,916)
Other segment items (2)(380,803)(355,498)$(371,529)
Depreciation and amortization expense(60,909)(59,201)$(60,565)
Interest expense, net(49,029)(51,248)$(53,806)
Equity in earnings of joint ventures5,964 5,530 $5,125 
Other, net4,831 89,865 $14,218 
Income tax expense(71,776)(91,652)$(55,212)
Net Income$211,823 $267,090 $150,556 
(1) Represents business activities related to other miscellaneous revenue streams.
(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.
XML 60 R44.htm IDEA: XBRL DOCUMENT v3.25.0.1
NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)
 12 Months Ended
Mar. 03, 2023
shares
Dec. 31, 2024
pharmacy
suite
segment
shares
Dec. 31, 2023
shares
Business Acquisition [Line Items]      
Treasury stock, shares, acquired (in shares) 2,475,166 9,255,591 7,946,301
Number of service locations | pharmacy   92  
Number of infusion sites | suite   93  
Number of operating segments | segment   1  
Legacy Health Systems      
Business Acquisition [Line Items]      
Ownership interest   50.00%  
Common Stock | Secondary Offering      
Business Acquisition [Line Items]      
Number of shares issued in transaction (in shares)     23,771,926
XML 61 R45.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Concentration Risk [Line Items]      
Unbilled receivables $ 105,300 $ 89,100  
Rebate receivable 54,400 52,000  
Investments in equity-method investees 24,500 20,900  
Proportionate share of earnings in equity-method investees 5,964 5,530 $ 5,125
Distribution from equity method investments $ 2,400 $ 4,000 $ 5,875
Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Largest Payer      
Concentration Risk [Line Items]      
Concentration risk 15.00% 14.00% 14.00%
Revenue from Contract with Customer Benchmark | Governmental Programs | Government Healthcare Programs      
Concentration Risk [Line Items]      
Concentration risk 12.00% 12.00% 12.00%
Accounts Receivable Benchmark | Governmental Programs | Government Healthcare Programs      
Concentration Risk [Line Items]      
Concentration risk 11.00% 12.00%  
Cost of Goods and Service, Product and Service Benchmark | Medical Supply Vendors | Four Vendors      
Concentration Risk [Line Items]      
Concentration risk 58.00% 72.00% 73.00%
Infusion pumps      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 7 years    
Computer Software      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 5 years    
Minimum | Referral sources      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 15 years    
Minimum | Trademarks and Trade Names      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 2 years    
Minimum | Other amortizable intangible assets      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 2 years    
Minimum | Equipment      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 3 years    
Maximum | Referral sources      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 20 years    
Maximum | Trademarks and Trade Names      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 15 years    
Maximum | Other amortizable intangible assets      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 9 years    
Maximum | Equipment      
Concentration Risk [Line Items]      
Intangible asset useful life (in years) 13 years    
XML 62 R46.htm IDEA: XBRL DOCUMENT v3.25.0.1
BUSINESS ACQUISITIONS AND DIVESTITURES - Additional Information (Details) - USD ($)
$ in Thousands
 1 Months Ended 12 Months Ended
May 31, 2023
Dec. 31, 2022
Aug. 31, 2022
Apr. 30, 2022
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 26, 2023
May 03, 2023
Dec. 31, 2021
Business Acquisition [Line Items]                    
Business combination, acquisition-related expenses           $ 21,100        
Goodwill   $ 1,533,424     $ 1,540,246 1,540,246 $ 1,533,424     $ 1,477,564
Sale price   18,400         18,400      
Proceeds from sale of assets   14,700     $ 0 3,743 14,670      
Consideration receivable   3,700         3,700      
Assets held for sale   8,800         8,800      
Liabilities held for sale   700         $ 700      
Gain on sale   $ 10,300                
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]             Other, net      
Amedisys, Inc.                    
Business Acquisition [Line Items]                    
Termination fee           $ 63,100   $ 106,000    
Revitalized, LLC                    
Business Acquisition [Line Items]                    
Percentage of the combined company held 100.00%                  
Net of cash acquired $ 12,500                  
Goodwill 6,700                  
Intangible assets $ 5,500                  
Rochester Home Infusion, Inc                    
Business Acquisition [Line Items]                    
Percentage of the combined company held     100.00%              
Net of cash acquired     $ 27,400              
Specialty Pharmacy Nursing Network, Inc.                    
Business Acquisition [Line Items]                    
Percentage of the combined company held       100.00%            
Net of cash acquired       $ 59,900            
Option Care, Combined Company | Amedisys, Inc.                    
Business Acquisition [Line Items]                    
Company's stockholders, ownership percentage following merger                 64.50%  
XML 63 R47.htm IDEA: XBRL DOCUMENT v3.25.0.1
REVENUE - Net Revenue Earned by Category of Payer (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disaggregation of Revenue [Line Items]      
Net revenue $ 4,998,202 $ 4,302,324 $ 3,944,735
Commercial payers      
Disaggregation of Revenue [Line Items]      
Net revenue 4,348,991 3,747,568 3,421,888
Government payers      
Disaggregation of Revenue [Line Items]      
Net revenue 584,271 500,891 477,818
Patients      
Disaggregation of Revenue [Line Items]      
Net revenue $ 64,940 $ 53,865 $ 45,029
XML 64 R48.htm IDEA: XBRL DOCUMENT v3.25.0.1
EMPLOYEE BENEFIT PLANS (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Retirement Benefits [Abstract]      
Employer matching contribution percent 100.00%    
Employer matching contribution percent of employees' gross pay 4.00%    
Defined contribution plan expense $ 13.3 $ 13.1 $ 12.2
Company contributions $ 13.3 $ 12.4 $ 11.8
XML 65 R49.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES - Income Tax Benefit (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
U.S. federal income tax expense (benefit):      
Current $ 47,239 $ 56,474 $ 4,103
Deferred 16,396 18,739 38,810
Federal income tax expense (benefit) 63,635 75,213 42,913
State income tax expense (benefit):      
Current 10,597 20,253 9,182
Deferred (2,456) (3,814) 3,117
State income tax expense 8,141 16,439 12,299
Total income tax expense (benefit) $ 71,776 $ 91,652 $ 55,212
XML 66 R50.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES - Income Tax Reconciliation (Details)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]      
U.S. federal statutory tax rate 21.00% 21.00% 21.00%
State and local income taxes net of federal tax benefit 3.50% 4.80% 5.00%
Valuation allowance (0.80%) (1.50%) 0.00%
Share based compensation impacts 1.20% 0.70% 0.40%
Other, net 0.40% 0.50% 0.40%
Effective income tax rate 25.30% 25.50% 26.80%
XML 67 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 31, 2024
Sep. 30, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Tax Examination [Line Items]          
Income tax expense (benefit)     $ 71,776,000 $ 91,652,000 $ 55,212,000
Effective income tax rate     25.30% 25.50% 26.80%
Termination fee income       $ 21,800,000  
Valuation allowance     $ 3,337,000 6,371,000  
Net operating losses     50,860,000 56,980,000  
Interest limitation carryforward     5,768,000 13,802,000  
Unrecognized tax benefits     0 $ 0 $ 0
Interest Limitation Carryforwards          
Income Tax Examination [Line Items]          
Interest limitation carryforward     5,800,000    
State          
Income Tax Examination [Line Items]          
Valuation allowance released $ 2,200,000 $ 5,800,000      
Valuation allowance     3,300,000    
State | Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income          
Income Tax Examination [Line Items]          
Net operating losses     15,300,000    
Federal          
Income Tax Examination [Line Items]          
Operating loss carryforwards     24,600,000    
Federal | Merger Operating Loss Carryforward          
Income Tax Examination [Line Items]          
Net operating losses     35,600,000    
Federal | Indefinite Carryforward Period          
Income Tax Examination [Line Items]          
Operating loss carryforwards     $ 11,000,000.0    
XML 68 R52.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Deferred tax assets:    
Price concessions $ 8,053 $ 5,365
Compensation and benefits 6,166 7,609
Interest limitation carryforward 5,768 13,802
Operating lease liability 23,880 26,378
Net operating losses 50,860 56,980
Other 12,676 7,556
Deferred tax assets before valuation allowance 107,403 117,690
Valuation allowance (3,337) (6,371)
Deferred tax assets net of valuation allowance 104,066 111,319
Deferred tax liabilities:    
Accelerated depreciation (12,630) (8,882)
Operating lease right-of-use asset (18,883) (21,504)
Intangible assets (48,412) (52,502)
Goodwill (59,303) (52,188)
Other (12,414) (11,163)
Deferred tax liabilities (151,642) (146,239)
Net deferred tax liabilities $ (47,576) $ (34,920)
XML 69 R53.htm IDEA: XBRL DOCUMENT v3.25.0.1
INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details) - Valuation Allowance, Deferred Tax Assets - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Change in Deferred Tax Asset Valuation Allowance      
Beginning balance $ 6,371 $ 13,056 $ 13,151
Charged (Benefit) to Costs and Expenses (3,034) (6,685) (95)
Charged (Benefit) to Other Accounts 0 0 0
Ending balance $ 3,337 $ 6,371 $ 13,056
XML 70 R54.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Warrants      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded (in shares) 0 0 0
Stock option awards      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded (in shares) 854,545 1,214,560 629,690
Restricted stock awards      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded (in shares) 376,743 340,331 205,652
Performance stock unit awards      
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]      
Antidilutive securities excluded (in shares) 286,881 0 0
XML 71 R55.htm IDEA: XBRL DOCUMENT v3.25.0.1
EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jun. 26, 2023
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]        
Net income $ 211,823 $ 267,090 $ 150,556  
Weighted average common shares outstanding, basic (in shares) 171,567 178,973 181,105  
Earnings per share, basic (in dollars per share) $ 1.23 $ 1.49 $ 0.83  
Effect of dilutive securities (in shares) 1,278 1,402 970  
Weighted average number of common shares outstanding, diluted (in shares) 172,845 180,375 182,075  
Earnings per share, diluted (in dollars per share) $ 1.23 $ 1.48 $ 0.83  
Amedisys, Inc.        
Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]        
Termination fee   $ 63,100   $ 106,000
XML 72 R56.htm IDEA: XBRL DOCUMENT v3.25.0.1
LEASES - Additional Information (Details) - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Leases [Abstract]      
Operating lease cost $ 32.7 $ 30.6 $ 29.1
Weighted-average remaining lease term, operating leases 6 years 6 months 6 years 9 months 18 days  
Weighted-average discount rate, operating leases 6.56% 6.16%  
Right of use asset obtained in exchange for operating lease liabilities $ 25.0 $ 30.5 $ 17.2
XML 73 R57.htm IDEA: XBRL DOCUMENT v3.25.0.1
LEASES - Maturities of Lease Liabilities (Details)
$ in Thousands
Dec. 31, 2024
USD ($)
Leases [Abstract]  
2025 $ 28,286
2026 25,523
2027 20,406
2028 13,907
2029 9,306
2030 and beyond 36,515
Total lease payments 133,943
Less: interest (27,123)
Present value of lease liabilities $ 106,820
XML 74 R58.htm IDEA: XBRL DOCUMENT v3.25.0.1
PROPERTY AND EQUIPMENT (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 247,911 $ 244,501  
Less: accumulated depreciation (120,544) (123,871)  
Property and equipment, net 127,367 120,630  
Depreciation expense 29,093 27,819 $ 32,243
Depreciation expense in cost of revenue      
Property, Plant and Equipment [Line Items]      
Depreciation expense 2,590 2,999 4,869
Depreciation expense in operating expenses      
Property, Plant and Equipment [Line Items]      
Depreciation expense 26,503 24,820 $ 27,374
Infusion pumps      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 37,659 36,943  
Equipment, furniture and other      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 24,055 23,593  
Leasehold improvements      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 116,675 99,725  
Computer software, purchased and internally developed      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross 46,532 50,572  
Assets under development      
Property, Plant and Equipment [Line Items]      
Property and equipment, gross $ 22,990 $ 33,668  
XML 75 R59.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]      
Goodwill impairment $ 0 $ 0 $ 0
Amortization expense for intangible assets $ 34,400,000 $ 34,200,000 $ 32,900,000
XML 76 R60.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Goodwill [Roll Forward]      
Goodwill - net book value, beginning of period $ 1,540,246 $ 1,533,424 $ 1,477,564
Acquisitions 0 6,998 54,543
Purchase accounting adjustments 0 (176) 1,317
Goodwill - net book value, end of period $ 1,540,246 $ 1,540,246 $ 1,533,424
XML 77 R61.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets $ 554,509 $ 554,519
Total accumulated amortization (253,499) (219,123)
Total intangible assets, net 301,010 335,396
Referral sources    
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets 514,388 514,388
Total accumulated amortization (230,371) (199,084)
Trademarks/names    
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets 39,136 39,136
Total accumulated amortization (22,599) (19,698)
Other amortizable intangible assets    
Finite-Lived Intangible Assets [Line Items]    
Total gross intangible assets 985 995
Total accumulated amortization $ (529) $ (341)
XML 78 R62.htm IDEA: XBRL DOCUMENT v3.25.0.1
GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]    
2025 $ 34,176  
2026 34,071  
2027 33,931  
2028 33,880  
2029 33,875  
2030 and beyond 131,077  
Total intangible assets, net $ 301,010 $ 335,396
XML 79 R63.htm IDEA: XBRL DOCUMENT v3.25.0.1
INDEBTEDNESS - Summary of Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Debt Instrument [Line Items]    
Principal Amount $ 1,131,617 $ 1,088,000
Discount (5,537) (6,974)
Debt Issuance Costs (14,927) (18,376)
Net Balance 1,111,153 1,062,650
Less: current portion (6,512) (6,000)
Total long-term debt 1,104,641 1,056,650
Senior Notes | First Lien Term Loan    
Debt Instrument [Line Items]    
Principal Amount 631,617 588,000
Discount (5,537) (6,974)
Debt Issuance Costs (7,555) (9,678)
Net Balance 618,525 571,348
Senior Notes | Senior Notes    
Debt Instrument [Line Items]    
Principal Amount 500,000 500,000
Discount 0 0
Debt Issuance Costs (7,372) (8,698)
Net Balance 492,628 491,302
Senior Notes | Revolver Facility    
Debt Instrument [Line Items]    
Principal Amount 0 0
Discount 0 0
Debt Issuance Costs 0 0
Net Balance $ 0 $ 0
XML 80 R64.htm IDEA: XBRL DOCUMENT v3.25.0.1
INDEBTEDNESS - Additional Information (Details) - USD ($)
 12 Months Ended
May 08, 2024
May 07, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Dec. 07, 2023
Jan. 13, 2023
Jan. 12, 2023
Oct. 31, 2021
Debt Instrument [Line Items]                  
Payments to extinguish debt     $ 6,384,000 $ 6,000,000 $ 6,000,000        
Net cash (used in) provided by financing activities     (218,206,000) (265,126,000) 15,268,000        
Debt issuance costs     14,927,000 18,376,000          
Proceeds from issuance of debt     49,959,000 0 0        
Loss on extinguishment of debt     377,000 0 $ 0        
Senior Notes | Revolver Facility                  
Debt Instrument [Line Items]                  
Debt issuance costs     0 $ 0          
First Lien Credit Agreement, Third Amendment | First Lien Term Loan | Senior Notes                  
Debt Instrument [Line Items]                  
Debt instrument, face amount $ 50,000,000                
Debt instrument, periodic payment, principal     $ 1,600,000            
Effective rate on term loans at end of period     6.82% 8.21%          
Weighted average interest rate paid on term loans during period     7.61% 7.83%          
Payments to extinguish debt     $ 400,000            
Net cash (used in) provided by financing activities     50,000,000            
Debt issuance costs and third party fees     1,600,000            
Debt issuance costs     100,000            
Proceeds from issuance of debt     50,000,000            
Loss on extinguishment of debt     $ 400,000            
First Lien Credit Agreement, Third Amendment | First Lien Term Loan | Senior Notes | SOFR                  
Debt Instrument [Line Items]                  
Basis spread on variable rate 2.25% 2.75%              
First Lien Credit Agreement, Third Amendment | First Lien Term Loan | Senior Notes | Interest Rate Floor                  
Debt Instrument [Line Items]                  
Basis spread on variable rate     0.50%            
First Lien Credit Agreement, Third Amendment | First Lien Term Loan | Senior Notes | Base Rate                  
Debt Instrument [Line Items]                  
Basis spread on variable rate     1.25%            
New First Lien Term Loan | First Lien Term Loan | Senior Notes                  
Debt Instrument [Line Items]                  
Debt instrument, face amount                 $ 600,000,000
Second Lien Credit Agreement | Senior Notes | Revolver Facility                  
Debt Instrument [Line Items]                  
Debt instrument, face amount           $ 400,000,000      
Available borrowing capacity     $ 395,900,000            
Second Lien Credit Agreement | Senior Notes | SOFR | Revolver Facility                  
Debt Instrument [Line Items]                  
Basis spread on variable rate     1.75%            
Second Lien Credit Agreement | Senior Notes | Base Rate | Revolver Facility                  
Debt Instrument [Line Items]                  
Basis spread on variable rate     0.75%            
Credit Agreements, Entered Into 2019 | Senior Notes | Revolver Facility                  
Debt Instrument [Line Items]                  
Debt instrument, face amount             $ 225,000,000 $ 175,000,000  
Undrawn letters of credit issued and outstanding     $ 4,100,000 $ 5,300,000          
Available borrowing capacity       $ 394,700,000          
Increase in borrowing capacity             $ 50,000,000    
Commitment fee percentage       2.50%          
Credit Agreements, Entered Into 2019 | Senior Notes | Revolver Facility | Minimum                  
Debt Instrument [Line Items]                  
Commitment fee, unused portion       0.25%          
Credit Agreements, Entered Into 2019 | Senior Notes | Revolver Facility | Maximum                  
Debt Instrument [Line Items]                  
Commitment fee, unused portion       0.375%          
Credit Agreements, Entered Into 2019 | Senior Notes | SOFR | Revolver Facility | Minimum                  
Debt Instrument [Line Items]                  
Basis spread on variable rate       1.25%          
Credit Agreements, Entered Into 2019 | Senior Notes | SOFR | Revolver Facility | Maximum                  
Debt Instrument [Line Items]                  
Basis spread on variable rate       1.75%          
Credit Agreements, Entered Into 2019 | Senior Notes | Interest Rate Floor | Revolver Facility                  
Debt Instrument [Line Items]                  
Basis spread on variable rate       0.00%          
Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate | Revolver Facility | Minimum                  
Debt Instrument [Line Items]                  
Basis spread on variable rate       0.25%          
Credit Agreements, Entered Into 2019 | Senior Notes | Base Rate | Revolver Facility | Maximum                  
Debt Instrument [Line Items]                  
Basis spread on variable rate       0.75%          
Credit Agreements, Entered Into 2019 | Second Lien Term Loan | Senior Notes                  
Debt Instrument [Line Items]                  
Effective rate on term loans at end of period     4.375% 4.375%          
Weighted average interest rate paid on term loans during period     4.375% 4.375%          
New Senior Unsecured Notes | Senior Notes                  
Debt Instrument [Line Items]                  
Debt instrument, face amount                 $ 500,000,000
Effective rate on term loans at end of period     4.375%            
XML 81 R65.htm IDEA: XBRL DOCUMENT v3.25.0.1
INDEBTEDNESS - Long-term Debt Maturities (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Debt Disclosure [Abstract]    
2025 $ 6,512  
2026 6,512  
2027 6,512  
2028 612,081  
2029 500,000  
Total $ 1,131,617 $ 1,088,000
XML 82 R66.htm IDEA: XBRL DOCUMENT v3.25.0.1
INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)
$ in Thousands
Dec. 31, 2024
USD ($)
Debt Instrument [Line Items]  
Total debt instruments $ 1,111,153
Markets for Identical Item (Level 1)  
Debt Instrument [Line Items]  
Total debt instruments 0
Significant Other Observable Inputs (Level 2)  
Debt Instrument [Line Items]  
Total debt instruments 1,094,774
Significant Unobservable Inputs (Level 3)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes  
Debt Instrument [Line Items]  
Total debt instruments 492,628
Senior Notes | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 618,525
Senior Notes | Markets for Identical Item (Level 1)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Markets for Identical Item (Level 1) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Significant Other Observable Inputs (Level 2)  
Debt Instrument [Line Items]  
Total debt instruments 460,000
Senior Notes | Significant Other Observable Inputs (Level 2) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments 634,774
Senior Notes | Significant Unobservable Inputs (Level 3)  
Debt Instrument [Line Items]  
Total debt instruments 0
Senior Notes | Significant Unobservable Inputs (Level 3) | First Lien Term Loan  
Debt Instrument [Line Items]  
Total debt instruments $ 0
XML 83 R67.htm IDEA: XBRL DOCUMENT v3.25.0.1
DERIVATIVE INSTRUMENTS - Additional Information (Details) - USD ($)
$ in Millions
 1 Months Ended
Oct. 31, 2021
Dec. 31, 2024
Derivative [Line Items]    
Total interest rate costs expected to reclassify during next 12 months   $ 2.8
First Lien Term Loan | Interest rate cap designated as cash flows hedge | Designated as Hedging Instrument | Senior Notes    
Derivative [Line Items]    
Notional amount of derivative $ 300.0  
Derivative term of contract 5 years  
XML 84 R68.htm IDEA: XBRL DOCUMENT v3.25.0.1
DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) - USD ($)
$ in Thousands
Dec. 31, 2024
Dec. 31, 2023
Derivative    
Total derivative assets $ 14,714 $ 19,929
Derivative Asset, Statement of Financial Position [Extensible Enumeration] Other noncurrent assets, Prepaid expenses and other current assets Other noncurrent assets, Prepaid expenses and other current assets
Designated as Hedging Instrument | Prepaid expenses and other current assets | Interest rate cap designated as cash flows hedge    
Derivative    
Total derivative assets $ 8,034 $ 9,746
Designated as Hedging Instrument | Other noncurrent assets | Interest rate cap designated as cash flows hedge    
Derivative    
Total derivative assets $ 6,680 $ 10,183
XML 85 R69.htm IDEA: XBRL DOCUMENT v3.25.0.1
DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) - Interest rate cap designated as cash flows hedge - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Derivative [Line Items]      
Pre-tax gains (losses) on interest rate derivatives recognized $ (5,215) $ (8,339) $ 28,869
Interest expense, net      
Derivative [Line Items]      
Gain (loss) location of derivative instruments $ 11,527 $ 10,974 $ 1,090
XML 86 R70.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED INCENTIVE COMPENSATION - Narrative (Details) - USD ($)
 1 Months Ended 12 Months Ended
May 31, 2024
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Value of shares surrendered to satisfy tax withholding obligations   $ 4,900,000 $ 0 $ 0
Stock-based compensation tax withholdings   $ 0 0 0
Initial percentage of target shares granted   100.00%    
Stock Option        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Share-based compensation expense   $ 5,900,000 $ 6,500,000 $ 2,500,000
Weighted-average grant-date fair value per share (in dollars per share)     $ 15.72 $ 12.51
Unrecognized compensation expense   $ 5,800,000    
Weighted average period of recognition   11 months 12 days    
Restricted Stock        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Share-based compensation expense   $ 21,400,000 $ 16,600,000 $ 10,200,000
Value of shares surrendered to satisfy tax withholding obligations   7,100,000 4,400,000 1,400,000
Unrecognized compensation expense   $ 28,800,000    
Weighted average period of recognition   1 year 1 month 2 days    
Value of shares vested in period   $ 19,400,000 9,900,000 3,700,000
Restricted Stock | Director        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Vesting period   3 years    
Performance Stock Units        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Vesting period   3 years    
Share-based compensation expense   $ 8,800,000 $ 7,500,000 $ 4,100,000
Unrecognized compensation expense   $ 11,600,000    
2024 Performance Stock Units        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Weighted average period of recognition   1 year 3 months 25 days    
Minimum        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Exercisable range of years   7 years    
Percentage of target shares granted   0.00%    
Minimum | Stock Option        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Vesting period   3 years    
Minimum | Restricted Stock        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Vesting period   1 year    
Minimum | Performance Stock Units        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Average performance period   2 years    
Maximum        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Exercisable range of years   10 years    
Percentage of target shares granted   200.00%    
Maximum | Stock Option        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Vesting period   4 years    
Maximum | Restricted Stock        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Vesting period   4 years    
Maximum | Performance Stock Units        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Average performance period   3 years    
The 2018 Plan        
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]        
Number of additional shares authorized (in shares) 4,000,000      
Number of shares authorized (in shares)   13,101,734 9,101,734  
XML 87 R71.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details) - Stock Option
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]    
Expected volatility 51.43% 51.19%
Risk-free interest rate 4.16% 3.91%
Expected life of options 6 years 2 months 12 days 6 years 2 months 12 days
Dividend rate 0.00% 0.00%
XML 88 R72.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details) - Stock Option
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2024
USD ($)
$ / shares
shares
Options  
Beginning balance (in shares) | shares 1,746,272
Granted (in shares) | shares 0
Exercised (in shares) | shares (161,553)
Forfeited and expired (in shares) | shares (101,486)
Ending balance (in shares) | shares 1,483,233
Exercisable (in shares) | shares 595,984
Weighted Average Exercise Price  
Beginning balance (in dollars per share) | $ / shares $ 25.08
Granted (in dollars per share) | $ / shares 0
Exercised (in dollars per share) | $ / shares 18.14
Forfeited and expired (in dollars per share) | $ / shares 26.05
Ending balance (in dollars per share) | $ / shares 25.79
Exercisable (in dollars per share) | $ / shares $ 22.96
Aggregate Intrinsic Value  
Balance at December 31, 2023 | $ $ 15,028
Granted | $ 0
Exercised | $ 1,875
Forfeited and expired | $ 32
Balance at December 31, 2024 | $ 1,590
Exercisable at December 31, 2024 | $ $ 1,365
Weighted Average Remaining Contractual Life 7 years 4 months 6 days
Weighted Average Remaining Contractual Life Exercisable 6 years 6 months 7 days
XML 89 R73.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)
 12 Months Ended
Dec. 31, 2024
$ / shares
shares
Options Outstanding  
Options Outstanding (in shares) | shares 1,483,233
Options Exercisable  
Options Exercisable (in shares) | shares 595,984
$0.00 - $8.24  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Lower range limit (in dollars per share) $ 0.00
Upper range limit (in dollars per share) $ 8.24
Options Outstanding  
Options Outstanding (in shares) | shares 9,901
Weighted Average Exercise Price (in dollars per share) $ 6.52
Weighted Average Remaining Contractual Life 2 years 1 month 6 days
Options Exercisable  
Options Exercisable (in shares) | shares 9,901
Weighted Average Exercise Price (in dollars per share) $ 6.52
$8.24 - $16.52  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Lower range limit (in dollars per share) 8.24
Upper range limit (in dollars per share) $ 16.52
Options Outstanding  
Options Outstanding (in shares) | shares 64,775
Weighted Average Exercise Price (in dollars per share) $ 12.14
Weighted Average Remaining Contractual Life 4 years
Options Exercisable  
Options Exercisable (in shares) | shares 64,775
Weighted Average Exercise Price (in dollars per share) $ 12.14
$16.52 - $24.76  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Lower range limit (in dollars per share) 16.52
Upper range limit (in dollars per share) $ 24.76
Options Outstanding  
Options Outstanding (in shares) | shares 355,616
Weighted Average Exercise Price (in dollars per share) $ 21.54
Weighted Average Remaining Contractual Life 6 years 8 months 12 days
Options Exercisable  
Options Exercisable (in shares) | shares 200,513
Weighted Average Exercise Price (in dollars per share) $ 21.05
$24.76 - $33.00  
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Lower range limit (in dollars per share) 24.76
Upper range limit (in dollars per share) $ 33.00
Options Outstanding  
Options Outstanding (in shares) | shares 1,052,941
Weighted Average Exercise Price (in dollars per share) $ 28.25
Weighted Average Remaining Contractual Life 7 years 9 months 18 days
Options Exercisable  
Options Exercisable (in shares) | shares 320,795
Weighted Average Exercise Price (in dollars per share) $ 26.85
XML 90 R74.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details) - Restricted Stock
 12 Months Ended
Dec. 31, 2024
$ / shares
shares
Restricted Stock  
Beginning balance (in shares) | shares 1,883,116
Granted (in shares) | shares 723,027
Vested and issued (in shares) | shares (770,137)
Forfeited and expired (in shares) | shares (170,594)
Ending balance (in shares) | shares 1,665,412
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]  
Beginning balance (in dollars per share) | $ / shares $ 26.28
Shares granted (in dollars per share) | $ / shares 32.71
Vested and issued (in dollars per share) | $ / shares 25.16
Forfeited and expired (in dollars per share) | $ / shares 28.25
Ending balance (in dollars per share) | $ / shares $ 29.41
XML 91 R75.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCKHOLDERS' EQUITY (Details) - USD ($)
 12 Months Ended
Mar. 03, 2023
Feb. 28, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Jan. 31, 2025
Dec. 06, 2023
Feb. 20, 2023
Aug. 06, 2019
Jun. 29, 2017
Mar. 09, 2015
Class of Warrant or Right [Line Items]                      
Proceeds from warrant exercises     $ 0 $ 0 $ 20,916,000            
Treasury stock, shares, acquired (in shares) 2,475,166   9,255,591 7,946,301              
Treasury stock acquired, average cost per share (in dollars per share)     $ 27.01 $ 31.46              
Shares repurchased   $ 75,000,000 $ 250,000,000 $ 250,000,000              
Treasury stock, shares (in shares)     17,585,613 8,330,022              
Preferred stock outstanding (in shares)     0 0              
Common Stock                      
Class of Warrant or Right [Line Items]                      
Share repurchase program, authorized amount             $ 500,000,000 $ 250,000,000      
Common Stock | Subsequent Event                      
Class of Warrant or Right [Line Items]                      
Share repurchase program, authorized amount           $ 500,000,000          
2017 Warrants | Common Stock                      
Class of Warrant or Right [Line Items]                      
Number of shares to be purchased (in shares)                 2,100,000    
Term of warrants                   10 years  
Exercise price of warrants (in dollars per share)                   $ 8.00  
Fair value of warrants                 $ 14,100,000    
Shares purchased from exercise of warrants (in shares)     0 188,350 1,130,089            
Proceeds from warrant exercises     $ 0                
Class of warrant or right, outstanding (in shares)     51,838 51,838 240,188            
2015 Warrants | Common Stock                      
Class of Warrant or Right [Line Items]                      
Number of shares to be purchased (in shares)                     900,000
Term of warrants                     10 years
Fair value of warrants                 $ 4,600,000    
Proceeds from warrant exercises     $ 0 $ 0 $ 20,900,000            
Class of warrant or right, outstanding (in shares)     11,765 13,888 15,231            
Number of warrants exercised (in shares)     0 0 900,272            
2015 Warrants | Common Stock | Minimum                      
Class of Warrant or Right [Line Items]                      
Exercise price of warrants (in dollars per share)                     $ 20.68
2015 Warrants | Common Stock | Maximum                      
Class of Warrant or Right [Line Items]                      
Exercise price of warrants (in dollars per share)                     $ 25.80
Common Stock | Secondary Offering                      
Class of Warrant or Right [Line Items]                      
Additional shares issued (in shares)       23,771,926              
XML 92 R76.htm IDEA: XBRL DOCUMENT v3.25.0.1
STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) - shares
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of the year 174,575,537  
Balance, end of the period 166,261,112 174,575,537
Common Stock    
Increase (Decrease) in Stockholders' Equity [Roll Forward]    
Balance, beginning of the year 174,576,000 181,958,000
Equity award issuances 941,000 564,000
Share repurchases (9,256,000) (7,946,000)
Balance, end of the period 166,261,000 174,576,000
XML 93 R77.htm IDEA: XBRL DOCUMENT v3.25.0.1
RELATED-PARTY TRANSACTIONS (Details) - USD ($)
$ in Thousands
 12 Months Ended
Mar. 03, 2023
Feb. 28, 2023
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Related Party Transaction [Line Items]          
NET REVENUE     $ 4,911,591 $ 4,222,656 $ 3,869,036
Shares repurchased   $ 75,000 $ 250,000 $ 250,000  
Treasury stock, shares, acquired (in shares) 2,475,166   9,255,591 7,946,301  
Joint Venture          
Related Party Transaction [Line Items]          
Due to joint ventures     $ 1,400 $ 500  
Due from joint ventures       100  
Joint Venture | Management Fee Income          
Related Party Transaction [Line Items]          
NET REVENUE     $ 6,200 $ 5,300 $ 4,100
XML 94 R78.htm IDEA: XBRL DOCUMENT v3.25.0.1
SEGMENT REPORTING (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Segment Reporting Information [Line Items]      
Infusion services net revenue $ 4,911,591 $ 4,222,656 $ 3,869,036
Other 86,611 79,668 75,699
Total Option Care Health revenue 4,998,202 4,302,324 3,944,735
Income (Expense) [Abstract]      
Cost of net revenues - drugs (3,446,735) (2,812,531) (2,562,494)
Salaries, benefits, and other employee expense (787,922) (760,499) (709,916)
Other segment items (380,803) (355,498) (371,529)
Depreciation and amortization expense (60,909) (59,201) (60,565)
Interest expense, net (49,029) (51,248) (53,806)
Equity in earnings of joint ventures 5,964 5,530 5,125
Other, net 4,831 89,865 14,218
INCOME TAX EXPENSE (71,776) (91,652) (55,212)
NET INCOME $ 211,823 $ 267,090 $ 150,556
Largest Payer | Revenue from Contract with Customer Benchmark | Customer Concentration Risk      
Income (Expense) [Abstract]      
Concentration risk 15.00% 14.00% 14.00%
XML 95 R79.htm IDEA: XBRL DOCUMENT v3.25.0.1
SUBSEQUENT EVENTS (Details)
$ in Millions
Jan. 24, 2025
USD ($)
Subsequent Event | Intramed Plus  
Subsequent Event [Line Items]  
Cash paid for business acquired $ 117.0
EXCEL 96 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

B-8<20'7$)_D]#$O*:!!F*_3Y> &X; =[6OF M%I\%+KDI5$-J4+2X01R\6Z,E@W>[2"%\WDVLH>9A&U*9+&=*4$\V\-XKI1I# M(.;#&7PD'Z3M'T2LK>[=L&\HL+JIX9:M6B5)AQR.(!T&Z7#@1O23!SD=.GH_ MH9^@'_OY(219Q9S_%E:)'-@CR)(A(D:?8!;EV1DC8/3#3HDMC:"\ZF7'#+*?HC2.)!,$SC M_Z=^Z,00M8+L)'V 6H4#.H*V_6RU66:TI?01^.30]\(Y)M&EDL<%,]56]?FO M5$OU%>?7VFR4F8OE2F&H5W895W2]6@VP.SYK'?(>X^ M?Z5#9.A_@X/>7]W2_,6*VI6RY"2BLE#1403/@ZZJ]X72SW?WPO+T6/6UO+Y&ULE5;[;]LV$/Y7 M#EHP- 72]3#5F8;R&M8@*7STG1#,>P'6J(LH1*IDE0<__<[4K;J+G+0 8;% MUWUW]]V#G&^E^JQ+S@V\-+70"Z\TIKV<3'16\H;I"]ER@3N%5 TS.%6;B6X5 M9[D3:NH)]?UDTK!*>,NY6UNIY5QVIJX$7RG07=,PM;OFM=PNO, [+#Q6F]+8 MA'?BSXEM]- ;KR5K* MSW9RGR\\WQK$:YX9B\#P\\QO>%U;(#3CRQ[3&U1:P>/Q ?T7YSOZLF::W\CZ MKRHWY<*;>9#S@G6U>93;7_G>G]CB9;+6[A^V_=D(-6:=-K+9"^.\J43_92][ M'HX$9OX) ;H7H,[N7I&S\I89MIPKN05E3R.:'3A7G30:5PD;E ]&X6Z%OQ]=??X] FNWM_"W1\?[U,/0>+_ M_(;=T6!W]!;Z_XC0FSCC5HZ#PX$K1Q(?2-HR#?@K9(VU[(:R (P3;]9<#;%R M0C@(X5TEP)2RT[BBSR]'COYW)81[472NXMNN:36<03@E29S:04+2*/P:,P)% MIT1E.L6=2FE*!*(1\>,8:$CB-(3?.%9L*>L8@J ^GD6R4$%K65>[LU@8_ M/;T(DB&EBI>V>S^C-H%S9!5]XR*W<+)'$,R%#P7LS)%7[^Q^4;U8[AVI%_"$ MF_FH&R*K.^O#B/V*6T(U&'E8^FG#Q<&?'IK@;925-I.K;_+N.U6.T..([2.) MBA%5,6PL7>;\K)"A(YU#_A+'ETM!QWI15!D_CJU=K4=SN;>T+TEKB&'KFH.K M"VX[\N[GU![[L!?=4-/J'P*=E> MU(F-I^]K4\^ 8LG[[INFMF%$9):D)^5'W*)8T7YH6\B,^F +:1K!DS2L'F<. M5:7$QS9S9@_/ M>E**'8I<8:_^3HFFZXVKC'B$9',#K]C3VL#N^=J_Z:_WJ\ M?RP],+6IA,:<*%#4OYC&'JC^ =)/C&S=I;^6!I\0;ECBFXTK>P#W"RG-86(5 M#*_ Y;]02P,$% @ (8!:6EL&2\/T!P LQ, !D !X;"]W;W)K&ULG5C;;N,X$OT5PA,,$D ;Z^;8S@UP.MF> #W=C4YV MYV&Q#[1$V]Q(HIJDXO9\_9XB9?F:3&->$HHBJTY5G3JD=;U4^L4LA+#L1UE4 MYJ:WL+:^[/=-MA E-^>J%A7>S)0NN<6CGO=-K07/W::RZ,=A>-$ON:QZM]=N M[JN^O5:-+60EOFIFFK+D>G4G"K6\Z46]]<0W.5]8FNC?7M=\+IZ$_5?]5>.I MWUG)92DJ(U7%M)C=]";1Y5U*Z]V"?TNQ-%MC1I%,E7JAA\?\IA<2(%&(S)(% MCG^OXH,H"C($&-];F[W.)6W<'J^M_]/%CEBFW(@/JOA#YG9QTQOU6"YFO"GL M-[7\3;3Q#,A>I@KC_K*E7SM(>BQKC%5ENQD(2EGY__Q'FX>M#:/PC0UQNR%V MN+TCA_*>6WY[K=62:5H-:S1PH;K= "?OSRY?Z/QT^?V.3S M/?OR_-O#-_;X^7GR^>/CW:<'-GEZ>GA^NNY;>*+U_:RU>N>MQF]8C6+VNZKL MPK"'*A?YKH$^('8XXS7.N_A=B_B>&M(LA?<_ZWZ[=NU:/8_X95ZS+J32L4I;Q4FDK M_Q1YP*:-I5GQRHN&6Y$SR F39-]HNV/>&:RLT M4S,_BZKP@JT$UP&# =C'I!;?&]B@S3,8@A.RJ+*LT89695)G36E0XDP8EBU0 M:@%SW$(PFB+W5@KY(F !TY7#KD7>9,)[!4A&P 7AX'A54US5G#65M&Q*PL8D M2)-QK5T4[&21#87*NFAD>[0&3[2,[9 MA)B*_9R.F%U>\V)EP/PE-Y0H.D6!ZTV6D[HYC4L<;@SB@%G55HHM%X*"!-NH MFXX2UZ7UD+8T\P%5Y-7JUU]&<32\,OL58IS,D1MG##M@8)_3SQL[+2B$HW'( MOE*R7.L9!WVWZSR=R4[),ZV0\TJ5,@.QJMS1R@18D^.\TRNW'3>$%T']@N,_ M1WG:-:Y4*/M,@I^9!,/;I)*;@,$[BO@/4XN,ZM?B"3P@QTRSSOU^,G#29B^L MUC+;BS(7J U.7I%WN46>J)Z58O-.\C8UAX.M,H)B5$5O!0;*Y;U$AUK14,D"+5 K3U790YI%) M$E!>JW'GP4%32K!E9\M!0MK*M3R1OI;+AS1HO$O G,FZ\1&BB3H-HXID%>.@LXC3;\WRXP2@ SE9/#AH >P;<6 M5[A$+Q9.#W9M$/X%A_;MBB=U1091QZ$LG8'CPK0K1)Y)2"I5K5UQK,_0T'HN MW$5@"GA[72OS]AS/%/#\"8.D6+@4E'3$4:8VEN@T(^Y[X9R*N:Q<0EKG8(!4 M^4X&:;J3Q@W4#J;3+=/!GRGT\-*MI5\A=- 0N^D5769P,:)K,L,E5Y13I&E] MT=T["MBI$'"1\CW]T;LA$5!.AP&@XL4U-OJHT$:#-*$?6TT M4N@N!*Y#'+S\?^BMTJEX%"31\#T7L7,Q2)(@C?=<7 3C\>@O/9Q&PXNS]SPD MWD,:!G%ZL>O!"7=\]9<^UNO>\9+N>'D^4EK7Y5OYXJK'<_(#@_@?$VP1P M\G((H:UQNZ5>\Q*)D'$3)Q?K?%]>YZY#)^F&XX]& C<<#]JRLU]9C<-B F!>._?]H MC((>3^D1W*=Q$@;),#H#:<;C(!RE9X>X3W%;&HS';DUP,1Z=_13VTT%,6Y(4 MQCW^-TM]&@] =N4K#: /]'1!XW 8T7B( M/ ;CQ(U'-!Z-0AJ/W7@XP#@)7613L<+MDD7P'@Z';9TV!3GV [R_]2&E%#A= MZ'.1.]\JZ[^I=+/=%ZF)_Q"S6>X_9_V.PTE"IPHQP];P?#CH,>T_$?D'JVKW M609GEU6E&RX$"*UI =[/E++K!W+0?:>[_3]02P,$% @ (8!:6IQR6G!\ M#0 "@ !D !X;"]W;W)K&ULS5II;]S($?TK M#:V\D !Z1,XMRQ8@^4 4R 57=O$8%W/^.B^+5&?JBQ&VW&RD>;A4 M:7[_YB ZJ&[")%GD^3?Z<96\.0B)(96JN" *$G_NU%N5ID0(;/SN:1[4 M1]+&]G5%_0/+#ED6TJJW>?HWG13K-P?S Y&HI2S3XB:__XOR\DR(7IRGEO\7 M]V[M<'8@XM(6^<9O!@<;G;F_\KO70VO#/-RS8>@W#)EO=Q!S^4X6\ORUR>^% MH=6@1AO;_\^O[=I_>WMZ]/"E"D^R>QWWWI M=@_W[(Z&XF.>%6LKWF>)2KH$3L!*S<^PXN=R^"3%=RH>B%$4B&$X'#]!;U3+ M-V)ZH[WT%H5XIVV8H(U=E*2$OW8 FU62A36T,D=:'^0L4YU\2 .Q<\_S8?1 M\.R9JP_:V$)<:Y6)KR3+=2XS,06+TV@FCB;!9#0[%D>S8#*9'(MI- \FPXFX M59G.C?B4%\J*21@&81C6%+%X-!L>B_'I,)@.YS@K"B)/\+ FB:MH')P.<8G' M$?Y-1N):6?L*46J,@M#;W'"B.9H&DP@$O^8%5)-VU<[4PW$P'4?_L45&_[\6 MF?/6&0>3$_G9!$L#H>LL] 3/*Q)DD7F M,-V4+!).8;Q)N-\BV/N$1<+)E+=_SL1'^2#FSN$#ML+;?+.5V8, 065@')T5 M.3_XNM8F@:)5EFSH-'];T@VL@TE0M6PAR:(M);T%$5V(BY51BOY,>P[N(0M)^$@ M1/E(4ZZ$X.Q(8SDX*6,L)K8UBP<8W>VV[-/G&_;S]_.&&?#!.RX3= M5,1.. <0A$Q^0P4CEH_%-BVM& YFDQ>DJ&:[OS_$?:>Q37[G6=I'#"6R6)-N MMRCM1,V6\;J75Z>^;1T5"^_M/L!ZQ=,6I+?R02Y2THKXO90&JDD?\ /63%-B M@8UU& VFM5)9CDJ)@6-1BJ7.<"RH,=_8@_TD(] 2*0PH"20S5E[#95*R 79\ M8>Z$:=AI-GCZ%BED@XN8O12>;* 6[!P.Q"]P2=/GM4%C^*=L#J54*ME0PR!YGG.%2NHT1W!#VG P"5^(+=;(+"LWW@M 3VZWJ8X=/6E6X!:KG1< M:+;<@TZWX@C1P4;FL 4SP%TH@"QFCU#'9R(WSL4E8S;GU(FB[=4^&<>Y2=@= MF.U>Y3"_4K&W.M,**@I!%1E MN^F#._&>P2EE&:1X8.T=%N!'E#&39WF9#::1XV4VF(^<3FC#@Y+&"I?W_AAG M57:5%EG+8OO]6OFTIEP<5I&SWS]Q:F9[9<4(@5&G&RR1.] MA-MQ4M)(<.N3%YN M:4=*6H RH"U7OU&/*$"N_?TMPE=3V#)]$%ODWOEZA2/=M8OEF7-KI,0[C;I? M'U>L94%L0_2S*L%C78:VR"_IZKL5"[SU,!R,ZUSVE+;OX3U=NY;) M$Q:PK-B. (URG 59-VP#RKVFY"R'Y+K6\;IK:A%+N\854L^]JU"4>I$?J2R1 MQ^E"*Y>U.[706Y.P5YYJ5XJY9M=9G@D3V1T-UD'3*0.@MU0*/&*G8Q.:C>K' M%$2QW&K4$?TOE5!$I)+BH4(/>YV / ]],ZQ&>I0.WGE#%8QKZ-R&*SHI4P4' M_4J2^GAI5WKL9^UN31XKE3BO[=,;9<@_KRJCXGR5D< P%!HQR\7C4>0Q*V2A MMB\Z=-&D5&I\"(OI(L5-@HS#\.PSI8R Y.4;T=F/V!7,&;6F^<(=I\!\HP;B M_7+I$I3X:XF#1F'@4]=>*$CVJ;!$\@=--QO9JQ QDO1Q(GKJ\O/ M-QX0I4R2*XMV<4/W8;([;?DGER^NEM(!)XIZHY;@D:H;I?BN/1Y!V5YV&H1Z M1&N\JI]"LG6A\U8XKD*U@TMJ7 -\VR'=>7"C:D>LJ)&"6.P$?CP-=QS9^ TX MI &_ X+T=46:/6M,>G +;\W^-\!^]ZA^9$^8GOHDV=.E.?UZK;B,VH+^Y9:8 M/QRW=340%_T(HJL6RMV'XU;JPI8R2XR\SY"SD5>,BR(GM$9GZ573PK2!S]&^ MTB$\&^8 1:1.Y<*)4=;X]+&(E!%&IY/!Z7,2C'HDF Q&_R\2C >S1H*OO0N1 MWTNC;(7#R(%<8=0NL &S4JT86A.FV''L>=/9/=I]&N'W@Z6F@3";\VCOPWPJ M'<\[6M"0%>&Y@))J3#F@H-3 K* =VCK?FV:&$. M;[R@W5LPDJX[@C9_6*$H*1!*IU47S3-&Z547P$42J?YE:W.#Y?=MK[+7+E6[ MIBYN@>> -K_Y'C16ID"910V\0[3:BK>@!019&)1MC19/I:@QAEW#YSEHI56@ MVJF?=))J-[C!*0Y J1I\+SD%+4OPM-0V!AW?(Q(@9S]=%MY,JJYN;&JO\\=9 MZ.CBN*\/"] *H8$/6*^7QWTM48">;^9[^4KU2%_$0=!KHKYVCS8_HDM]7(*, MYF/#S7)HA'6M?%-S0["2]&T5@_9B7<& 34ZM#J(%67F/-NDI%),0F&<^$Z!C M3;-BUM?%B@=*I:$)6ET2"$/;VG5W\O\ 1V5^%(5^N6XR.9VW7/Y1['33F,/I M[ AWR>G%Y71]1EU3?L7=3P.-Z-1W0;+') M'% +_LD:)]*&?DA5*,DITK.JA^4:Y*&&A*1T6G1'&W9'> FW#:#9I89!'M-Y1LUYF@0)L<)H7N"((N4>[#]P"_PD)).8U"Y:TCO72U_[*A&M^!3H^S. M$HBC?BC3>Q/QF'=V!@'\J[E.LO]C QMBY!'NVCMDJA(ZZF'%'/RQN">7#.L1 MI$M@+L)\LEDC$>1&4VY5WV.:,W2\09+AMLI0?J%$Y!5Y3:W*6[E]=DS4)\7Q M69-#^X=K?ES^8_.UIT2/:M&C_[;H#NATW 6UA@HE3J"N0+N)+O>NU831GUQF M)?%1#?&1<5;DQ1QZSEJ0(1R,N"(E:NN3(9;>2X&_--AQQ9T9.9Y?CD)7^P!2!T5\ S%*M0&5V^DK^$, MSF@!/W/AY\/*>\HN[\0/CZ9PO"[(RQ96)QKR*^L78>L=5)P;9&0*H9+@A:MV MI.V NW968(Z,WBPATA6HX:)3]YTP=_%0HY,*A.V6FB^5,&^!?FAN(=.F+:0" M0&S'%.L]*(I@&B_XZ*\6 M!?[=QR,F79?5)<^+3Y^8SW

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�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end XML 97 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 98 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 100 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.0.1 html 260 418 1 false 90 0 false 7 false false R1.htm 0000001 - Document - COVER PAGE Sheet http://www.bioscrip.com/role/COVERPAGE COVER PAGE Cover 1 false false R2.htm 0000002 - Document - Audit Information Sheet http://www.bioscrip.com/role/AuditInformation Audit Information Cover 2 false false R3.htm 9952151 - Statement - CONSOLIDATED BALANCE SHEETS Sheet http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS CONSOLIDATED BALANCE SHEETS Statements 3 false false R4.htm 9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical) Sheet http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical CONSOLIDATED BALANCE SHEETS (Parenthetical) Statements 4 false false R5.htm 9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Sheet http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME Statements 5 false false R6.htm 9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Sheet http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) Statements 6 false false R7.htm 9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 7 false false R8.htm 9952156 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Sheet http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY CONSOLIDATED STATEMENTS OF STOCKHOLDERS??? EQUITY Statements 8 false false R9.htm 9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Sheet http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS Notes 9 false false R10.htm 9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 10 false false R11.htm 9952159 - Disclosure - BUSINESS ACQUISITIONS AND DIVESTITURES Sheet http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURES BUSINESS ACQUISITIONS AND DIVESTITURES Notes 11 false false R12.htm 9952160 - Disclosure - REVENUE Sheet http://www.bioscrip.com/role/REVENUE REVENUE Notes 12 false false R13.htm 9952161 - Disclosure - EMPLOYEE BENEFIT PLANS Sheet http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS EMPLOYEE BENEFIT PLANS Notes 13 false false R14.htm 9952162 - Disclosure - INCOME TAXES Sheet http://www.bioscrip.com/role/INCOMETAXES INCOME TAXES Notes 14 false false R15.htm 9952163 - Disclosure - EARNINGS PER SHARE Sheet http://www.bioscrip.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 15 false false R16.htm 9952164 - Disclosure - LEASES Sheet http://www.bioscrip.com/role/LEASES LEASES Notes 16 false false R17.htm 9952165 - Disclosure - PROPERTY AND EQUIPMENT Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT PROPERTY AND EQUIPMENT Notes 17 false false R18.htm 9952166 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 18 false false R19.htm 9952167 - Disclosure - INDEBTEDNESS Sheet http://www.bioscrip.com/role/INDEBTEDNESS INDEBTEDNESS Notes 19 false false R20.htm 9952168 - Disclosure - DERIVATIVE INSTRUMENTS Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS DERIVATIVE INSTRUMENTS Notes 20 false false R21.htm 9952169 - Disclosure - FAIR VALUE MEASURMENTS Sheet http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS FAIR VALUE MEASURMENTS Notes 21 false false R22.htm 9952170 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 22 false false R23.htm 9952171 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION STOCK-BASED INCENTIVE COMPENSATION Notes 23 false false R24.htm 9952172 - Disclosure - STOCKHOLDERS' EQUITY Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITY STOCKHOLDERS' EQUITY Notes 24 false false R25.htm 9952173 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS RELATED-PARTY TRANSACTIONS Notes 25 false false R26.htm 9952174 - Disclosure - SEGMENT REPORTING Sheet http://www.bioscrip.com/role/SEGMENTREPORTING SEGMENT REPORTING Notes 26 false false R27.htm 9952175 - Disclosure - SUBSEQUENT EVENTS Sheet http://www.bioscrip.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 27 false false R28.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 28 false false R29.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 29 false false R30.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 30 false false R31.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 31 false false R32.htm 9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 32 false false R33.htm 9955512 - Disclosure - REVENUE (Tables) Sheet http://www.bioscrip.com/role/REVENUETables REVENUE (Tables) Tables http://www.bioscrip.com/role/REVENUE 33 false false R34.htm 9955513 - Disclosure - INCOME TAXES - Income Taxes (Tables) Sheet http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables INCOME TAXES - Income Taxes (Tables) Tables 34 false false R35.htm 9955514 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://www.bioscrip.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://www.bioscrip.com/role/EARNINGSPERSHARE 35 false false R36.htm 9955515 - Disclosure - LEASES (Tables) Sheet http://www.bioscrip.com/role/LEASESTables LEASES (Tables) Tables http://www.bioscrip.com/role/LEASES 36 false false R37.htm 9955516 - Disclosure - PROPERTY AND EQUIPMENT (Tables) Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables PROPERTY AND EQUIPMENT (Tables) Tables http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT 37 false false R38.htm 9955517 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 38 false false R39.htm 9955518 - Disclosure - INDEBTEDNESS (Tables) Sheet http://www.bioscrip.com/role/INDEBTEDNESSTables INDEBTEDNESS (Tables) Tables http://www.bioscrip.com/role/INDEBTEDNESS 39 false false R40.htm 9955519 - Disclosure - DERIVATIVE INSTRUMENTS (Tables) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables DERIVATIVE INSTRUMENTS (Tables) Tables http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS 40 false false R41.htm 9955520 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Tables) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONTables STOCK-BASED INCENTIVE COMPENSATION (Tables) Tables http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION 41 false false R42.htm 9955521 - Disclosure - STOCKHOLDERS' EQUITY (Tables) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables STOCKHOLDERS' EQUITY (Tables) Tables http://www.bioscrip.com/role/STOCKHOLDERSEQUITY 42 false false R43.htm 9955522 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://www.bioscrip.com/role/SEGMENTREPORTINGTables SEGMENT REPORTING (Tables) Tables http://www.bioscrip.com/role/SEGMENTREPORTING 43 false false R44.htm 9955523 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) Sheet http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details) Details http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS 44 false false R45.htm 9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Sheet http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details) Details 45 false false R46.htm 9955525 - Disclosure - BUSINESS ACQUISITIONS AND DIVESTITURES - Additional Information (Details) Sheet http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails BUSINESS ACQUISITIONS AND DIVESTITURES - Additional Information (Details) Details 46 false false R47.htm 9955526 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details) Sheet http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails REVENUE - Net Revenue Earned by Category of Payer (Details) Details 47 false false R48.htm 9955527 - Disclosure - EMPLOYEE BENEFIT PLANS (Details) Sheet http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails EMPLOYEE BENEFIT PLANS (Details) Details http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS 48 false false R49.htm 9955528 - Disclosure - INCOME TAXES - Income Tax Benefit (Details) Sheet http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails INCOME TAXES - Income Tax Benefit (Details) Details 49 false false R50.htm 9955529 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details) Sheet http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails INCOME TAXES - Income Tax Reconciliation (Details) Details 50 false false R51.htm 9955530 - Disclosure - INCOME TAXES - Narrative (Details) Sheet http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails INCOME TAXES - Narrative (Details) Details 51 false false R52.htm 9955531 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details) Sheet http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details) Details 52 false false R53.htm 9955532 - Disclosure - INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details) Sheet http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details) Details 53 false false R54.htm 9955533 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Sheet http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) Details 54 false false R55.htm 9955534 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Details) Sheet http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Details) Details 55 false false R56.htm 9955535 - Disclosure - LEASES - Additional Information (Details) Sheet http://www.bioscrip.com/role/LEASESAdditionalInformationDetails LEASES - Additional Information (Details) Details 56 false false R57.htm 9955536 - Disclosure - LEASES - Maturities of Lease Liabilities (Details) Sheet http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails LEASES - Maturities of Lease Liabilities (Details) Details 57 false false R58.htm 9955537 - Disclosure - PROPERTY AND EQUIPMENT (Details) Sheet http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails PROPERTY AND EQUIPMENT (Details) Details http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables 58 false false R59.htm 9955538 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details) Details 59 false false R60.htm 9955539 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details) Details 60 false false R61.htm 9955540 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) Details 61 false false R62.htm 9955541 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details) Sheet http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details) Details 62 false false R63.htm 9955542 - Disclosure - INDEBTEDNESS - Summary of Debt (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails INDEBTEDNESS - Summary of Debt (Details) Details 63 false false R64.htm 9955543 - Disclosure - INDEBTEDNESS - Additional Information (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails INDEBTEDNESS - Additional Information (Details) Details 64 false false R65.htm 9955544 - Disclosure - INDEBTEDNESS - Long-term Debt Maturities (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails INDEBTEDNESS - Long-term Debt Maturities (Details) Details 65 false false R66.htm 9955545 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) Sheet http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details) Details 66 false false R67.htm 9955546 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails DERIVATIVE INSTRUMENTS - Additional Information (Details) Details 67 false false R68.htm 9955547 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details) Details 68 false false R69.htm 9955548 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) Sheet http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details) Details 69 false false R70.htm 9955549 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Narrative (Details) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails STOCK-BASED INCENTIVE COMPENSATION - Narrative (Details) Details 70 false false R71.htm 9955550 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details) Details 71 false false R72.htm 9955551 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details) Details 72 false false R73.htm 9955552 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details) Details 73 false false R74.htm 9955553 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details) Sheet http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details) Details 74 false false R75.htm 9955554 - Disclosure - STOCKHOLDERS' EQUITY (Details) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails STOCKHOLDERS' EQUITY (Details) Details http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables 75 false false R76.htm 9955555 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) Sheet http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details) Details 76 false false R77.htm 9955556 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED-PARTY TRANSACTIONS (Details) Details http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS 77 false false R78.htm 9955557 - Disclosure - SEGMENT REPORTING (Details) Sheet http://www.bioscrip.com/role/SEGMENTREPORTINGDetails SEGMENT REPORTING (Details) Details http://www.bioscrip.com/role/SEGMENTREPORTINGTables 78 false false R79.htm 9955558 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://www.bioscrip.com/role/SUBSEQUENTEVENTS 79 false false All Reports Book All Reports bios-20241231.htm bios-20241231.xsd bios-20241231_cal.xml bios-20241231_def.xml bios-20241231_lab.xml bios-20241231_pre.xml bios-20241231_g1.jpg bios-20241231_g2.jpg http://fasb.org/srt/2024 http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 103 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "bios-20241231.htm": { "nsprefix": "bios", "nsuri": "http://www.bioscrip.com/20241231", "dts": { "inline": { "local": [ "bios-20241231.htm" ] }, "schema": { "local": [ "bios-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "bios-20241231_cal.xml" ] }, "definitionLink": { "local": [ "bios-20241231_def.xml" ] }, "labelLink": { "local": [ "bios-20241231_lab.xml" ] }, "presentationLink": { "local": [ "bios-20241231_pre.xml" ] } }, "keyStandard": 393, "keyCustom": 25, "axisStandard": 36, "axisCustom": 0, "memberStandard": 48, "memberCustom": 40, "hidden": { "total": 14, "http://fasb.org/us-gaap/2024": 10, "http://xbrl.sec.gov/dei/2024": 4 }, "contextCount": 260, "entityCount": 1, "segmentCount": 90, "elementCount": 778, "unitCount": 7, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 956, "http://xbrl.sec.gov/dei/2024": 39, "http://xbrl.sec.gov/cyd/2024": 15, "http://xbrl.sec.gov/ecd/2024": 5, "http://fasb.org/srt/2024": 4 }, "report": { "R1": { "role": "http://www.bioscrip.com/role/COVERPAGE", "longName": "0000001 - Document - COVER PAGE", "shortName": "COVER PAGE", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.bioscrip.com/role/AuditInformation", "longName": "0000002 - Document - Audit Information", "shortName": "Audit Information", "isDefault": "false", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:AuditorName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R3": { "role": "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS", "longName": "9952151 - Statement - CONSOLIDATED BALANCE SHEETS", "shortName": "CONSOLIDATED BALANCE SHEETS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "longName": "9952152 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)", "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "longName": "9952153 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R6": { "role": "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical", "longName": "9952154 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "shortName": "CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "longName": "9952155 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS", "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationAmortizationAndAccretionNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R8": { "role": "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "longName": "9952156 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS\u2019 EQUITY", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-9", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS", "longName": "9952157 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "longName": "9952158 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURES", "longName": "9952159 - Disclosure - BUSINESS ACQUISITIONS AND DIVESTITURES", "shortName": "BUSINESS ACQUISITIONS AND DIVESTITURES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.bioscrip.com/role/REVENUE", "longName": "9952160 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS", "longName": "9952161 - Disclosure - EMPLOYEE BENEFIT PLANS", "shortName": "EMPLOYEE BENEFIT PLANS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.bioscrip.com/role/INCOMETAXES", "longName": "9952162 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHARE", "longName": "9952163 - Disclosure - EARNINGS PER SHARE", "shortName": "EARNINGS PER SHARE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.bioscrip.com/role/LEASES", "longName": "9952164 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeFinanceLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:LesseeOperatingLeasesTextBlock", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT", "longName": "9952165 - Disclosure - PROPERTY AND EQUIPMENT", "shortName": "PROPERTY AND EQUIPMENT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "longName": "9952166 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.bioscrip.com/role/INDEBTEDNESS", "longName": "9952167 - Disclosure - INDEBTEDNESS", "shortName": "INDEBTEDNESS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS", "longName": "9952168 - Disclosure - DERIVATIVE INSTRUMENTS", "shortName": "DERIVATIVE INSTRUMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS", "longName": "9952169 - Disclosure - FAIR VALUE MEASURMENTS", "shortName": "FAIR VALUE MEASURMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952170 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION", "longName": "9952171 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION", "shortName": "STOCK-BASED INCENTIVE COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY", "longName": "9952172 - Disclosure - STOCKHOLDERS' EQUITY", "shortName": "STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS", "longName": "9952173 - Disclosure - RELATED-PARTY TRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.bioscrip.com/role/SEGMENTREPORTING", "longName": "9952174 - Disclosure - SEGMENT REPORTING", "shortName": "SEGMENT REPORTING", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.bioscrip.com/role/SUBSEQUENTEVENTS", "longName": "9952175 - Disclosure - SUBSEQUENT EVENTS", "shortName": "SUBSEQUENT EVENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R28": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": null }, "R29": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "29", "firstAnchor": { "contextRef": "c-260", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-260", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R30": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "a", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "a", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R31": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "longName": "9955511 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.bioscrip.com/role/REVENUETables", "longName": "9955512 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables", "longName": "9955513 - Disclosure - INCOME TAXES - Income Taxes (Tables)", "shortName": "INCOME TAXES - Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHARETables", "longName": "9955514 - Disclosure - EARNINGS PER SHARE (Tables)", "shortName": "EARNINGS PER SHARE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.bioscrip.com/role/LEASESTables", "longName": "9955515 - Disclosure - LEASES (Tables)", "shortName": "LEASES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables", "longName": "9955516 - Disclosure - PROPERTY AND EQUIPMENT (Tables)", "shortName": "PROPERTY AND EQUIPMENT (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "longName": "9955517 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSTables", "longName": "9955518 - Disclosure - INDEBTEDNESS (Tables)", "shortName": "INDEBTEDNESS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDebtTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables", "longName": "9955519 - Disclosure - DERIVATIVE INSTRUMENTS (Tables)", "shortName": "DERIVATIVE INSTRUMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONTables", "longName": "9955520 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION (Tables)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "41", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables", "longName": "9955521 - Disclosure - STOCKHOLDERS' EQUITY (Tables)", "shortName": "STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "42", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.bioscrip.com/role/SEGMENTREPORTINGTables", "longName": "9955522 - Disclosure - SEGMENT REPORTING (Tables)", "shortName": "SEGMENT REPORTING (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "43", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "longName": "9955523 - Disclosure - NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)", "shortName": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-46", "name": "us-gaap:TreasuryStockSharesAcquired", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "bios:NumberOfServiceLocations", "unitRef": "pharmacy", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R45": { "role": "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails", "longName": "9955524 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:UnbilledReceivablesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:UnbilledReceivablesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "longName": "9955525 - Disclosure - BUSINESS ACQUISITIONS AND DIVESTITURES - Additional Information (Details)", "shortName": "BUSINESS ACQUISITIONS AND DIVESTITURES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "longName": "9955526 - Disclosure - REVENUE - Net Revenue Earned by Category of Payer (Details)", "shortName": "REVENUE - Net Revenue Earned by Category of Payer (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-78", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:DisaggregationOfRevenueTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R48": { "role": "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails", "longName": "9955527 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)", "shortName": "EMPLOYEE BENEFIT PLANS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails", "longName": "9955528 - Disclosure - INCOME TAXES - Income Tax Benefit (Details)", "shortName": "INCOME TAXES - Income Tax Benefit (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails", "longName": "9955529 - Disclosure - INCOME TAXES - Income Tax Reconciliation (Details)", "shortName": "INCOME TAXES - Income Tax Reconciliation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails", "longName": "9955530 - Disclosure - INCOME TAXES - Narrative (Details)", "shortName": "INCOME TAXES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "bios:TerminationFeeIncomeTaxEffect", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R52": { "role": "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails", "longName": "9955531 - Disclosure - INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)", "shortName": "INCOME TAXES - Deferred Income Tax Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-4", "name": "bios:DeferredTaxAssetsBadDebtReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "bios:DeferredTaxAssetsBadDebtReserve", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails", "longName": "9955532 - Disclosure - INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details)", "shortName": "INCOME TAXES - Valuation Allowance for Deferred Tax Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-99", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-95", "name": "us-gaap:ValuationAllowancesAndReservesBalance", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:SummaryOfValuationAllowanceTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R54": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails", "longName": "9955533 - Disclosure - EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "shortName": "EARNINGS PER SHARE - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-102", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-102", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails", "longName": "9955534 - Disclosure - EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Details)", "shortName": "EARNINGS PER SHARE - Schedule of Basic and Diluted Earnings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R56": { "role": "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails", "longName": "9955535 - Disclosure - LEASES - Additional Information (Details)", "shortName": "LEASES - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails", "longName": "9955536 - Disclosure - LEASES - Maturities of Lease Liabilities (Details)", "shortName": "LEASES - Maturities of Lease Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails", "longName": "9955537 - Disclosure - PROPERTY AND EQUIPMENT (Details)", "shortName": "PROPERTY AND EQUIPMENT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails", "longName": "9955538 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails", "longName": "9955539 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAcquiredDuringPeriod", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R61": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "longName": "9955540 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Carrying Amount and Accumulated Amortization of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R62": { "role": "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails", "longName": "9955541 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details)", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Future Amortization Expense of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails", "longName": "9955542 - Disclosure - INDEBTEDNESS - Summary of Debt (Details)", "shortName": "INDEBTEDNESS - Summary of Debt (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtInstrumentUnamortizedDiscount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R64": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "longName": "9955543 - Disclosure - INDEBTEDNESS - Additional Information (Details)", "shortName": "INDEBTEDNESS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RepaymentsOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R65": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails", "longName": "9955544 - Disclosure - INDEBTEDNESS - Long-term Debt Maturities (Details)", "shortName": "INDEBTEDNESS - Long-term Debt Maturities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "longName": "9955545 - Disclosure - INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)", "shortName": "INDEBTEDNESS - Estimated Fair Values of Debt Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LongTermDebtFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "longName": "9955546 - Disclosure - DERIVATIVE INSTRUMENTS - Additional Information (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "longName": "9955547 - Disclosure - DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Balance Sheet Location of Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DerivativeAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails", "longName": "9955548 - Disclosure - DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)", "shortName": "DERIVATIVE INSTRUMENTS - Pre-tax Gain (Loss) on Derivative Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-191", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-191", "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "longName": "9955549 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails", "longName": "9955550 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Assumptions Used to Compute Fair Value of Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-205", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-205", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails", "longName": "9955551 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Summary of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-207", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-207", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails", "longName": "9955552 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Summary of Outstanding and Exercisable Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails", "longName": "9955553 - Disclosure - STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details)", "shortName": "STOCK-BASED INCENTIVE COMPENSATION - Summary of Restricted Stock Award Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-223", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-223", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "longName": "9955554 - Disclosure - STOCKHOLDERS' EQUITY (Details)", "shortName": "STOCKHOLDERS' EQUITY (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromWarrantExercises", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:TreasuryStockAcquiredAverageCostPerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R76": { "role": "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails", "longName": "9955555 - Disclosure - STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details)", "shortName": "STOCKHOLDERS' EQUITY - Schedule of Changes in Shares of Common Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-20", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R77": { "role": "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "longName": "9955556 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)", "shortName": "RELATED-PARTY TRANSACTIONS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "77", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-256", "name": "us-gaap:AccountsPayableOtherCurrentAndNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R78": { "role": "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "longName": "9955557 - Disclosure - SEGMENT REPORTING (Details)", "shortName": "SEGMENT REPORTING (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "78", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherIncome", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "unique": true } }, "R79": { "role": "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails", "longName": "9955558 - Disclosure - SUBSEQUENT EVENTS (Details)", "shortName": "SUBSEQUENT EVENTS (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "79", "firstAnchor": { "contextRef": "c-259", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-259", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "bios-20241231.htm", "first": true, "unique": true } } }, "tag": { "bios_A2015WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "A2015WarrantsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2015 Warrants", "label": "2015 Warrants [Member]", "documentation": "2015 Warrants [Member]" } } }, "auth_ref": [] }, "bios_A2017WarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "A2017WarrantsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Warrants", "label": "2017 Warrants [Member]", "documentation": "2017 Warrants [Member]" } } }, "auth_ref": [] }, "bios_A2018PlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "A2018PlanMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "The 2018 Plan", "label": "2018 Plan [Member]", "documentation": "2018 Plan [Member]" } } }, "auth_ref": [] }, "bios_A2024PerformanceStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "A2024PerformanceStockUnitsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2024 Performance Stock Units", "label": "2024 Performance Stock Units [Member]", "documentation": "2024 Performance Stock Units" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r93", "r862" ] }, "us-gaap_AccountsPayableOtherCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableOtherCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due to joint ventures", "label": "Accounts Payable, Other", "documentation": "Amount of obligations incurred and payable classified as other." } } }, "auth_ref": [ "r171" ] }, "bios_AccountsReceivableBenchmarkMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "AccountsReceivableBenchmarkMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable Benchmark", "label": "Accounts Receivable, Benchmark [Member]", "documentation": "Accounts Receivable, Benchmark" } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r1041" ] }, "bios_AccruedExpensesAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "AccruedExpensesAndOtherCurrentLiabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Accrued Expenses And Other Current Liabilities", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Used to reflect the current portion of the liabilities, combined with the aggregate carrying amount, as of the balance sheet date, of current obligations not separately disclosed in the balance sheet due to materiality considerations." } } }, "auth_ref": [] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r38", "r216", "r656" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r19", "r20", "r113", "r227", "r651", "r683", "r684" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r11", "r20", "r567", "r570", "r620", "r679", "r680", "r1007", "r1008", "r1009", "r1028", "r1029", "r1030", "r1031" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r930" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r108" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r698", "r1028", "r1029", "r1030", "r1031", "r1136", "r1203" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r943" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r943" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r943" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r943" ] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of shares surrendered to satisfy tax withholding obligations", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based incentive compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r56", "r57", "r465" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operations:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "bios_AggregateIntrinsicValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "AggregateIntrinsicValueAbstract", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value", "label": "Aggregate Intrinsic Value [Abstract]", "documentation": "Aggregate Intrinsic Value [Abstract]" } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r988" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r901", "r912", "r922", "r955" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r904", "r915", "r925", "r958" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r989" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r943" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r950" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r905", "r916", "r926", "r950", "r959", "r963", "r971" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r969" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r497", "r506" ] }, "bios_AmedisysIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "AmedisysIncMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amedisys, Inc.", "label": "Amedisys, Inc. [Member]", "documentation": "Amedisys, Inc." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCostsAndDiscounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfFinancingCostsAndDiscounts", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization of deferred financing costs", "label": "Amortization of Debt Issuance Costs and Discounts", "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs." } } }, "auth_ref": [ "r405", "r833", "r834", "r1017", "r1152" ] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization expense for intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8", "r344", "r351", "r829" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r292" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AssetUnderConstructionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetUnderConstructionMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets under development", "label": "Asset under Construction [Member]", "documentation": "Asset in process of being built." } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL ASSETS", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r168", "r180", "r220", "r259", "r296", "r304", "r316", "r319", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r556", "r558", "r597", "r646", "r740", "r822", "r823", "r862", "r879", "r1083", "r1084", "r1158" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": [ "r211", "r230", "r259", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r556", "r558", "r597", "r862", "r1083", "r1084", "r1158" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT ASSETS:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r259", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r556", "r558", "r597", "r1083", "r1084", "r1158" ] }, "us-gaap_AssetsNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsNoncurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "NONCURRENT ASSETS:", "label": "Assets, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Assets held for sale", "label": "Disposal Group, Including Discontinued Operation, Assets", "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r91", "r92", "r140", "r209", "r210" ] }, "bios_AuditInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "AuditInformationAbstract", "lang": { "en-us": { "role": { "label": "Audit Information [Abstract]", "documentation": "Audit Information" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://www.bioscrip.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Firm ID", "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r884", "r885", "r908" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://www.bioscrip.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Location", "label": "Auditor Location" } } }, "auth_ref": [ "r884", "r885", "r908" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://www.bioscrip.com/role/AuditInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Auditor Name", "label": "Auditor Name" } } }, "auth_ref": [ "r884", "r885", "r908" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r966" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r967" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r962" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r962" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r493", "r494", "r495", "r496" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r965" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r964" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r963" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r963" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Axis]", "label": "Statement of Financial Position Location, Balance [Axis]", "documentation": "Information by location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r364", "r1169", "r1170" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position Location, Balance [Domain]", "label": "Statement of Financial Position Location, Balance [Domain]", "documentation": "Location in statement of financial position where disaggregated cumulative balance has been reported." } } }, "auth_ref": [ "r72", "r75", "r364", "r1169", "r1170" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BaseRateMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails", "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r345", "r346", "r347", "r348", "r349", "r552", "r846", "r847" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails", "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r58", "r61", "r345", "r346", "r347", "r348", "r349", "r552", "r846", "r847" ] }, "us-gaap_BusinessAcquisitionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionLineItems", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Line Items]", "label": "Business Acquisition [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r552" ] }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of the combined company held", "label": "Business Acquisition, Percentage of Voting Interests Acquired", "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination." } } }, "auth_ref": [ "r59" ] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "bios_BusinessCombinationConsiderationTransferredNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "BusinessCombinationConsiderationTransferredNetOfCashAcquired", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net of cash acquired", "label": "Business Combination, Consideration Transferred, Net Of Cash Acquired", "documentation": "Business Combination, Consideration Transferred, Net Of Cash Acquired" } } }, "auth_ref": [] }, "bios_BusinessCombinationContingentConsiderationAssetTerminationFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "BusinessCombinationContingentConsiderationAssetTerminationFee", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee", "label": "Business Combination, Contingent Consideration, Asset, Termination Fee", "documentation": "Business Combination, Contingent Consideration, Asset, Termination Fee" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date." } } }, "auth_ref": [ "r62" ] }, "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAdditionalDisclosuresAcquisitionCostExpensed", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business combination, acquisition-related expenses", "label": "Business Combination, Separately Recognized Transactions, Additional Disclosures, Acquisition Cost Expensed", "documentation": "For transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination, such as related to pre-existing relationships with the acquiree, this element represents the disclosure of the amount of acquisition related costs which have been expensed." } } }, "auth_ref": [ "r60" ] }, "us-gaap_BusinessCombinationsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationsPolicy", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisitions", "label": "Business Combinations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy." } } }, "auth_ref": [ "r159", "r160", "r161", "r162" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r89", "r134", "r135" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r24", "r214", "r811" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r25" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash and cash equivalents - beginning of the period", "periodEndLabel": "CASH AND CASH EQUIVALENTS - END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r24", "r131", "r255" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCREASE IN CASH AND CASH EQUIVALENTS", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r131" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r941" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": [ "r938" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r936" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Domain]", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r193", "r223", "r224", "r225", "r259", "r286", "r287", "r289", "r291", "r298", "r299", "r331", "r374", "r376", "r377", "r378", "r381", "r382", "r414", "r415", "r418", "r421", "r428", "r597", "r689", "r690", "r691", "r692", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r727", "r749", "r772", "r795", "r796", "r797", "r798", "r799", "r993", "r1018", "r1032" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r223", "r224", "r225", "r298", "r414", "r415", "r416", "r418", "r421", "r426", "r428", "r689", "r690", "r691", "r692", "r835", "r993", "r1018" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r50" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of warrants (in dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r429" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Line Items]", "label": "Class of Warrant or Right [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares to be purchased (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r429" ] }, "bios_ClassOfWarrantOrRightNumberOfSecuritiesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesExercised", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of warrants exercised (in shares)", "label": "Class of Warrant or Right, Number of Securities Exercised", "documentation": "Class of Warrant or Right, Number of Securities Exercised" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of warrant or right, outstanding (in shares)", "label": "Class of Warrant or Right, Outstanding", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Table]", "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r50" ] }, "bios_ClassofWarrantorRightSecuritiesExercised": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "ClassofWarrantorRightSecuritiesExercised", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares purchased from exercise of warrants (in shares)", "label": "Class of Warrant or Right, Securities Exercised", "documentation": "Class of Warrant or Right, Securities Exercised" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r942" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r942" ] }, "bios_CommercialCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "CommercialCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial payers", "label": "Commercial Customer [Member]", "documentation": "Commercial Customer [Member]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/COMMITMENTSANDCONTINGENCIES" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r141", "r366", "r367", "r803", "r1073", "r1078" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r870", "r871", "r872", "r874", "r875", "r876", "r877", "r1028", "r1029", "r1031", "r1136", "r1200", "r1203" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r107" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r107", "r727" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r107" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares, outstanding (in shares)", "periodStartLabel": "Balance, beginning of the year", "periodEndLabel": "Balance, end of the period", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r12", "r107", "r727", "r746", "r1203", "r1204" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock; $0.0001 par value: 250,000,000 shares authorized, 183,846,725 shares issued and 166,261,112 shares outstanding as of December\u00a031, 2024; 182,905,559 shares issued and 174,575,537 shares outstanding as of December\u00a031, 2023.", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r107", "r650", "r862" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r947" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r946" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r948" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r945" ] }, "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndEmployeeBenefitPlansTextBlock", "presentation": [ "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANS" ], "lang": { "en-us": { "role": { "terseLabel": "EMPLOYEE BENEFIT PLANS", "label": "Compensation and Employee Benefit Plans [Text Block]", "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans." } } }, "auth_ref": [ "r148", "r149", "r150", "r151" ] }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CompensationAndRetirementDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Retirement Benefits [Abstract]", "label": "Retirement Benefits [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets:", "label": "Components of Deferred Tax Assets and Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "NET COMPREHENSIVE INCOME", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r21", "r239", "r241", "r247", "r642", "r662", "r663" ] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer Software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r806", "r810", "r1060", "r1062", "r1063", "r1064", "r1066", "r1067", "r1070", "r1071" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r31", "r32", "r83", "r84", "r325", "r802" ] }, "bios_ConcentrationRiskBusinessRiskPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "ConcentrationRiskBusinessRiskPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentrations of Business Risk", "label": "Concentration Risk, Business Risk, Policy [Policy Text Block]", "documentation": "Concentration Risk, Business Risk, Policy [Policy Text Block]" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r31", "r32", "r83", "r84", "r325", "r686", "r802" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r31", "r32", "r83", "r84", "r325", "r802", "r1000" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r802" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r31", "r32", "r83", "r84", "r325" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r30", "r31", "r32", "r33", "r83", "r167", "r802" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r31", "r32", "r83", "r84", "r325", "r802" ] }, "us-gaap_ConsolidationPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConsolidationPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Principles of Consolidation", "label": "Consolidation, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary." } } }, "auth_ref": [ "r67", "r814" ] }, "us-gaap_ContractWithCustomerReceivableAfterAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerReceivableAfterAllowanceForCreditLoss", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rebate receivable", "label": "Contract with Customer, Receivable, after Allowance for Credit Loss", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right to consideration is unconditional." } } }, "auth_ref": [ "r431", "r432", "r451", "r801" ] }, "us-gaap_CorporateJointVentureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateJointVentureMember", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Joint Venture", "label": "Corporate Joint Venture [Member]", "documentation": "Corporation owned and operated by a small group of ventures to accomplish a mutually beneficial venture or project." } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "COST OF REVENUE", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r117", "r118", "r637" ] }, "us-gaap_CostOfGoodsProductLineMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsProductLineMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Goods and Service, Product and Service Benchmark", "label": "Cost of Goods and Service, Product and Service Benchmark [Member]", "documentation": "Cost of product sold and service rendered from specified product or service, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r999" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Cost of net revenues - drugs", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r119", "r259", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r597", "r822", "r1083" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense in cost of revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostOfSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of Revenue", "label": "Cost of Goods and Service [Policy Text Block]", "documentation": "Disclosure of accounting policy for cost of product sold and service rendered." } } }, "auth_ref": [ "r1002" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "bios_CreditAgreementsEnteredInto2019Member": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "CreditAgreementsEnteredInto2019Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Agreements, Entered Into 2019", "label": "Credit Agreements, Entered Into 2019 [Member]", "documentation": "Credit Agreements, Entered Into 2019 [Member]" } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r373", "r1081" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [ "r373", "r1081", "r1082" ] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": { "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1001", "r1021", "r1128" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": { "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1001", "r1021", "r1128" ] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer Concentration Risk", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r136", "r325" ] }, "us-gaap_CustomerListsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerListsMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Referral sources", "label": "Customer Lists [Member]", "documentation": "Information about customers such as their name and contact information; it may also be an extensive database that includes other information about the customers such as their order history and demographic information." } } }, "auth_ref": [ "r64", "r1060", "r1062", "r1063", "r1064", "r1066", "r1067", "r1070", "r1071" ] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r893", "r982" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r893", "r982" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r895", "r984" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r895", "r984" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r897", "r986" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r895", "r984" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r888", "r977" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r889", "r978" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r889", "r978" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r887", "r976" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r887", "r976" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r887", "r976" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r890", "r979" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r892", "r981" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r892", "r981" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r893", "r982" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r896", "r985" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r894", "r983" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r891", "r980" ] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESS" ], "lang": { "en-us": { "role": { "terseLabel": "INDEBTEDNESS", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r142", "r257", "r359", "r360", "r361", "r362", "r363", "r372", "r373", "r383", "r389", "r390", "r391", "r392", "r393", "r394", "r399", "r406", "r407", "r409", "r605" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r18", "r95", "r96", "r169", "r172", "r263", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r830", "r831", "r832", "r833", "r834", "r860", "r1019", "r1074", "r1075", "r1076", "r1151", "r1153" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentCarryingAmount", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal Amount", "totalLabel": "Total", "label": "Long-Term Debt, Gross", "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt." } } }, "auth_ref": [ "r18", "r172", "r410" ] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, face amount", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r384", "r605", "r606", "r831", "r832", "r860" ] }, "bios_DebtInstrumentIncreaseInBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "DebtInstrumentIncreaseInBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in borrowing capacity", "label": "Debt Instrument, Increase in Borrowing Capacity", "documentation": "Debt Instrument, Increase in Borrowing Capacity" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective rate on term loans at end of period", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r98", "r412", "r605", "r606", "r860" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r263", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r408", "r830", "r831", "r832", "r833", "r834", "r860", "r1019", "r1151", "r1153" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r18", "r263", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r830", "r831", "r832", "r833", "r834", "r860", "r1019", "r1074", "r1075", "r1076", "r1151", "r1153" ] }, "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentPeriodicPaymentPrincipal", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, periodic payment, principal", "label": "Debt Instrument, Periodic Payment, Principal", "documentation": "Amount of the required periodic payments applied to principal." } } }, "auth_ref": [ "r18" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": [ "r18", "r44", "r47", "r88", "r145", "r146", "r263", "r384", "r385", "r386", "r387", "r388", "r390", "r395", "r396", "r397", "r398", "r400", "r401", "r402", "r403", "r404", "r405", "r408", "r830", "r831", "r832", "r833", "r834", "r860", "r1019", "r1151", "r1153" ] }, "us-gaap_DebtInstrumentUnamortizedDiscount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentUnamortizedDiscount", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Discount", "label": "Debt Instrument, Unamortized Discount", "documentation": "Amount, after accumulated amortization, of debt discount." } } }, "auth_ref": [ "r1086", "r1150", "r1151", "r1153" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": { "parentTag": "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1021", "r1127", "r1128" ] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs and third party fees", "label": "Debt Issuance Costs, Gross", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1151", "r1153" ] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Debt Issuance Costs", "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r1086", "r1150", "r1151", "r1153" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes - net", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r8", "r190", "r1021" ] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Deferred tax liabilities", "label": "Deferred Tax Liabilities, Gross", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r103", "r104", "r170", "r529" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Deferred Income Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r512", "r513", "r647" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": { "parentTag": "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r1021", "r1127", "r1128" ] }, "us-gaap_DeferredTaxAssetInterestCarryforward": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetInterestCarryforward", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails", "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest limitation carryforward", "label": "Deferred Tax Asset, Interest Carryforward", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward." } } }, "auth_ref": [ "r1125" ] }, "bios_DeferredTaxAssetsBadDebtReserve": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "DeferredTaxAssetsBadDebtReserve", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price concessions", "label": "Deferred Tax Assets, Bad Debt Reserve", "documentation": "Deferred Tax Assets, Bad Debt Reserve" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets before valuation allowance", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r530" ] }, "bios_DeferredTaxAssetsLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "DeferredTaxAssetsLeaseLiability", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Deferred Tax Assets, Lease Liability", "documentation": "Deferred Tax Assets, Lease Liability" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxLiabilities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets net of valuation allowance", "label": "Deferred Tax Assets, Net of Valuation Allowance", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r1122" ] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails", "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating losses", "label": "Deferred Tax Assets, Operating Loss Carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r1125" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r1125" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation and benefits", "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs." } } }, "auth_ref": [ "r1125" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails", "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "negatedTerseLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r531" ] }, "us-gaap_DeferredTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Net deferred tax liabilities", "label": "Deferred Tax Liabilities, Net", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting." } } }, "auth_ref": [ "r1122" ] }, "bios_DeferredTaxLiabilitiesAcceleratedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "DeferredTaxLiabilitiesAcceleratedDepreciation", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accelerated depreciation", "label": "Deferred Tax Liabilities, Accelerated Depreciation", "documentation": "Deferred Tax Liabilities, Accelerated Depreciation" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesDeferredExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesDeferredExpenseAbstract", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax liabilities:", "label": "Deferred Tax Liabilities, Deferred Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsGoodwill", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill", "label": "Deferred Tax Liabilities, Goodwill", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from goodwill." } } }, "auth_ref": [ "r65", "r66", "r1125" ] }, "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Intangible assets", "label": "Deferred Tax Liabilities, Intangible Assets", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill." } } }, "auth_ref": [ "r1125" ] }, "bios_DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "DeferredTaxLiabilitiesOperatingLeaseRightOfUseAsset", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease right-of-use asset", "label": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset", "documentation": "Deferred Tax Liabilities, Operating Lease Right-Of-Use Asset" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxLiabilitiesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxLiabilitiesOther", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_DeferredIncomeTaxLiabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESDeferredIncomeTaxAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other", "label": "Deferred Tax Liabilities, Other", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other." } } }, "auth_ref": [ "r1125" ] }, "us-gaap_DefinedContributionPlanCostRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanCostRecognized", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Defined contribution plan expense", "label": "Defined Contribution Plan, Cost", "documentation": "Amount of cost for defined contribution plan." } } }, "auth_ref": [ "r461" ] }, "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company contributions", "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount", "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer matching contribution percent of employees' gross pay", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "presentation": [ "http://www.bioscrip.com/role/EMPLOYEEBENEFITPLANSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employer matching contribution percent", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "documentation": "Percentage employer matches of the employee's percentage contribution matched." } } }, "auth_ref": [] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r8", "r37" ] }, "us-gaap_DepreciationAmortizationAndAccretionNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAmortizationAndAccretionNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "verboseLabel": "Depreciation and amortization expense", "label": "Depreciation, Amortization and Accretion, Net", "documentation": "The aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a noncash item, the net amount is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r8" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "negatedTerseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r8", "r296", "r308", "r319", "r822", "r823" ] }, "us-gaap_DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumeration", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "label": "Derivative Asset, Statement of Financial Position [Extensible Enumeration]", "documentation": "Indicates line item in statement of financial position that includes derivative asset." } } }, "auth_ref": [ "r560" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeAssets", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total derivative assets", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r231", "r232", "r578", "r579", "r589", "r596", "r710", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r733", "r734", "r784", "r786", "r787", "r788", "r789", "r790", "r813", "r853", "r856", "r872", "r1138", "r1139", "r1140", "r1201" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r717", "r719", "r732", "r733", "r734", "r736", "r737", "r738", "r739", "r741", "r742", "r743", "r744", "r760", "r761", "r762", "r763", "r766", "r767", "r768", "r769", "r784", "r785", "r787", "r789", "r870", "r872", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r73", "r76", "r77", "r166", "r717", "r719", "r732", "r733", "r734", "r736", "r737", "r738", "r739", "r741", "r742", "r743", "r744", "r760", "r761", "r762", "r763", "r766", "r767", "r768", "r769", "r784", "r785", "r787", "r789", "r813", "r870", "r872", "r1141", "r1142", "r1143", "r1144", "r1145", "r1146", "r1147", "r1148" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "DERIVATIVE INSTRUMENTS", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r165", "r564", "r572" ] }, "us-gaap_DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangementAbstract", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative", "label": "Derivative Liability, Fair Value, Gross Liability Including Not Subject to Master Netting Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLineItems", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r572" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount of derivative", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r1133", "r1134" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTable", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date." } } }, "auth_ref": [ "r13", "r68", "r69", "r70", "r71", "r74", "r76", "r78", "r80", "r81", "r572" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative term of contract", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Instruments", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r13", "r68", "r69", "r71", "r79", "r262", "r282" ] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Designated as Hedging Instrument", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r13" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director", "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r1003", "r1040", "r1202" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r450", "r836", "r837", "r838", "r839", "r840", "r841", "r842" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r450", "r836", "r837", "r838", "r839", "r840", "r841", "r842" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/REVENUETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Net Revenue Earned by Category of Payer", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r1088" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATION" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED INCENTIVE COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r463", "r467", "r498", "r499", "r501", "r849" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale price", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "bios_DisposalGroupIncludingDiscontinuedOperationConsiderationReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationReceivable", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consideration receivable", "label": "Disposal Group, Including Discontinued Operation, Consideration, Receivable", "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Receivable" } } }, "auth_ref": [] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain on sale", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal", "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations." } } }, "auth_ref": [ "r357", "r1017", "r1072" ] }, "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposalStatementOfIncomeExtensibleList", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal, Statement of Income or Comprehensive Income [Extensible Enumeration]", "documentation": "Indicates line item in statement of income that includes gain (loss) recognized on sale or disposal of disposal group. Excludes discontinued operation." } } }, "auth_ref": [ "r358" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Annual Report", "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r884", "r885", "r908" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Financial Statement Error Correction Flag", "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r884", "r885", "r908", "r951" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r929" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Documents Incorporated by Reference", "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r882" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Domestic Tax Jurisdiction [Member]", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r516" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": [ "r940" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER COMMON SHARE:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, basic (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r248", "r274", "r275", "r276", "r277", "r278", "r279", "r284", "r286", "r289", "r290", "r291", "r295", "r550", "r555", "r575", "r576", "r643", "r664", "r816" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings per share, diluted (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r248", "r274", "r275", "r276", "r277", "r278", "r279", "r286", "r289", "r290", "r291", "r295", "r550", "r555", "r575", "r576", "r643", "r664", "r816" ] }, "us-gaap_EarningsPerShareDilutedLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDilutedLineItems", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "label": "Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r286", "r287", "r289" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARE" ], "lang": { "en-us": { "role": { "terseLabel": "EARNINGS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r283", "r292", "r293", "r294" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails", "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Effective income tax rate", "terseLabel": "Effective income tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r516", "r852" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal statutory tax rate", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r261", "r516", "r540", "r852" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation allowance", "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r520", "r852", "r1022", "r1118" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share based compensation impacts", "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r852", "r1022", "r1118", "r1120" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments." } } }, "auth_ref": [ "r852", "r1022", "r1118", "r1119" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxReconciliationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State and local income taxes net of federal tax benefit", "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r519", "r852", "r1022", "r1118" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r96" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period of recognition", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r500" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r1115" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r881" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r881" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r881" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r991" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Public Float", "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r881" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r881" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r881" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r881" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Voluntary Filers", "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Well-known Seasoned Issuer", "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r992" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r934" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]" } } }, "auth_ref": [ "r987" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label": "Equity Awards Adjustments [Member]" } } }, "auth_ref": [ "r987" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r987" ] }, "bios_EquipmentFurnitureAndOtherMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "EquipmentFurnitureAndOtherMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment, furniture and other", "label": "Equipment, Furniture, And Other [Member]", "documentation": "Equipment, Furniture, And Other [Member]" } } }, "auth_ref": [] }, "us-gaap_EquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r12", "r208", "r243", "r244", "r245", "r269", "r270", "r271", "r273", "r278", "r280", "r282", "r297", "r332", "r333", "r356", "r430", "r538", "r539", "r547", "r548", "r549", "r551", "r554", "r555", "r566", "r567", "r568", "r569", "r570", "r571", "r574", "r598", "r599", "r600", "r601", "r602", "r603", "r607", "r609", "r620", "r661", "r679", "r680", "r681", "r698", "r772" ] }, "us-gaap_EquityInterestIssuedOrIssuableByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableByTypeAxis", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Interest Type [Axis]", "label": "Equity Interest Type [Axis]", "documentation": "Information by type of equity interests that are issued or issuable in a business combination." } } }, "auth_ref": [] }, "us-gaap_EquityInterestIssuedOrIssuableTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityInterestIssuedOrIssuableTypeDomain", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Interest Issued or Issuable, Type [Domain]", "label": "Equity Interest Issued or Issuable, Type [Domain]", "documentation": "Name of equity interest issued or issuable to acquire an entity in a business combination." } } }, "auth_ref": [ "r163" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r328", "r329", "r330", "r546", "r994", "r995", "r996", "r1129", "r1130", "r1131", "r1132" ] }, "us-gaap_EquityMethodInvestmentDividendsOrDistributions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentDividendsOrDistributions", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Distribution from equity method investments", "label": "Proceeds from Equity Method Investment, Distribution", "documentation": "Amount of distribution received from equity method investee for return on investment, classified as operating activities. Excludes distribution for return of investment, classified as investing activities." } } }, "auth_ref": [ "r6", "r8", "r116", "r658" ] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership interest", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r328" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investments in equity-method investees", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r296", "r311", "r319", "r327", "r1005", "r1045" ] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r6", "r85", "r329" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r944" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r901", "r912", "r922", "r955" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r898", "r909", "r919", "r952" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r950" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r397", "r454", "r455", "r456", "r457", "r458", "r459", "r577", "r579", "r580", "r581", "r582", "r588", "r589", "r591", "r630", "r631", "r632", "r831", "r832", "r843", "r844", "r845", "r853", "r856" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.bioscrip.com/role/FAIRVALUEMEASURMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASURMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r584", "r586", "r587", "r588", "r591", "r592", "r593", "r594", "r595", "r640", "r853", "r857" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Markets for Identical Item (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r397", "r454", "r459", "r579", "r589", "r630", "r843", "r844", "r845", "r853" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r397", "r454", "r459", "r579", "r580", "r589", "r631", "r831", "r832", "r843", "r844", "r845", "r853" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r397", "r454", "r455", "r456", "r457", "r458", "r459", "r579", "r580", "r581", "r582", "r589", "r632", "r831", "r832", "r843", "r844", "r845", "r853", "r856" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r397", "r454", "r455", "r456", "r457", "r458", "r459", "r577", "r579", "r580", "r581", "r582", "r588", "r589", "r591", "r630", "r631", "r632", "r831", "r832", "r843", "r844", "r845", "r853", "r856" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Federal income tax expense (benefit)", "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r260", "r514", "r515" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. federal income tax expense (benefit):", "label": "Federal Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "bios_FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income", "label": "Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member]", "documentation": "Federal Net Operating Loss Carryfowards Available To Offset Future Taxable Income [Member]" } } }, "auth_ref": [] }, "bios_FiniteLivedCustomerListsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "FiniteLivedCustomerListsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Referral sources, net", "label": "Finite Lived Customer Lists, Net", "documentation": "Finite Lived Customer Lists, Net" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetUsefulLife", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible asset useful life (in years)", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Total accumulated amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r218", "r337", "r350", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030 and beyond", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five", "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r1068", "r1205" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r352", "r806", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r352", "r806", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r352", "r806", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r352", "r806", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r352", "r806", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r343", "r345", "r346", "r347", "r349", "r350", "r353", "r354", "r638", "r639", "r806" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total gross intangible assets", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r337", "r350", "r639", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets [Line Items]", "label": "Finite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r343", "r350", "r353", "r354", "r355", "r638", "r806", "r829" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r343", "r345", "r346", "r347", "r349", "r350", "r353", "r354", "r806" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSFutureAmortizationExpenseofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total intangible assets, net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r638", "r1067" ] }, "bios_FiniteLivedIntangibleAssetsNetExcludingCustomerLists": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "FiniteLivedIntangibleAssetsNetExcludingCustomerLists", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible assets, net", "label": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists", "documentation": "Finite-Lived Intangible Assets, Net, Excluding Customer Lists" } } }, "auth_ref": [] }, "bios_FirstLienCreditAgreementThirdAmendmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "FirstLienCreditAgreementThirdAmendmentMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Credit Agreement, Third Amendment", "label": "First Lien Credit Agreement, Third Amendment [Member]", "documentation": "First Lien Credit Agreement, Third Amendment" } } }, "auth_ref": [] }, "bios_FirstLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "FirstLienTermLoanMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Term Loan", "verboseLabel": "First Lien Term Loan", "label": "First Lien Term Loan [Member]", "documentation": "First Lien Term Loan [Member]" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r905", "r916", "r926", "r959" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r905", "r916", "r926", "r959" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r905", "r916", "r926", "r959" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r905", "r916", "r926", "r959" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r905", "r916", "r926", "r959" ] }, "bios_FourVendorsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "FourVendorsMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Four Vendors", "label": "Four Vendors [Member]", "documentation": "Four Vendors" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r939" ] }, "us-gaap_GainLossOnSaleOfOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnSaleOfOtherAssets", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on sale of assets", "label": "Gain (Loss) on Disposition of Other Assets", "documentation": "Amount of gain (loss) on sale or disposal of other assets." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss on extinguishment of debt", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r8", "r40", "r41" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Goodwill - net book value, beginning of period", "periodEndLabel": "Goodwill - net book value, end of period", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r217", "r338", "r641", "r823", "r828", "r854", "r862", "r1049", "r1056" ] }, "us-gaap_GoodwillAcquiredDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAcquiredDuringPeriod", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Acquisitions", "label": "Goodwill, Acquired During Period", "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination." } } }, "auth_ref": [ "r340", "r828" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r1047", "r1059" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill, Intangible Assets, Property and Equipment, and Referral Sources", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r1047", "r1059" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill impairment", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r8", "r339", "r341", "r342", "r828", "r854" ] }, "us-gaap_GoodwillPurchaseAccountingAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillPurchaseAccountingAdjustments", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase accounting adjustments", "label": "Goodwill, Measurement Period Adjustment", "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r0", "r1055" ] }, "us-gaap_GoodwillRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GovernmentContractsConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GovernmentContractsConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Governmental Programs", "label": "Government Contracts Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City." } } }, "auth_ref": [ "r136" ] }, "bios_GovernmentCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "GovernmentCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government payers", "label": "Government Customer [Member]", "documentation": "Government Customer [Member]" } } }, "auth_ref": [] }, "bios_GovernmentHealthcareProgramsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "GovernmentHealthcareProgramsMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Government Healthcare Programs", "label": "Government Healthcare Programs [Member]", "documentation": "Government Healthcare Programs" } } }, "auth_ref": [] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "GROSS PROFIT", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r114", "r119", "r179", "r259", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r597", "r818", "r822", "r1034", "r1036", "r1037", "r1038", "r1039", "r1083" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r13", "r563" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r13" ] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "ICFR Auditor Attestation Flag", "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r884", "r885", "r908" ] }, "bios_IncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "IncomeExpenseAbstract", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income (Expense) [Abstract]", "label": "Income (Expense) [Abstract]", "documentation": "Income (Expense)" } } }, "auth_ref": [] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "INCOME BEFORE INCOME TAXES", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r115", "r175", "r179", "r644", "r659", "r818", "r822", "r1034", "r1036", "r1037", "r1038", "r1039" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Equity in earnings of joint ventures", "terseLabel": "Proportionate share of earnings in equity-method investees", "verboseLabel": "Equity in earnings of joint ventures", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r8", "r116", "r174", "r296", "r309", "r319", "r327", "r658" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r358", "r364", "r365", "r583", "r585", "r590", "r676", "r678", "r757", "r806", "r855", "r1171" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statement of Income Location, Balance [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r364", "r365", "r583", "r585", "r590", "r676", "r678", "r757", "r806", "r855", "r1171" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Axis]", "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r254", "r516", "r517", "r524", "r535", "r852", "r1124" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Jurisdiction [Domain]", "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r254", "r516", "r517", "r524", "r535", "r852", "r1124" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r261", "r508", "r516", "r521", "r522", "r523", "r526", "r533", "r541", "r543", "r544", "r545", "r694", "r852" ] }, "us-gaap_IncomeTaxExaminationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationLineItems", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax Examination [Line Items]", "label": "Income Tax Examination [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r524" ] }, "us-gaap_IncomeTaxExaminationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationTable", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Tax, Examination [Table]", "label": "Income Tax, Examination [Table]", "documentation": "Disclosure of information about income tax examination currently in progress or completed during current period by tax authority. Includes, but is not limited to, description of examination, jurisdiction conducting examination, tax year under examination, likelihood of unfavorable settlement, range of possible loss, liability recorded, increase (decrease) of liability from prior period, and penalty and interest incurred or accrued." } } }, "auth_ref": [ "r1121" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 6.0 }, "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails", "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAX EXPENSE", "totalLabel": "Total income tax expense (benefit)", "verboseLabel": "Income tax expense (benefit)", "negatedTerseLabel": "INCOME TAX EXPENSE", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r184", "r191", "r281", "r282", "r296", "r310", "r319", "r514", "r516", "r542", "r667", "r852" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r242", "r510", "r511", "r526", "r527", "r532", "r537", "r688" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r26", "r254", "r534", "r535" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableTrade": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayableTrade", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable, Trade", "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee benefits", "label": "Increase (Decrease) in Employee Related Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "label": "Increase (Decrease) in Other Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other noncurrent assets and liabilities", "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net", "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Receivables", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "bios_IndefiniteCarryforwardPeriodMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "IndefiniteCarryforwardPeriodMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indefinite Carryforward Period", "label": "Indefinite Carryforward Period [Member]", "documentation": "Indefinite Carryforward Period" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r905", "r916", "r926", "r950", "r959", "r963", "r971" ] }, "bios_InfusionPumpsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "InfusionPumpsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Infusion pumps", "label": "Infusion Pumps [Member]", "documentation": "Infusion Pumps [Member]" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r969" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r886", "r975" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r886", "r975" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r886", "r975" ] }, "us-gaap_InterestExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense, net", "label": "Interest Expense [Member]", "documentation": "Primary financial statement caption encompassing interest expense." } } }, "auth_ref": [ "r17" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense, net", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r307", "r1011" ] }, "bios_InterestLimitationCarryforwardsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "InterestLimitationCarryforwardsMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Limitation Carryforwards", "label": "Interest Limitation Carryforwards [Member]", "documentation": "Interest Limitation Carryforwards [Member]" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r250", "r252", "r253" ] }, "us-gaap_InterestRateCapMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateCapMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails", "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate cap designated as cash flows hedge", "label": "Interest Rate Cap [Member]", "documentation": "Contract in which the cap writer, in return for a premium, agrees to limit, or cap, the cap holder's risk associated with an increase in interest rates. If rates go above a specified interest-rate-level (the strike price or the cap rate), the cap holder is entitled to receive cash payments equal to the excess of the market rate over the strike price multiplied by the notional principal amount." } } }, "auth_ref": [ "r808" ] }, "us-gaap_InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateCashFlowHedgeGainLossToBeReclassifiedDuringNext12MonthsNet", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total interest rate costs expected to reclassify during next 12 months", "label": "Interest Rate Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months, Net", "documentation": "The estimated net amount of unrealized gains or losses on interest rate cash flow hedges as of the balance sheet date expected to be reclassified to earnings within the next twelve months." } } }, "auth_ref": [ "r82" ] }, "us-gaap_InterestRateFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestRateFloorMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest Rate Floor", "label": "Interest Rate Floor [Member]", "documentation": "Contracts in which the floor writer, in return for a premium, agrees to limit the risk associated with a decline in interest rates based on a notional amount. If rates fall below an agreed rate, the floor holder will receive cash payments from the floor writer equal to the difference between the market rate and an agreed rate multiplied by the notional principal amount." } } }, "auth_ref": [ "r808" ] }, "bios_IntramedPlusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "IntramedPlusMember", "presentation": [ "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intramed Plus", "label": "Intramed Plus [Member]", "documentation": "Intramed Plus" } } }, "auth_ref": [] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r229", "r812", "r862" ] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r185", "r213", "r228", "r334", "r335", "r336", "r636", "r815" ] }, "us-gaap_InvestmentIncomeNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNet", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Equity in earnings of joint ventures", "label": "Investment Income, Net", "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r123", "r124", "r126" ] }, "us-gaap_JuniorLienMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "JuniorLienMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Lien Term Loan", "label": "Junior Lien [Member]", "documentation": "Legal right, after the claims of senior lien holders are satisfied, for a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes second mortgage loans." } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Salaries, benefits, and other employee expense", "label": "Labor and Related Expense", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r1010" ] }, "bios_LargestPayerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "LargestPayerMember", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Largest Payer", "label": "Largest Payer [Member]", "documentation": "Largest Payer" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r139", "r619" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "bios_LegacyHealthSystemsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "LegacyHealthSystemsMember", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legacy Health Systems", "label": "Legacy Health Systems [Member]", "documentation": "Legacy Health Systems [Member]" } } }, "auth_ref": [] }, "us-gaap_LesseeFinanceLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeFinanceLeasesTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Finance Leases [Text Block]", "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability." } } }, "auth_ref": [ "r608" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Leases [Policy Text Block]", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r613" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Maturities of Lease Liabilities, Operating", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1155" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2030 and beyond", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Less: interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r618" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.bioscrip.com/role/LEASES" ], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r608" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Undrawn letters of credit issued and outstanding", "label": "Letters of Credit Outstanding, Amount", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r18", "r95", "r96", "r97", "r100", "r101", "r102", "r105", "r259", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r557", "r558", "r559", "r597", "r726", "r817", "r879", "r1083", "r1158", "r1159" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r112", "r173", "r653", "r862", "r1020", "r1046", "r1149" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r97", "r212", "r259", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r557", "r558", "r559", "r597", "r862", "r1083", "r1158", "r1159" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "CURRENT LIABILITIES:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "totalLabel": "Total noncurrent liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r18", "r100", "r101", "r102", "r105", "r259", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r557", "r558", "r559", "r597", "r1083", "r1158", "r1159" ] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "NONCURRENT LIABILITIES:", "label": "Liabilities, Noncurrent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities held for sale", "label": "Disposal Group, Including Discontinued Operation, Liabilities", "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of." } } }, "auth_ref": [ "r2", "r91", "r92", "r140", "r209", "r210" ] }, "us-gaap_LienCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LienCategoryAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lien Category [Axis]", "label": "Lien Category [Axis]", "documentation": "Information by category of lien, for example, but not limited to, senior or junior." } } }, "auth_ref": [] }, "us-gaap_LienCategoryDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LienCategoryDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lien Category [Domain]", "label": "Lien Category [Domain]", "documentation": "Legal claim on the property of another party to secure the payment of a debt or the satisfaction of an obligation by category, for example, but not limited to, senior or junior." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Available borrowing capacity", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r94", "r99" ] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commitment fee, unused portion", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net Balance", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r18", "r172", "r396", "r411", "r831", "r832", "r860", "r1166" ] }, "us-gaap_LongTermDebtCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of long-term debt", "negatedLabel": "Less: current portion", "label": "Long-Term Debt, Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation." } } }, "auth_ref": [ "r221" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total debt instruments", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r1137", "r1138", "r1139", "r1140" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Long-Term Debt, Maturity, Year One", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r263", "r401" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2029", "label": "Long-Term Debt, Maturity, Year Five", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r263", "r401" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Long-Term Debt, Maturity, Year Four", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r263", "r401" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Long-Term Debt, Maturity, Year Three", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r263", "r401" ] }, "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails": { "parentTag": "us-gaap_DebtInstrumentCarryingAmount", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSLongtermDebtMaturitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Long-Term Debt, Maturity, Year Two", "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r10", "r263", "r401" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails_1": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt, net of discount, deferred financing costs and current portion", "verboseLabel": "Total long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r222" ] }, "us-gaap_LongTermDebtWeightedAverageInterestRateOverTime": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtWeightedAverageInterestRateOverTime", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average interest rate paid on term loans during period", "label": "Long-Term Debt, Weighted Average Interest Rate, over Time", "documentation": "Weighted average interest rate of long-term debt outstanding calculated over time." } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r18", "r1074", "r1075", "r1076" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r18", "r39", "r1074", "r1075", "r1076" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]", "documentation": "Information by name or description of a single external customer or a group of external customers." } } }, "auth_ref": [ "r325", "r838", "r864", "r867", "r1088", "r1168", "r1172", "r1173", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199" ] }, "bios_ManagementFeeIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "ManagementFeeIncomeMember", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Management Fee Income", "label": "Management Fee Income [Member]", "documentation": "Management Fee Income" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r206", "r207", "r368", "r369", "r370", "r371", "r462", "r507", "r582", "r635", "r675", "r677", "r685", "r718", "r719", "r780", "r781", "r782", "r783", "r791", "r804", "r805", "r827", "r835", "r848", "r856", "r857", "r858", "r859", "r865", "r1085", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r942" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r942" ] }, "bios_MergerOperatingLossCarryforwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "MergerOperatingLossCarryforwardMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Merger Operating Loss Carryforward", "label": "Merger Operating Loss Carryforward [Member]", "documentation": "Merger Operating Loss Carryforward [Member]" } } }, "auth_ref": [] }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURES" ], "lang": { "en-us": { "role": { "terseLabel": "BUSINESS ACQUISITIONS AND DIVESTITURES", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings." } } }, "auth_ref": [ "r90", "r158" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r206", "r207", "r368", "r369", "r370", "r371", "r462", "r507", "r582", "r635", "r675", "r677", "r685", "r718", "r719", "r780", "r781", "r782", "r783", "r791", "r804", "r805", "r827", "r835", "r848", "r856", "r857", "r858", "r865", "r1085", "r1160", "r1161", "r1162", "r1163", "r1164", "r1165" ] }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterestOwnershipPercentageByParent", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Company's stockholders, ownership percentage following merger", "label": "Subsidiary, Ownership Percentage, Parent", "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage." } } }, "auth_ref": [] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r962" ] }, "us-gaap_MovementInValuationAllowancesAndReservesRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MovementInValuationAllowancesAndReservesRollForward", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in Deferred Tax Asset Valuation Allowance", "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r970" ] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]", "documentation": "Single external customer or group of external customers." } } }, "auth_ref": [ "r325", "r838", "r864", "r867", "r1088", "r1168", "r1172", "r1173", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r943" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash (used in) provided by financing activities", "terseLabel": "Net cash (used in) provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r251" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r251" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r131", "r132", "r133" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "NET INCOME", "verboseLabel": "Net income", "terseLabel": "Net Income (Loss)", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r120", "r133", "r176", "r210", "r237", "r240", "r245", "r259", "r272", "r274", "r275", "r276", "r277", "r278", "r281", "r282", "r288", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r550", "r555", "r576", "r597", "r660", "r748", "r770", "r771", "r878", "r1083" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "bios_NewFirstLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "NewFirstLienTermLoanMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New First Lien Term Loan", "label": "New First Lien Term Loan [Member]", "documentation": "New First Lien Term Loan [Member]" } } }, "auth_ref": [] }, "bios_NewSeniorUnsecuredNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "NewSeniorUnsecuredNotesMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "New Senior Unsecured Notes", "label": "New Senior Unsecured Notes [Member]", "documentation": "New Senior Unsecured Notes [Member]" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r942" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r905", "r916", "r926", "r950", "r959" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r933" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r932" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r950" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r970" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r970" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total other (expense) income", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r125" ] }, "bios_NumberOfInfusionSites": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "NumberOfInfusionSites", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of infusion sites", "label": "Number Of Infusion Sites", "documentation": "Number Of Infusion Sites" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r823", "r1035" ] }, "bios_NumberOfServiceLocations": { "xbrltype": "integerItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "NumberOfServiceLocations", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of service locations", "label": "Number Of Service Locations", "documentation": "Number Of Service Locations" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenseMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense in operating expenses", "label": "Operating Expense [Member]", "documentation": "Primary financial statement caption encompassing expenses associated with normal operations." } } }, "auth_ref": [ "r17" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OPERATING COSTS AND EXPENSES:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "totalLabel": "OPERATING INCOME", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r179", "r818", "r1034", "r1036", "r1037", "r1038", "r1039" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1154" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/LEASESMaturitiesofLeaseLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r611" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "verboseLabel": "Current portion of operating lease liability", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r611" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r611" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Operating lease liabilities", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r612", "r614" ] }, "us-gaap_OperatingLeasePaymentsUse": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePaymentsUse", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for operating leases", "label": "Operating Lease, Payments, Use", "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r612", "r614" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use asset", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r610" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash operating lease costs", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r1017" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average discount rate, operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r617", "r861" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average remaining lease term, operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r616", "r861" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating loss carryforwards", "label": "Operating Loss Carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r536" ] }, "bios_OptionCareCombinedCompanyMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "OptionCareCombinedCompanyMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Option Care, Combined Company", "label": "Option Care, Combined Company [Member]", "documentation": "Option Care, Combined Company" } } }, "auth_ref": [] }, "bios_OptionExercisePriceRangeFourMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "OptionExercisePriceRangeFourMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$24.76 - $33.00", "label": "Option Exercise Price, Range Four [Member]", "documentation": "Option Exercise Price, Range Four [Member]" } } }, "auth_ref": [] }, "bios_OptionExercisePriceRangeOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "OptionExercisePriceRangeOneMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$0.00 - $8.24", "label": "Option Exercise Price, Range One [Member]", "documentation": "Option Exercise Price, Range One [Member]" } } }, "auth_ref": [] }, "bios_OptionExercisePriceRangeThreeMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "OptionExercisePriceRangeThreeMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$16.52 - $24.76", "label": "Option Exercise Price, Range Three [Member]", "documentation": "Option Exercise Price, Range Three [Member]" } } }, "auth_ref": [] }, "bios_OptionExercisePriceRangeTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "OptionExercisePriceRangeTwoMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "$8.24 - $16.52", "label": "Option Exercise Price, Range Two [Member]", "documentation": "Option Exercise Price, Range Two [Member]" } } }, "auth_ref": [] }, "bios_OptionsExercisableAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "OptionsExercisableAbstract", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Exercisable", "label": "Options Exercisable [Abstract]", "documentation": "Options Exercisable [Abstract]" } } }, "auth_ref": [] }, "bios_OptionsOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "OptionsOutstandingAbstract", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Outstanding", "label": "Options Outstanding [Abstract]", "documentation": "Options Outstanding [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r219" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized (loss) gain on cash flow hedges, net of income tax benefit (expense) of $1,284, $2,158 and $(7,259), respectively", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r234" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOMEParenthetical" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Change in unrealized (loss) gain on cash flow hedges, income tax benefit (expense)", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r235" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-tax gains (losses) on interest rate derivatives recognized", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax", "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r233", "r234", "r561", "r562", "r565" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSPretaxGainLossonDerivativeInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) location of derivative instruments", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax", "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness." } } }, "auth_ref": [ "r187", "r234", "r236" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER COMPREHENSIVE (LOSS) INCOME, NET OF TAX:", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "OTHER COMPREHENSIVE (LOSS) INCOME", "verboseLabel": "Other comprehensive income (loss)", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r5", "r11", "r164", "r238", "r241", "r278" ] }, "us-gaap_OtherCostAndExpenseOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCostAndExpenseOperating", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other segment items", "label": "Other Cost and Expense, Operating", "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation." } } }, "auth_ref": [ "r121", "r666", "r822" ] }, "us-gaap_OtherExpenseDisclosureNonoperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherExpenseDisclosureNonoperatingAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER INCOME (EXPENSE):", "label": "Other Expense, Nonoperating [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIncome", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other", "label": "Other Income", "documentation": "Amount of revenue and income classified as other." } } }, "auth_ref": [ "r665", "r750", "r792", "r793", "r794" ] }, "us-gaap_OtherIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherIntangibleAssetsMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other amortizable intangible assets", "label": "Other Intangible Assets [Member]", "documentation": "Intangible assets classified as other." } } }, "auth_ref": [ "r829", "r1060", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1069", "r1070", "r1071" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r101" ] }, "us-gaap_OtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentAssetsMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other noncurrent assets", "label": "Other Noncurrent Assets [Member]", "documentation": "Primary financial statement caption encompassing other noncurrent assets." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r127" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 19.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other adjustments", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r942" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due from joint ventures", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r226", "r735", "r823", "r1167" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r903", "r914", "r924", "r957" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r906", "r917", "r927", "r960" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r906", "r917", "r927", "r960" ] }, "srt_OwnershipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipAxis", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Axis]", "label": "Ownership [Axis]", "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "srt_OwnershipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "OwnershipDomain", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership [Domain]", "label": "Ownership [Domain]", "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment." } } }, "auth_ref": [] }, "bios_PatientCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "PatientCustomerMember", "presentation": [ "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Patients", "label": "Patient Customer [Member]", "documentation": "Patient Customer [Member]" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r931" ] }, "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromOtherInvestingActivities", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other investing activities", "label": "Payments for (Proceeds from) Other Investing Activities", "documentation": "Amount of cash (inflow) outflow from investing activities classified as other." } } }, "auth_ref": [ "r997", "r1012" ] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of company stock and related excise taxes", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r130" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Deferred financing costs", "label": "Payments of Debt Issuance Costs", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r23" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock-based compensation tax withholdings", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r249" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for business acquired", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r22", "r553" ] }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Business acquisitions, net of cash acquired", "label": "Payments to Acquire Businesses, Net of Cash Acquired", "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase." } } }, "auth_ref": [ "r22" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Acquisition of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r129" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r941" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r941" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r933" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r950" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r943" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r932" ] }, "bios_PerformanceStockUnitMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "PerformanceStockUnitMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance stock unit awards", "label": "Performance Stock Unit [Member]", "documentation": "Performance Stock Unit" } } }, "auth_ref": [] }, "bios_PerformanceStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "PerformanceStockUnitsMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Stock Units", "label": "Performance Stock Units [Member]", "documentation": "Performance Stock Units" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r1089", "r1090", "r1091", "r1092", "r1093", "r1094", "r1095", "r1096", "r1097", "r1098", "r1099", "r1100", "r1101", "r1102", "r1103", "r1104", "r1105", "r1106", "r1107", "r1108", "r1109", "r1110", "r1111", "r1112", "r1113", "r1114" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": [ "r934" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r990" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": [ "r933" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockMember", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r870", "r871", "r874", "r875", "r876", "r877", "r1200", "r1203" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r106", "r414" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r106", "r727" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, shares, outstanding (in shares)", "terseLabel": "Preferred stock outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r106", "r727", "r746", "r1203", "r1204" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock; $0.0001 par value; 12,500,000 shares authorized, no shares outstanding as of December\u00a031, 2024 and 2023, respectively.", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r106", "r649", "r862" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1006" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSBalanceSheetLocationofDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of debt", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r1015" ] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r998", "r1013" ] }, "us-gaap_ProceedsFromSaleOfProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleOfProductiveAssets", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of assets", "label": "Proceeds from Sale of Productive Assets", "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets." } } }, "auth_ref": [ "r128" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation tax withholdings", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r4", "r16" ] }, "us-gaap_ProceedsFromWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromWarrantExercises", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from warrant exercises", "label": "Proceeds from Warrant Exercises", "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants." } } }, "auth_ref": [ "r1014" ] }, "bios_ProceedsTaxWithholdingShareBasedPaymentArrangement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "ProceedsTaxWithholdingShareBasedPaymentArrangement", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation tax withholdings", "label": "Proceeds, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Proceeds, Tax Withholding, Share-Based Payment Arrangement" } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]", "documentation": "Information by product and service, or group of similar products and similar services." } } }, "auth_ref": [ "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r322", "r637", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r809", "r836", "r863", "r865", "r866", "r868", "r869", "r1004", "r1079", "r1080", "r1088", "r1168", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]", "documentation": "Product or service, or a group of similar products or similar services." } } }, "auth_ref": [ "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r322", "r637", "r668", "r669", "r670", "r671", "r672", "r673", "r674", "r809", "r836", "r863", "r865", "r866", "r868", "r869", "r1004", "r1079", "r1080", "r1088", "r1168", "r1172", "r1173", "r1174", "r1175", "r1176", "r1177", "r1178", "r1179", "r1180", "r1181", "r1182", "r1183", "r1184", "r1185", "r1186", "r1187", "r1188", "r1189", "r1190", "r1191", "r1192", "r1193", "r1194", "r1195", "r1196", "r1197", "r1198", "r1199" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r9", "r619" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENT" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r138", "r186", "r188", "r189" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r139", "r215", "r657" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r619" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0, "order": 2.0 }, "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r9", "r619", "r645", "r657", "r862" ] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r9", "r186", "r188", "r655" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment, Type [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r139", "r619" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r931" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r931" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r206", "r207", "r368", "r369", "r370", "r371", "r453", "r462", "r493", "r494", "r495", "r507", "r582", "r633", "r634", "r635", "r675", "r677", "r685", "r718", "r719", "r780", "r781", "r782", "r783", "r791", "r804", "r805", "r827", "r835", "r848", "r856", "r857", "r858", "r859", "r865", "r872", "r1077", "r1085", "r1139", "r1161", "r1162", "r1163", "r1164", "r1165" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r194", "r195", "r196", "r197", "r198", "r206", "r207", "r368", "r369", "r370", "r371", "r453", "r462", "r493", "r494", "r495", "r507", "r582", "r633", "r634", "r635", "r675", "r677", "r685", "r718", "r719", "r780", "r781", "r782", "r783", "r791", "r804", "r805", "r827", "r835", "r848", "r856", "r857", "r858", "r859", "r865", "r872", "r1077", "r1085", "r1139", "r1161", "r1162", "r1163", "r1164", "r1165" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r898", "r909", "r919", "r952" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyDomain", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Domain]", "label": "Related and Nonrelated Parties [Domain]", "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r326", "r460", "r624", "r625", "r648", "r654", "r721", "r722", "r723", "r724", "r725", "r745", "r747", "r779" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r624", "r625", "r1157" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r326", "r753", "r754", "r757" ] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party [Axis]", "label": "Related and Nonrelated Parties [Axis]", "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest." } } }, "auth_ref": [ "r326", "r460", "r624", "r625", "r648", "r654", "r721", "r722", "r723", "r724", "r725", "r745", "r747", "r779", "r1157" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONS" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED-PARTY TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r621", "r622", "r623", "r625", "r626", "r695", "r696", "r697", "r755", "r756", "r757", "r776", "r778" ] }, "us-gaap_RepaymentsOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfDebt", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayments of debt principal", "terseLabel": "Payments to extinguish debt", "label": "Repayments of Debt", "documentation": "Amount of cash outflow for short-term and long-term debt. Excludes payment of lease obligation." } } }, "auth_ref": [ "r1016" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r899", "r910", "r920", "r953" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r900", "r911", "r921", "r954" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r907", "r918", "r928", "r961" ] }, "bios_RestrictedStockAwardMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "RestrictedStockAwardMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock awards", "label": "Restricted Stock Award [Member]", "documentation": "Restricted Stock Award [Member]" } } }, "auth_ref": [] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockMember", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r28" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r109", "r147", "r652", "r682", "r684", "r693", "r728", "r862" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r208", "r269", "r270", "r271", "r273", "r278", "r280", "r282", "r332", "r333", "r356", "r538", "r539", "r547", "r548", "r549", "r551", "r554", "r555", "r566", "r568", "r569", "r571", "r574", "r607", "r609", "r679", "r681", "r698", "r1203" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_Revenues", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NET REVENUE", "netLabel": "Infusion services net revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r177", "r178", "r296", "r305", "r306", "r315", "r319", "r322", "r324", "r325", "r449", "r450", "r637" ] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer Benchmark", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r325", "r999" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r192", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r807" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.bioscrip.com/role/REVENUE" ], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r192", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r452" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 }, "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/REVENUENetRevenueEarnedbyCategoryofPayerDetails", "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NET REVENUE", "verboseLabel": "Net revenue", "totalLabel": "Total Option Care Health revenue", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r177", "r178", "r246", "r259", "r296", "r305", "r306", "r315", "r319", "r322", "r324", "r325", "r331", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r597", "r644", "r822", "r1083" ] }, "bios_RevitalizedLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "RevitalizedLLCMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revitalized, LLC", "label": "Revitalized, LLC [Member]", "documentation": "Revitalized, LLC" } } }, "auth_ref": [] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolver Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/LEASESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Right of use asset obtained in exchange for operating lease liabilities", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r615", "r861" ] }, "bios_RochesterHomeInfusionIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "RochesterHomeInfusionIncMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Rochester Home Infusion, Inc", "label": "Rochester Home Infusion, Inc [Member]", "documentation": "Rochester Home Infusion, Inc" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r970" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r970" ] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares issued in transaction (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Carrying Amount and Accumulated Amortization of Intangible Assets", "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]", "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company." } } }, "auth_ref": [ "r1061", "r1066" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Security, Excluded EPS Calculation [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r28" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails", "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability." } } }, "auth_ref": [ "r58", "r61", "r552" ] }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Estimated Fair Values of Debt Obligations", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Shares of Common Stock", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income Tax Expense (Benefit)", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r1126" ] }, "us-gaap_ScheduleOfDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDebtTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Debt", "label": "Schedule of Debt [Table Text Block]", "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets and Liabilities", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r1122" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Pre-tax Income (Loss) Recognized in the Statements of Comprehensive Income (Loss)", "label": "Derivative Instruments, Gain (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r73", "r76", "r563" ] }, "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Amount and Location of Derivatives in the Balance Sheet", "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]", "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position." } } }, "auth_ref": [ "r74" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHARETables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Basic and Diluted Earnings Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTable", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]", "label": "Earnings Per Share, Diluted, by Common Class, Including Two-Class Method [Table]", "documentation": "Disclosure of information about diluted earnings per share by class of stock. Includes, but is not limited to, two-class method." } } }, "auth_ref": [ "r27", "r29", "r286", "r287", "r289" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation", "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r518", "r852", "r1118" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r328", "r329", "r330", "r546", "r994", "r995", "r996", "r1129", "r1130", "r1131", "r1132" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Asset, Finite-Lived [Table]", "label": "Intangible Asset, Finite-Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": [ "r343", "r350", "r353", "r354", "r355", "r638", "r806", "r829" ] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of the Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": [ "r828", "r1048", "r1049", "r1050", "r1051", "r1052", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058" ] }, "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Maturities", "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt." } } }, "auth_ref": [ "r10" ] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r9", "r619" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Table]", "label": "Related Party Transaction [Table]", "documentation": "Disclosure of information about related party transaction." } } }, "auth_ref": [ "r86", "r87", "r753", "r754", "r757" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Results of Operations for Reportable Segment", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r34", "r35", "r36" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r464", "r466", "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r493", "r494", "r495", "r496" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Option, Exercise Price Range [Table]", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]", "documentation": "Disclosure of information about share-based payment arrangement by range of exercise prices." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Outstanding Options by Exercise Price Range", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]", "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r14", "r15", "r152" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Awards", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r157" ] }, "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Restricted Stock Award Activity", "label": "Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock, Class of Stock [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r42", "r43", "r44", "r45", "r46", "r47", "r143", "r145", "r146", "r147", "r223", "r224", "r225", "r298", "r414", "r415", "r416", "r418", "r421", "r426", "r428", "r689", "r690", "r691", "r692", "r835", "r993", "r1018" ] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Future Amortization Expense for Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r829", "r1068" ] }, "bios_SecondLienCreditAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "SecondLienCreditAgreementMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Second Lien Credit Agreement", "label": "Second Lien Credit Agreement [Member]", "documentation": "Second Lien Credit Agreement" } } }, "auth_ref": [] }, "bios_SecondLienTermLoanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "SecondLienTermLoanMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Second Lien Term Loan [Member]", "documentation": "Second Lien Term Loan [Member]" } } }, "auth_ref": [] }, "bios_SecondaryOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "SecondaryOfferingMember", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Secondary Offering", "label": "Secondary Offering [Member]", "documentation": "Secondary Offering" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": [ "r1135" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r880" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r883" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTING" ], "lang": { "en-us": { "role": { "terseLabel": "SEGMENT REPORTING", "label": "Segment Reporting Disclosure [Text Block]", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r180", "r296", "r300", "r301", "r302", "r303", "r304", "r312", "r313", "r314", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r325", "r819", "r820", "r821", "r822", "r824", "r825", "r826" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://www.bioscrip.com/role/SEGMENTREPORTINGDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Segment Reporting Information [Line Items]", "label": "Segment Reporting Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r122" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, General and Administrative Expenses", "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption." } } }, "auth_ref": [ "r1116" ] }, "us-gaap_SeniorLienMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorLienMember", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Lien Term Loan", "label": "Senior Lien [Member]", "documentation": "Legal right, before the claims of other creditors, of a creditor to possess property or other collateral in satisfaction of an outstanding debt in the event of borrower default or bankruptcy. Excludes first mortgage loans." } } }, "auth_ref": [] }, "us-gaap_SeniorNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SeniorNotesMember", "presentation": [ "http://www.bioscrip.com/role/DERIVATIVEINSTRUMENTSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails", "http://www.bioscrip.com/role/INDEBTEDNESSEstimatedFairValuesofDebtObligationsDetails", "http://www.bioscrip.com/role/INDEBTEDNESSSummaryofDebtDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Senior Notes", "label": "Senior Notes [Member]", "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based incentive compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Average performance period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r849" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r849" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited and expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r485" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited and expired (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r485" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r483" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r480", "r481" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r480", "r481" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Vested and issued (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of shares vested in period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value", "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash." } } }, "auth_ref": [ "r487" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vested and issued (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r484" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r494" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r493" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r495" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]", "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r464", "r466", "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r493", "r494", "r495", "r496" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r850" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r474" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r487" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited and expired (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired." } } }, "auth_ref": [ "r1095" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited and expired (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price of options that were either forfeited or expired." } } }, "auth_ref": [ "r1095" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average grant-date fair value per share (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r486" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance at December 31, 2023", "periodEndLabel": "Balance at December 31, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r472", "r473" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r472", "r473" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofRestrictedStockAwardActivityDetails", "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r468", "r469", "r470", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r492", "r493", "r494", "r495", "r496" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r477" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Based Incentive Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r463", "r471", "r490", "r491", "r492", "r493", "r496", "r502", "r503", "r504", "r505" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range [Axis]", "label": "Exercise Price Range [Axis]", "documentation": "Information by range of option prices pertaining to options granted." } } }, "auth_ref": [ "r54" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price Range [Domain]", "label": "Exercise Price Range [Domain]", "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lower range limit (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit", "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Exercisable (in shares)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r53" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options Outstanding (in shares)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding", "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices." } } }, "auth_ref": [ "r153", "r154" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upper range limit (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit", "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range." } } }, "auth_ref": [ "r55" ] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Axis]", "label": "Supplier [Axis]", "documentation": "Information by supplier." } } }, "auth_ref": [] }, "us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Supplier [Domain]", "label": "Supplier [Domain]", "documentation": "Specific identification or general nature of (for example, a construction contractor, a consulting firm) the party from whom the goods or services were or are to be received." } } }, "auth_ref": [] }, "bios_ShareBasedPaymentArrangementInitialPercentageOfTargetSharesGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "ShareBasedPaymentArrangementInitialPercentageOfTargetSharesGranted", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial percentage of target shares granted", "label": "Share-Based Payment Arrangement, Initial Percentage Of Target Shares Granted", "documentation": "Share-Based Payment Arrangement, Initial Percentage Of Target Shares Granted" } } }, "auth_ref": [] }, "bios_ShareBasedPaymentArrangementPercentageOfTargetSharesGranted": { "xbrltype": "percentItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "ShareBasedPaymentArrangementPercentageOfTargetSharesGranted", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of target shares granted", "label": "Share-Based Payment Arrangement, Percentage Of Target Shares Granted", "documentation": "Share-Based Payment Arrangement, Percentage Of Target Shares Granted" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONAssumptionsUsedtoComputeFairValueofStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Expected life of options", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r492" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable at December 31, 2024", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r51" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r51" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r155" ] }, "bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsForfeitedAndExpirationsIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited and expired", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeited And Expirations, Intrinsic Value" } } }, "auth_ref": [] }, "bios_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsGrantsinPeriodIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value", "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Intrinsic Value" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding." } } }, "auth_ref": [ "r52" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable range of years", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r156" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price (in dollars per share)", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price", "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices." } } }, "auth_ref": [ "r153", "r154" ] }, "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofOutstandingandExercisableStockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Contractual Life", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r155" ] }, "bios_SharesIssuedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "SharesIssuedDuringPeriodShares", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity award issuances", "label": "Shares Issued During Period, Shares", "documentation": "Shares Issued During Period, Shares" } } }, "auth_ref": [] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r134", "r256" ] }, "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SoftwareAndSoftwareDevelopmentCostsMember", "presentation": [ "http://www.bioscrip.com/role/PROPERTYANDEQUIPMENTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Computer software, purchased and internally developed", "label": "Software and Software Development Costs [Member]", "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use." } } }, "auth_ref": [] }, "bios_SpecialtyPharmacyNursingNetworkIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "SpecialtyPharmacyNursingNetworkIncMember", "presentation": [ "http://www.bioscrip.com/role/BUSINESSACQUISITIONSANDDIVESTITURESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Specialty Pharmacy Nursing Network, Inc.", "label": "Specialty Pharmacy Nursing Network, Inc. [Member]", "documentation": "Specialty Pharmacy Nursing Network, Inc." } } }, "auth_ref": [] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "totalLabel": "State income tax expense", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r515", "r1021", "r1117", "r1128" ] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperationsAbstract", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxBenefitDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State income tax expense (benefit):", "label": "State and Local Income Tax Expense (Benefit), Continuing Operations [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "State and Local Jurisdiction [Member]", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r516" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock [Axis]", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r193", "r223", "r224", "r225", "r259", "r286", "r287", "r289", "r291", "r298", "r299", "r331", "r374", "r376", "r377", "r378", "r381", "r382", "r414", "r415", "r418", "r421", "r428", "r597", "r689", "r690", "r691", "r692", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r727", "r749", "r772", "r795", "r796", "r797", "r798", "r799", "r993", "r1018", "r1032" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r12", "r107", "r110", "r111", "r208", "r243", "r244", "r245", "r269", "r270", "r271", "r273", "r278", "r280", "r282", "r297", "r332", "r333", "r356", "r430", "r538", "r539", "r547", "r548", "r549", "r551", "r554", "r555", "r566", "r567", "r568", "r569", "r570", "r571", "r574", "r598", "r599", "r600", "r601", "r602", "r603", "r607", "r609", "r620", "r661", "r679", "r680", "r681", "r698", "r772" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r269", "r270", "r271", "r297", "r609", "r637", "r687", "r709", "r720", "r721", "r722", "r723", "r724", "r725", "r727", "r730", "r731", "r732", "r733", "r734", "r736", "r737", "r738", "r739", "r741", "r742", "r743", "r744", "r745", "r747", "r751", "r752", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r772", "r873" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Consolidated balance sheet data:", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r269", "r270", "r271", "r297", "r326", "r609", "r637", "r687", "r709", "r720", "r721", "r722", "r723", "r724", "r725", "r727", "r730", "r731", "r732", "r733", "r734", "r736", "r737", "r738", "r739", "r741", "r742", "r743", "r744", "r745", "r747", "r751", "r752", "r758", "r759", "r760", "r761", "r762", "r763", "r764", "r765", "r766", "r767", "r768", "r769", "r772", "r873" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r902", "r913", "r923", "r956" ] }, "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of warrants", "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants", "documentation": "Value of preferred stock and warrants for common stock issued." } } }, "auth_ref": [] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional shares issued (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r12", "r106", "r107", "r147", "r689", "r772", "r796" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONSummaryofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Exercised (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r12", "r106", "r107", "r147", "r477" ] }, "bios_StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "StockIssuedValueRestrictedStockStockOptionsExercisedAndTaxWithholdings", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Exercise of stock options, vesting of restricted stock, and related tax withholdings", "label": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings", "documentation": "Stock Issued, Value, Restricted Stock, Stock Options Exercised and Tax Withholdings" } } }, "auth_ref": [] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockOptionMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock option awards", "label": "Equity Option [Member]", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r872" ] }, "srt_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share repurchase program, authorized amount", "label": "Share Repurchase Program, Authorized, Amount", "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership." } } }, "auth_ref": [ "r1087" ] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYScheduleofChangesinSharesofCommonStockDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Share repurchases", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r12", "r106", "r107", "r147", "r692", "r772", "r798" ] }, "bios_StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "StockRepurchasedDuringPeriodValueIncludingRelatedTaxEffects", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchase of company stock, and related tax effects", "label": "Stock Repurchased During Period, Value, Including Related Tax Effects", "documentation": "Stock Repurchased During Period, Value, Including Related Tax Effects" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS", "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 equity", "periodStartLabel": "Equity, beginning balance", "periodEndLabel": "Equity, ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r107", "r110", "r111", "r137", "r729", "r746", "r773", "r774", "r862", "r879", "r1020", "r1046", "r1149", "r1203" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS\u2019 EQUITY:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "STOCKHOLDERS' EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r144", "r258", "r413", "r415", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r430", "r573", "r775", "r777", "r800" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r604", "r628" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r628" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r604", "r628" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r628" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails", "http://www.bioscrip.com/role/SUBSEQUENTEVENTSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r604", "r628" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.bioscrip.com/role/SUBSEQUENTEVENTS" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r627", "r629" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SummaryOfValuationAllowanceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SummaryOfValuationAllowanceTextBlock", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESIncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Valuation Allowance", "label": "Summary of Valuation Allowance [Table Text Block]", "documentation": "Tabular disclosure of valuation allowances to reduce deferred tax assets to net realizable value, including identification of the deferred tax asset more likely than not will not be fully realized and the corresponding amount of the valuation allowance." } } }, "auth_ref": [ "r1123" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flows information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SupplierConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplierConcentrationRiskMember", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medical Supply Vendors", "label": "Supplier Concentration Risk [Member]", "documentation": "Reflects the percentage that purchases in the period from one or more significant suppliers is to cost of goods or services, as defined by the entity, such as total cost of sales or services, product line cost of sales or services, segment cost of sales or services. Risk is the materially adverse effects of loss of a material supplier or a supplier of critically needed goods or services." } } }, "auth_ref": [ "r136" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r949" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward [Axis]", "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r536" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax Credit Carryforward, Name [Domain]", "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r536" ] }, "bios_TerminationFeeIncomeTaxEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://www.bioscrip.com/20241231", "localname": "TerminationFeeIncomeTaxEffect", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Termination fee income", "label": "Termination Fee Income, Tax Effect", "documentation": "Termination Fee Income, Tax Effect" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Axis]", "label": "Title and Position [Axis]", "documentation": "Information by title and position of individual or group within organization." } } }, "auth_ref": [ "r1040", "r1156" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.bioscrip.com/role/STOCKBASEDINCENTIVECOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title and Position [Domain]", "label": "Title and Position [Domain]", "documentation": "Title and position of individual or group within organization." } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r941" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r948" ] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts Receivable", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r181", "r182", "r183", "r1042", "r1043", "r1044" ] }, "us-gaap_TrademarksAndTradeNamesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksAndTradeNamesMember", "presentation": [ "http://www.bioscrip.com/role/GOODWILLANDOTHERINTANGIBLEASSETSCarryingAmountandAccumulatedAmortizationofIntangibleAssetsDetails", "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Trademarks and Trade Names", "terseLabel": "Trademarks/names", "label": "Trademarks and Trade Names [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof." } } }, "auth_ref": [ "r63", "r1060", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1069", "r1070", "r1071" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r969" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r971" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.bioscrip.com/role/COVERPAGE" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r972" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r973" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement Expiration Date" } } }, "auth_ref": [ "r973" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r971" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r971" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r974" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r972" ] }, "us-gaap_TreasuryStockAcquiredAverageCostPerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockAcquiredAverageCostPerShare", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock acquired, average cost per share (in dollars per share)", "label": "Shares Acquired, Average Cost Per Share", "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased." } } }, "auth_ref": [ "r48" ] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r48" ] }, "us-gaap_TreasuryStockCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonShares", "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETSParenthetical", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares (in shares)", "label": "Treasury Stock, Common, Shares", "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r48" ] }, "us-gaap_TreasuryStockCommonValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockCommonValue", "crdr": "debit", "calculation": { "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDBALANCESHEETS" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Treasury stock; 17,585,613 and 8,330,022 shares outstanding, at cost, as of December\u00a031, 2024 and 2023, respectively.", "label": "Treasury Stock, Common, Value", "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r48", "r49", "r110" ] }, "us-gaap_TreasuryStockSharesAcquired": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockSharesAcquired", "presentation": [ "http://www.bioscrip.com/role/NATUREOFOPERATIONSANDPRESENTATIONOFFINANCIALSTATEMENTSDetails", "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury stock, shares, acquired (in shares)", "label": "Treasury Stock, Shares, Acquired", "documentation": "Number of shares that have been repurchased during the period and are being held in treasury." } } }, "auth_ref": [ "r12", "r107", "r147" ] }, "us-gaap_TreasuryStockValueAcquiredCostMethod": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TreasuryStockValueAcquiredCostMethod", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares repurchased", "label": "Treasury Stock, Value, Acquired, Cost Method", "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method." } } }, "auth_ref": [ "r12", "r48", "r147" ] }, "us-gaap_UnbilledReceivablesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnbilledReceivablesCurrent", "crdr": "debit", "presentation": [ "http://www.bioscrip.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unbilled receivables", "label": "Unbilled Receivables, Current", "documentation": "Amount received for services rendered and products shipped, but not yet billed, for non-contractual agreements due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r968" ] }, "us-gaap_UnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UnrecognizedTaxBenefits", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Unrecognized Tax Benefits", "documentation": "Amount of unrecognized tax benefits." } } }, "auth_ref": [ "r509", "r525", "r851" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESNarrativeDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Valuation allowance released", "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r528" ] }, "us-gaap_ValuationAllowanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceLineItems", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance [Line Items]", "label": "Valuation Allowance [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceOfDeferredTaxAssetsMember", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation Allowance, Deferred Tax Assets", "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]", "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward." } } }, "auth_ref": [ "r1023", "r1024", "r1025", "r1026", "r1027" ] }, "us-gaap_ValuationAllowanceTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceTable", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred Tax Asset, Valuation Allowance [Table]", "label": "Deferred Tax Asset, Valuation Allowance [Table]", "documentation": "Disclosure of information about valuation allowance representing portion of deferred tax asset for which it is more likely than not that tax benefit will not be realized." } } }, "auth_ref": [ "r1123" ] }, "us-gaap_ValuationAllowancesAndReservesBalance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesBalance", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount", "documentation": "Amount of valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r264", "r268" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Charged (Benefit) to Costs and Expenses", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense." } } }, "auth_ref": [ "r265" ] }, "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Charged (Benefit) to Other Accounts", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account", "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense." } } }, "auth_ref": [ "r266" ] }, "us-gaap_ValuationAllowancesAndReservesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesDomain", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]", "documentation": "Valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r268" ] }, "us-gaap_ValuationAllowancesAndReservesTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowancesAndReservesTypeAxis", "presentation": [ "http://www.bioscrip.com/role/INCOMETAXESValuationAllowanceforDeferredTaxAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]", "documentation": "Information by valuation and qualifying accounts and reserves." } } }, "auth_ref": [ "r264", "r265", "r266", "r267", "r268" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [ "http://www.bioscrip.com/role/INDEBTEDNESSAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } } }, "auth_ref": [ "r937" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r870", "r871", "r874", "r875", "r876", "r877" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [ "r1138", "r1139", "r1140" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://www.bioscrip.com/role/STOCKHOLDERSEQUITYDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Term of warrants", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1138", "r1139", "r1140" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, diluted (in shares)", "totalLabel": "Weighted average number of common shares outstanding, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r285", "r291" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.bioscrip.com/role/CONSOLIDATEDSTATEMENTSOFCOMPREHENSIVEINCOME", "http://www.bioscrip.com/role/EARNINGSPERSHAREScheduleofBasicandDilutedEarningsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average common shares outstanding, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r284", "r291" ] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r935" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "16", "SubTopic": "10", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "470", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479172/805-740-25-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "740", "Section": "25", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479172/805-740-25-9" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480238/815-25-50-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/275/tableOfContent" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "710", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/710/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/712/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "715", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/715/tableOfContent" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/805/tableOfContent" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479515/805-10-05-4" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/815/tableOfContent" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r179": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r180": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r181": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-11B" }, "r182": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-15" }, "r183": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-6" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12A", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(a)", "Footnote": "4", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "12B", "Paragraph": "Column A", "Subparagraph": "(b)", "Footnote": "4", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "14", "Paragraph": "Column A", "Footnote": "2", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column A", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column B", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column C", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column D", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column E", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "17", "Paragraph": "Column F", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 11", "Section": "L", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 4", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/330/tableOfContent" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-4" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "70", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480627/815-20-45-3" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/850/tableOfContent" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-12" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r806": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "217", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r857": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r858": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r859": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r860": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r861": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53" }, "r862": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r863": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2" }, "r864": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r865": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r866": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r867": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r868": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r869": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r870": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r871": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r872": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r873": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r874": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r875": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r876": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r877": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r878": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r879": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r933": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r934": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r935": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r936": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r937": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r938": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r939": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r940": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r941": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r942": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r943": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r944": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r945": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r946": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r947": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r948": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r949": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r950": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r951": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r952": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r953": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r954": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r955": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r956": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r957": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r958": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r959": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r960": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r961": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r962": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r963": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r964": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r965": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r966": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r967": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r968": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r969": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r970": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r971": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r972": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r973": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r974": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r975": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r976": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r977": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r978": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r979": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r980": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r981": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r982": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r983": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r984": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r985": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r986": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r987": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r988": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r989": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r990": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r991": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r992": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r993": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r994": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r995": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r996": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "705", "Publisher": "FASB", "URI": "https://asc.fasb.org/705/tableOfContent" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "6", "Subsection": "04", "Paragraph": "12", "Subparagraph": "(b)(1)", "Publisher": "SEC" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Staff Accounting Bulletin (SAB)", "Number": "Topic 5", "Section": "Y", "Paragraph": "Question 2", "Publisher": "SEC" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column C)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SX 210.12-09(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1069": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1070": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1071": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r1072": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5" }, "r1073": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r1074": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1075": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1076": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r1077": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r1078": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r1079": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r1080": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r1081": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1082": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r1083": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1084": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r1085": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r1086": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r1087": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "505", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4" }, "r1088": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r1089": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1090": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1091": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1092": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1093": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1094": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1095": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1096": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1097": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1098": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1099": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1100": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1101": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1102": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1103": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1104": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1105": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1106": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1107": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1108": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1109": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1110": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1111": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1112": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1113": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1114": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1115": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1116": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "35", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1" }, "r1117": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r1118": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1119": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r1120": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r1121": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r1122": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1123": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r1124": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r1125": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r1126": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1127": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r1128": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r1129": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1130": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1131": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1132": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A" }, "r1133": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r1134": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B" }, "r1135": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1136": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r1137": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1138": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1139": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1140": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1141": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1142": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1143": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1144": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1145": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1146": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1147": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1148": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1149": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r1150": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1151": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1152": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3" }, "r1153": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1" }, "r1154": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r1155": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r1156": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1157": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3" }, "r1158": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1159": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1160": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1161": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1162": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1163": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1164": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1165": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1166": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1167": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1168": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1169": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1170": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1171": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1172": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1173": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1174": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1175": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1176": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1177": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1178": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1179": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1180": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1181": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1182": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1183": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1184": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1185": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1186": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1187": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1188": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1189": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1190": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1191": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1192": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1193": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1194": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1195": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1196": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1197": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1198": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1199": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1200": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1201": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r1202": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r1203": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1204": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1205": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" } } } ZIP 104 0001014739-25-000012-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001014739-25-000012-xbrl.zip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�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end XML 105 bios-20241231_htm.xml IDEA: XBRL DOCUMENT 0001014739 2024-01-01 2024-12-31 0001014739 2024-06-28 0001014739 2025-02-21 0001014739 2024-12-31 0001014739 2023-12-31 0001014739 2023-01-01 2023-12-31 0001014739 2022-01-01 2022-12-31 0001014739 2022-12-31 0001014739 2021-12-31 0001014739 us-gaap:PreferredStockMember 2021-12-31 0001014739 us-gaap:CommonStockMember 2021-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2021-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001014739 us-gaap:RetainedEarningsMember 2021-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001014739 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0001014739 us-gaap:PreferredStockMember 2022-12-31 0001014739 us-gaap:CommonStockMember 2022-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2022-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001014739 us-gaap:RetainedEarningsMember 2022-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-12-31 0001014739 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0001014739 us-gaap:PreferredStockMember 2023-12-31 0001014739 us-gaap:CommonStockMember 2023-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2023-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001014739 us-gaap:RetainedEarningsMember 2023-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-12-31 0001014739 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-12-31 0001014739 us-gaap:PreferredStockMember 2024-12-31 0001014739 us-gaap:CommonStockMember 2024-12-31 0001014739 us-gaap:TreasuryStockCommonMember 2024-12-31 0001014739 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001014739 us-gaap:RetainedEarningsMember 2024-12-31 0001014739 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001014739 us-gaap:CommonStockMember bios:SecondaryOfferingMember 2023-01-01 2023-12-31 0001014739 2023-03-03 2023-03-03 0001014739 bios:LegacyHealthSystemsMember 2024-12-31 0001014739 srt:MinimumMember us-gaap:CustomerListsMember 2024-12-31 0001014739 srt:MaximumMember us-gaap:CustomerListsMember 2024-12-31 0001014739 srt:MinimumMember us-gaap:TrademarksAndTradeNamesMember 2024-12-31 0001014739 srt:MaximumMember us-gaap:TrademarksAndTradeNamesMember 2024-12-31 0001014739 srt:MinimumMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0001014739 srt:MaximumMember us-gaap:OtherIntangibleAssetsMember 2024-12-31 0001014739 bios:InfusionPumpsMember 2024-12-31 0001014739 srt:MinimumMember us-gaap:EquipmentMember 2024-12-31 0001014739 srt:MaximumMember us-gaap:EquipmentMember 2024-12-31 0001014739 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-12-31 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2024-01-01 2024-12-31 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-12-31 0001014739 bios:LargestPayerMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-12-31 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2024-01-01 2024-12-31 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2023-01-01 2023-12-31 0001014739 bios:GovernmentHealthcareProgramsMember us-gaap:RevenueFromContractWithCustomerMember us-gaap:GovernmentContractsConcentrationRiskMember 2022-01-01 2022-12-31 0001014739 bios:GovernmentHealthcareProgramsMember bios:AccountsReceivableBenchmarkMember us-gaap:GovernmentContractsConcentrationRiskMember 2024-01-01 2024-12-31 0001014739 bios:GovernmentHealthcareProgramsMember bios:AccountsReceivableBenchmarkMember us-gaap:GovernmentContractsConcentrationRiskMember 2023-01-01 2023-12-31 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2024-01-01 2024-12-31 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2023-01-01 2023-12-31 0001014739 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember bios:FourVendorsMember 2022-01-01 2022-12-31 0001014739 bios:OptionCareCombinedCompanyMember bios:AmedisysIncMember 2023-05-03 0001014739 bios:AmedisysIncMember 2023-06-26 0001014739 bios:RevitalizedLLCMember 2023-05-31 0001014739 bios:RevitalizedLLCMember 2023-05-01 2023-05-31 0001014739 2022-12-01 2022-12-31 0001014739 bios:RochesterHomeInfusionIncMember 2022-08-31 0001014739 bios:RochesterHomeInfusionIncMember 2022-08-01 2022-08-31 0001014739 bios:SpecialtyPharmacyNursingNetworkIncMember 2022-04-30 0001014739 bios:SpecialtyPharmacyNursingNetworkIncMember 2022-04-01 2022-04-30 0001014739 bios:CommercialCustomerMember 2024-01-01 2024-12-31 0001014739 bios:CommercialCustomerMember 2023-01-01 2023-12-31 0001014739 bios:CommercialCustomerMember 2022-01-01 2022-12-31 0001014739 bios:GovernmentCustomerMember 2024-01-01 2024-12-31 0001014739 bios:GovernmentCustomerMember 2023-01-01 2023-12-31 0001014739 bios:GovernmentCustomerMember 2022-01-01 2022-12-31 0001014739 bios:PatientCustomerMember 2024-01-01 2024-12-31 0001014739 bios:PatientCustomerMember 2023-01-01 2023-12-31 0001014739 bios:PatientCustomerMember 2022-01-01 2022-12-31 0001014739 us-gaap:StateAndLocalJurisdictionMember 2024-03-01 2024-03-31 0001014739 us-gaap:StateAndLocalJurisdictionMember 2023-09-01 2023-09-30 0001014739 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0001014739 us-gaap:DomesticCountryMember bios:MergerOperatingLossCarryforwardMember 2024-12-31 0001014739 us-gaap:DomesticCountryMember 2024-12-31 0001014739 us-gaap:DomesticCountryMember bios:IndefiniteCarryforwardPeriodMember 2024-12-31 0001014739 bios:InterestLimitationCarryforwardsMember 2024-12-31 0001014739 us-gaap:StateAndLocalJurisdictionMember bios:FederalNetOperatingLossCarryfowardsAvailableToOffsetFutureTaxableIncomeMember 2024-12-31 0001014739 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2021-12-31 0001014739 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-01-01 2022-12-31 0001014739 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2022-12-31 0001014739 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-01-01 2023-12-31 0001014739 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2023-12-31 0001014739 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2024-01-01 2024-12-31 0001014739 us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember 2024-12-31 0001014739 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001014739 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001014739 us-gaap:WarrantMember 2022-01-01 2022-12-31 0001014739 us-gaap:StockOptionMember 2024-01-01 2024-12-31 0001014739 us-gaap:StockOptionMember 2023-01-01 2023-12-31 0001014739 us-gaap:StockOptionMember 2022-01-01 2022-12-31 0001014739 bios:RestrictedStockAwardMember 2024-01-01 2024-12-31 0001014739 bios:RestrictedStockAwardMember 2023-01-01 2023-12-31 0001014739 bios:RestrictedStockAwardMember 2022-01-01 2022-12-31 0001014739 bios:PerformanceStockUnitMember 2024-01-01 2024-12-31 0001014739 bios:PerformanceStockUnitMember 2023-01-01 2023-12-31 0001014739 bios:PerformanceStockUnitMember 2022-01-01 2022-12-31 0001014739 bios:AmedisysIncMember 2023-12-31 0001014739 bios:InfusionPumpsMember 2024-12-31 0001014739 bios:InfusionPumpsMember 2023-12-31 0001014739 bios:EquipmentFurnitureAndOtherMember 2024-12-31 0001014739 bios:EquipmentFurnitureAndOtherMember 2023-12-31 0001014739 us-gaap:LeaseholdImprovementsMember 2024-12-31 0001014739 us-gaap:LeaseholdImprovementsMember 2023-12-31 0001014739 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2024-12-31 0001014739 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2023-12-31 0001014739 us-gaap:AssetUnderConstructionMember 2024-12-31 0001014739 us-gaap:AssetUnderConstructionMember 2023-12-31 0001014739 us-gaap:CostOfSalesMember 2024-01-01 2024-12-31 0001014739 us-gaap:CostOfSalesMember 2023-01-01 2023-12-31 0001014739 us-gaap:CostOfSalesMember 2022-01-01 2022-12-31 0001014739 us-gaap:OperatingExpenseMember 2024-01-01 2024-12-31 0001014739 us-gaap:OperatingExpenseMember 2023-01-01 2023-12-31 0001014739 us-gaap:OperatingExpenseMember 2022-01-01 2022-12-31 0001014739 us-gaap:CustomerListsMember 2024-12-31 0001014739 us-gaap:CustomerListsMember 2023-12-31 0001014739 us-gaap:TrademarksAndTradeNamesMember 2024-12-31 0001014739 us-gaap:TrademarksAndTradeNamesMember 2023-12-31 0001014739 us-gaap:OtherIntangibleAssetsMember 2024-12-31 0001014739 us-gaap:OtherIntangibleAssetsMember 2023-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:SecondLienTermLoanMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:SecondLienTermLoanMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-05-08 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-05-07 2024-05-07 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-05-08 2024-05-08 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-01-01 2024-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember us-gaap:InterestRateFloorMember 2024-01-01 2024-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember us-gaap:BaseRateMember 2024-01-01 2024-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:FirstLienCreditAgreementThirdAmendmentMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0001014739 bios:NewFirstLienTermLoanMember us-gaap:SeniorLienMember us-gaap:SeniorNotesMember 2021-10-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:SecondLienCreditAgreementMember us-gaap:SeniorNotesMember 2023-12-07 0001014739 us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:SecondLienCreditAgreementMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2023-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:SecondLienCreditAgreementMember us-gaap:SeniorNotesMember us-gaap:SecuredOvernightFinancingRateSofrMember 2024-01-01 2024-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:SecondLienCreditAgreementMember us-gaap:SeniorNotesMember us-gaap:BaseRateMember 2024-01-01 2024-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2023-01-12 0001014739 us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2023-01-13 0001014739 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember us-gaap:BaseRateMember 2023-01-01 2023-12-31 0001014739 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember us-gaap:BaseRateMember 2023-01-01 2023-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember us-gaap:InterestRateFloorMember 2023-01-01 2023-12-31 0001014739 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-01-01 2023-12-31 0001014739 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember us-gaap:SecuredOvernightFinancingRateSofrMember 2023-01-01 2023-12-31 0001014739 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0001014739 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0001014739 us-gaap:RevolvingCreditFacilityMember bios:CreditAgreementsEnteredInto2019Member us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0001014739 bios:NewSeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2021-10-31 0001014739 bios:NewSeniorUnsecuredNotesMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2023-12-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2023-01-01 2023-12-31 0001014739 bios:CreditAgreementsEnteredInto2019Member us-gaap:JuniorLienMember us-gaap:SeniorNotesMember 2024-01-01 2024-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel1Member us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2024-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:FairValueInputsLevel1Member us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:FairValueInputsLevel2Member us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:FairValueInputsLevel3Member us-gaap:SeniorNotesMember 2024-12-31 0001014739 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001014739 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001014739 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001014739 bios:FirstLienTermLoanMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2021-10-31 0001014739 bios:FirstLienTermLoanMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:SeniorNotesMember 2021-10-01 2021-10-31 0001014739 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0001014739 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001014739 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-12-31 0001014739 us-gaap:OtherNoncurrentAssetsMember us-gaap:InterestRateCapMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0001014739 us-gaap:InterestRateCapMember 2024-01-01 2024-12-31 0001014739 us-gaap:InterestRateCapMember 2023-01-01 2023-12-31 0001014739 us-gaap:InterestRateCapMember 2022-01-01 2022-12-31 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2024-01-01 2024-12-31 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2023-01-01 2023-12-31 0001014739 us-gaap:InterestRateCapMember us-gaap:InterestExpenseMember 2022-01-01 2022-12-31 0001014739 bios:A2018PlanMember 2024-05-01 2024-05-31 0001014739 bios:A2018PlanMember 2024-12-31 0001014739 bios:A2018PlanMember 2023-12-31 0001014739 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001014739 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001014739 srt:MinimumMember 2024-01-01 2024-12-31 0001014739 srt:MaximumMember 2024-01-01 2024-12-31 0001014739 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001014739 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001014739 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-12-31 0001014739 us-gaap:EmployeeStockOptionMember 2023-12-31 0001014739 us-gaap:EmployeeStockOptionMember 2024-12-31 0001014739 bios:OptionExercisePriceRangeOneMember 2024-01-01 2024-12-31 0001014739 bios:OptionExercisePriceRangeOneMember 2024-12-31 0001014739 bios:OptionExercisePriceRangeTwoMember 2024-01-01 2024-12-31 0001014739 bios:OptionExercisePriceRangeTwoMember 2024-12-31 0001014739 bios:OptionExercisePriceRangeThreeMember 2024-01-01 2024-12-31 0001014739 bios:OptionExercisePriceRangeThreeMember 2024-12-31 0001014739 bios:OptionExercisePriceRangeFourMember 2024-01-01 2024-12-31 0001014739 bios:OptionExercisePriceRangeFourMember 2024-12-31 0001014739 srt:MinimumMember us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0001014739 srt:MaximumMember us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0001014739 srt:DirectorMember us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0001014739 us-gaap:RestrictedStockMember 2024-01-01 2024-12-31 0001014739 us-gaap:RestrictedStockMember 2023-01-01 2023-12-31 0001014739 us-gaap:RestrictedStockMember 2022-01-01 2022-12-31 0001014739 us-gaap:RestrictedStockMember 2023-12-31 0001014739 us-gaap:RestrictedStockMember 2024-12-31 0001014739 bios:PerformanceStockUnitsMember 2024-01-01 2024-12-31 0001014739 srt:MinimumMember bios:PerformanceStockUnitsMember 2024-01-01 2024-12-31 0001014739 srt:MaximumMember bios:PerformanceStockUnitsMember 2024-01-01 2024-12-31 0001014739 bios:PerformanceStockUnitsMember 2023-01-01 2023-12-31 0001014739 bios:PerformanceStockUnitsMember 2022-01-01 2022-12-31 0001014739 bios:PerformanceStockUnitsMember 2024-12-31 0001014739 bios:A2024PerformanceStockUnitsMember 2024-01-01 2024-12-31 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2019-08-06 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2017-06-29 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2024-12-31 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2023-12-31 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2022-12-31 0001014739 bios:A2017WarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2015-03-09 0001014739 srt:MinimumMember bios:A2015WarrantsMember us-gaap:CommonStockMember 2015-03-09 0001014739 srt:MaximumMember bios:A2015WarrantsMember us-gaap:CommonStockMember 2015-03-09 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2019-08-06 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2024-12-31 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2023-12-31 0001014739 bios:A2015WarrantsMember us-gaap:CommonStockMember 2022-12-31 0001014739 us-gaap:CommonStockMember 2023-02-20 0001014739 us-gaap:CommonStockMember 2023-12-06 0001014739 us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2025-01-31 0001014739 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001014739 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001014739 bios:ManagementFeeIncomeMember us-gaap:CorporateJointVentureMember 2024-01-01 2024-12-31 0001014739 bios:ManagementFeeIncomeMember us-gaap:CorporateJointVentureMember 2023-01-01 2023-12-31 0001014739 bios:ManagementFeeIncomeMember us-gaap:CorporateJointVentureMember 2022-01-01 2022-12-31 0001014739 us-gaap:CorporateJointVentureMember 2024-12-31 0001014739 us-gaap:CorporateJointVentureMember 2023-12-31 0001014739 2023-02-28 2023-02-28 0001014739 bios:IntramedPlusMember us-gaap:SubsequentEventMember 2025-01-24 2025-01-24 0001014739 2024-10-01 2024-12-31 iso4217:USD shares iso4217:USD shares bios:pharmacy bios:suite bios:segment pure 0001014739 2024 FY false P15Y P2Y P2Y P3Y http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#PrepaidExpenseAndOtherAssetsCurrent P3Y P7Y P1Y 10-K true 2024-12-31 --12-31 false 001-11993 OPTION CARE HEALTH, INC. DE 05-0489664 3000 Lakeside Dr. Suite 300N Bannockburn IL 60015 312 940-2443 Common Stock, $0.0001 par value per share OPCH NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 4748081376 165315961 <div style="margin-bottom:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Portions of the registrant’s definitive proxy statement for its 2025 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission (the “SEC”) within 120 days after the close of the registrant’s fiscal year are incorporated by reference into Part III of this Annual Report on Form 10-K.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity framework designed to identify, detect, protect, respond to and recover from risks stemming from threats to the security of our information, systems and network using a governance-led risk-based approach. The framework is informed, in part, by the National Institute of Standards and Technology (NIST) Cybersecurity Framework, although this does not necessarily mean that we meet all technical standards, specifications or requirements outlined in the NIST framework. Additionally, we maintain a Systems and Organization Controls (SOC) 2 Type 2 attestation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to maintain an information technology infrastructure that implements physical, administrative, and technical controls. These controls are adjusted based on risk and designed to protect the confidentiality, integrity, and availability of our information systems, including the customer information, personal information, and proprietary information stored on our networks.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a cybersecurity incident response plan and dedicated teams to respond to cybersecurity incidents. When a cybersecurity incident occurs, we have cross-functional teams that are responsible for leading the initial assessment of priority and severity. Our information security team assists in taking any remedial action in response to an incident, and external experts may also be engaged as appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our overarching approach to cybersecurity risk management centers on governance, people, processes, and technology. We provide security awareness training to help employees understand their information protection and cybersecurity responsibilities. This includes mandatory annual cybersecurity training and monthly phishing simulations. We also perform periodic internal tabletops or simulation exercises involving technical experts, business and functional leaders, as well as separate exercises with select critical third-party service providers.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conduct third-party assessments of potential new vendors who process, store or transmit our data, which include a formal security review. This can include the review of documentation related to a vendor’s security attestations, such as SOC 2 Type 2 or HITRUST certifications.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We leverage third-party cybersecurity companies to assess our cybersecurity program and procedures and reaffirm our compliance with SOC 2 standards as well as the HIPAA Security Rule. These assessments aid in continual improvement and help us identify and address risks from cybersecurity threats.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also consider cybersecurity, along with our other top risks, within our enterprise risk management framework. This framework involves internal reporting at the business and enterprise levels, considering key risk indicators, trends and countermeasures. Our Senior Vice President, Chief Information Security Officer (CISO) serves on the Enterprise Risk Committee that assesses our enterprise-wide risks and oversees risk mitigation activities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not identified risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected us or our results of operations, cash flow or financial condition. However, the scope and impact of any future incident, or the identification of new information related to prior cybersecurity incidents, cannot be predicted. See “Item 1A. Risk Factors” for more information about our cybersecurity-related risks.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed and implemented a cybersecurity framework designed to identify, detect, protect, respond to and recover from risks stemming from threats to the security of our information, systems and network using a governance-led risk-based approach. The framework is informed, in part, by the National Institute of Standards and Technology (NIST) Cybersecurity Framework, although this does not necessarily mean that we meet all technical standards, specifications or requirements outlined in the NIST framework. Additionally, we maintain a Systems and Organization Controls (SOC) 2 Type 2 attestation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to maintain an information technology infrastructure that implements physical, administrative, and technical controls. These controls are adjusted based on risk and designed to protect the confidentiality, integrity, and availability of our information systems, including the customer information, personal information, and proprietary information stored on our networks.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a cybersecurity incident response plan and dedicated teams to respond to cybersecurity incidents. When a cybersecurity incident occurs, we have cross-functional teams that are responsible for leading the initial assessment of priority and severity. Our information security team assists in taking any remedial action in response to an incident, and external experts may also be engaged as appropriate.</span></div> true true true false <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quality and Compliance Committee of our Board of Directors provides board-level oversight of cybersecurity risk. As part of its oversight role, the Quality and Compliance Committee receives reports about our practices, programs, or notable threats or incidents related to cybersecurity throughout the year, including through periodic updates from our CISO and other leaders. The Quality and Compliance Committee provides regular reports to the full Board about these matters and other areas within its responsibility, and the CISO and other leaders provide updates regarding cybersecurity matters to the full Board as appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. Our CISO collaborates with senior leaders and other members of our organization to identify and analyze cybersecurity risks and implement controls as appropriate and feasible to mitigate these risks. The CISO also supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, including by collaborating with internal and external stakeholders. Our CISO is supported by a management-led Security Council, which consists of our Chief Executive Officer, Chief Financial Officer and other senior leaders throughout our organization, and which reviews and discusses our cybersecurity program as well as emerging cyber risks, threats, and industry trends, among other topics.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quality and Compliance Committee of our Board of Directors provides board-level oversight of cybersecurity risk. As part of its oversight role, the Quality and Compliance Committee receives reports about our practices, programs, or notable threats or incidents related to cybersecurity throughout the year, including through periodic updates from our CISO and other leaders. The Quality and Compliance Committee provides regular reports to the full Board about these matters and other areas within its responsibility, and the CISO and other leaders provide updates regarding cybersecurity matters to the full Board as appropriate.</span></div> As part of its oversight role, the Quality and Compliance Committee receives reports about our practices, programs, or notable threats or incidents related to cybersecurity throughout the year, including through periodic updates from our CISO and other leaders. The Quality and Compliance Committee provides regular reports to the full Board about these matters and other areas within its responsibility, and the CISO and other leaders provide updates regarding cybersecurity matters to the full Board as appropriate.<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. Our CISO collaborates with senior leaders and other members of our organization to identify and analyze cybersecurity risks and implement controls as appropriate and feasible to mitigate these risks. The CISO also supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, including by collaborating with internal and external stakeholders. Our CISO is supported by a management-led Security Council, which consists of our Chief Executive Officer, Chief Financial Officer and other senior leaders throughout our organization, and which reviews and discusses our cybersecurity program as well as emerging cyber risks, threats, and industry trends, among other topics.</span></div> true <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. Our CISO collaborates with senior leaders and other members of our organization to identify and analyze cybersecurity risks and implement controls as appropriate and feasible to mitigate these risks. The CISO also supervises efforts to prevent, detect, mitigate and remediate cybersecurity risks and incidents through various means, including by collaborating with internal and external stakeholders. Our CISO is supported by a management-led Security Council, which consists of our Chief Executive Officer, Chief Financial Officer and other senior leaders throughout our organization, and which reviews and discusses our cybersecurity program as well as emerging cyber risks, threats, and industry trends, among other topics.</span></div> Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. Our CISO reports to our Chief Information Officer and leads our overall cybersecurity function. true Our CISO has over 20 years of experience in various security roles, which include managing information security, developing cybersecurity strategy, and implementing cybersecurity programs. KPMG LLP Chicago, Illinois 412565000 343849000 409733000 377658000 388131000 274004000 112198000 98744000 1322627000 1094255000 127367000 120630000 86528000 84159000 16993000 20092000 284017000 315304000 1540246000 1540246000 43965000 42349000 2099116000 2122780000 3421743000 3217035000 610779000 426513000 63028000 92508000 77783000 75010000 22044000 18278000 6512000 6000000 780146000 618309000 1104641000 1056650000 84776000 85484000 47576000 34920000 366000 0 1237359000 1177054000 2017505000 1795363000 0.0001 0.0001 12500000 12500000 0 0 0 0 0.0001 0.0001 250000000 250000000 183846725 166261112 182905559 174575537 18000 18000 17585613 8330022 507598000 255107000 1231435000 1204270000 669336000 457513000 11047000 14978000 1404238000 1421672000 3421743000 3217035000 4998202000 4302324000 3944735000 3985209000 3321101000 3077817000 1012993000 981223000 866918000 630251000 607427000 566122000 60909000 59201000 60565000 691160000 666628000 626687000 321833000 314595000 240231000 49029000 51248000 53806000 5964000 5530000 5125000 4831000 89865000 14218000 -38234000 44147000 -34463000 283599000 358742000 205768000 71776000 91652000 55212000 211823000 267090000 150556000 -1284000 -2158000 7259000 -3931000 -6181000 21610000 -3931000 -6181000 21610000 207892000 260909000 172166000 1.23 1.49 0.83 1.23 1.48 0.83 171567000 178973000 181105000 172845000 180375000 182075000 211823000 267090000 150556000 63498000 62200000 65434000 22581000 18533000 19713000 12656000 12766000 49187000 0 0 9403000 -377000 0 0 4628000 4446000 4304000 5964000 5530000 5125000 36143000 30479000 16783000 2400000 4000000 5875000 -4504000 -1244000 0 32075000 -224000 36889000 114127000 51000000 41010000 15601000 6290000 16798000 183395000 47703000 98885000 -29480000 15546000 -7770000 6133000 -1727000 10535000 21911000 17529000 21395000 -3420000 8372000 15335000 323392000 371295000 267547000 35606000 41866000 35358000 0 3743000 14670000 0 12494000 87364000 864000 5889000 0 -36470000 -56506000 -108052000 12382000 3115000 352000 252726000 250261000 0 0 0 20916000 49959000 0 0 6384000 6000000 6000000 77000 0 0 3404000 -5750000 0 -218206000 -265126000 15268000 68716000 49663000 174763000 343849000 294186000 119423000 412565000 343849000 294186000 71553000 69804000 50372000 64522000 75241000 13438000 28505000 27391000 25311000 0 18000 -2403000 1138855000 39867000 -451000 1175886000 16783000 16783000 -352000 -352000 20916000 20916000 150556000 150556000 21610000 21610000 0 18000 -2403000 1176906000 190423000 21159000 1386103000 30479000 30479000 3115000 3115000 252704000 252704000 267090000 267090000 -6181000 -6181000 0 18000 -255107000 1204270000 457513000 14978000 1421672000 36143000 36143000 8978000 8978000 252491000 252491000 211823000 211823000 -3931000 -3931000 0 18000 -507598000 1231435000 669336000 11047000 1404238000 NATURE OF OPERATIONS AND PRESENTATION OF FINANCIAL STATEMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Organization and Business </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s stock is listed on the Nasdaq Global Select Market as of December 31, 2024. During the year ended December 31, 2023, HC Group Holdings I, LLC. (“HC I”), a former affiliated shareholder, completed sales of 23,771,926 shares of its Option Care common stock which resulted in the full divestment by HC 1 at that time. In addition, the Company repurchased 2,475,166 shares from HC I on March 3, 2023 under the Company’s share repurchase program. See Note 16, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders’ Equity</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company’s share repurchase program. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Option Care Health, and its wholly-owned subsidiaries, provides infusion therapy and other ancillary healthcare services through a national network of 92 full service pharmacies and 93 stand-alone ambulatory infusion sites. The Company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings. The Company operates in one segment, infusion services.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States. GAAP requires management to make certain estimates and assumptions in determining assets, liabilities, revenue, expenses, and related disclosures. Actual amounts could differ materially from those estimates.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in companies that are 50% owned and are accounted for as equity-method investments. The Company’s share of earnings from equity-method investments is included in the line entitled “Equity in earnings of joint ventures” in the consolidated statements of comprehensive income. See “Equity-Method Investments” within Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company’s equity-method investments.</span></div> 23771926 2475166 92 93 1 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation </span>— The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles (“GAAP”) in the United States. GAAP <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s consolidated financial statements include the accounts of Option Care Health, Inc. and its subsidiaries. All intercompany transactions and balances are eliminated in consolidation.</span></div> 0.50 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents consisted of money market funds.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company’s accounts receivable are reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental healthcare programs, such as Medicare and Medicaid.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”), an allowance for doubtful accounts is established only as a result of an adverse change in the Company’s payers’ ability to pay outstanding billings. In addition, the company assesses if there have been any changes to historical credit losses to determine if an allowance for credit losses is needed. The Company had an immaterial allowance for doubtful accounts and credit losses as of December 31, 2024 and 2023.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Included in accounts receivable are earned but unbilled gross receivables of $105.3 million and $89.1 million as of December 31, 2024 and 2023, respectively. Delays ranging from one day up to several weeks between the date of service and billing can occur due to delays in obtaining certain required payer-specific documentation from internal and external sources.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a further discussion of the Company’s revenue recognition policy.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Inventories, which consist primarily of pharmaceuticals, is stated at the lower of first‑in, first‑out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Included in prepaid expenses and other current assets are rebates receivable from pharmaceutical and medical supply manufacturers of $54.4 million and $52.0 million for the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company has lease agreements for facilities, warehouses, office space and property and equipment. At the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (“ROU asset”) and operating lease liabilities in the consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, which represent the Company’s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The rates are estimated primarily using a methodology dependent on the Company’s financial condition, creditworthiness, and availability of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases may contain rent escalations; however, the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. See Note 8, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of leases.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, Property and Equipment, and Referral Sources </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate that impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter on a qualitative basis. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company’s goodwill and other intangible assets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets arising from the Company’s acquisitions are amortized on a straight‑line basis over the estimated useful life of each asset. Referral sources have a useful life of <span style="-sec-ix-hidden:f-396">fifteen</span> to twenty years. Trademarks/names have a useful life ranging from <span style="-sec-ix-hidden:f-398">two</span> to fifteen years. The useful lives for other amortizable intangible assets range from approximately <span style="-sec-ix-hidden:f-400">two</span> to nine years. The Company does not have any indefinite‑lived intangible assets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight‑line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and <span style="-sec-ix-hidden:f-404">three</span> to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight‑line basis over the software’s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses long‑lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. If circumstances require that a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flows basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December 31, 2024 and 2023, the balance of the investments was $24.5 million and $20.9 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $6.0 million, $5.5 million and $5.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December 31, 2024, 2023 and 2022, the Company received distributions from the investees of $2.4 million, $4.0 million and $5.9 million, respectively. See Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing goods and services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the expected consideration to be received at the time of patient acceptance, based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. See Note 4, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for a further discussion of revenue.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 718”). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company’s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company accounts for business acquisitions in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company’s business acquisitions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense (benefit). Tax related interest and penalties are classified as a component of income tax expense (benefit).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15%, 14% and 14% for the years ended December 31, 2024, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023 and 2022, approximately 12%, 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December 31, 2024 and 2023, approximately 11% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, approximately 58% of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the years ended December 31, 2023 and 2022, approximately 72% and 73%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue or decreased gross profit, which could adversely affect the Company’s financial condition or operating results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The fair value measurement accounting standard, ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 820”), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— In November 2024, the FASB issued ASU 2024-03,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU improves the disclosures around a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;A, and research and development). The amendments in this ASU do not change or remove current presentation requirements or current expense disclosure requirements. However, the amendments affect where this information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The Company is required to adopt this ASU for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The ASU allows investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. This ASU also improves the effectiveness and comparability of disclosures by adding disclosures of pretax income (loss) and income tax expense (benefit) to be consistent with U.S. Securities and Exchange Commission (“SEC”) Regulation S-X and removing disclosures that no longer are considered cost beneficial or relevant. The Company is required to adopt this ASU for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This ASU improves the disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities, including those public entities that have a single reportable segment, to enable investors to develop more decision-useful financial analyses. The Company is required to adopt this ASU for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU was adopted during the year ended December 31, 2024 and applied retrospectively to all prior periods presented in the financial statements. The adoption did not have any material impact on the Company’s results of operations, cash flows, financial position, or disclosures. See Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, for further discussion.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU is the result of the Board’s decision to incorporate into the Codification 14 disclosures referred by the SEC. The ASU represents changes to clarify or improve disclosure and presentation requirements of a variety of Topics. Many of the amendments allow users to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the SEC’s requirements. Also, the amendments align the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption permitted. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. As of December 31, 2024 and 2023, cash equivalents consisted of money market funds.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Accounts Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company’s accounts receivable are reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing services, which is inclusive of adjustments for price concessions. The majority of accounts receivable are due from private insurance carriers and governmental healthcare programs, such as Medicare and Medicaid.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Price concessions may result from patient hardships, patient uncollectible accounts sent to collection agencies, lack of recovery due to not receiving prior authorization, differing interpretations of covered therapies in payer contracts, different pricing methodologies, or various other reasons. In accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span> (“ASC 606”), an allowance for doubtful accounts is established only as a result of an adverse change in the Company’s payers’ ability to pay outstanding billings. 105300000 89100000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Inventories, which consist primarily of pharmaceuticals, is stated at the lower of first‑in, first‑out cost or net realizable value basis, which the Company believes is reflective of the physical flow of inventories.</span></div> 54400000 52000000.0 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company has lease agreements for facilities, warehouses, office space and property and equipment. At the inception of a contract, the Company determines if the contract is a lease or contains an embedded lease arrangement. Operating leases are included in the operating lease right-of-use asset (“ROU asset”) and operating lease liabilities in the consolidated financial statements.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets, which represent the Company’s right to use the leased assets, and operating lease liabilities, which represent the present value of unpaid lease payments, are both recognized by the Company at the lease commencement date. The Company utilizes its estimated incremental borrowing rate at the lease commencement date to determine the present value of unpaid lease obligations. The rates are estimated primarily using a methodology dependent on the Company’s financial condition, creditworthiness, and availability of certain observable data. In particular, the Company considers its actual cost of borrowing for collateralized loans and its credit rating, along with the corporate bond yield curve in estimating its incremental borrowing rates. ROU assets are recorded as the amount of operating lease liability, adjusted for prepayments, accrued lease payments, initial direct costs, lease incentives, and impairment of the ROU asset. Tenant improvement allowances used to fund leasehold improvements are recognized when earned and reduce the related ROU asset. Tenant improvement allowances are recognized through the ROU asset as a reduction of expense over the term of the lease.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases may contain rent escalations; however, the Company recognizes the lease expense on a straight-line basis over the expected lease term. The Company reviews the terms of any lease renewal options to determine if it is reasonably certain that the renewal options will be exercised. The Company has determined that the expected lease term is typically the minimum non-cancelable period of the lease.</span></div>The Company has lease agreements that contain both lease and non-lease components which the Company has elected to account for as a single lease component for all asset classes. Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and are expensed on a straight-line basis over the term of the lease. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill, Intangible Assets, Property and Equipment, and Referral Sources </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed. The Company accounts for goodwill under ASC Topic 350, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intangibles</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company tests goodwill for impairment annually, or more frequently whenever events or circumstances indicate that impairment may exist. Goodwill is stated at cost less accumulated impairment losses. The Company completes its goodwill impairment test annually in the fourth quarter on a qualitative basis. See Note 10, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Goodwill and Other Intangible Assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the Company’s goodwill and other intangible assets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets arising from the Company’s acquisitions are amortized on a straight‑line basis over the estimated useful life of each asset. Referral sources have a useful life of <span style="-sec-ix-hidden:f-396">fifteen</span> to twenty years. Trademarks/names have a useful life ranging from <span style="-sec-ix-hidden:f-398">two</span> to fifteen years. The useful lives for other amortizable intangible assets range from approximately <span style="-sec-ix-hidden:f-400">two</span> to nine years. The Company does not have any indefinite‑lived intangible assets.</span></div> P20Y P15Y P9Y <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment is recorded at cost, net of accumulated depreciation. Depreciation on owned property and equipment is provided for on a straight‑line basis over the estimated useful lives of owned assets. Leasehold improvements are amortized over the estimated useful life of the property or over the term of the lease, whichever is shorter. Estimated useful lives are seven years for infusion pumps and <span style="-sec-ix-hidden:f-404">three</span> to thirteen years for equipment. Major repairs, which extend the useful life of an asset, are capitalized in the property and equipment accounts. Routine maintenance and repairs are expensed as incurred. Computer software is included in property and equipment and consists of purchased software and internally-developed software. The Company capitalizes application-stage development costs for significant internally-developed software projects. Once the software is ready for its intended use, these costs are amortized on a straight‑line basis over the software’s estimated useful life, generally five years. Costs recognized in the preliminary project phase and the post-implementation phase, as well as maintenance and training costs, are expensed as incurred.</span></div>The Company assesses long‑lived assets for impairment whenever events or circumstances indicate that a certain asset or asset group may be impaired. If circumstances require that a long-lived asset or asset group be tested for possible impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying amount. If the carrying amount of the long-lived asset or asset group is not recoverable on an undiscounted cash flows basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. P7Y P13Y P5Y <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-Method Investments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company’s investments in certain unconsolidated entities are accounted for under the equity method. The balance of these investments is included in other noncurrent assets in the accompanying consolidated balance sheets. As of December 31, 2024 and 2023, the balance of the investments was $24.5 million and $20.9 million, respectively. The investments are increased to reflect the Company’s capital contributions and equity in earnings of the investees. The investments are decreased to reflect the Company’s equity in losses of the investees and for distributions received that are not in excess of the carrying amount of the investments. The Company’s proportionate share of earnings or losses of the investees is recorded in equity in earnings of joint ventures in the accompanying consolidated statements of comprehensive income. The Company’s proportionate share of earnings was $6.0 million, $5.5 million and $5.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Distributions from the investees are treated as cash inflows from operating activities in the consolidated statements of cash flows. During the years ended December 31, 2024, 2023 and 2022, the Company received distributions from the investees of $2.4 million, $4.0 million and $5.9 million, respectively. See Note 17, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Related-Party Transactions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for discussion of related-party transactions with these investees.</span></div> 24500000 20900000 6000000.0 5500000 5100000 2400000 4000000.0 5900000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hedging Instruments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company uses derivative financial instruments to limit its exposure to increases in the interest rate of its variable rate debt instruments. The derivative financial instruments are recognized on the consolidated balance sheets at fair value. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At inception of the hedge, the Company designated the derivative instruments as a hedge of the cash flows related to the interest on the variable rate debt. For all instruments designated as hedges, the Company documents the hedging relationships and its risk management objective of the hedging relationship. For all hedging instruments, the terms of the hedge perfectly offset the hedged expected cash flows.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Net revenue is reported at the net realizable value amount that reflects the consideration the Company expects to receive in exchange for providing goods and services. Revenues are from government payers, commercial payers, and patients for goods and services provided and are based on a gross price based on payer contracts, fee schedules, or other arrangements less any implicit price concessions.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the nature of the healthcare industry and the reimbursement environment in which the Company operates, certain estimates are required to record revenue and accounts receivable at their net realizable values at the time goods or services are provided. Inherent in these estimates is the risk that they will have to be revised or updated as additional information becomes available.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assesses the expected consideration to be received at the time of patient acceptance, based on the verification of the patient’s insurance coverage, historical information with the patient, similar patients, or the payer. Performance obligations are determined based on the nature of the services provided by the Company. The majority of the Company’s performance obligations are to provide infusion services to deliver medicine, nutrients, or fluids directly into the body.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides a variety of infusion-related therapies to patients, which frequently include multiple deliverables of pharmaceutical drugs and related nursing services. After applying the criteria from ASC 606, the Company concluded that multiple performance obligations exist in its contracts with its customers. Revenue is allocated to each performance obligation based on relative standalone price, determined based on reimbursement rates established in the third-party payer contracts. Pharmaceutical drug revenue is recognized at the time the pharmaceutical drug is delivered to the patient, and nursing revenue is recognized on the date of service. </span></div>The Company's outstanding performance obligations relate to contracts with a duration of less than one year. Therefore, the Company has elected to apply the practical expedient provided by ASC 606 and is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. Any unsatisfied or partially unsatisfied performance obligations at the end of a reporting period are generally completed prior to the patient being discharged. <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Revenue </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Cost of revenue consists of the actual cost of pharmaceuticals and other medical supplies dispensed to patients, as well as all other costs directly related to the production of revenue. These costs include warehousing costs, purchasing costs, freight costs, cash discounts, wages and related costs for pharmacists and nurses, along with depreciation expense relating to revenue-generating assets, such as infusion pumps.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also receives rebates from pharmaceutical and medical supply manufacturers. Rebates are generally volume-based incentives and are recorded as a reduction of inventory and are accounted for as a reduction of cost of goods sold when the related inventory is sold.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, General and Administrative Expenses </span>— Selling, general and administrative expenses mainly consist of salaries for administrative employees that directly and indirectly support the operations, occupancy costs, marketing expenditures, insurance, and professional fees. <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company accounts for stock-based incentive compensation expense in accordance with ASC Topic 718, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation-Stock Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 718”). Stock-based incentive compensation expense is based on the grant date fair value. The Company estimates the fair value of stock option awards using a Black-Scholes option pricing model and the fair value of restricted stock unit awards using the closing price of the Company’s common stock on the grant date. For awards with a service-based vesting condition, the Company recognizes expense on a straight-line basis over the service period of the award. For awards with performance-based vesting conditions, the Company will recognize expense when it is probable that the performance-based conditions will be met. When the Company determines that it is probable that the performance-based conditions will be met, a cumulative catch-up of expense will be recorded as if the award had been vesting on a straight-line basis from the award date. The award will continue to be expensed on a straight-line basis through the remainder of the vesting period and will be updated if the Company determines that there has been a change in the probability of achieving the performance-based conditions. The Company records the impact of forfeited awards in the period in which the forfeiture occurs.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Acquisitions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — The Company accounts for business acquisitions in accordance with ASC Topic 805, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span>, with assets and liabilities being recorded at their acquisition date fair value and goodwill being calculated as the purchase price in excess of the net identifiable assets. <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company accounts for income taxes using the asset and liability method. Deferred tax assets and liabilities are reported for book-tax basis differences and are measured based on currently enacted tax laws using rates expected to apply to taxable income in the years in which the differences are expected to reverse. The effect of a change in tax rate on deferred taxes is recognized in income tax expense in the period that includes the enactment date of the change. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts more likely than not to be realized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes income tax positions that are more likely than not to be sustained on their technical merits. The Company measures recognized income tax positions at the maximum benefit that is more likely than not, based on cumulative probability, realizable upon final settlement of the position. Interest and penalties related to unrecognized tax benefits are reported in income tax expense (benefit). Tax related interest and penalties are classified as a component of income tax expense (benefit).</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentrations of Business Risk </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company generates revenue from managed care contracts and other agreements with commercial third-party payers. Revenue related to the Company’s largest payer was approximately 15%, 14% and 14% for the years ended December 31, 2024, 2023 and 2022, respectively. There were no other managed care contracts that represent greater than 10% of revenue for the years presented.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December 31, 2024, 2023 and 2022, approximately 12%, 12% and 12%, respectively, of the Company’s revenue was reimbursable through direct government healthcare programs such as Medicare and Medicaid. As of December 31, 2024 and 2023, approximately 11% and 12%, respectively, of the Company’s accounts receivable was related to these programs. Governmental programs pay for services based on fee schedules and rates that are determined by the related governmental agency. Laws and regulations pertaining to government programs are complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change in the near term.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not require its patients nor other payers to carry collateral for any amounts owed for goods or services provided. Other than as discussed above, concentrations of credit risk relating to trade accounts receivable is limited due to the Company’s diversity of patients and payers. Further, the Company generally does not provide charity care; however, Option Care Health offers a financial assistance program for patients that meet certain defined hardship criteria.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December 31, 2024, approximately 58% of the Company’s pharmaceutical and medical supply purchases were from three vendors. For the years ended December 31, 2023 and 2022, approximately 72% and 73%, respectively, of the Company’s pharmaceutical and medical supply purchases were from four vendors. Although there are a limited number of suppliers, the Company believes that other vendors could provide similar products on comparable terms. However, a change in suppliers could cause delays in service delivery and possible losses in revenue or decreased gross profit, which could adversely affect the Company’s financial condition or operating results.</span></div> 0.15 0.14 0.14 0.12 0.12 0.12 0.11 0.12 0.58 0.72 0.73 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The fair value measurement accounting standard, ASC Topic 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 820”), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available. The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.</span></div><div style="margin-bottom:10pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div>FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The three levels of inputs within the fair value hierarchy are defined in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other assets or liabilities measured at fair value at December 31, 2024 or 2023.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— In November 2024, the FASB issued ASU 2024-03,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU improves the disclosures around a public business entity’s expenses and address requests from investors for more detailed information about the types of expenses (including purchases of inventory, employee compensation, depreciation, amortization, and depletion) in commonly presented expense captions (such as cost of sales, SG&amp;A, and research and development). The amendments in this ASU do not change or remove current presentation requirements or current expense disclosure requirements. However, the amendments affect where this information appears in the notes to financial statements because entities are required to include certain current disclosures in the same tabular format disclosure as the other disaggregation requirements in the amendments. The Company is required to adopt this ASU for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU addresses investor requests for more transparency about income tax information through improvements to income tax disclosures primarily related to the rate reconciliation and income taxes paid information. The ASU improves the transparency of income tax disclosures by requiring consistent categories and greater disaggregation of information in the rate reconciliation and income taxes paid disaggregated by jurisdiction. The ASU allows investors to better assess, in their capital allocation decisions, how an entity’s worldwide operations and related tax risks and tax planning and operational opportunities affect its income tax rate and prospects for future cash flows. This ASU also improves the effectiveness and comparability of disclosures by adding disclosures of pretax income (loss) and income tax expense (benefit) to be consistent with U.S. Securities and Exchange Commission (“SEC”) Regulation S-X and removing disclosures that no longer are considered cost beneficial or relevant. The Company is required to adopt this ASU for annual periods beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In November 2023, the FASB issued ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. This ASU improves the disclosures about a public entity’s reportable segments and addresses requests from investors for additional, more detailed information about a reportable segment’s expenses. The ASU improves financial reporting by requiring disclosure of incremental segment information on an annual and interim basis for all public entities, including those public entities that have a single reportable segment, to enable investors to develop more decision-useful financial analyses. The Company is required to adopt this ASU for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. This ASU was adopted during the year ended December 31, 2024 and applied retrospectively to all prior periods presented in the financial statements. The adoption did not have any material impact on the Company’s results of operations, cash flows, financial position, or disclosures. See Note 18, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Segment Reporting</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, for further discussion.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, the FASB issued ASU 2023-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This ASU is the result of the Board’s decision to incorporate into the Codification 14 disclosures referred by the SEC. The ASU represents changes to clarify or improve disclosure and presentation requirements of a variety of Topics. Many of the amendments allow users to more easily compare entities subject to the SEC’s existing disclosures with those entities that were not previously subject to the SEC’s requirements. Also, the amendments align the requirements in the Codification with the SEC’s regulations. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption permitted. If by June 30, 2027, the SEC has not removed the applicable requirement from Regulation S-X or Regulation S-K, the pending content of the related amendment will be removed from the Codification and will not become effective. The Company is currently evaluating the impact of this ASU on its results of operations, cash flows, financial position, and disclosures.</span></div> BUSINESS ACQUISITIONS AND DIVESTITURES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amedisys, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On May 3, 2023, the Company entered into a definitive merger agreement with Amedisys. Under the terms of the merger agreement, the Company would issue new shares of its common stock to Amedisys stockholders, which would result in the Company’s stockholders holding approximately 64.5% of the combined company.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 26, 2023, the Company entered into an agreement to terminate the Amedisys Merger Agreement. Under the terms of the Mutual Termination Agreement, the Company received a payment of $106.0 million in cash on behalf of Amedisys. The Termination Fee is included in Other, net in the consolidated statements of comprehensive income and in Net cash provided by operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company incurred $21.1 million in merger-related expenses, which are included in Other, net in the consolidated statements of comprehensive income and in Net cash provided by operating activities in the consolidated statements of cash flows.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revitalized, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In May 2023, pursuant to the equity purchase agreement dated May 1, 2023, the Company completed the acquisition of 100% of the membership interests in Revitalized, LLC for a purchase price, net of cash acquired, of $12.5 million, which primarily consisted of $6.7 million of goodwill and $5.5 million of intangible assets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Respiratory Therapy Asset Sale — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company closed the transaction in December 2022, for a sale price of $18.4 million comprised of $14.7 million in proceeds received at the time of closing and $3.7 million recorded as a current asset which was paid in the year ended December 31, 2023. Pursuant to the final transaction terms, $8.8 million of assets were sold, along with $0.7 million of liabilities that were previously classified as held for sale at the lower of their carrying amount or fair values less cost to sell. As a result of the transaction, a $10.3 million pre-tax gain on sale was recorded within <span style="-sec-ix-hidden:f-451">Other, net</span> in the Company’s consolidated statements of comprehensive income within the year ended December 31, 2022.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Rochester Home Infusion, Inc. —</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In August 2022, pursuant to the stock purchase agreement dated June 10, 2022, the Company completed the acquisition of 100% of the equity interests in Rochester Home Infusion, Inc. (“RHI”) for a purchase price, net of cash acquired, of $27.4 million.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Specialty Pharmacy Nursing Network, Inc. — </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, pursuant to the equity purchase agreement dated February 7, 2022, the Company completed the acquisition of 100% of the equity interests in Specialty Pharmacy Nursing Network, Inc. (“SPNN”) for a purchase price, net of cash acquired, of $59.9 million.</span></div> 0.645 106000000 21100000 1 12500000 6700000 5500000 18400000 14700000 3700000 8800000 700000 10300000 1 27400000 1 59900000 REVENUE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,348,991 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,747,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,421,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,998,202 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,302,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,944,735 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the net revenue earned by category of payer for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial payers</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,348,991 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,747,568 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,421,888 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government payers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">584,271 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,891 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477,818 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patients</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,940 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,029 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,998,202 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,302,324 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,944,735 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4348991000 3747568000 3421888000 584271000 500891000 477818000 64940000 53865000 45029000 4998202000 4302324000 3944735000 EMPLOYEE BENEFIT PLANS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) plan and matches 100% of employee contributions, up to 4% of employee compensation. The Company recorded expense for the defined contribution plan of $13.3 million, $13.1 million and $12.2 million for the years ended December 31, 2024, 2023 and 2022, respectively. In the years ended December 31, 2024, 2023 and 2022, Company contributions of $13.3 million, $12.4 million and $11.8 million, respectively, were paid.</span></div> 1 0.04 13300000 13100000 12200000 13300000 12400000 11800000 INCOME TAXES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,913 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,141 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,299 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,776 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,652 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,212 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December 31, 2024, 2023 and 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share based compensation impacts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded income tax expense of $71.8 million, $91.7 million, and $55.2 million, which represents an effective tax rate of 25.3%, 25.5%, and 26.8% for the years ended December 31, 2024, 2023, and 2022, respectively. In March 2024, the Company released $2.2 million of state valuation allowance. The variance in the Company’s effective tax rate of 25.3% for the year ended December 31, 2024 compared to the federal statutory rate of 21% is primarily attributable to the difference in state taxes, various non-deductible expenses, and a change in state valuation allowance. The variance in the Company’s effective tax rate of 25.3% and 25.5% for the years ended December 31, 2024 and 2023, respectively, is also primarily attributable to the difference in state taxes, various non-deductible expenses, and a change in state valuation allowance.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense for the year ended December 31, 2023 includes $21.8 million of tax expense related to the Termination Fee payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses. In September 2023, the Company released $5.8 million of state valuation allowance. The variance in the Company’s effective tax rate of 25.5% and 26.8% for the years ended December 31, 2023 and 2022, respectively, is primarily attributable to the difference in state taxes, various nondeductible expenses, and a change in state valuation allowance.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income tax assets and liabilities were as follows as of December 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Price concessions</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest limitation carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,802 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,860 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,980 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,403 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,690 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,066 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,319 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,883)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,504)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59,303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151,642)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,239)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,576)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,920)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets are generally required to be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized. For the year ended December 31, 2024, the Company maintains a valuation allowance of $3.3 million against certain state net operating losses (“NOL”). In assessing the realizability of deferred tax assets, the Company considers whether it is more likely than not that some or all the deferred tax assets will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the periods in which those temporary differences are deductible. The Company considers the scheduled reversal of deferred tax liabilities, including the effect in available carryback and carryforward periods, projected taxable income and tax-planning strategies, in making this assessment. On a quarterly basis, the Company evaluates all positive and negative evidence in determining if the valuation allowance is fairly stated.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, the Company had $35.6 million of tax-effected federal NOL carryforwards all of which are currently available to offset future taxable income in the United States and reflected as a deferred tax asset of the company. Tax-effected federal NOL carryforwards of $24.6 million expire beginning in 2028 through 2036, and $11.0 million of tax-effected federal NOLs have an indefinite carryforward period. At December 31, 2024, the Company had $5.8 million tax-effected amounts of interest limitation carryforwards which have an indefinite carryforward period. At December 31, 2024, the Company also had $15.3 million tax-effected amounts of cumulative state NOL carryforwards available to offset future taxable income in various states. These state NOL carryforwards will begin to expire beginning in 2025 through 2043, with some having an indefinite carryforward period.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, 2023 and 2022, there were no unrecognized tax benefits for uncertain tax positions. Tax related interest and penalties are classified as a component of income tax expense.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the valuation allowance for deferred tax assets for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged (Benefit) to Costs and Expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged (Benefit) to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022: Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,056 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023: Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024: Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,034)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The company files income tax returns in the U.S. and various state and local jurisdictions. There are no ongoing Federal or state income tax audits as of December 31, 2024. The statute remains open for examination by the Internal Revenue Service beginning with year 2021 in state jurisdictions for periods beginning in 2020.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax expense (benefit) consists of the following for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,239 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,474 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,103 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,396 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,739 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,810 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63,635 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,213 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,913 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income tax expense (benefit):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,597 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,253 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,182 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,456)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,814)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,117 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,141 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,299 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total income tax expense (benefit)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,776 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,652 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,212 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 47239000 56474000 4103000 16396000 18739000 38810000 63635000 75213000 42913000 10597000 20253000 9182000 -2456000 -3814000 3117000 8141000 16439000 12299000 71776000 91652000 55212000 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The difference between the statutory federal income tax rate and the effective tax rate is as follows for the years ended December 31, 2024, 2023 and 2022:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.755%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.126%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.129%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local income taxes net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share based compensation impacts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.210 0.210 0.210 0.035 0.048 0.050 -0.008 -0.015 0.000 0.012 0.007 0.004 0.004 0.005 0.004 0.253 0.255 0.268 71800000 91700000 55200000 0.253 0.255 0.268 -2200000 0.253 0.253 0.255 21800000 -5800000 0.255 0.268 <div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of deferred income tax assets and liabilities were as follows as of December 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Price concessions</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,053 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Compensation and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,166 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,609 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest limitation carryforward</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,768 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,802 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,880 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,378 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,860 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,980 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,676 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,556 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets before valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,403 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117,690 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,337)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,371)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets net of valuation allowance</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,066 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,319 </span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,630)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,882)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use asset</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,883)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21,504)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,412)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,502)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(59,303)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(52,188)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,414)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11,163)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(151,642)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(146,239)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(47,576)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(34,920)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8053000 5365000 6166000 7609000 5768000 13802000 23880000 26378000 50860000 56980000 12676000 7556000 107403000 117690000 3337000 6371000 104066000 111319000 12630000 8882000 18883000 21504000 48412000 52502000 59303000 52188000 12414000 11163000 151642000 146239000 47576000 34920000 3300000 35600000 24600000 11000000.0 5800000 15300000 0 0 0 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the valuation allowance for deferred tax assets for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged (Benefit) to Costs and Expenses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Charged (Benefit) to Other Accounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at End of Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022: Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,151 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,056 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023: Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,056 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,685)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,371 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024: Valuation allowance for deferred tax assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,371 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,034)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,337 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 13151000 95000 0 13056000 13056000 6685000 0 6371000 6371000 3034000 0 3337000 EARNINGS PER SHARE<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company presents basic and diluted earnings per share for its common stock. Basic earnings per share is calculated by dividing the net income of the Company by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is determined by adjusting the profit or loss and the weighted average number of shares of common stock outstanding for the effects of all potentially dilutive securities.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The earnings are used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. The computation of diluted shares for the years ended December 31, 2024, 2023 and 2022 includes the effect of shares that would be issued in connection with warrants, stock options, restricted stock awards and performance stock unit awards, as these common stock equivalents are dilutive to the earnings per share.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">854,545</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,214,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,690</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376,743</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340,331</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,652</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,881</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s basic and diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1) (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Common Share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1) (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,845 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,075 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Common Share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company’s common stock equivalents that were excluded from the calculation of earnings per share as they would be anti-dilutive: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">854,545</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,214,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629,690</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock awards</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">376,743</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340,331</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205,652</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Performance stock unit awards</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,881</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td></tr></table></div> 0 0 0 854545 1214560 629690 376743 340331 205652 286881 0 0 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the Company’s basic and diluted earnings per share and shares outstanding (in thousands, except per share data):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1) (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Common Share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, basic</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income (1) (2)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">211,823 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267,090 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,556 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,567 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">178,973 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,105 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,278 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,402 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding, diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172,845 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">180,375 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">182,075 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Earnings per Common Share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Earnings per common share, diluted</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.23 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.48 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.83 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Net income for the year ended December 31, 2023 includes $63.1 million related to the termination payment received on behalf of Amedisys, under the terms of the Mutual Termination Agreement, net of merger-related expenses and taxes. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Net income for the year ended December 31, 2022 includes the impact of the Company’s Respiratory Therapy Asset Sale. See Note 3, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Acquisitions and Divestitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div> 211823000 267090000 150556000 171567000 178973000 181105000 1.23 1.49 0.83 211823000 267090000 150556000 171567000 178973000 181105000 1278000 1402000 970000 172845000 180375000 182075000 1.23 1.48 0.83 63100000 LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, 2023 and 2022, the Company incurred operating lease expenses of $32.7 million, $30.6 million, and $29.1 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income. As of December 31, 2024 and December 31, 2023, the weighted-average remaining lease term was 6.5 years and 6.8 years, respectively, and the weighted-average discount rate was 6.56% and 6.16%, respectively. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,286 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,820 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, 2023 and 2022, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the consolidated statements of cash flows of $25.0 million, $30.5 million, and $17.2 million, respectively, related to the increases in the operating lease ROU asset and operating lease liabilities. As of December 31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div> LEASES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, 2023 and 2022, the Company incurred operating lease expenses of $32.7 million, $30.6 million, and $29.1 million, respectively, including short-term lease expenses, which were included as a component of selling, general and administrative expenses in the consolidated statements of comprehensive income. As of December 31, 2024 and December 31, 2023, the weighted-average remaining lease term was 6.5 years and 6.8 years, respectively, and the weighted-average discount rate was 6.56% and 6.16%, respectively. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,286 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,820 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, 2023 and 2022, the Company commenced new leases, extensions and amendments, resulting in non-cash operating activities in the consolidated statements of cash flows of $25.0 million, $30.5 million, and $17.2 million, respectively, related to the increases in the operating lease ROU asset and operating lease liabilities. As of December 31, 2024, the Company did not have any significant operating or financing leases that had not yet commenced.</span></div> 32700000 30600000 29100000 P6Y6M P6Y9M18D 0.0656 0.0616 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating leases mature as follows (in thousands): </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,286 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,523 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,406 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,907 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,306 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and beyond</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,515 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27,123)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,820 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28286000 25523000 20406000 13907000 9306000 36515000 133943000 27123000 106820000 25000000.0 30500000 17200000 PROPERTY AND EQUIPMENT<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of December 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,911 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,630 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense is recorded within cost of revenue and operating expenses within the consolidated statements of comprehensive income, depending on the nature of the underlying fixed assets. The depreciation expense included in cost of revenue relates to revenue-generating assets, such as infusion pumps. The depreciation expense included in operating expenses is related to infrastructure items, such as furniture, computer and office equipment, and leasehold improvements. The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,093 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,819 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment was as follows as of December 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion pumps</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,659 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36,943 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equipment, furniture and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,055 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,593 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">116,675 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99,725 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computer software, purchased and internally developed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46,532 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,572 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Assets under development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,990 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,668 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247,911 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">244,501 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(120,544)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123,871)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">127,367 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120,630 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The following table presents the amount of depreciation expense recorded in cost of revenue and operating expenses for the years ended December 31, 2024, 2023 and 2022 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in cost of revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,590 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,999 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation expense in operating expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,503 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,820 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,374 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,093 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,819 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,243 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 37659000 36943000 24055000 23593000 116675000 99725000 46532000 50572000 22990000 33668000 247911000 244501000 120544000 123871000 127367000 120630000 2590000 2999000 4869000 26503000 24820000 27374000 29093000 27819000 32243000 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill is not amortized, but is evaluated for impairment annually in the fourth quarter of the fiscal year, or more frequently if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Circumstances that could trigger an interim impairment test include: a significant adverse change in the business climate or legal factors; an adverse action or assessment by a regulator; unanticipated competition; the loss of key personnel; a change in reporting units; the likelihood that a reporting unit or significant portion of a reporting unit will be sold or otherwise disposed of; and the results of testing for recoverability of a significant asset group within a reporting unit.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A qualitative impairment analysis was performed in the fourth quarter of 2024, 2023 and 2022, to assess whether it is more likely than not that the fair value of the Company’s reporting units are less than their carrying value. The Company assessed relevant events and circumstances including macroeconomic conditions, industry and market considerations, overall financial performance, entity-specific events, and changes in the Company’s stock price. The Company determined that there was no goodwill impairment in 2024, 2023 or 2022.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The determination of fair value for acquisitions and the allocation of that value requires the Company to make significant estimates and assumptions. These estimates and assumptions primarily include, but are not limited to, the selection of appropriate peer group companies; control premiums appropriate for acquisitions in the industries in which the Company competes; the discount rate; terminal growth rates; and forecasts of revenue, operating income, depreciation and amortization, and capital expenditures. Actual financial results could differ from those estimates due to the inherent uncertainty involved in making such estimates. Changes in assumptions concerning future financial results or other underlying assumptions could have a significant impact on either the fair value of the reporting unit, the amount of the goodwill impairment charge, or both. The Company did not recognize any accumulated impairment losses at the beginning of the period.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill consist of the following activity for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,533,424 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540,246 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of December 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,010 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $34.4 million, $34.2 million and $32.9 million for the years ended December 31, 2024, 2023 and 2022, respectively. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense for intangible assets recorded at December 31, 2024, is as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and beyond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,010 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the carrying amount of goodwill consist of the following activity for the years ended December 31, 2024, 2023 and 2022 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,477,564 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,543 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,317 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,533,424 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,998 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540,246 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase accounting adjustments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,540,246 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1477564000 54543000 1317000 1533424000 6998000 -176000 1540246000 0 0 1540246000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount and accumulated amortization of intangible assets consist of the following as of December 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">514,388 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,136 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">995 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross intangible assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,509 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554,519 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Referral sources</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(230,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(199,084)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trademarks/names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(22,599)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other amortizable intangible assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(529)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(341)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated amortization</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253,499)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,123)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total intangible assets, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,010 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 514388000 514388000 39136000 39136000 985000 995000 554509000 554519000 230371000 199084000 22599000 19698000 529000 341000 253499000 219123000 301010000 335396000 34400000 34200000 32900000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected future amortization expense for intangible assets recorded at December 31, 2024, is as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,071 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,931 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,880 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2030 and beyond</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131,077 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">301,010 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 34176000 34071000 33931000 33880000 33875000 131077000 301010000 INDEBTEDNESS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131,617 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104,641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2024, the Company entered into the Third Amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021. The Third Amendment, among other things, (i) increases borrowings by $50.0 million and (ii) reduces the interest rate on the First Lien Term Loan from Term SOFR (including a credit spread adjustment) plus 2.75% to Term SOFR plus 2.25% and removes the credit spread adjustment with respect to such First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal balance of the First Lien Term Loan is repayable in quarterly installments of $1.6 million plus interest, with a final payment of all remaining outstanding principal due on October 27, 2028. The quarterly principal payments commenced in March 2022. Under the Third Amendment, interest on the First Lien Term Loan is payable monthly on either (i) SOFR (with a floor of 0.50% per annum) plus an applicable margin of 2.25% for Term SOFR Loans (as such term is defined in the Third Amendment); or (ii) a base rate determined in accordance with the Third Amendment, plus 1.25% for Base Rate Loans (as such term is defined in the Third Amendment). The interest rate on the First Lien Term Loan was 6.82% and 8.21% as of December 31, 2024 and 2023, respectively. The weighted average interest rate incurred on the First Lien Term Loan was 7.61% and 7.83% for the years ended December 31, 2024 and 2023, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company assessed whether the repayment of the First Lien Term Loan indebtedness resulted in an insubstantial modification or an extinguishment of the existing debt for each loan in the syndication by grouping lenders as follows: (i) Lenders participating in both the First Lien Term Loan and Senior Notes; (ii) previous lenders that exited; and (iii) new lenders. The Company determined that $0.4 million of the First Lien Term Loan were extinguished. The First Lien Term Loan had insubstantial modifications for lenders that participated in both debt instruments, which resulted in a cash inflow from financing activities of $50.0 million in the consolidated statements of cash flows. The Company incurred $1.6 million in fees, of which $0.1 million was capitalized, relative to the First Lien Term Loan and an immaterial amount of the total fees incurred was netted against the $50.0 million of debt proceeds as financing activities within the consolidated statements of cash flows. The Company recognized a loss on extinguishment of debt of $0.4 million included in the line entitled “Other, net” in the consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective June 30, 2023, the Company entered into an agreement, dated as of June 8, 2023, to amend the First Lien Term Loan to replace LIBOR and related definitions and provisions with SOFR as the new reference rate. The Company entered into the First Lien Term Loan Agreement (the “First Lien Credit Agreement Amendment”), which commenced in October 2021 (the “October 2021 Refinancing”) to provide $600.0 million of refinanced borrowings.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 7, 2023, the Company entered into the Second Amendment to the amended and restated First Lien Credit Agreement dated as of October 27, 2021. The Second Amendment, among other things, creates a Revolver Facility which provides for borrowings up to $400.0 million. As of December 31, 2024, the Company had $4.1 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $395.9 million. As of December 31, 2023, the Company had $5.3 million of undrawn letters of credit issued and outstanding, resulting in net borrowing availability under the Revolver Facility of $394.7 million. The Revolver Facility matures on the date that is the earlier of (i) December 7, 2028 and (ii) the date that is 91 days prior to the stated maturity date applicable to any Term B Loans. Borrowings under the Revolver Facility bear interest at a rate equal to, at the option of the Company, either (i) the Term SOFR applicable thereto plus the Applicable Rate or (ii) the then-applicable Base Rate plus the Applicable Rate, which Applicable Rate shall be, subject to certain caveats thereto, as follows (i) until delivery of financial statements and related Compliance Certificate for the first full fiscal quarter ending after the effective date of the Second Amendment, (A) for Term SOFR Loans, 1.75%, or (B) for Base Rate Loans, 0.75% and (ii) thereafter, the Applicable Rate for Term SOFR Loans and Base Rate Loans, based upon the Total Net Leverage Ratio as set forth in the most recent Compliance Certificate received by the Administrative Agent pursuant to the terms of the Credit Agreement.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrently with the creation of the Revolver Facility, the Company terminated the asset-based lending revolving credit facility (the “ABL Facility”) with a maturity date of October 27, 2026. Prior to the transition to the Revolver Facility, the ABL Facility had been in effect from August 6, 2019 to December 7, 2023. Effective January 13, 2023, the Company entered into an agreement to amend the ABL Facility and increase the amount of borrowing availability from $175.0 million by $50.0 million to $225.0 million total borrowing availability. As a result of the amended agreement, SOFR was established as the new reference rate, replacing LIBOR. Prior to the termination of the ABL Facility in December 2023, the ABL Facility bore interest at a rate equal to, at the Company’s election, either (i) a base rate determined in accordance with the ABL Credit Agreement plus an applicable margin, which is equal to between 0.25% and 0.75% based on the historical excess availability as a percentage of the Line Cap (as such term is defined in the ABL Credit Agreement); and (ii) SOFR (with a floor of —% per annum) plus an applicable margin, which is equal to between 1.25% and 1.75% based on the historical excess availability as a percentage of the Line Cap. The ABL Facility contained commitment fees payable on the unused portion ranging from 0.25% to 0.375%, depending on various factors including the Company’s leverage ratio, type of loan and rate type, and letter of credit fees of 2.50%. Borrowings under the ABL Facility were secured by a first priority security interest in the Company’s and each of its subsidiaries’ inventory, accounts receivable, cash, deposit accounts and certain assets and property related thereto (the “ABL Priority Collateral”), in each case subject to certain exceptions, and a third priority security interest in each of the Company’s subsidiaries’ capital stock (subject to certain exceptions) and substantially all of the Company’s property and assets (other than the ABL Priority Collateral).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In conjunction with the October 2021 Refinancing, the Company also issued $500.0 million in aggregate principal of unsecured senior notes (“Senior Notes”). The Senior Notes bear interest at a rate of 4.375% per annum payable semi-annually in arrears on October 31 and April 30 of each year, commencing on April 30, 2022. The Senior Notes mature on October 31, 2029. The interest rate on the Senior Notes was 4.375% as of both December 31, 2024 and 2023. The weighted average interest rate incurred on the Senior Notes was 4.375% for both years ended December 31, 2024 and 2023.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131,617 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company engaged in hedging activities to limit its exposure to changes in interest rates. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company’s debt obligations as of December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,153 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094,774 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,555)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618,525 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,372)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,628 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131,617 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,537)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,153 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,512)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,104,641 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt consisted of the following as of December 31, 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.549%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Principal Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Discount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Debt Issuance Costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Balance</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revolver Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">588,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,678)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">571,348 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,698)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">491,302 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,088,000 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,974)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18,376)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,062,650 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,056,650 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 0 631617000 5537000 7555000 618525000 500000000 0 7372000 492628000 1131617000 5537000 14927000 1111153000 6512000 1104641000 0 0 0 0 588000000 6974000 9678000 571348000 500000000 0 8698000 491302000 1088000000 6974000 18376000 1062650000 6000000 1056650000 50000000 0.0275 0.0225 1600000 0.0050 0.0225 0.0125 0.0682 0.0821 0.0761 0.0783 400000 50000000 1600000 100000 50000000 -400000 600000000 400000000 4100000 395900000 5300000 394700000 0.0175 0.0075 175000000 50000000 225000000 0.0025 0.0075 0 0.0125 0.0175 0.0025 0.00375 0.0250 500000000 0.04375 0.04375 0.04375 0.04375 0.04375 <div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term debt matures as follows (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fiscal Year Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Minimum Payments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,512 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">612,081 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,131,617 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6512000 6512000 6512000 612081000 500000000 1131617000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated fair values of the Company’s debt obligations as of December 31, 2024 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financial Instrument</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Value as of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Markets for Identical Item (Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Other Observable Inputs (Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant Unobservable Inputs (Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">First Lien Term Loan</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">618,525 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,774 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Senior Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">492,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">460,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,111,153 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,094,774 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 618525000 0 634774000 0 492628000 0 460000000 0 1111153000 0 1094774000 0 DERIVATIVE INSTRUMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes derivative financial instruments for hedging and non-trading purposes to limit the Company’s exposure to its variable interest rate risk. Use of derivative financial instruments in hedging strategies subjects the Company to certain risks, such as market and credit risks. Market risk represents the possibility that the value of the derivative financial instrument will change. Credit risk related to a derivative financial instrument represents the possibility that the counterparty will not fulfill the terms of the contract. The notional, or contractual, amount of the Company’s derivative financial instruments is used to measure interest to be paid or received and does not represent the Company’s exposure due to credit risk. Credit risk is monitored through established approval procedures, including reviewing credit ratings when appropriate.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, the Company entered into an interest rate cap hedge with a notional amount of $300.0 million for a five-year term beginning November 30, 2021. The hedge partially offsets risk associated with the First Lien Term Loan’s variable interest rate. The interest rate cap instrument perfectly offsets the terms of the interest rates associated with the variable interest rate of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company’s derivative instruments in the consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-828"><span style="-sec-ix-hidden:f-829">Balance Sheet Caption</span></span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,714 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The gain and loss associated with the changes in the fair value of the effective portion of hedging instruments are recorded into other comprehensive (loss) income. The gain and loss associated with the changes in the fair value of the hedging instrument is recognized in net income through interest expense. The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s consolidated statements of comprehensive income (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s consolidated statement of comprehensive income related to the Company’s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,527 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects to reclassify $2.8 million of total interest rate costs from accumulated other comprehensive income (loss) against interest expense during the next 12 months.</span></div> 300000000.0 P5Y <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amount and location of the Company’s derivative instruments in the consolidated balance sheets (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value - Derivatives in Asset Position</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><span style="-sec-ix-hidden:f-828"><span style="-sec-ix-hidden:f-829">Balance Sheet Caption</span></span></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,034 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,746 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other noncurrent assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,680 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,183 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total derivative assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,714 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,929 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 8034000 9746000 6680000 10183000 14714000 19929000 The following table presents the pre-tax (loss) gain from derivative instruments recognized in other comprehensive (loss) income in the Company’s consolidated statements of comprehensive income (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.547%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,215)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8,339)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28,869 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the amount and location of pre-tax income (loss) recognized in the Company’s consolidated statement of comprehensive income related to the Company’s derivative instruments (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:33.599%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Income Statement Caption</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest rate cap designated as cash flows hedge</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,527 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,974 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,090 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -5215000 -8339000 28869000 11527000 10974000 1090000 2800000 FAIR VALUE MEASUREMENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are determined by maximizing the use of observable inputs and minimizing the use of unobservable inputs. The hierarchy places the highest priority on unadjusted quoted market prices in active markets for identical assets or liabilities (Level 1 measurements) and gives the lowest priority to unobservable inputs (Level 3 measurements). The three levels of inputs within the fair value hierarchy are defined in Note 2, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Company believes its valuation methods are appropriate and consistent with other market participants, the use of</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different fair value measurement at the reporting date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Lien Term Loan</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the First Lien Term Loan is derived from a broker quote on the loans in the syndication (Level 2 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the First Lien Term Loan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Senior Notes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the Senior Notes is derived from a broker quote (Level 2 inputs). See Note 11, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the carrying amount and fair value of the Senior Notes.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Rate Cap</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the interest rate cap is derived from the interest rates prevalent in the market and future expectations of those interest rates (Level 2 inputs). The Company determines the fair value of the investments based on quoted prices from third-party brokers. See Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for further discussion of the fair value of the interest rate cap.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Money Market Funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The fair value of the money market funds is derived from the closing price reported by the fund sponsor and classified as cash and cash equivalents on the Company’s consolidated balance sheets (Level 1 inputs).</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no other assets or liabilities measured at fair value at December 31, 2024 or 2023.</span></div> COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is involved in legal proceedings and is subject to investigations, inspections, audits, inquiries, and similar actions by governmental authorities, arising in the normal course of the Company’s business. Some of these suits may purport or may be determined to be class actions and/or involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. From time to time, the Company may also be involved in legal proceedings as a plaintiff involving antitrust, tax, contract, intellectual property, and other matters. Gain contingencies, if any, are recognized when they are realized.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of legal proceedings are often uncertain and difficult to predict, and the costs incurred in litigation can be substantial, regardless of the outcome. The Company does not believe that any of these pending matters, after consideration of applicable reserves and rights to indemnification, will have a material adverse effect on the Company’s consolidated balance sheets.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, substantial unanticipated verdicts, fines, and rulings may occur. As a result, the Company may from time to time incur judgments, enter into settlements, or revise expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on its results of operations in the period in which the amounts are accrued and/or its cash flows in the period in which the amounts are paid.</span></div> STOCK-BASED INCENTIVE COMPENSATION<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Incentive Plans </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Under the Company’s 2018 Equity Incentive Plan (the “2018 Plan”), approved at the annual meeting by stockholders on May 3, 2018, the Company may issue, among other things, incentive stock options, non-qualified stock options, stock appreciation rights, restricted stock units, stock grants, and performance units to key employees and directors. The 2018 plan is administered by the Company’s Compensation Committee, a standing committee of the Board of Directors. In May 2024, an additional 4,000,000 shares were authorized for issuance under the amended 2018 Plan, resulting in a total of 13,101,734 shares of common stock authorized for issuance as of December 31, 2024. As of December 31, 2023, a total of 9,101,734 shares of common stock were authorized for issuance under the amended 2018 Plan.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Options granted under the 2018 Plan typically vest over a <span style="-sec-ix-hidden:f-850">three</span>- or four-year period and, in certain instances, may fully vest upon a change in control of the Company. The options also typically have an exercise price that may not be less than 100% of its fair market value on the date of grant and are exercisable <span style="-sec-ix-hidden:f-852">seven</span> to ten years after the date of grant, subject to earlier termination in certain circumstances.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense from stock options is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to stock options of $5.9 million, $6.5 million and $2.5 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no options granted during the year ended December 31, 2024. The weighted average grant-date fair value of options granted during the years ended December 31, 2023 and 2022 was $15.72 and $12.51, respectively. The fair value of stock options granted was estimated on the date of grant using a Black-Scholes pricing model. The assumptions used to compute the fair value of options for the years ended December 31, 2023 and 2022 are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.150%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.43%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.19%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.91%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December 31, 2024 is as follows: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,746,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.08 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(161,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483,233 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.35 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595,984 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52 years</span></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, 2023 and 2022, an immaterial number of shares were surrendered to satisfy tax withholding obligations on the exercise of stock options. No cash was received from stock option exercises under share-based payment arrangements for the years ended December 31, 2024, 2023 and 2022.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The maximum term of stock options under these plans is ten years. Options outstanding as of December 31, 2024 expire on various dates ranging from September 2025 through July 2033. The following table outlines the outstanding and exercisable stock options as of December 31, 2024:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Option Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $8.24</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.24 - $16.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$16.52 - $24.76</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$24.76 - $33.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595,984 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, there was $5.8 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 0.95 years.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Restricted stock grants subject solely to an employee’s continued service with the Company generally will become fully vested within <span style="-sec-ix-hidden:f-926">one</span> to four years from the grant date and, in certain instances, may fully vest upon a change in control of the Company. Restricted stock grants subject solely to a Director’s continued service with the Company generally will become fully vested on a pro-rata basis over three years from the date of grant. </span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense from restricted stock is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to restricted stock awards of $21.4 million, $16.6 million and $10.2 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of restricted stock is valued as the closing price of the Company’s common stock on the date of the grant.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity for the year ended December 31, 2024 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,883,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(770,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,665,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024, 2023 and 2022, shares were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards with a cost basis of $7.1 million, $4.4 million and $1.4 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, there was $28.8 million in unrecognized compensation expense related to unvested restricted stock awards that is expected to be recognized over a weighted average period of 1.09 years. The total fair value of restricted stock awards vested during the years ended December 31, 2024, 2023 and 2022 was $19.4 million, $9.9 million and $3.7 million, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Performance Stock Units </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Performance-based stock units (“PSU”) are generally earned based on the attainment of specified goals achieved over a designated performance period. During the years ended December 31, 2024, 2023 and 2022, the Company’s Compensation Committee approved PSU awards to certain senior executives of the Company with grant dates in 2024, 2023 and 2022, respectively. All PSU awards offer a three-year-cliff vesting schedule. Each PSU award reflects a target number of shares (“Target Shares”) that may be issued to the award recipient. PSU awards may be earned upon the completion of a two-year-average or three-year-average performance period.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whether PSU awards are earned at the end of the performance period will be determined based on the achievement of certain performance objectives over the performance period. The performance objectives include achieving a target growth for adjusted EBITDA and revenue combined in addition to a target growth for cash flows from operations over the performance period. Depending on the results achieved during the performance period, the actual number of shares that a grant recipient receives at the end of the period may range from 0% to 200% of the Target Shares granted. Each period begins with 100% of the Target Shares and true-up or true-down adjustments are considered every quarter-end based on the forecasted performance period results.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Target Shares and PSU awards are based on the fair value of the underlying shares as of market close on the grant date. Compensation expense for PSU awards is recognized on a straight-line basis over the requisite service period. During the years ended December 31, 2024, 2023 and 2022, the Company recognized compensation expense related to the PSU awards of $8.8 million, $7.5 million and $4.1 million, respectively. During the years ended December 31, 2024, shares were surrendered to satisfy tax withholding obligations on the performance-based stock units with a cost basis of $4.9 million. There were no shares surrendered to satisfy tax withholding obligations on the PSU awards during the years ended December 31, 2023 or 2022. As of December 31, 2024, there were $11.6 million in unrecognized compensation expense related to unvested PSU awards that are expected to be recognized over a weighted-average period of 1.32 years.</span></div> 4000000 13101734 9101734 P4Y P10Y 5900000 6500000 2500000 15.72 12.51 The assumptions used to compute the fair value of options for the years ended December 31, 2023 and 2022 are as follows:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:67.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.149%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.150%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.43%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51.19%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.16%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.91%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected life of options</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2 years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividend rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">—</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0.5143 0.5119 0.0416 0.0391 P6Y2M12D P6Y2M12D 0 0 <div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity for the year ended December 31, 2024 is as follows: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.133%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,746,272 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.08 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,028 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(161,553)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18.14 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,875 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101,486)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.05 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483,233 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.79 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,590 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.35 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at December 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595,984 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.96 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,365 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52 years</span></td></tr></table></div> 1746272 25.08 15028000 0 0 0 161553 18.14 1875000 101486 26.05 32000 1483233 25.79 1590000 P7Y4M6D 595984 22.96 1365000 P6Y6M7D 0 0 0 P10Y The following table outlines the outstanding and exercisable stock options as of December 31, 2024:<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.550%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Range of Option Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options Exercisable</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$0.00 - $8.24</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,901 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.52 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$8.24 - $16.52</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,775 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.14 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$16.52 - $24.76</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">355,616 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.54 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,513 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.05 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$24.76 - $33.00</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,052,941 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">320,795 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.85 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,483,233 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">595,984 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div> 0.00 8.24 9901 6.52 P2Y1M6D 9901 6.52 8.24 16.52 64775 12.14 P4Y 64775 12.14 16.52 24.76 355616 21.54 P6Y8M12D 200513 21.05 24.76 33.00 1052941 28.25 P7Y9M18D 320795 26.85 1483233 595984 5800000 P0Y11M12D P4Y P3Y 21400000 16600000 10200000 <div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock award activity for the year ended December 31, 2024 is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,883,116 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.28 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">723,027 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.71 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested and issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(770,137)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.16 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited and expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,594)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28.25 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2024</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,665,412 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29.41 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1883116 26.28 723027 32.71 770137 25.16 170594 28.25 1665412 29.41 7100000 4400000 1400000 28800000 P1Y1M2D 19400000 9900000 3700000 P3Y P2Y P3Y 0 2 1 8800000 7500000 4100000 4900000 0 0 11600000 P1Y3M25D STOCKHOLDERS’ EQUITY<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, HC I completed secondary offerings of 23,771,926 shares of common stock. As of December 31, 2023, HC I no longer held shares of the Company’s common stock.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2017 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Prior to the Merger, BioScrip issued warrants to certain debt holders pursuant to a Warrant Purchase Agreement dated as of June 29, 2017. In conjunction with the Merger, the 2017 Warrants were amended to entitle the purchasers of the warrants to purchase 2.1 million shares of common stock. The 2017 Warrants have a 10-year term and an exercise price of $8.00 per share and may be exercised by payment of the exercise price in cash or surrender of shares of common stock into which the 2017 Warrants are being converted in an aggregate amount sufficient to cover the exercise price. The 2017 Warrants are classified as equity instruments, and the fair value of these warrants of $14.1 million was recorded in paid-in capital as of the Merger Date. During the years ended December 31, 2024, 2023, and 2022, warrant holders exercised warrants to purchase 0, 188,350, and 1,130,089 shares of common stock, respectively. No proceeds were received from these exercises as the warrant holders elected to surrender shares to pay the exercise price. At December 31, 2024, 2023, and 2022, the remaining warrant holders are entitled to purchase 51,838, 51,838, and 240,188 shares of common stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2015 Warrants </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— Prior to the Merger, BioScrip issued warrants pursuant to a Common Stock Warrant Agreement dated as of March 9, 2015 which entitle the holders to purchase 0.9 million shares of common stock. The 2015 Warrants have a 10-year term and have exercise prices in a range of $20.68 per share to $25.80 per share. The 2015 Warrants were assumed by the Company in conjunction with the Merger and are classified as equity instruments, and the fair value of these warrants of $4.6 million was recorded in paid in capital as of the Merger Date. During the years ended December 31, 2024 and 2023, warrant holders exercised an immaterial number of warrants to purchase shares of common stock. During the year ended December 31, 2022, warrant holders exercised warrants to purchase 900,272 shares of common stock. During the years ended December 31, 2024 and 2023, no cash proceeds were received from warrant exercises. During the year ended December 31, 2022, $20.9 million of cash was received as proceeds from warrant exercises. At December 31, 2024, 2023, and 2022, the remaining warrant holders are entitled to purchase 11,765, 13,888, and 15,231 shares of common stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— On February 20, 2023, the Company’s Board of Directors approved a share repurchase program of up to an aggregate $250.0 million of common stock of the Company. On December 6, 2023, the Company’s Board of Directors approved an increase to its share repurchase program authorization from $250.0 million to $500 million. Under the share repurchase program, repurchases may occur in any number of methods depending on timing, market conditions, regulatory requirements, and other corporate considerations. The share repurchase program has no specified expiration date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December 31, 2024 and 2023, the Company purchased 9,255,591 and 7,946,301 shares of common stock for an average share price of $27.01 and $31.46, totaling $250.0 million and $250.0 million, respectively. All repurchased shares became treasury stock. As of December 31, 2024, the Company completed share repurchases under its prior share repurchase program. In January 2025, the Company’s Board of Directors approved a new $500.0 million stock repurchase program. This program has no specified expiration date.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shares Outstanding </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The following table shows the Company’s changes in shares of common stock for the years ended December 31, 2024 and 2023 (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,261 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Treasury Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— As of December 31, 2024 and 2023, the Company held 17,585,613 and 8,330,022 shares of treasury stock, respectively.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company had no preferred stock outstanding as of December 31, 2024 or 2023.</span></div> 23771926 2100000 P10Y 8.00 14100000 0 188350 1130089 0 51838 51838 240188 900000 P10Y 20.68 25.80 4600000 0 0 900272 0 0 20900000 11765 13888 15231 250000000 250000000 500000000 9255591 7946301 27.01 31.46 250000000 250000000 500000000 The following table shows the Company’s changes in shares of common stock for the years ended December 31, 2024 and 2023 (in thousands):<div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:78.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,946)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">174,576 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity award issuances</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">941 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share repurchases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,256)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance at December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,261 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 181958000 564000 7946000 174576000 941000 9256000 166261000 17585613 8330022 0 0 RELATED-PARTY TRANSACTIONS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transactions with Equity-Method Investees </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">— The Company provides management services to its joint ventures such as accounting, invoicing and collections in addition to day-to-day managerial support of the operations of the businesses. The Company recorded management fee income of $6.2 million, $5.3 million and $4.1 million for the years ended December 31, 2024, 2023 and 2022, respectively. Management fees are recorded in net revenues in the accompanying consolidated statements of comprehensive income.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had amounts due to its joint ventures totaling $1.4 million as of December 31, 2024. The Company had amounts due to its joint ventures of $0.5 million and due from its joint ventures of $0.1 million as of December 31, 2023. These receivables were included in prepaid expenses and other current assets in the accompanying balance sheets and these payables were included in accrued expenses and other current liabilities in the accompanying balance sheets. These balances primarily relate to cash collections received by the Company on behalf of the joint ventures, offset by certain pharmaceutical inventories and other expenses paid for by the Company on behalf of the joint ventures.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> — On February 28, 2023, we entered into a Share Repurchase Agreement (the “Share Repurchase Agreement”) with HC I, pursuant to which we agreed to repurchase, subject to the terms and conditions contained therein, up to $75.0 million of our common stock then held by HC I at the same purchase price per share as the underwriter in a concurrent underwritten public offering of our common stock held by HC I. On March 3, 2023, the transactions contemplated by the Share Repurchase Agreement closed, and we repurchased directly from HC I 2,475,166 shares of our common stock.</span></div> 6200000 5300000 4100000 1400000 500000 100000 75000000 2475166 SEGMENT REPORTING<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted ASU 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and has revised prior year disclosures to conform with the current year presentation. The Company operates as a single reportable segment, infusion services. Infusion services derives revenue through the clinical management of infusion therapy, nursing support and care coordination in order to provide solutions to complex patient conditions in the home or other nonhospital settings. The Company’s infusion services segment activities are managed on a consolidated basis and therapies are distributed and administered in a similar manner.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments have been identified based on the financial information utilized by the Company’s Chief Executive Officer, the chief operating decision maker (“CODM”). The CODM uses net income as a measure of profitability to assess segment performance and deciding on how to allocate resources such as capital investments, share repurchases, and acquisitions. The CODM does not use or receive total assets by segment to make decisions regarding resources; therefore, the total asset disclosure by segment has not been included.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects results of operations of the Company’s reportable segment (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion services net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222,656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Option Care Health revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,944,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Expense) Income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of net revenues - drugs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,446,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,812,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,562,494)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries, benefits, and other employee expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment items (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,090 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,556 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents business activities related to other miscellaneous revenue streams.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.</span></div> <div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects results of operations of the Company’s reportable segment (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"><div style="margin-bottom:10pt;text-indent:18pt"><span><br/></span></div></td><td colspan="15" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Infusion services net revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,911,591 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,222,656 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,869,036 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue (1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,611 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,668 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75,699 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Option Care Health revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,998,202 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,302,324 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,944,735 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Expense) Income:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of net revenues - drugs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,446,735)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,812,531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,562,494)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries, benefits, and other employee expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(787,922)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(760,499)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(709,916)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment items (2)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(380,803)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(355,498)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(371,529)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,909)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,201)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49,029)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53,806)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in earnings of joint ventures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,964 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,530 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,125 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,831 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,865 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,218 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71,776)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91,652)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,212)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">211,823 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">267,090 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150,556 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents business activities related to other miscellaneous revenue streams.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Other segment items includes expenses for medical supplies, delivery and packaging, leases, professional services, and other expenses.</span></div> 4911591000 4222656000 3869036000 86611000 79668000 75699000 4998202000 4302324000 3944735000 3446735000 2812531000 2562494000 787922000 760499000 709916000 380803000 355498000 371529000 60909000 59201000 60565000 49029000 51248000 53806000 5964000 5530000 5125000 4831000 89865000 14218000 71776000 91652000 55212000 211823000 267090000 150556000 SUBSEQUENT EVENTS<div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated whether any subsequent events occurred since December 31, 2024 and noted the following subsequent event:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 24, 2025 the Company completed the acquisition of all equity interests in Intramed Plus, Inc., a leading provider of home and alternate site infusion services in the Southeastern United States. The total purchase price for the transaction was approximately $117 million, paid in cash.</span></div> 117000000 false false false false 185 true